<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, viewport-fit=cover, maximum-scale=1.0, user-scalable=no">
    <meta name="theme-color" content="#0f172a">
    <meta name="apple-mobile-web-app-capable" content="yes">
    <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
    <title>NCLEX Study Tool</title>
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0/css/all.min.css" rel="stylesheet">
    <style>
        :root {
            --primary: #0f172a;
            --secondary: #1e293b;
            --accent: #3b82f6;
            --text: #f8fafc;
            --success: #22c55e;
            --danger: #ef4444;
            --warning: #f59e0b;
            --border: #334155;
        }

        body {
            background-color: var(--primary);
            color: var(--text);
            font-family: 'Segoe UI', system-ui, sans-serif;
            padding-bottom: 80px;
        }

        .nexus-nav {
            background: var(--secondary);
            border-bottom: 1px solid var(--border);
            position: sticky;
            top: 0;
            z-index: 1000;
            padding: 1rem 0;
            box-shadow: 0 10px 30px rgba(0, 0, 0, 0.5);
        }

        .control-panel {
            background: rgba(15, 23, 42, 0.98);
            backdrop-filter: blur(15px);
            border-bottom: 1px solid var(--border);
            padding: 15px 0;
            position: sticky;
            top: 82px;
            z-index: 999;
        }

        .nexus-card {
            background: var(--secondary);
            border: 1px solid var(--border);
            border-radius: 16px;
            padding: 25px;
            margin-bottom: 25px;
            height: 100%;
            display: flex;
            flex-direction: column;
            transition: 0.3s;
        }

        .nexus-card:hover {
            border-color: var(--accent);
            transform: translateY(-5px);
            box-shadow: 0 20px 40px rgba(0, 0, 0, 0.4);
        }

        .card-icon {
            height: 60px;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .btn-accent {
            background-color: var(--accent);
            border-color: var(--accent);
            color: var(--primary);
        }

        .btn-accent:hover {
            background-color: #0066cc;
            border-color: #0066cc;
            color: var(--primary);
        }

        .btn-outline-purple {
            color: #8b5cf6;
            border-color: #8b5cf6;
        }

        .btn-outline-purple:hover {
            color: #7c3aed;
            background-color: rgba(139, 92, 246, 0.1);
            border-color: #7c3aed;
        }

        .border-purple {
            border-color: #8b5cf6 !important;
        }

        .mission-title-display {
            background: rgba(59, 130, 246, 0.1);
            border-left: 3px solid var(--accent);
            padding: 8px 12px;
            border-radius: 0 4px 4px 0;
        }

        /* Drag-and-drop cloze styling */
        .drag-drop-cloze {
            max-width: 100%;
        }

        .cloze-text {
            background: rgba(255, 255, 255, 0.05);
            padding: 20px;
            border-radius: 8px;
            line-height: 1.6;
            font-size: 1.1rem;
        }

        .drop-zone {
            display: inline-block;
            min-width: 80px;
            padding: 4px 8px;
            margin: 0 4px;
            border: 2px dashed var(--accent);
            border-radius: 4px;
            background: rgba(59, 130, 246, 0.1);
            text-align: center;
            cursor: pointer;
            transition: all 0.3s ease;
        }

        .drop-zone:hover {
            background: rgba(59, 130, 246, 0.2);
            border-color: var(--warning);
        }

        .drop-zone.filled {
            border: 2px solid var(--success);
            background: rgba(34, 197, 94, 0.1);
        }

        .dropped-option {
            background: var(--success);
            color: white;
            padding: 2px 6px;
            border-radius: 3px;
            cursor: pointer;
        }

        .dropped-option:hover {
            opacity: 0.8;
        }

        .options-pool {
            background: rgba(0, 0, 0, 0.2);
            padding: 15px;
            border-radius: 8px;
        }

        .options-label {
            font-weight: bold;
            color: var(--accent);
            margin-bottom: 10px;
        }

        .options-container {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
        }

        .draggable-option {
            display: inline-block;
            background: var(--secondary);
            color: white;
            padding: 8px 12px;
            border-radius: 6px;
            cursor: grab;
            border: 1px solid var(--border);
            transition: all 0.3s ease;
        }

        .draggable-option:hover {
            background: var(--accent);
            transform: translateY(-2px);
        }

        .draggable-option.dragging {
            opacity: 0.5;
            transform: rotate(5deg);
        }

        .cloze-instructions {
            text-align: center;
            color: var(--text);
            font-style: italic;
            margin-top: 10px;
        }

        /* Highlight selection styling */
        .highlight-select {
            max-width: 100%;
        }

        .highlight-instruction {
            background: rgba(59, 130, 246, 0.1);
            padding: 12px;
            border-radius: 6px;
            border-left: 4px solid var(--accent);
            font-weight: 500;
        }

        .highlight-text {
            background: rgba(255, 255, 255, 0.05);
            padding: 20px;
            border-radius: 8px;
            line-height: 1.7;
            font-size: 1.05rem;
            margin-top: 15px;
        }

        .text-highlight {
            background: rgba(59, 130, 246, 0.2);
            border-radius: 3px;
            padding: 2px 4px;
            cursor: pointer;
            transition: all 0.3s ease;
            border: 1px solid transparent;
        }

        .text-highlight:hover {
            background: rgba(59, 130, 246, 0.4);
            border-color: var(--accent);
        }

        .text-highlight.selected {
            background: var(--success);
            color: white;
            border-color: var(--success);
            box-shadow: 0 0 8px rgba(34, 197, 94, 0.4);
        }

        .text-highlight.highlight-correct {
            border-bottom: 2px solid var(--success);
        }

        .text-highlight.highlight-distractor {
            border-bottom: 2px solid var(--danger);
        }

        .point-label {
            font-weight: 800;
            color: var(--accent);
            text-transform: uppercase;
            font-size: 0.65rem;
            margin-top: 15px;
            letter-spacing: 1.5px;
            display: block;
            border-left: 4px solid var(--accent);
            padding-left: 10px;
            margin-bottom: 5px;
        }

        .point-value {
            font-size: 0.92rem;
            color: #cbd5e1;
            line-height: 1.6;
        }

        .ae-common {
            background: rgba(255, 255, 255, 0.05);
            padding: 10px;
            border-radius: 6px;
            margin-top: 5px;
            font-size: 0.85rem;
            border: 1px solid var(--warning);
        }

        .ae-severe {
            background: rgba(239, 68, 68, 0.1);
            border: 1px solid var(--danger);
            color: #fca5a5;
            padding: 10px;
            border-radius: 6px;
            margin-top: 8px;
            font-size: 0.85rem;
            font-weight: 600;
        }

        .inter-table {
            width: 100%;
            margin-top: 10px;
            font-size: 0.85rem;
            border-collapse: separate;
            border-spacing: 0 5px;
        }

        .inter-table td {
            padding: 10px;
            background: rgba(0, 0, 0, 0.3);
            border-radius: 4px;
        }

        .inter-table tr.critical td {
            border-left: 5px solid var(--danger);
            background: rgba(239, 68, 68, 0.1);
        }

        .data-strip {
            display: flex;
            gap: 10px;
            margin-top: 15px;
        }

        .logistics-box {
            flex: 1;
            padding: 12px;
            border-radius: 10px;
            font-size: 0.85rem;
            border: 1px solid rgba(255, 255, 255, 0.1);
        }

        .box-dosage {
            background: rgba(34, 197, 94, 0.1);
            color: #4ade80;
        }

        .box-admin {
            background: rgba(245, 158, 11, 0.1);
            color: #fcd34d;
        }

        .box-title {
            font-weight: 800;
            font-size: 0.65rem;
            text-transform: uppercase;
            display: block;
            margin-bottom: 5px;
            opacity: 0.8;
        }

        /* MISSION OVERLAY */
        .mission-container {
            display: flex;
            height: 100vh;
            width: 100vw;
            position: fixed;
            top: 0;
            left: 0;
            z-index: 2100;
            background: var(--primary);
        }

        .chart-pane {
            width: 45%;
            background: #f1f5f9 !important;
            border-right: 4px solid var(--border);
            display: flex;
            flex-direction: column;
        }

        .chart-pane * {
            color: #0f172a !important;
        }

        .chart-header,
        .chart-header * {
            background: #334155 !important;
            color: white !important;
        }

        .chart-tabs {
            background: #e2e8f0 !important;
            display: flex;
            border-bottom: 1px solid #cbd5e1;
        }

        .chart-tab {
            padding: 12px 20px;
            cursor: pointer;
            border-right: 1px solid #cbd5e1;
            font-weight: 600;
            font-size: 0.85rem;
        }

        .chart-tab.active {
            background: white !important;
            color: var(--accent) !important;
            border-bottom: 3px solid var(--accent);
        }

        .chart-content {
            padding: 25px;
            flex-grow: 1;
            overflow-y: auto;
            background: white !important;
            line-height: 1.6;
        }

        .work-pane {
            width: 55%;
            padding: 40px;
            overflow-y: auto;
            background: var(--primary);
        }

        /* BOWTIE */
        .bowtie-container {
            display: flex;
            gap: 20px;
            align-items: stretch;
            margin-top: 30px;
        }

        .bowtie-wing {
            flex: 1;
            background: rgba(255, 255, 255, 0.03);
            border: 2px solid var(--border);
            border-radius: 20px;
            padding: 20px;
        }

        .bowtie-center {
            width: 250px;
            background: rgba(245, 158, 11, 0.05);
            border: 2px solid var(--warning);
            border-radius: 20px;
            padding: 20px;
        }

        .bowtie-label {
            font-size: 0.7rem;
            font-weight: 900;
            color: var(--accent);
            margin-bottom: 15px;
        }

        .bw-option {
            background: var(--secondary);
            padding: 10px;
            border-radius: 8px;
            margin-bottom: 8px;
            display: flex;
            align-items: center;
            cursor: pointer;
        }

        .bw-option input {
            margin-right: 10px;
        }

        /* SIDECAR */
        .pharma-sidecar {
            position: fixed;
            right: -400px;
            top: 0;
            width: 400px;
            height: 100vh;
            background: var(--secondary);
            z-index: 2200;
            box-shadow: -10px 0 30px rgba(0, 0, 0, 0.5);
            transition: 0.4s;
            display: flex;
            flex-direction: column;
            border-left: 2px solid var(--accent);
        }

        .pharma-sidecar.active {
            right: 0;
        }

        .sidecar-header {
            background: var(--primary);
            padding: 20px;
            border-bottom: 1px solid var(--border);
        }

        .sidecar-content {
            flex-grow: 1;
            overflow-y: auto;
            padding: 20px;
            background: var(--primary);
        }

        .sidecar-toggle {
            position: fixed;
            right: 20px;
            bottom: 100px;
            width: 60px;
            height: 60px;
            border-radius: 50%;
            background: var(--accent);
            color: white;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            z-index: 2300;
            border: none;
        }

        /* ============================================
           MOBILE RESPONSIVE - TABLET (max-width: 768px)
           ============================================ */
        @media (max-width: 768px) {
            /* --- NAV BAR --- */
            .nexus-nav {
                padding: 0.6rem 0;
            }

            .nexus-nav h3 {
                font-size: 1.1rem !important;
            }

            .nexus-nav p {
                display: none;
            }

            .nexus-nav .container-fluid {
                flex-wrap: wrap;
                gap: 8px;
            }

            .nav-buttons {
                width: 100%;
                justify-content: center !important;
                flex-wrap: wrap;
                gap: 6px !important;
            }

            .nav-buttons .btn {
                font-size: 0.75rem !important;
                padding: 0.35rem 0.7rem !important;
            }

            .nav-buttons > span {
                width: 100%;
                text-align: center;
                font-size: 0.8rem;
            }

            /* --- CONTROL PANEL (Drug Filters) --- */
            .control-panel {
                top: 62px;
                padding: 10px 0;
            }

            .control-panel .row {
                flex-direction: column;
                gap: 8px !important;
            }

            .control-panel .col-md-4 {
                text-align: center !important;
            }

            .control-panel .btn-group {
                width: 100% !important;
            }

            .control-panel .btn {
                font-size: 0.8rem;
                padding: 0.4rem 0.6rem;
            }

            /* --- HOME SCREEN --- */
            .display-4 {
                font-size: 1.6rem !important;
            }

            .display-4 .me-3 {
                margin-right: 0.5rem !important;
            }

            .col-md-4 .nexus-card {
                margin-bottom: 0;
            }

            /* --- DRUG REFERENCE CARDS --- */
            .col-md-6.mb-4 {
                flex: 0 0 100%;
                max-width: 100%;
            }

            .nexus-card {
                padding: 18px;
                border-radius: 12px;
            }

            .nexus-card h4 {
                font-size: 1.1rem;
            }

            .point-label {
                font-size: 0.6rem;
            }

            .point-value {
                font-size: 0.85rem;
            }

            .nexus-card .row .col-md-6 {
                flex: 0 0 100%;
                max-width: 100%;
            }

            .data-strip {
                flex-direction: column;
                gap: 8px;
            }

            .inter-table {
                font-size: 0.78rem;
            }

            .inter-table td {
                padding: 6px 8px;
            }

            .ae-common, .ae-severe {
                font-size: 0.8rem;
                padding: 8px;
            }

            /* --- MISSION MODAL --- */
            .mission-container {
                flex-direction: column;
                height: 100vh;
                height: 100dvh;
                overflow-y: auto;
            }

            .chart-pane {
                width: 100% !important;
                height: auto;
                min-height: 35vh;
                max-height: 45vh;
                border-right: none;
                border-bottom: 3px solid var(--border);
                overflow-y: auto;
            }

            .work-pane {
                width: 100% !important;
                height: auto;
                min-height: 55vh;
                padding: 20px 15px;
                overflow-y: auto;
            }

            .chart-header {
                padding: 10px 12px !important;
            }

            .chart-header h5 {
                font-size: 0.95rem !important;
            }

            .chart-header span {
                font-size: 0.7rem !important;
            }

            .chart-tabs {
                flex-wrap: wrap;
            }

            .chart-tab {
                padding: 8px 12px;
                font-size: 0.72rem;
                white-space: nowrap;
            }

            .chart-content {
                padding: 15px;
                font-size: 0.88rem;
            }

            .mission-container .btn {
                font-size: 0.85rem !important;
                padding: 0.45rem 0.9rem !important;
            }

            .step-badge {
                font-size: 0.75rem !important;
            }

            .work-pane h3 {
                font-size: 1.15rem !important;
            }

            .mission-title-display {
                font-size: 0.8rem;
                padding: 6px 10px;
            }

            /* --- BOWTIE --- */
            .bowtie-container {
                flex-direction: column;
                gap: 15px;
            }

            .bowtie-center {
                width: 100%;
            }

            .bowtie-wing {
                padding: 15px;
            }

            .bw-option {
                font-size: 0.88rem;
                padding: 10px 8px;
            }

            /* --- DRAG-AND-DROP CLOZE --- */
            .cloze-text {
                font-size: 0.95rem;
                padding: 15px;
                line-height: 1.8;
            }

            .drop-zone {
                min-width: 60px;
                padding: 4px 6px;
                font-size: 0.85rem;
            }

            .draggable-option {
                padding: 8px 12px;
                font-size: 0.85rem;
                touch-action: none;
            }

            .options-pool {
                padding: 12px;
            }

            /* --- HIGHLIGHT SELECT --- */
            .highlight-text {
                font-size: 0.95rem;
                padding: 15px;
            }

            .text-highlight {
                padding: 3px 5px;
            }

            /* --- SIDECAR (Drug Reference Panel) --- */
            .pharma-sidecar {
                width: 85vw;
                right: -85vw;
            }

            .sidecar-toggle {
                width: 50px;
                height: 50px;
                right: 12px;
                bottom: 80px;
            }

            .sidecar-toggle i {
                font-size: 1.2rem !important;
            }

            /* --- EXAM VIEW --- */
            #examModal, #examSelectionModal {
                padding: 15px !important;
            }

            #examModal .container,
            #examSelectionModal .container {
                padding: 0;
            }

            #examModal h2, #examModal h3 {
                font-size: 1.1rem !important;
            }

            #examModal .fs-5 {
                font-size: 0.95rem !important;
            }

            #examModal label {
                padding: 12px 14px !important;
                font-size: 0.9rem;
            }

            #examModal .d-flex.justify-content-between.align-items-center {
                flex-wrap: wrap;
                gap: 8px;
            }

            #examModal .btn-lg {
                font-size: 0.9rem !important;
                padding: 0.5rem 1.2rem !important;
            }

            #examSelectionModal h2 {
                font-size: 1.2rem !important;
            }

            #examSelectionModal .col-md-6 {
                flex: 0 0 100%;
                max-width: 100%;
            }

            /* --- MISSION SELECTOR --- */
            #missionSelectorModal {
                padding: 15px !important;
            }

            #missionSelectorModal h2 {
                font-size: 1.2rem !important;
            }

            #missionSelectorModal h4 {
                font-size: 1rem !important;
            }

            #missionSelectorModal .col-md-4,
            #missionSelectorModal .col-md-6 {
                flex: 0 0 100%;
                max-width: 100%;
            }

            .mission-btn {
                font-size: 0.85rem;
            }
        }

        /* ============================================
           MOBILE RESPONSIVE - PHONE (max-width: 480px)
           ============================================ */
        @media (max-width: 480px) {
            /* --- NAV BAR --- */
            .nexus-nav h3 {
                font-size: 0.95rem !important;
            }

            .nexus-nav .badge {
                font-size: 0.55rem !important;
                padding: 0.2rem 0.4rem !important;
            }

            .nav-buttons .btn {
                font-size: 0.7rem !important;
                padding: 0.3rem 0.5rem !important;
            }

            /* --- CONTROL PANEL --- */
            .control-panel {
                top: 52px;
            }

            /* --- HOME SCREEN --- */
            .display-4 {
                font-size: 1.3rem !important;
            }

            .lead {
                font-size: 0.9rem !important;
            }

            body {
                padding-bottom: 60px;
            }

            /* --- DRUG CARDS --- */
            .nexus-card {
                padding: 14px;
                margin-bottom: 15px;
            }

            .nexus-card h4 {
                font-size: 1rem;
                word-break: break-word;
            }

            .point-value {
                font-size: 0.82rem;
            }

            .logistics-box {
                font-size: 0.78rem;
                padding: 10px;
            }

            /* --- MISSION WORK PANE --- */
            .work-pane {
                padding: 15px 12px !important;
            }

            .work-pane h3 {
                font-size: 1.05rem !important;
                line-height: 1.4;
            }

            /* Mission action buttons at bottom */
            .work-pane .mt-5 {
                margin-top: 1.5rem !important;
                position: sticky;
                bottom: 0;
                background: var(--primary);
                padding: 12px 0;
                z-index: 10;
            }

            .mission-container .btn {
                font-size: 0.8rem !important;
                padding: 0.4rem 0.8rem !important;
            }

            /* --- BOWTIE --- */
            .bowtie-wing, .bowtie-center {
                padding: 12px;
                border-radius: 12px;
            }

            .bowtie-label {
                font-size: 0.65rem;
            }

            .bw-option {
                font-size: 0.82rem;
                padding: 8px;
            }

            /* --- DRAG-AND-DROP --- */
            .cloze-text {
                font-size: 0.88rem;
                padding: 12px;
            }

            .draggable-option {
                padding: 6px 10px;
                font-size: 0.82rem;
            }

            /* --- EXAM --- */
            #examModal {
                padding: 10px !important;
            }

            #examModal h2 {
                font-size: 1rem !important;
                line-height: 1.4;
            }

            #examModal .fs-5 {
                font-size: 0.88rem !important;
            }

            #examModal label {
                padding: 10px 12px !important;
                margin-bottom: 8px !important;
            }

            #feedbackContainer {
                font-size: 0.9rem;
            }

            #feedbackContainer h4 {
                font-size: 1rem;
            }

            /* --- SIDECAR --- */
            .pharma-sidecar {
                width: 92vw;
                right: -92vw;
            }

            .sidecar-toggle {
                width: 44px;
                height: 44px;
                right: 8px;
                bottom: 70px;
            }

            .sidecar-toggle i {
                font-size: 1rem !important;
            }
        }

        /* ============================================
           TOUCH DEVICE ENHANCEMENTS
           ============================================ */
        @media (hover: none) and (pointer: coarse) {
            /* Larger tap targets for touch */
            .btn {
                min-height: 44px;
                min-width: 44px;
            }

            .chart-tab {
                min-height: 44px;
                display: flex;
                align-items: center;
            }

            .bw-option {
                min-height: 48px;
            }

            .text-highlight {
                padding: 4px 6px;
                line-height: 2;
            }

            /* Disable hover effects that don't work on touch */
            .nexus-card:hover {
                transform: none;
                box-shadow: none;
            }

            .draggable-option:hover {
                transform: none;
            }

            /* Active states for touch feedback */
            .nexus-card:active {
                border-color: var(--accent);
                transform: scale(0.98);
            }

            .btn:active {
                transform: scale(0.96);
            }

            .draggable-option:active {
                background: var(--accent);
                transform: scale(0.95);
            }

            .text-highlight:active {
                background: rgba(59, 130, 246, 0.4);
            }
        }

        /* Safe area for iPhones with notch/Dynamic Island */
        @supports (padding-top: env(safe-area-inset-top)) {
            .nexus-nav {
                padding-top: calc(0.6rem + env(safe-area-inset-top));
            }

            .mission-container {
                padding-top: env(safe-area-inset-top);
            }

            #examModal, #examSelectionModal, #missionSelectorModal {
                padding-top: calc(15px + env(safe-area-inset-top)) !important;
            }

            body {
                padding-bottom: calc(80px + env(safe-area-inset-bottom));
            }
        }
    </style>
</head>

<body>

    <nav class="nexus-nav">
        <div class="container-fluid px-4 d-flex justify-content-between align-items-center">
            <div>
                <h3 class="mb-0 fw-bold"><i class="fas fa-microscope text-accent me-3"></i>NCLEX Study Tool <span
                        class="badge bg-primary ms-2" style="font-size: 0.7rem">v3.3</span></h3>
                <p class="small text-secondary mb-0">High-Fidelity Clinical Study Platform</p>
            </div>
            <div class="d-flex align-items-center gap-3 nav-buttons">
                <span class="text-secondary">Welcome to NCLEX Study Tool</span>
            </div>
        </div>
    </nav>

    <div class="control-panel shadow-lg">
        <div class="container-fluid px-4">
            <div class="row g-3 align-items-center">
                <div class="col-md-4"><input type="text" id="drugSearch"
                        class="form-control bg-dark text-white border-secondary" placeholder="Search..."
                        onkeyup="renderDrugs()"></div>
                <div class="col-md-4 text-center">
                    <div class="btn-group w-100 shadow">
                        <button id="btn-cv" class="btn btn-outline-primary active-cv"
                            onclick="toggleFilter('cv')">Cardio</button>
                        <button id="btn-dm" class="btn btn-outline-success active-dm"
                            onclick="toggleFilter('dm')">Diabetes</button>
                    </div>
                </div>
                <div class="col-md-4 text-end">
                    <div class="btn-group"><button id="sort-az" class="btn btn-outline-light active"
                            onclick="setSort('az')">A-Z</button><button id="sort-class" class="btn btn-outline-light"
                            onclick="setSort('class')">Class</button></div>
                    <span id="counter" class="badge bg-accent ms-2 py-2">Loading...</span>
                </div>
            </div>
        </div>
    </div>

    <div class="container-fluid px-4 mt-4">
        <div class="row" id="drug-grid"></div>
    </div>

    <script>
/* SOURCE: data_lipids_statins.js */
const data_lipids_statins = [
    {
        g: "Atorvastatin", b: "Lipitor", c: "Statin (HMG-CoA Reductase Inhibitor)", cat: "cv",
        m: "Competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. By blocking this pathway, the drug reduces the concentration of cholesterol within hepatocytes. This intracellular depletion triggers a profound compensatory response: the upregulation of high-affinity LDL receptors on the hepatocyte membrane. These receptors capture circulating LDL and VLDL remnants from the plasma, significantly lowering systemic LDL-C levels. Furthermore, Atorvastatin inhibits the hepatic synthesis of VLDL and provides 'pleiotropic' benefits, including the stabilization of existing atherosclerotic plaques, improvement in endothelial function, and reduction of vascular inflammation.",
        ind: "Primary Hyperlipidemia (Type IIa and IIb), primary prevention of cardiovascular disease in asymptomatic patients with multiple risk factors (Diabetes, Hypertension, Smoking), secondary prevention of major clinical CV events (Myocardial Infarction, Stroke, Revascularization) in patients with established coronary artery disease, and treatment of elevated serum TG levels.",
        con: "Active liver disease (cirrhosis, hepatitis, persistent and unexplained transaminitis), Pregnancy (Category X - cholesterol is essential for fetal steroid synthesis and cell membrane development), Breastfeeding, and known hypersensitivity to any component of the formulation.",
        aec: "Gastrointestinal distress including dyspepsia, flatulence, and constipation; headache; dizziness; and mild, transient myalgia without significant elevation in Creatine Kinase (CK) levels.",
        aes: "RHABDOMYOLYSIS: Severe skeletal muscle breakdown leading to myoglobinuria, which can precipitate acute renal failure. HEPATOTOXICITY: Clinically significant elevations in ALT/AST (>3x upper limit). New-onset Type 2 Diabetes mellitus (dose-related). Potential for cognitive impairment or memory loss (reversible).",
        inter: [
            {d: "Grapefruit Juice", m: "Potent inhibitor of CYP3A4; results in toxic plasma concentrations of atorvastatin and extreme Rhabdomyolysis risk.", s: "critical"},
            {d: "Warfarin", m: "Potentiates the anticoagulant effect; increases the International Normalized Ratio (INR) and heightens bleeding risk.", s: "high"},
            {d: "Gemfibrozil", m: "Synergistic myopathy risk; dramatically increases the likelihood of skeletal muscle breakdown.", s: "high"},
            {d: "Clarithromycin", m: "Inhibits CYP3A4 metabolism; significantly increases statin-induced toxicity.", s: "high"}
        ],
        dosage: "Adult: 10 mg to 80 mg orally once daily. Pediatric (10-17 years): 10 mg to 20 mg once daily. Dosage is individualized based on baseline LDL levels and therapeutic goals.",
        admin: "Administer orally once daily. While it can be taken at any time, EVENING dosing is physiologically preferred as hepatic cholesterol synthesis peaks during the night. Can be taken without regard to food. Maintain a consistent daily schedule.",
        nurse: "Obtain baseline Liver Function Tests (ALT, AST) and a fasting lipid panel. Re-test LFTs if signs of liver injury appear (jaundice, RUQ pain, dark urine). If the patient reports unexplained muscle pain, tenderness, or weakness, immediately check Creatine Kinase (CK) levels and monitor renal function. Instruct the patient to strictly avoid grapefruit and its juice."
    },
    {
        g: "Simvastatin", b: "Zocor", c: "Statin (HMG-CoA Reductase Inhibitor)", cat: "cv",
        m: "Blocks the conversion of HMG-CoA to mevalonate in the liver by inhibiting HMG-CoA reductase. This action leads to an increase in the density of LDL receptors on the surface of liver cells, facilitating the clearance of LDL-C from the systemic circulation. Simvastatin has a high hepatic extraction ratio but lower lipid solubility than some other agents in its class, requiring specific metabolic activation.",
        ind: "Hypercholesterolemia, mixed dyslipidemia, and reduction of risk for total mortality by reducing coronary heart disease death and non-fatal myocardial infarction in high-risk patients.",
        con: "Active liver disease, pregnancy, breastfeeding, and concomitant use of potent CYP3A4 inhibitors (e.g., ketoconazole, protease inhibitors, erythromycin).",
        aec: "Abdominal pain, nausea, constipation, upper respiratory tract infection, headache, insomnia, and mild elevation in HbA1c.",
        aes: "Myopathy and Rhabdomyolysis (risk is notably higher at the 80mg dose), severe drug-induced hepatotoxicity, and hypersensitivity reactions.",
        inter: [
            {d: "Amiodarone", m: "Increases simvastatin concentration; do not exceed 20mg of simvastatin daily.", s: "high"},
            {d: "Verapamil/Diltiazem", m: "Limit simvastatin dose to 10mg daily to prevent toxic accumulation.", s: "high"},
            {d: "Grapefruit Juice", m: "Potent increase in drug levels via CYP3A4 inhibition; significantly heightens Rhabdo risk.", s: "critical"}
        ],
        dosage: "Adult: 5 mg to 40 mg orally once daily. The 80 mg dose is restricted to patients who have safely used the dose for >12 months without myopathy.",
        admin: "MUST be administered in the EVENING. Dosage should be titrated every 4 weeks based on patient response. Swallow tablets whole; do not crush or chew.",
        nurse: "Perform baseline LFTs and monitor periodically. Evaluate patient for muscle tenderness, specifically in the calves or back. Advise patient to limit alcohol consumption to minimize hepatic strain."
    },
    {
        g: "Rosuvastatin", b: "Crestor", c: "Statin (HMG-CoA Reductase Inhibitor)", cat: "cv",
        m: "High-potency, hydrophilic inhibitor of HMG-CoA reductase. Its long half-life (19 hours) and high hepatoselectivity allow for significant LDL reduction (up to 63%). It is not significantly metabolized by the CYP3A4 isoenzyme, instead utilizing CYP2C9, which reduces the risk of common statin-drug interactions. It works by reducing hepatic cholesterol synthesis and increasing the number of LDL receptors on the hepatocyte membrane.",
        ind: "Hyperlipidemia, mixed dyslipidemia, primary dysbetalipoproteinemia, slowing the progression of atherosclerosis, and primary prevention of cardiovascular disease in patients with multiple risk factors and elevated C-reactive protein.",
        con: "Pregnancy, active liver disease, breastfeeding, and severe renal impairment (CrCl < 30 mL/min).",
        aec: "Myalgia, headache, asthenia (weakness), nausea, abdominal pain, and constipation.",
        aes: "Rhabdomyolysis (highest risk at 40mg dose or in patients of Asian descent), proteinuria (usually transient and not indicative of progressive renal disease), and immune-mediated necrotizing myopathy.",
        inter: [
            {d: "Antacids (Al/Mg)", m: "Reduced absorption; separate administration by at least 2 hours.", s: "med"},
            {d: "Cyclosporine", m: "Extreme increase in rosuvastatin plasma levels (7-fold increase); avoid combination.", s: "critical"},
            {d: "Warfarin", m: "Increased INR and bleeding risk; monitor PT/INR closely upon initiation or dose change.", s: "high"}
        ],
        dosage: "Adult: 5 mg to 40 mg once daily. Asian patients should start at 5 mg due to significantly increased bioavailability in this population. Maximum 40mg dose avoided in many populations.",
        admin: "Can be administered at any time of day, with or without food. Swallow tablets whole. Maintain a consistent daily schedule.",
        nurse: "Check renal function (CrCl) baseline. Monitor for dark urine and unexplained muscle pain. Perform baseline LFTs and monitor if liver injury signs occur."
    },
    {
        g: "Lovastatin", b: "Mevacor, Altoprev", c: "Statin (HMG-CoA Reductase Inhibitor)", cat: "cv",
        m: "A lactone prodrug that is hydrolyzed in the liver to its active beta-hydroxyacid form. It competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This results in an increase in LDL receptor expression, enhancing the catabolism of LDL and VLDL remnants.",
        ind: "Primary hypercholesterolemia (Type IIa and IIb), slowing progression of coronary atherosclerosis in patients with CAD.",
        con: "Pregnancy (Category X), breastfeeding, active hepatic disease, unexplained persistent elevations of serum transaminases.",
        aec: "GI upset (cramping, diarrhea, flatulence), myalgia, dizziness, headache, skin rash, and pruritus.",
        aes: "Rhabdomyolysis with acute renal failure, severe transaminitis, blurred vision, and cataracts (rare).",
        inter: [
            {d: "Strong CYP3A4 Inhibitors", m: "Extreme increase in statin levels and Rhabdomyolysis risk.", s: "critical"},
            {d: "Amiodarone", m: "Increases risk of myopathy; do not exceed 20mg lovastatin daily.", s: "high"},
            {d: "Gemfibrozil", m: "Avoid combination; extreme risk of skeletal muscle breakdown.", s: "critical"}
        ],
        dosage: "Immediate-release: 20 mg to 80 mg/day (single or divided). Extended-release: 20 mg to 60 mg/day.",
        admin: "Immediate-release MUST be administered WITH THE EVENING MEAL to increase absorption. Extended-release (Altoprev) should be taken at bedtime.",
        nurse: "Monitor LFTs at baseline and periodically. Advise patient to report any unexplained muscle pain. Baseline and periodic eye exams recommended by some manufacturers."
    },
    {
        g: "Pravastatin", b: "Pravachol", c: "Statin (HMG-CoA Reductase Inhibitor)", cat: "cv",
        m: "Hydrophilic HMG-CoA reductase inhibitor. Unlike lipophilic statins (simvastatin/lovastatin), it does not easily cross the blood-brain barrier and is not significantly metabolized by the CYP450 system (specifically CYP3A4). This leads to a much lower potential for drug-drug interactions, as it is cleared primarily through renal and biliary excretion.",
        ind: "Hyperlipidemia, secondary prevention of MI and stroke, primary prevention in patients with high cholesterol and clinical CAD risk.",
        con: "Active liver disease, pregnancy, breastfeeding, hypersensitivity.",
        aec: "Rash, myalgia, fatigue, GI distress (nausea/vomiting), headache, dizziness.",
        aes: "Myopathy, hepatotoxicity (incidence is statistically lower than lipophilic statins).",
        inter: [{d: "Bile Acid Resins", m: "Reduced absorption; take pravastatin 1h before or 4h after resin.", s: "med"}],
        dosage: "Adult: 10 mg to 80 mg once daily. Adjust dose in significant renal or hepatic impairment.",
        admin: "Administer once daily, usually at bedtime. Can be taken without regard to food. Maintain a consistent daily schedule.",
        nurse: "Excellent choice for patients on complex drug regimens (HIV, transplant) due to lack of CYP3A4 metabolism. Monitor lipid panels for efficacy."
    },
    {
        g: "Fluvastatin", b: "Lescol, Lescol XL", c: "Statin (HMG-CoA Reductase Inhibitor)", cat: "cv",
        m: "Inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL clearance. It is the first fully synthetic statin and is metabolized primarily by the CYP2C9 isoenzyme.",
        ind: "Hyperlipidemia, secondary prevention of CAD progression following PTCA.",
        con: "Liver disease, pregnancy, breastfeeding.",
        aec: "Myalgia, dyspepsia, headache, insomnia, abdominal pain.",
        aes: "Hepatotoxicity, rhabdomyolysis, hypersensitivity reactions.",
        inter: [{d: "Fluconazole", m: "Inhibits CYP2C9; increases fluvastatin levels and toxicity.", s: "med"}],
        dosage: "Oral: 20 mg to 80 mg daily. 80 mg dose is administered as XL (Extended Release).",
        admin: "Immediate release: Take in the evening. Extended-release (XL): Take at any time of day with or without food. Maintain consistent schedule.",
        nurse: "Obtain baseline LFTs and lipid profile. Monitor ALT/AST if clinical signs of liver injury occur (jaundice, dark urine). Instruct patient to take the regular formulation in the evening to match hepatic cholesterol synthesis cycles. Educate patient to report any new, unexplained muscle pain, tenderness, or weakness immediately, especially if accompanied by malaise or fever. Monitor for signs of insomnia or cognitive change."
    }
];

</script>
    <script>
/* SOURCE: data_lipids_resins.js */
const data_lipids_resins = [
    {
        g: "Ezetimibe", b: "Zetia", c: "Cholesterol Absorption Inhibitor", cat: "cv",
        m: "Selectively inhibits the absorption of cholesterol and related phytosterols in the small intestine. Specifically targets the Niemann-Pick C1-Like 1 (NPC1L1) protein transporter on the brush border of enterocytes. This reduces the delivery of intestinal cholesterol to the liver, leading to a depletion of hepatic cholesterol stores and a compensatory increase in LDL receptor expression on hepatocytes, which decreases serum LDL-C.",
        ind: "Primary hyperlipidemia (as monotherapy or adjunct to statins), homozygous sitosterolemia, and homozygous familial hypercholesterolemia.",
        con: "Moderate to severe hepatic impairment, pregnancy or breastfeeding (when combined with statins), and known hypersensitivity.",
        aec: "Fatigue, diarrhea, abdominal pain, arthralgia (joint pain), and sinusitis or upper respiratory tract infection.",
        aes: "Cholelithiasis (gallstones - risk increases if used with fibrates), severe myopathy/rhabdomyolysis (rare), and angioedema.",
        inter: [
            {d: "Bile Acid Resins", m: "Decreased absorption of ezetimibe; separate administration by at least 2-4 hours.", s: "med"},
            {d: "Fibrates", m: "Significant increase in risk of gallstones; monitor for RUQ pain.", s: "high"},
            {d: "Cyclosporine", m: "Increases drug levels of both agents; monitor closely.", s: "med"}
        ],
        dosage: "Oral: 10 mg once daily. No dosage adjustment needed for elderly or mild renal impairment.",
        admin: "Take once daily without regard to food. Can be co-administered with statins (except for combination tablets with different rules).",
        nurse: "Monitor LFTs at baseline when used with statins. Monitor for cholecystitis symptoms (intolerance to fatty foods, RUQ pain)."
    },
    {
        g: "Cholestyramine", b: "Questran, Prevalite", c: "Bile Acid Sequestrant (Resin)", cat: "cv",
        m: "A non-absorbable anion-exchange resin that binds with bile acids in the intestine to form an insoluble complex that is excreted in the feces. This prevents the enterohepatic reabsorption of bile acids, forcing the liver to convert more internal cholesterol into new bile acids, which dramatically lowers serum LDL levels.",
        ind: "Primary hypercholesterolemia, pruritus associated with partial biliary obstruction, and off-label for certain types of diarrhea (bile acid malabsorption).",
        con: "Complete biliary obstruction (where bile cannot reach the gut), hypersensitivity, and history of bowel obstruction.",
        aec: "Severe constipation (most common), bloating, flatulence, nausea, and abdominal distention.",
        aes: "Vitamin A, D, E, K deficiency (due to impaired fat-soluble vitamin absorption), fecal impaction, metabolic acidosis (rare), and hyperchloremia.",
        inter: [{d: "All Oral Meds", m: "Resin binds almost all oral drugs in gut; take others 1h before or 4-6h after resin.", s: "critical"}],
        dosage: "Oral: 4 g to 24 g daily, typically divided into two to four doses. Powder packets are 4 g each.",
        admin: "MUST be mixed with 2-6 oz of fluid (water, juice, soup, or milk). Do not take in dry powder form (serious aspiration/choking risk). Sips of water during day to aid digestion.",
        nurse: "Monitor for severe constipation; provide stool softeners as needed. Monitor PT/INR if on warfarin (increased risk of bleeding due to Vitamin K loss). Increase fluid and fiber intake."
    },
    {
        g: "Colesevelam", b: "Welchol", c: "Bile Acid Sequestrant", cat: "cv",
        m: "Non-absorbable polymer that binds bile acids in the intestine. Also improves glycemic control by increasing GLP-1 secretion and affecting hepatic glucose production (mechanism not fully understood). Better tolerated than older resins.",
        ind: "Primary hyperlipidemia (Type IIa), Type 2 Diabetes Mellitus glycemic control (adjunct to diet and exercise).",
        con: "Bowel obstruction, serum TG > 500 mg/dL, and history of triglyceride-induced pancreatitis.",
        aec: "Constipation, dyspepsia, nausea, abdominal pain, and pharyngitis.",
        aes: "Bowel obstruction, severe hypertriglyceridemia flare, Vitamin K deficiency (less common than cholestyramine).",
        inter: [{d: "Narrow-Index Drugs", m: "Potential for reduced absorption; separate administration by 4h.", s: "med"}],
        dosage: "Oral: 3.75 g daily (as 6 tablets once daily or 3 tablets BID, or 1 powder packet).",
        admin: "Take with meals and a full glass of liquid. Swallow tablets whole; do not crush or chew. Take powder as an oral suspension.",
        nurse: "Preferred resin due to improved GI tolerance and fewer drug-drug interactions. Monitor TG levels baseline and periodically."
    },
    {
        g: "Colestipol", b: "Colestid", c: "Bile Acid Sequestrant", cat: "cv",
        m: "Binds bile acids in the gut to prevent reabsorption into the enterohepatic circulation. Leads to increased hepatic conversion of cholesterol to bile acids and upregulation of LDL receptors.",
        ind: "Primary hypercholesterolemia.",
        con: "Biliary obstruction, hypersensitivity.",
        aec: "Constipation, flatulence, bloating, nausea, and headache.",
        aes: "Fecal impaction, esophageal obstruction (if granules are taken without adequate fluid).",
        inter: [{d: "All Oral Meds", m: "May bind other drugs; separate administration by 1h before or 4h after.", s: "high"}],
        dosage: "Tablets: 2 g to 16 g daily. Granules: 5 g to 30 g daily in single or divided doses.",
        admin: "Granules must be mixed with at least 90 mL of liquid (water, juice) or soft food (yogurt/applesauce). Do not take dry.",
        nurse: "Monitor bowel frequency and consistency; provide stool softeners as needed to prevent fecal impaction. Encourage the patient to increase daily fluid and dietary fiber intake to mitigate severe constipation. Instruct the patient to take other medications at least 1 hour before or 4-6 hours after colestipol to prevent binding and decreased absorption. Assess for signs of Vitamin A, D, E, or K deficiency with long-term use."
    }
];

</script>
    <script>
/* SOURCE: data_lipids_fibrates_misc.js */
const data_lipids_fibrates_misc = [
    {
        g: "Gemfibrozil", b: "Lopid", c: "Fibric Acid Derivative (Fibrate)", cat: "cv",
        m: "Activates the peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which increases the expression of lipoprotein lipase and reduces the expression of apolipoprotein C-III (an inhibitor of lipoprotein lipase). This process dramatically enhances the lipolysis and elimination of triglyceride-rich particles from the plasma and reduces hepatic uptake of free fatty acids, thereby decreasing VLDL production. It also increases the synthesis of apolipoproteins A-I and A-II, leading to a significant rise in HDL-C levels. It is highly effective at lowering VLDL and increasing HDL.",
        ind: "Treatment of severe hypertriglyceridemia (Type IV or V hyperlipidemia) in patients at risk for pancreatitis, and reduction of coronary heart disease risk in Type IIb patients with low HDL and elevated LDL/TGs who have failed diet/exercise.",
        con: "Gallbladder disease (increased biliary cholesterol excretion), primary biliary cirrhosis, severe renal dysfunction (CrCl < 30 mL/min), and severe hepatic impairment.",
        aec: "Dyspepsia (heartburn), abdominal pain, diarrhea, nausea, fatigue, and mild decrease in hemoglobin/hematocrit.",
        aes: "Cholelithiasis (gallstones - major risk due to increased biliary cholesterol), severe myopathy and Rhabdomyolysis (especially if mixed with statins), hepatotoxicity (elevated ALT/AST), and acute renal failure.",
        inter: [
            {d: "Statins (All)", m: "Extreme risk of severe myopathy and Rhabdomyolysis; combination generally contraindicated.", s: "critical"},
            {d: "Warfarin", m: "Displaces warfarin from protein-binding sites; extreme bleeding risk and INR elevation.", s: "high"},
            {d: "Repaglinide", m: "CONTRAINDICATED; inhibits metabolism via CYP2C8 leading to severe prolonged hypoglycemia.", s: "critical"}
        ],
        dosage: "Oral: 600 mg twice daily. Total 1200 mg/day.",
        admin: "Administer orally 30 minutes BEFORE the morning and evening meals. Taking with food may reduce GI upset but can also alter absorption efficiency. Swallow tablets whole.",
        nurse: "Monitor LFTs, CBC (risk of anemia), and serum lipids baseline and periodically. Assess for signs of gallstones (RUQ pain, nausea after fatty meals). Ensure patient is not taking statins concurrently. Instruct patient to report any unexplained muscle pain."
    },
    {
        g: "Fenofibrate", b: "Tricor, Lipofen, Antara", c: "Fibric Acid Derivative (Fibrate)", cat: "cv",
        m: "Activates PPAR-alpha to increase TG catabolism and decrease hepatic TG production. More potent TG reduction and safer profile with statins compared to gemfibrozil, though risk remains elevated. Reduces VLDL and increases HDL by upregulating Apo A-I/A-II. It works by increasing the activity of lipoprotein lipase, which breaks down triglycerides in the blood.",
        ind: "Hypertriglyceridemia, mixed dyslipidemia, and primary hypercholesterolemia as an adjunct to diet.",
        con: "Severe renal disease (CrCl < 30), active liver disease, gallbladder disease, and nursing mothers.",
        aec: "Dyspepsia, nasopharyngitis, liver enzyme elevation, muscle pain, headache, and abdominal pain.",
        aes: "Gallstones (cholelithiasis), myopathy, pancreatitis, and pulmonary embolism (rarely reported).",
        inter: [
            {d: "Warfarin", m: "Increases bleeding risk and potentiates anticoagulant effect; monitor INR closely.", s: "high"},
            {d: "Bile Acid Resins", m: "Inhibit absorption of fenofibrate; separate administration by at least 2-4 hours.", s: "med"}
        ],
        dosage: "Oral: 48 mg to 145 mg once daily. Dosage depends on specific brand and micronized formulation.",
        admin: "Take once daily. Formulations like Lipofen MUST be taken with food to ensure absorption; Tricor can be taken without regard to food. Maintain consistent schedule.",
        nurse: "Monitor creatinine and LFTs baseline and periodically. Evaluate patient for myopathy symptoms (pain/weakness). Monitor for RUQ pain or jaundice."
    },
    {
        g: "Alirocumab", b: "Praluent", c: "PCSK9 Inhibitor (Monoclonal Antibody)", cat: "cv",
        m: "A fully human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting PCSK9, it prevents the degradation of LDL receptors on the surface of hepatocytes. This keeps more LDL receptors active and available to clear LDL-C from the blood, resulting in dramatic and rapid LDL reduction (often >50% beyond statin therapy).",
        ind: "Refractory high LDL cholesterol in adults with clinical atherosclerotic CV disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) requiring additional lowering.",
        con: "History of prior serious hypersensitivity to alirocumab or any of its components.",
        aec: "Injection site reactions (redness, pain, itching), flu-like symptoms (cough, sore throat), and myalgia.",
        aes: "Serious allergic reactions (rash, urticaria), vasculitis, and neurocognitive effects (rare/unconfirmed).",
        inter: [],
        dosage: "Subcutaneous: 75 mg to 150 mg every 2 weeks. Can be administered as 300 mg once every 4 weeks.",
        admin: "Subcutaneous injection in thigh, abdomen, or upper arm. Keep refrigerated. Allow to reach room temperature for 30-40 min before use. Do not shake.",
        nurse: "Teach self-injection technique. Monitor for signs of hypersensitivity. Verify that patient is also adherent to a high-intensity statin if tolerated. Monitor lipid panel at 4-8 weeks."
    },
    {
        g: "Evolocumab", b: "Repatha", c: "PCSK9 Inhibitor (Monoclonal Antibody)", cat: "cv",
        m: "Monoclonal antibody that inhibits the PCSK9 enzyme, thereby increasing the number of high-affinity LDL receptors on the liver surface. This results in enhanced uptake of LDL from the systemic circulation and significantly lowers serum LDL-C levels (often by 60% or more).",
        ind: "LDL reduction in patients with clinical CVD or familial hypercholesterolemia; prevention of myocardial infarction and stroke.",
        con: "Prior serious hypersensitivity reactions to the drug.",
        aec: "Nasopharyngitis, upper respiratory tract infection, back pain, and dizziness.",
        aes: "Injection site rash, angioedema, and serious systemic allergic reactions.",
        inter: [],
        dosage: "Subcutaneous: 140 mg every 2 weeks or 420 mg once monthly.",
        admin: "SC injection in abdomen, thigh, or arm. Rotate sites. Refrigerate and protect from light. Use within 30 days if removed from fridge.",
        nurse: "Refrigerate; do not shake. Assess for latex allergy (needle cap may contain dry natural rubber). Monitor lipid response at 4-8 weeks. Teach patient disposal of sharps."
    },
    {
        g: "Bempedoic acid", b: "Nexletol", c: "ACL Inhibitor", cat: "cv",
        m: "Inhibits adenosine triphosphate-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. It is a prodrug that is activated only in the liver by a specific enzyme (very long-chain acyl-CoA synthetase 1) not found in most peripheral tissues (muscle), which reduces muscle-related side effects common with statins.",
        ind: "Hyperlipidemia in adults who require additional LDL lowering; specifically indicated for statin-intolerant patients or HeFH.",
        con: "Prior serious hypersensitivity.",
        aec: "Muscle spasms, abdominal pain, anemia, and increased liver enzymes.",
        aes: "Hyperuricemia (Gout - can worsen pre-existing gout), Tendon rupture (specifically the Achilles, higher risk if >60y or using corticosteroids).",
        inter: [
            {d: "Simvastatin/Pravastatin", m: "Increases statin plasma levels; limit simvastatin to 20mg or pravastatin to 40mg.", s: "high"}
        ],
        dosage: "Oral: 180 mg once daily.",
        admin: "Take orally once daily with or without food. Maintain consistent schedule.",
        nurse: "Monitor uric acid levels. Advise patient to report any joint pain or tendon swelling immediately. Monitor LFTs baseline."
    },
    {
        g: "Niacin", b: "Niaspan (ER), Slo-Niacin, Nicobid", c: "Vitamin B3 / Antilipemic", cat: "cv",
        m: "Inhibits the release of free fatty acids from adipose tissue and reduces the hepatic production of VLDL and TG. It also reduces the catabolism of HDL, leading to a significant increase in HDL-C levels. In high doses, it also has direct vasodilatory effects on peripheral vessels.",
        ind: "Severe Hypertriglyceridemia, mixed dyslipidemia, and reduction of recurrent MI risk (secondary prevention). Often used when TG levels exceed 500 mg/dL.",
        con: "Active peptic ulcer disease, active liver disease, and arterial bleeding.",
        aec: "INTENSE FLUSHING and itching (histamine and prostaglandin release), dyspepsia, headache, and tingling of extremities.",
        aes: "Hepatotoxicity (elevated LFTs), hyperglycemia (significant caution in diabetics), hyperuricemia (gout flare), and hypotension.",
        inter: [
            {d: "Alcohol", m: "Increases risk of flushing and potentiates liver toxicity.", s: "high"},
            {d: "Bile Acid Resins", m: "Binds niacin; separate administration by at least 4-6 hours.", s: "med"}
        ],
        dosage: "Oral: 500 mg to 2000 mg once daily at bedtime. Start low (e.g., 500mg) and titrate slowly over weeks.",
        admin: "Take Aspirin 325mg (or NSAID) 30 min before dose to reduce flushing. Take with a low-fat snack at bedtime. Do not take with hot fluids or spicy foods.",
        nurse: "Monitor BP, blood glucose (especially in diabetics), and uric acid. Assess LFTs periodically. Educate patient that flushing is common and often subsides with time."
    },
    {
        g: "Omega-3", b: "Lovaza, Vascepa, Epanova", c: "Fish Oil / Antilipemic", cat: "cv",
        m: "Reduces hepatic triglyceride synthesis by inhibiting key enzymes (like diacylglycerol acyltransferase) and increases the clearance of TG from circulating VLDL particles. Provides high concentrations of EPA and DHA to stabilize myocardial membranes.",
        ind: "Severe Hypertriglyceridemia (TGs > 500 mg/dL) as an adjunct to diet. Vascepa is used specifically for CV risk reduction.",
        con: "Hypersensitivity to fish or shellfish.",
        aec: "GI upset, fishy eructation (burps), altered taste (dysgeusia), and dyspepsia.",
        aes: "Increased bleeding risk (prolongs bleeding time), AFib or Flutter (especially in patients with established CVD).",
        inter: [{d: "Anticoagulants/NSAIDs", m: "Increased hemorrhage risk via additive antiplatelet effects.", s: "high"}],
        dosage: "Oral: 2 g to 4 g daily (Vascepa: 2g twice daily).",
        admin: "Take with food to minimize fishy taste. Swallow capsules whole; do not break, crush, or chew.",
        nurse: "Monitor for bruising or bleeding. Check for fish/shellfish allergy history. Monitor EKG for new-onset AFib in high-risk patients. Monitor TG levels."
    }
];

</script>
    <script>
/* SOURCE: data_raas_ace.js */
const data_raas_ace = [
    {
        g: "Lisinopril", b: "Prinivil, Zestril", c: "ACE Inhibitor", cat: "cv",
        m: "Competitively inhibits the Angiotensin-Converting Enzyme (ACE), preventing the conversion of Angiotensin I to Angiotensin II, a potent vasoconstrictor. By blocking Angiotensin II, it also decreases the secretion of Aldosterone from the adrenal cortex, which promotes sodium and water excretion while retaining potassium. Furthermore, it increases levels of bradykinin, which promotes vasodilation but also triggers the characteristic dry, non-productive cough. This combined effect reduces peripheral vascular resistance (afterload) and reduces blood volume (preload).",
        ind: "Management of Hypertension (as monotherapy or in combination), Heart Failure with reduced ejection fraction (HFrEF) to reduce mortality, stabilization following acute Myocardial Infarction (to increase survival), and slowing the progression of Diabetic Nephropathy.",
        con: "Pregnancy (Black Box: fetal injury and death), history of angioedema (hereditary or induced by previous ACE-I therapy), bilateral renal artery stenosis, and concurrent use with aliskiren in patients with diabetes mellitus.",
        aec: "Persistent dry, hacking, non-productive cough (hallmark), dizziness, headache, fatigue, and orthostatic hypotension.",
        aes: "Angioedema (potentially fatal airway swelling involving face, lips, or tongue), Hyperkalemia (serum K+ > 5.0 mEq/L), first-dose hypotension (syncope risk), and acute renal failure (especially in renal artery stenosis).",
        inter: [
            {d: "Spironolactone", m: "Severe synergistic hyperkalemia risk; requires strict potassium monitoring.", s: "high"},
            {d: "NSAIDs", m: "Decreases antihypertensive effect and increases risk of acute kidney injury.", s: "med"},
            {d: "Lithium", m: "Inhibits renal clearance of lithium; significant risk of toxic lithium levels.", s: "high"}
        ],
        dosage: "Oral: Hypertension: 10 mg to 40 mg once daily. Heart Failure: 5 mg to 40 mg daily. Post-MI: 5 mg initially, then 5-10 mg daily.",
        admin: "Orally once daily at the same time each day. Monitor blood pressure for 2 to 6 hours after the first dose to detect orthostatic hypotension. Can be taken with or without food.",
        nurse: "Monitor serum Potassium and Creatinine levels strictly. Assess for signs of facial, lip, or tongue swelling (Emergency Intervention). Teach patient to avoid potassium-based salt substitutes. Notify provider if a persistent cough develops."
    },
    {
        g: "Captopril", b: "Capoten", c: "ACE Inhibitor", cat: "cv",
        m: "Competitively inhibits ACE, resulting in lower levels of Angiotensin II and Aldosterone. It was the first ACE-I developed; unlike newer agents, it has a short half-life and contains a sulfhydryl group that may contribute to certain unique side effects. It reduces systemic vascular resistance and blood volume by inhibiting the RAAS pathway and increasing vasodilatory bradykinin levels.",
        ind: "Hypertension, Heart Failure, Diabetic Nephropathy (especially Type 1), and left ventricular dysfunction following Myocardial Infarction to improve clinical outcomes.",
        con: "Pregnancy, history of ACE-I induced angioedema, and bilateral renal artery stenosis.",
        aec: "Metallic or salty taste disturbance (dysgeusia), dry cough, skin rash, and orthostatic hypotension.",
        aes: "NEUTROPENIA and Agranulocytosis (higher risk than other ACEIs; requires monitoring), proteinuria, and severe angioedema.",
        inter: [
            {d: "Food", m: "Decreases absorption by 30-40%; must be taken on an empty stomach.", s: "med"},
            {d: "Allopurinol", m: "Increased risk of hypersensitivity reactions and neutropenia.", s: "high"}
        ],
        dosage: "Oral: 25 mg to 150 mg daily, typically divided into two or three doses (BID or TID). Maximum dose 450 mg/day.",
        admin: "MUST be taken on an EMPTY STOMACH (1 hour before or 2 hours after meals) for maximum absorption. Swallow tablets whole.",
        nurse: "Monitor CBC with differential at baseline and every 2 weeks for the first 3 months of therapy (due to Neutropenia risk). Monitor renal function and serum potassium."
    },
    {
        g: "Enalapril", b: "Vasotec (Oral), Enalaprilat (IV)", c: "ACE Inhibitor", cat: "cv",
        m: "An oral prodrug that is hydrolyzed in the liver to its active metabolite, enalaprilat. It inhibits ACE to cause systemic vasodilation and decreased aldosterone-mediated fluid retention. By preventing the formation of Angiotensin II, it reduces the workload on the heart and decreases arterial pressure. It is unique as the only ACE inhibitor available in an intravenous formulation for acute management.",
        ind: "Hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction (to prevent the clinical development of heart failure).",
        con: "Pregnancy, history of angioedema, and hypersensitivity.",
        aec: "Dry cough, dizziness, headache, hypotension, and fatigue.",
        aes: "Angioedema, severe hyperkalemia, and acute renal failure, particularly in patients with renal artery stenosis.",
        inter: [{d: "Potassium Supplements", m: "Major risk of fatal hyperkalemia; monitor K+ levels strictly.", s: "critical"}],
        dosage: "Oral: 5 mg to 40 mg daily (single or divided). IV (Enalaprilat): 1.25 mg slow push over 5 minutes every 6 hours.",
        admin: "Available in Oral and IV forms. Enalaprilat is the ONLY ACE-I for IV use. When giving IV, ensure slow administration over 5 minutes and monitor BP continuously.",
        nurse: "Assess BP and renal labs. Monitor for first-dose hypotension, particularly in patients already receiving diuretic therapy or those with volume depletion."
    },
    {
        g: "Ramipril", b: "Altace", c: "ACE Inhibitor", cat: "cv",
        m: "Long-acting, highly lipophilic ACE inhibitor with high tissue penetration. It inhibits the conversion of Angio I to Angio II, reducing vasoconstriction and aldosterone release. It provides significant cardioprotection by improving endothelial function and preventing ventricular remodeling post-MI. It effectively reduces peripheral resistance without increasing heart rate.",
        ind: "Hypertension, heart failure following MI, and reduction in the risk of MI, stroke, or cardiovascular death in patients aged 55+ with established CVD or diabetes.",
        con: "Pregnancy (Black Box: Category D/X), history of angioedema, and hypersensitivity.",
        aec: "Dry cough, orthostatic hypotension, headache, and dizziness.",
        aes: "Hyperkalemia, angioedema, renal impairment, and syncope.",
        inter: [{d: "Diuretics", m: "Potentiates severe first-dose hypotension; monitor BP closely.", s: "med"}],
        dosage: "Oral: 2.5 mg to 10 mg once daily. Maximum dose 20 mg/day.",
        admin: "Take once or twice daily. For patients with dysphagia, capsules can be opened and the contents sprinkled on applesauce or mixed with water/juice.",
        nurse: "Monitor labs (K+, Cr) and BP. Instruct patient to report any facial swelling or difficulty breathing immediately. Assess for volume status."
    },
    {
        g: "Benazepril", b: "Lotensin", c: "ACE Inhibitor", cat: "cv",
        m: "Competitively inhibits the ACE enzyme, blocking the production of Angiotensin II. This leads to reduced vasoconstriction and a decrease in the secretion of aldosterone, resulting in lowered blood pressure and reduced sodium retention. It increases plasma renin activity and decreases aldosterone levels while potentially increasing bradykinin concentrations in the lung tissue.",
        ind: "Management of Hypertension, either as monotherapy or in combination with thiazide diuretics.",
        con: "Pregnancy, history of ACE-I induced angioedema.",
        aec: "Dry, persistent cough, headache, dizziness, and somnolence.",
        aes: "Angioedema, hyperkalemia, renal dysfunction, and symptomatic hypotension.",
        inter: [{d: "Diuretics", m: "Additive hypotensive effect; risk of excessive BP drop.", s: "med"}],
        dosage: "Oral: 10 mg to 40 mg once daily. Initial dose may be lower in patients on diuretics.",
        admin: "Administer orally once daily. Maintain consistent timing to ensure stable blood levels. Can be taken with or without food.",
        nurse: "Monitor blood pressure and serum potassium levels. Assess for signs of angioedema. Advise patient to use caution when rising from a seated position."
    },
    {
        g: "Fosinopril", b: "Monopril", c: "ACE Inhibitor", cat: "cv",
        m: "Inhibits ACE to prevent Angiotensin II formation. Fosinopril is unique because it is a phosphorus-containing ACE inhibitor that is cleared by both hepatic and renal routes (dual clearance). This compensatory clearance allows for safer use in patients with mild-to-moderate renal or hepatic impairment without significant dose adjustment.",
        ind: "Hypertension and Heart Failure (as adjunct to diuretics and digitalis).",
        con: "Pregnancy, history of angioedema.",
        aec: "Dry cough, dizziness, nausea, vomiting, and fatigue.",
        aes: "Angioedema, hypotension, hyperkalemia, and liver enzyme elevation.",
        inter: [{d: "Antacids", m: "Aluminum or magnesium antacids can reduce absorption; separate by 2 hours.", s: "med"}],
        dosage: "Oral: 10 mg to 40 mg once daily. Max dose 80 mg/day.",
        admin: "Once daily. Swallow tablets whole. Can be taken without regard to food.",
        nurse: "Preferred ACE-I for patients with mild renal impairment due to dual clearance. Monitor BP and electrolytes. Assess for hepatic dysfunction signs."
    }
];

</script>
    <script>
/* SOURCE: data_raas_arb_dri.js */
const data_raas_arb_dri = [
    {
        g: "Losartan", b: "Cozaar", c: "Angiotensin II Receptor Blocker (ARB)", cat: "cv",
        m: "Selectively and competitively blocks the binding of Angiotensin II to the AT1 receptor found in many tissues, including vascular smooth muscle and the adrenal gland. By preventing Angiotensin II from binding to its receptor, it blocks the potent vasoconstrictor and aldosterone-secreting effects of Angiotensin II. Unlike ACE inhibitors, ARBs do not inhibit the breakdown of bradykinin, which significantly reduces the incidence of the dry, persistent cough often associated with ACE-I therapy. This action results in a decrease in systemic vascular resistance and blood pressure.",
        ind: "Management of Hypertension (monotherapy or in combination), treatment of Diabetic Nephropathy in patients with Type 2 Diabetes and a history of hypertension (reduces the rate of progression of renal disease), and stroke prevention in patients with hypertension and left ventricular hypertrophy (LVH).",
        con: "Pregnancy (Black Box: fetal injury and death), known hypersensitivity to losartan, and concurrent use with aliskiren in patients with diabetes.",
        aec: "Dizziness, headache, fatigue, diarrhea, muscle cramps, and upper respiratory tract infection symptoms.",
        aes: "Hyperkalemia (less common than with ACEIs but still significant), renal impairment (acute kidney injury in susceptible patients), Angioedema (rare but life-threatening), and severe symptomatic hypotension.",
        inter: [
            {d: "NSAIDs/COX-2 Inhibitors", m: "Blunts the BP-lowering effect and significantly increases the risk of acute renal failure.", s: "high"},
            {d: "Fluconazole", m: "Increases plasma levels of the active metabolite of losartan by inhibiting its metabolism.", s: "med"},
            {d: "Potassium-Sparing Diuretics", m: "Additive risk of severe hyperkalemia; monitor serum K+ strictly.", s: "high"}
        ],
        dosage: "Oral: 25 mg to 100 mg daily, administered as a single dose or divided into two equal doses. Pediatric (6-16y): 0.7 mg/kg once daily up to 50 mg.",
        admin: "Administer orally once or twice daily. Can be taken with or without food. Maintain a consistent daily schedule to ensure stable plasma concentrations.",
        nurse: "Monitor blood pressure at baseline and periodically. Monitor renal function (Creatinine/eGFR) and serum potassium levels. Instruct female patients of childbearing age to use effective contraception and notify the provider immediately if pregnancy occurs."
    },
    {
        g: "Valsartan", b: "Diovan", c: "Angiotensin II Receptor Blocker (ARB)", cat: "cv",
        m: "Selectively and competitively blocks the binding of Angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland. This antagonizes the vasoconstrictor and aldosterone-secreting effects of Angiotensin II, leading to systemic vasodilation and increased sodium and water excretion. Valsartan has high affinity for the AT1 receptor (over 20,000 times greater than for the AT2 receptor). Like other ARBs, it does not interfere with bradykinin metabolism, making it a suitable alternative for patients who develop a cough on ACE inhibitors.",
        ind: "Hypertension (monotherapy or in combination), Heart Failure (NYHA Class II-IV) in patients who are intolerant of ACE inhibitors, and reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or dysfunction following a Myocardial Infarction.",
        con: "Pregnancy (Black Box: fetal toxicity), hypersensitivity to valsartan, and concurrent use with aliskiren in patients with diabetes.",
        aec: "Headache, dizziness, fatigue, abdominal pain, and viral infections.",
        aes: "Severe hypotension (especially in volume-depleted patients), Hyperkalemia, Renal failure (especially in patients with renal artery stenosis), and rare cases of hepatotoxicity.",
        inter: [
            {d: "Cyclosporine", m: "Increases the risk of renal toxicity and hyperkalemia; avoid or monitor closely.", s: "high"},
            {d: "Lithium", m: "Increases serum lithium concentrations; risk of lithium toxicity.", s: "high"},
            {d: "NSAIDs", m: "May reduce the antihypertensive effect and worsen renal function.", s: "med"}
        ],
        dosage: "Oral: Hypertension: 80 mg to 320 mg once daily. Heart Failure: 40 mg to 160 mg twice daily. Post-MI: 20 mg to 160 mg twice daily.",
        admin: "Orally once or twice daily depending on the indication. Can be taken with or without food. Titrate dose based on patient response and tolerance.",
        nurse: "Assess blood pressure and heart rate baseline and periodically. Monitor serum potassium and renal function labs. Assess for signs of fluid volume deficit (dehydration) before starting therapy."
    },
    {
        g: "Candesartan", b: "Atacand", c: "Angiotensin II Receptor Blocker (ARB)", cat: "cv",
        m: "A potent, long-acting, selective AT1 receptor blocker. It is administered as the prodrug candesartan cilexetil, which is completely converted to the active candesartan during absorption from the GI tract. It inhibits the vasoconstrictor and aldosterone-secreting effects of Angiotensin II by blocking the binding of Angiotensin II to the AT1 receptor in many tissues. It demonstrates a very slow dissociation from the AT1 receptor, providing a prolonged antihypertensive effect.",
        ind: "Management of Hypertension in adults and children (1 to <17 years), and treatment of Heart Failure (NYHA Class II-IV and LVEF <= 40%) to reduce CV death and HF hospitalization.",
        con: "Pregnancy (Black Box: Category D/X), hypersensitivity, and concurrent use with aliskiren in diabetics.",
        aec: "Dizziness, back pain, upper respiratory tract infection, pharyngitis, and rhinitis.",
        aes: "Hyperkalemia, renal impairment (elevated BUN/Creatinine), Angioedema (rare), and symptomatic hypotension.",
        inter: [
            {d: "Potassium Supplements", m: "Severe risk of life-threatening hyperkalemia; avoid or monitor strictly.", s: "high"},
            {d: "NSAIDs", m: "Increased risk of renal dysfunction and decreased antihypertensive efficacy.", s: "med"},
            {d: "Lithium", m: "May increase lithium levels and toxicity.", s: "high"}
        ],
        dosage: "Oral: Hypertension: 8 mg to 32 mg once daily (titrated). Heart Failure: 4 mg initially, titrating up to 32 mg once daily.",
        admin: "Administer orally once daily. Swallow tablets whole with a glass of water. Maintain consistent timing each day.",
        nurse: "Monitor serum potassium and renal function. Check blood pressure frequently during titration. Instruct patient to report any swelling of the face, lips, or tongue immediately."
    },
    {
        g: "Aliskiren", b: "Tekturna", c: "Direct Renin Inhibitor (DRI)", cat: "cv",
        m: "Binds directly to the active site of the renin enzyme, inhibiting the conversion of Angiotensinogen to Angiotensin I. This effectively inhibits the entire Renin-Angiotensin-Aldosterone System (RAAS) at its very source, the rate-limiting step. This leads to a decrease in plasma renin activity and a reduction in blood pressure through vasodilation and reduced sodium/water retention.",
        ind: "Management of Hypertension, either as monotherapy or in combination with other antihypertensive agents.",
        con: "Pregnancy (Black Box: fetal injury), concurrent use with ACE inhibitors or ARBs in patients with diabetes or renal impairment (eGFR < 60 mL/min).",
        aec: "Diarrhea (dose-related), cough (rare), headache, and abdominal pain.",
        aes: "ANGIOEDEMA (potentially involving the larynx and glottis), Hyperkalemia (especially if used with other RAAS suppressants), and severe hypotension.",
        inter: [
            {d: "High-Fat Meals", m: "Substantially decreases the absorption and bioavailability of the drug (by approx 70%).", s: "high"},
            {d: "Itraconazole/Ketoconazole", m: "Strong inhibitors of P-glycoprotein; significantly increases aliskiren plasma levels.", s: "high"},
            {d: "Cyclosporine", m: "Extreme increase in aliskiren concentration; combination is contraindicated.", s: "critical"}
        ],
        dosage: "Oral: 150 mg to 300 mg once daily.",
        admin: "Take once daily at the same time each day. IMPORTANT: Avoid taking with high-fat meals as this will drastically reduce absorption. Be consistent with regard to meals.",
        nurse: "Monitor for signs of angioedema (throat or face swelling, difficulty breathing). Monitor serum potassium levels closely, especially in high-risk patients (DM, renal impairment). Instruct patient to stop medication and contact provider immediately if pregnancy is suspected."
    }
];

</script>
    <script>
/* SOURCE: data_ccb.js */
const data_ccb = [
    {
        g: "Amlodipine", b: "Norvasc", c: "Calcium Channel Blocker (Dihydropyridine)", cat: "cv",
        m: "Selectively inhibits the transmembrane influx of calcium ions into vascular smooth muscle cells and cardiac muscle cells. It is significantly more selective for vascular smooth muscle than for myocardial tissue (approx. 80:1 ratio), leading to potent peripheral vasodilation and a reduction in systemic vascular resistance (afterload). This lowers blood pressure and decreases myocardial oxygen demand without significantly affecting heart rate, SA node, or AV conduction at therapeutic doses. It also increases blood flow to the heart muscle through coronary vasodilation and is effective in preventing coronary artery spasm.",
        ind: "Management of Hypertension (as monotherapy or in combination), Chronic Stable Angina Pectoris, and Vasospastic (Prinzmetal's or Variant) Angina.",
        con: "Known hypersensitivity to amlodipine or other dihydropyridines, severe hypotension (SBP < 90), and cardiogenic shock.",
        aec: "Common: Peripheral edema (dependent edema of ankles and feet - dose-related), flushing, headache, dizziness, and palpitations. Nausea and fatigue.",
        aes: "Severe symptomatic hypotension, worsening of angina or acute Myocardial Infarction (paradoxical response especially upon initiation or dose increase), and GINGIVAL HYPERPLASIA (rare but clinically significant gum overgrowth).",
        inter: [
            {d: "Simvastatin", m: "Inhibits simvastatin metabolism; increases risk of myopathy. Limit simvastatin dose to 20 mg daily.", s: "high"},
            {d: "CYP3A4 Inhibitors", m: "Increases amlodipine concentration and the subsequent risk of profound hypotension.", s: "med"}
        ],
        dosage: "Oral: 2.5 mg to 10 mg once daily. Maximum dose is 10 mg/day. Pediatric (6-17y): 2.5-5 mg once daily.",
        admin: "Administered orally once daily. Can be taken with or without food. Maintain consistent daily timing to ensure stable plasma levels. If a dose is missed for more than 12 hours, skip and take next scheduled dose; do not double.",
        nurse: "Check blood pressure before administration. Assess for peripheral edema (shoes may feel tight by the end of the day). Advise meticulous oral hygiene and regular dental visits to prevent gingival hyperplasia. Monitor for increased frequency of angina during start of therapy. Teach patient to report any swelling of the face or tongue (rare angioedema)."
    },
    {
        g: "Nifedipine", b: "Procardia, Adalat CC", c: "Calcium Channel Blocker (Dihydropyridine)", cat: "cv",
        m: "Inhibits the influx of calcium ions across the cell membrane of vascular smooth muscle. It produces potent coronary and peripheral vasodilation. Unlike non-dihydropyridines, it has minimal effect on the SA and AV nodes at clinical doses, making it useful for blood pressure control but often triggering a compensatory sympathetic (reflex) response. The rapid drop in blood pressure caused by immediate-release forms triggers reflex tachycardia and increases myocardial oxygen demand, which is why long-acting forms are preferred for hypertension.",
        ind: "Hypertension (Extended Release formulations ONLY), Chronic Stable Angina, and Vasospastic (Prinzmetal's) Angina. Off-label for Raynaud's and preterm labor.",
        con: "Hypersensitivity, ST-elevation MI (STEMI), and concurrent use of strong CYP3A4 inducers (e.g., Rifampin) which drastically reduce drug levels. Cardiogenic shock.",
        aec: "Common: Facial flushing, headache, dizziness, peripheral edema, nausea, and palpitations.",
        aes: "REFLEX TACHYCARDIA: Especially with immediate-release forms. Severe hypotension, heart failure exacerbation, and rare hepatotoxicity. Potential for profound syncope.",
        inter: [
            {d: "Grapefruit Juice", m: "Inhibits metabolism; significant increase in drug levels and risk of severe hypotensive crisis.", s: "critical"},
            {d: "Beta Blockers", m: "May be used to prevent reflex tachycardia but increases risk of symptomatic hypotension.", s: "med"}
        ],
        dosage: "Extended Release (ER/XL): 30 mg to 90 mg once daily. Immediate Release (IR): 10 mg to 20 mg TID. Max 120-180 mg/day depending on form.",
        admin: "Do NOT crush, chew, or break Extended Release (ER/CC/XL) tablets. The immediate-release capsule is NOT for hypertensive crisis (SL route) due to fatal BP drops and MI risk. Administer at consistent times.",
        nurse: "Monitor heart rate for reflex tachycardia. Ensure the patient is using the long-acting formulation for chronic HTN management. Monitor for pedal edema. Teach patient to swallow whole. Assess for signs of GI obstruction in patients with pre-existing severe narrowing of the GI tract (related to the ghost pill shell)."
    },
    {
        g: "Felodipine", b: "Plendil", c: "Calcium Channel Blocker (Dihydropyridine)", cat: "cv",
        m: "Highly vascular-selective calcium channel blocker that prevents the entry of calcium into smooth muscle cells. This results in significant peripheral vasodilation and a reduction in systemic vascular resistance (afterload) with minimal effects on the cardiac conduction system. It has a higher affinity for vascular smooth muscle than for cardiac muscle, making it a potent antihypertensive agent with minimal negative inotropic effects at therapeutic doses.",
        ind: "Management of Hypertension, often used as part of a combination regimen with other antihypertensive agents.",
        con: "Severe hypotension, cardiogenic shock, and known hypersensitivity to the drug or other dihydropyridines.",
        aec: "Common: Peripheral edema, headache, flushing, dizziness, and palpitations.",
        aes: "Severe symptomatic hypotension, syncope, and gingival hyperplasia. Rare cases of angioedema.",
        inter: [
            {d: "Grapefruit Juice", m: "Increases bioavailability significantly by inhibiting intestinal CYP3A4; risk of toxicity.", s: "high"},
            {d: "Anticonvulsants (Phenytoin)", m: "Decreases felodipine levels significantly.", s: "med"}
        ],
        dosage: "Oral: 2.5 mg to 10 mg once daily. Dosage is typically titrated at intervals of no less than 2 weeks based on clinical response.",
        admin: "Take once daily. Swallow extended-release tablets whole; do not crush or chew. Take consistently with or without food. Avoid high-fat meals which can increase the rate of absorption.",
        nurse: "Check BP before administration. Monitor for significant ankle swelling. Advise patient to use caution when rising from a lying or sitting position to prevent falls. Evaluate for gingival changes baseline and periodically."
    },
    {
        g: "Nicardipine", b: "Cardene, Cardene IV", c: "Calcium Channel Blocker (Dihydropyridine)", cat: "cv",
        m: "Inhibits calcium influx in smooth muscle. Highly selective for arterial vessels with little effect on the heart muscle. Potent coronary and systemic vasodilator. The IV form allows for rapid, precise titration of blood pressure in acute settings without significant negative inotropy. It increases coronary blood flow and decreases systemic vascular resistance, making it ideal for hypertensive emergencies involving target organ damage.",
        ind: "Management of Chronic Angina and Hypertension (Oral); Short-term treatment of hypertensive crisis or emergency (IV). Also used for post-operative BP control.",
        con: "Advanced aortic stenosis (risk of severe hypotension due to fixed cardiac output). Hypersensitivity.",
        aec: "Common: Flushing, headache, pedal edema, nausea, tachycardia (reflex), and dizziness.",
        aes: "Severe hypotension, paradoxical tachycardia, phlebitis at the IV site, and exacerbation of heart failure. Rare thrombocytopenia.",
        inter: [{d: "Cyclosporine", m: "Increases cyclosporine levels; monitor serum levels closely to prevent nephrotoxicity.", s: "med"}],
        dosage: "Oral: 20-40 mg three times daily (TID). IV: 5 mg/hr initially, titrating up to 15 mg/hr based on target BP goals.",
        admin: "Available in Oral and IV forms. Change peripheral IV sites every 12 hours to prevent irritation and phlebitis. Titrate IV slowly based on continuous blood pressure response. Do not stop IV infusion abruptly.",
        nurse: "Monitor IV site for redness or pain (drug is a potent irritant). Monitor BP continuously during infusion. Ensure large-bore IV access if possible. Monitor for signs of heart failure (crackles, dyspnea) if used in patients with LV dysfunction."
    },
    {
        g: "Verapamil", b: "Calan, Isoptin, Verelan", c: "Calcium Channel Blocker (Non-Dihydropyridine)", cat: "cv",
        m: "Inhibits calcium ion entry into myocardial cells and the specialized conduction system (SA and AV nodes). It exerts significant negative inotropic (force), negative chronotropic (rate), and negative dromotropic (conduction) effects. It also causes moderate peripheral vasodilation and significantly increases the refractory period of the AV node. This action suppresses supraventricular tachycardias and reduces the workload of the heart by decreasing the force of contraction and afterload.",
        ind: "Supraventricular Tachyarrhythmias (A-Fib/Flutter rate control, PSVT), Angina Pectoris (especially vasospastic), and Hypertension.",
        con: "Severe Heart Failure (HFrEF), 2nd or 3rd degree heart block, sick sinus syndrome (without pacemaker), and cardiogenic shock. Severe hypotension.",
        aec: "Common: CONSTIPATION (most common and severe side effect due to gut smooth muscle blockade), dizziness, nausea, headache, and peripheral edema.",
        aes: "SEVERE BRADYCARDIA, heart block, Heart Failure exacerbation (due to negative inotropy), and profound hypotension. Hepatotoxicity (rare).",
        inter: [
            {d: "Digoxin", m: "Increases digoxin plasma levels by 50-70%; extremely high risk of fatal digitalis toxicity.", s: "critical"},
            {d: "Beta Blockers", m: "Additive suppression of SA/AV node and contractility; significant risk of fatal HF and heart block.", s: "high"},
            {d: "Grapefruit Juice", m: "Significant increase in drug levels via CYP3A4 inhibition; avoid combination.", s: "high"}
        ],
        dosage: "Oral: 120 mg to 480 mg daily in divided doses (BID/TID) or SR once daily. IV: 5 mg to 10 mg given over 2 minutes.",
        admin: "Oral and IV routes. For constipation: Teach patient to increase dietary fiber and fluid intake significantly. For IV: Monitor EKG and BP continuously throughout administration. Give IV dose slowly over 2 minutes (3 mins in elderly).",
        nurse: "Check APICAL PULSE before administration (HOLD and notify provider if HR < 60 bpm). Assess for signs of HF (crackles, peripheral edema, SOB). Monitor EKG for PR interval prolongation. Evaluate bowel habits daily. Teach patient to avoid grapefruit juice."
    },
    {
        g: "Diltiazem", b: "Cardizem, Tiazac, Dilacor", c: "Calcium Channel Blocker (Non-Dihydropyridine)", cat: "cv",
        m: "Inhibits calcium ion influx during depolarization of cardiac and vascular smooth muscle cells. It significantly slows AV node conduction and prolongs the nodal refractory period. It exhibits less negative inotropic effect than verapamil but is a more potent coronary and peripheral vasodilator. This results in a decreased ventricular rate in atrial arrhythmias and a reduction in myocardial oxygen demand. It effectively dilates both main coronary and collateral arteries.",
        ind: "Rate control in Atrial Fibrillation and Atrial Flutter, conversion of PSVT to sinus rhythm, management of chronic stable Angina, and treatment of Hypertension.",
        con: "Acute Myocardial Infarction with pulmonary congestion, 2nd or 3rd degree heart block, sick sinus syndrome, and severe hypotension.",
        aec: "Common: Peripheral edema, headache, dizziness, nausea, and skin rash. Fatigue and weakness.",
        aes: "Severe Bradycardia, AV block, Heart Failure exacerbation, and rare clinical hepatotoxicity. Acute generalized exanthematous pustulosis (AGEP).",
        inter: [
            {d: "Beta Blockers", m: "Increased risk of severe bradycardia and AV conduction delay; use with caution.", s: "high"},
            {d: "Statins (CYP3A4)", m: "Inhibits metabolism; increases risk of statin-induced myopathy and toxicity.", s: "med"}
        ],
        dosage: "Oral: 120 mg to 360 mg daily (divided or CD/XR/LA). IV: 0.25 mg/kg bolus over 2 min, then 5-15 mg/hr continuous infusion.",
        admin: "Oral and IV routes. Do NOT crush or chew CD/LA/XR/XT formulations. Continuous EKG and BP monitoring are mandatory for IV drip administration. IV bolus dose should be followed by a titration drip for AFib management.",
        nurse: "Monitor heart rate and rhythm via EKG continuously. Assess for peripheral edema and signs of heart failure (weight gain, dyspnea). Monitor LFTs baseline and periodically. Teach patient to report any new rash or skin eruption immediately."
    }
];

</script>
    <script>
/* SOURCE: data_beta_blockers.js */
const data_beta_blockers = [
    {
        g: "Metoprolol", b: "Lopressor (Tartrate), Toprol XL (Succinate)", c: "Beta-1 Selective Adrenergic Blocker", cat: "cv",
        m: "Selectively blocks Beta-1 adrenergic receptors primarily located in the heart tissue. At therapeutic doses, it has little to no effect on the Beta-2 receptors in the lungs or liver. This blockade reduces heart rate (negative chronotropy), reduces cardiac output, and decreases myocardial oxygen demand by lowering contractility (negative inotropy). It also inhibits the release of renin from the kidneys, further contributing to its long-term antihypertensive effect. High doses may lose selectivity and partially block Beta-2 receptors, which could potentially cause bronchoconstriction.",
        ind: "Management of Hypertension, Angina Pectoris, Heart Failure (NYHA Class II-III, once stabilized), and post-Myocardial Infarction to reduce long-term cardiovascular mortality and prevent ventricular remodeling.",
        con: "Sinus bradycardia (HR < 45 bpm), 2nd or 3rd degree heart block, cardiogenic shock, and overt (acute decompensated) heart failure. Known hypersensitivity to the drug or other beta-blockers.",
        aec: "Common: Fatigue, dizziness, depression, erectile dysfunction (impotence), nausea, diarrhea, and cold extremities.",
        aes: "SEVERE BRADYCARDIA, heart block, worsening acute heart failure, and masking the sympathetic signs of hypoglycemia (tachycardia). Abrupt withdrawal can cause rebound hypertension, angina, or MI.",
        inter: [
            {d: "Insulin / Oral Hypoglycemics", m: "Masks common sympathetic signs of low blood sugar (tachycardia, tremors); monitor BG strictly.", s: "high"},
            {d: "CCBs (Verapamil / Diltiazem)", m: "Additive suppression of SA/AV node and contractility; significant risk of severe HF and heart block.", s: "high"},
            {d: "Digoxin", m: "Additive slowing of AV node conduction; monitor for bradycardia.", s: "med"}
        ],
        dosage: "Oral: 25 mg to 200 mg daily. IV: 5 mg bolus q2min (up to 3 doses) during acute MI management. Succinate is once daily; Tartrate is BID.",
        admin: "Oral and IV routes. Tartrate (Lopressor) is immediate-release and MUST be taken WITH or immediately following food to increase bioavailability. Succinate (Toprol XL) is extended-release and can be taken without food. Do not crush XL.",
        nurse: "Check Apical Pulse and BP before administration; HOLD if HR < 60 or SBP < 90. Do NOT stop medication abruptly (risk of rebound HTN, Angina, or MI). Monitor BG closely in diabetics as it masks hypoglycemia. Assess for signs of worsening heart failure including crackles and peripheral edema."
    },
    {
        g: "Atenolol", b: "Tenormin", c: "Beta-1 Selective Adrenergic Blocker", cat: "cv",
        m: "Competitively blocks Beta-1 receptors in heart muscle, reducing heart rate and myocardial contractility. It is significantly more hydrophilic than metoprolol or propranolol, resulting in extremely low lipid solubility. This minimizes penetration across the blood-brain barrier and potentially reduces the incidence of CNS side effects like vivid dreams, nightmares, and insomnia. It is not metabolized by the liver and is excreted almost entirely unchanged by the kidneys, providing a predictable action profile.",
        ind: "Management of Hypertension, Chronic Stable Angina Pectoris, and secondary prevention of MI to reduce cardiovascular mortality. Also used off-label for alcohol withdrawal.",
        con: "Sinus bradycardia, 2nd or 3rd degree heart block, cardiogenic shock, and uncompensated heart failure. Hypersensitivity.",
        aec: "Common: Fatigue, cold extremities (due to reduced peripheral blood flow), dizziness, GI upset, and hypotension.",
        aes: "Severe symptomatic bradycardia, AV node block, and bronchospasm (at high doses where B1 selectivity is lost). Rebound tachycardia upon sudden cessation.",
        inter: [
            {d: "NSAIDs", m: "May decrease the antihypertensive effect of atenolol via prostaglandin inhibition.", s: "med"},
            {d: "Calcium Channel Blockers", m: "Additive effect on slowing the heart rate.", s: "high"}
        ],
        dosage: "Oral: 25 mg to 100 mg once daily. IV: 5 mg slow injection over 5 minutes for acute management of arrhythmias.",
        admin: "Oral and IV routes. Dose adjustment is essential in patients with significant renal impairment (CrCl < 35 mL/min) as the drug is not metabolized. Take at the same time each day.",
        nurse: "Check apical pulse and BP before every dose. Monitor renal function (BUN/Creatinine). Instruct patient to rise slowly from a sitting position to avoid orthostatic hypotension. Educate the patient not to skip doses. Monitor for signs of respiratory distress if the patient has a history of mild asthma."
    },
    {
        g: "Propranolol", b: "Inderal, Hemangeol, Innopran XL", c: "Non-Selective Beta-Adrenergic Blocker", cat: "cv",
        m: "Competitively and non-selectively blocks both Beta-1 (heart) and Beta-2 (lungs, liver, peripheral vessels) adrenergic receptors. This results in decreased heart rate, reduced myocardial contractility, and lowered blood pressure. It also induces bronchoconstriction by blocking B2 receptors in the lungs and inhibits glycogenolysis in the liver, which can both precipitate hypoglycemia and mask its sympathetic symptoms. It is highly lipid-soluble and readily crosses the blood-brain barrier.",
        ind: "Hypertension, Angina Pectoris, cardiac dysrhythmias, Migraine prophylaxis, Essential Tremor, and off-label for Stage Fright or performance anxiety. Also used for pheochromocytoma.",
        con: "BRONCHIAL ASTHMA, COPD, Bradycardia, Heart Block > 1st degree, and uncompensated Heart Failure. Known hypersensitivity.",
        aec: "Common: Fatigue, dizziness, vivid dreams, insomnia (due to high lipid solubility), and cold extremities. Nausea and vomiting.",
        aes: "BRONCHOSPASM: Life-threatening in patients with respiratory disease. Severe bradycardia, agranulocytosis, and anaphylaxis. Hypoglycemia unawareness.",
        inter: [
            {d: "Albuterol (Beta-2 Agonists)", m: "Antagonizes and blocks the effect of the rescue inhaler (Beta-2 blockade); lethal combo in asthma.", s: "critical"},
            {d: "Insulin", m: "Prolongs hypoglycemia and masks compensatory tachycardia and tremors.", s: "high"}
        ],
        dosage: "Oral: 40 mg to 320 mg daily in divided doses. IV: 1 mg to 3 mg slow push (not to exceed 1 mg/min). Max 640 mg/day.",
        admin: "Oral and IV routes. Absolute contraindication in patients with reactive airway disease (Asthma/COPD). Assess respiratory status before every dose. For IV use, monitor EKG and BP continuously. Do not stop abruptly.",
        nurse: "Auscultate lung sounds baseline and periodically for wheezing. Check HR and BP. HOLD if wheezing or HR < 60 bpm. Teach patient that this drug may cause sleep disturbances. Monitor blood glucose closely in diabetic patients. Advise patient to carry a medical ID card."
    },
    {
        g: "Nadolol", b: "Corgard", c: "Non-selective Beta Blocker", cat: "cv",
        m: "Competitively blocks both Beta-1 and Beta-2 receptors. Like atenolol, it is highly hydrophilic and has a very low lipid solubility, resulting in negligible CNS penetration. It is not metabolized by the liver and is excreted unchanged by the kidneys. It possesses a very long half-life (20-24 hours), which allows for once-daily dosing. It reduces cardiac output and decreases both systolic and diastolic blood pressure. It also reduces heart rate and myocardial contractility.",
        ind: "Management of Hypertension and long-term treatment of Angina Pectoris. Sometimes used for portal hypertension.",
        con: "Bronchial asthma, overt heart failure, cardiogenic shock, 2nd/3rd degree heart block, and severe bradycardia.",
        aec: "Common: Fatigue, dizziness, bradycardia, cold extremities, and gastrointestinal upset.",
        aes: "Bronchospasm, severe bradycardia, and progression of renal impairment. Rebound symptoms if stopped suddenly.",
        inter: [{d: "NSAIDs", m: "Decreases antihypertensive efficacy.", s: "med"}],
        dosage: "Oral: 40 mg to 240 mg once daily. Adjust based on renal function.",
        admin: "Take once daily without regard to food. Dosage reduction is mandatory in patients with renal failure based on creatinine clearance (CrCl). Swallow tablets whole.",
        nurse: "Auscultate lung sounds baseline and periodically for wheezing (Beta-2 blockade). Check heart rate and blood pressure before administration; HOLD if HR < 60 bpm. Monitor BUN and Creatinine as the drug is renally excreted. Educate patient that this medication is long-acting and must be taken exactly as prescribed to maintain stable levels."
    },
    {
        g: "Carvedilol", b: "Coreg, Coreg CR", c: "Alpha/Beta-Adrenergic Blocker", cat: "cv",
        m: "A non-selective beta blocker (B1, B2) that also possesses Alpha-1 receptor blocking activity. This results in peripheral vasodilation (via alpha blockade) and heart rate/contractility reduction (via beta blockade). It also possesses antioxidant properties and prevents the growth of vascular smooth muscle. This combined mechanism reduces the workload on the heart more effectively than pure beta blockers, particularly in heart failure, by decreasing afterload and preventing cardiac remodeling.",
        ind: "Heart Failure (HFrEF), Hypertension, and Left ventricular dysfunction following a Myocardial Infarction to increase survival rates.",
        con: "Severe chronic heart failure (decompensated), asthma, severe hepatic impairment, 2nd/3rd degree heart block, and severe bradycardia.",
        aec: "Common: Dizziness, fatigue, weight gain, diarrhea, and hyperglycemia. Postural hypotension.",
        aes: "Severe bradycardia, postural hypotension (syncope), worsening HF (if initiated too aggressively), and Stevens-Johnson syndrome (rare). Hypoglycemia masking.",
        inter: [
            {d: "Digoxin", m: "Increases digoxin plasma levels by 15%; monitor for toxicity.", s: "med"},
            {d: "Insulin", m: "Increases risk of hypoglycemia and masks symptoms.", s: "high"}
        ],
        dosage: "Oral: 3.125 mg to 50 mg twice daily. Extended release (CR): 10 mg to 80 mg once daily.",
        admin: "Oral only. MUST TAKE WITH FOOD to slow the rate of absorption and minimize the risk of severe orthostatic hypotension. Taper slowly over 1-2 weeks when discontinuing.",
        nurse: "Monitor blood pressure and heart rate. Weigh patient daily and report a weight gain of > 2 lb in 24 hours or 5 lb in a week (signs of worsening heart failure). Assess for signs of fluid overload including new crackles or peripheral edema. Inform diabetic patients that carvedilol may increase blood glucose levels and mask symptoms of hypoglycemia."
    },
    {
        g: "Labetalol", b: "Trandate", c: "Alpha/Beta-Adrenergic Blocker", cat: "cv",
        m: "Competitively blocks alpha-1, beta-1, and beta-2 receptors. By blocking alpha-1 receptors, it reduces blood pressure by decreasing peripheral vascular resistance. By blocking beta receptors, it protects the heart from reflex tachycardia that typically occurs with pure vasodilators. This balanced action makes it highly effective for rapid blood pressure control without significantly reducing cardiac output in most patients.",
        ind: "Hypertensive Crisis/Emergency (IV), and chronic Hypertension (Oral). Also used for blood pressure control in pregnancy (preeclampsia).",
        con: "Asthma, overt heart failure, cardiogenic shock, severe bradycardia, and heart block greater than 1st degree.",
        aec: "Common: Dizziness, nausea, scalp tingling (unique sensation during initiation), and orthostatic hypotension.",
        aes: "Severe bradycardia, drug-induced hepatotoxicity, and bronchospasm. Risk of syncope with initial IV doses.",
        inter: [{d: "Beta Agonists", m: "Mutual antagonism of effects.", s: "high"}],
        dosage: "Oral: 100 mg to 400 mg twice daily. IV: 20 mg slow bolus over 2 min; may repeat 40-80 mg q10min up to 300 mg total.",
        admin: "Oral and IV routes. Keep patient SUPINE during and for at least 3 hours after IV administration to prevent syncope and serious orthostatic drops. Monitor BP continuously during IV push.",
        nurse: "Monitor blood pressure and heart rate every 5 minutes during IV bolus administration. Perform baseline and periodic LFTs. Teach patient to rise very slowly from a sitting or lying position. Advise patient that a transient 'scalp tingling' sensation is a common and harmless side effect of initiation. Monitor for wheezing."
    }
];

</script>
    <script>
/* SOURCE: data_adrenergics.js */
const data_adrenergics = [
    {
        g: "Prazosin", b: "Minipress", c: "Alpha-1 Adrenergic Blocker", cat: "cv",
        m: "Selectively and competitively inhibits postsynaptic alpha-1 adrenergic receptors in the smooth muscle of blood vessels. This action inhibits the vasoconstrictor effect of circulating catecholamines (norepinephrine), leading to significant peripheral vasodilation of both arterioles and veins. The result is a decrease in total peripheral resistance and a profound reduction in systemic blood pressure. Unlike non-selective alpha-blockers, prazosin typically does not cause significant reflex tachycardia because it does not block presynaptic alpha-2 receptors. It also helps relax smooth muscle in the bladder neck and prostate, though it is used primarily for hypertension.",
        ind: "Management of Hypertension (often as an adjunct to other antihypertensives) and off-label treatment of PTSD-related nightmares and sleep disturbances (due to CNS alpha-1 blockade).",
        con: "Known hypersensitivity to prazosin or other quinazolines (terazosin, doxazosin). Use with extreme caution in patients with preexisting cataracts or undergoing cataract surgery (Floppy Iris Syndrome risk).",
        aec: "Common: Dizziness, drowsiness, headache, lack of energy (asthenia), nausea, and palpitations. Nasal congestion and dry mouth may occur.",
        aes: "FIRST-DOSE SYNCOPE: Severe orthostatic hypotension causing sudden loss of consciousness, typically within 30-90 minutes of the initial dose. Priapism (rare medical emergency) and significant fluid retention (edema).",
        inter: [
            {d: "PDE-5 Inhibitors (Viagra)", m: "Additive vasodilatory effects; extreme risk of severe, symptomatic hypotension.", s: "high"},
            {d: "Beta Blockers", m: "Increases risk of severe first-dose postural hypotension and syncope.", s: "high"},
            {d: "NSAIDs", m: "May decrease the antihypertensive effect by promoting sodium and water retention.", s: "med"}
        ],
        dosage: "Oral: Initial dose 1 mg two or three times daily. Maintenance: 6 mg to 15 mg daily in divided doses. Maximum dose is 20 mg/day.",
        admin: "Administer orally. The VERY FIRST DOSE (and the first dose of any significant dose increase) should be taken at BEDTIME to minimize the risk of injury from first-dose syncope. Maintain consistent hydration.",
        nurse: "Monitor blood pressure for 2-6 hours after the first dose. Teach patient to rise very slowly from a sitting or lying position (orthostatic safety). Advise avoiding hazardous activities for 24 hours after the first dose or dose increases. Monitor for peripheral edema and weight gain. Instruct patient to report any painful, prolonged erection immediately."
    },
    {
        g: "Terazosin", b: "Hytrin", c: "Alpha-1 Adrenergic Blocker", cat: "cv",
        m: "Competitively inhibits postsynaptic alpha-1 adrenergic receptors, resulting in potent vasodilation of both veins and arterioles. This reduces peripheral vascular resistance and lowers systemic blood pressure. It also selectively relaxes smooth muscle in the bladder neck and prostate capsule, improving urine flow and reducing the symptoms of BPH. It has a longer duration of action than prazosin, allowing for once-daily dosing. It does not significantly affect heart rate in the steady state, though reflex tachycardia can occur during initial titration.",
        ind: "Management of Hypertension (monotherapy or in combination) and symptomatic treatment of Benign Prostatic Hyperplasia (BPH).",
        con: "Hypersensitivity to terazosin or other alpha-1 blockers. Use with caution in patients with hepatic impairment or those undergoing cataract surgery.",
        aec: "Common: Dizziness, asthenia (weakness), nasal congestion, peripheral edema, somnolence, and nausea.",
        aes: "Postural hypotension, first-dose syncope (loss of consciousness), and rare thrombocytopenia. Intraoperative Floppy Iris Syndrome (IFIS) during eye surgery. Risk of priapism.",
        inter: [{d: "Antihypertensives", m: "Additive hypotensive effects; increased risk of dizziness and falls.", s: "med"}],
        dosage: "Oral: Initial 1 mg at bedtime. Maintenance for HTN: 1 mg to 5 mg daily. Maintenance for BPH: up to 10 mg once daily. Max 20 mg/day.",
        admin: "Administer orally once daily at BEDTIME. If therapy is interrupted for several days, the patient must restart at the 1 mg initial dose to prevent syncope. Swallow tablets whole.",
        nurse: "Assess blood pressure periodically, specifically checking for orthostatic drops. Monitor for fluid retention and weight gain. Evaluate urinary symptoms if used for BPH (flow, urgency, frequency). Teach the patient the 'First-Dose at Bedtime' rule and orthostatic safety precautions. Advise the patient to notify their ophthalmologist of terazosin use before any eye procedures."
    },
    {
        g: "Doxazosin", b: "Cardura, Cardura XL", c: "Alpha-1 Adrenergic Blocker", cat: "cv",
        m: "Selectively inhibits postsynaptic alpha-1 adrenergic receptors. By blocking these receptors, it causes peripheral vasodilation of both arterioles and veins, which decreases total peripheral resistance and lowers blood pressure. It has a long half-life (approx. 22 hours), allowing for consistent 24-hour blood pressure control with once-daily dosing. It also relaxes smooth muscle in the prostate and bladder neck, making it highly effective for male patients with concurrent BPH. It may also have a modest beneficial effect on lipid profiles by slightly lowering LDL and total cholesterol.",
        ind: "Management of Hypertension (often as part of a combination) and treatment of Benign Prostatic Hyperplasia (BPH).",
        con: "Hypersensitivity to doxazosin or other quinazolines. Use with caution in patients with hepatic impairment. Use with caution in patients with pre-existing severe gastrointestinal narrowing (for XL form).",
        aec: "Common: Dizziness, headache, fatigue, edema, somnolence, and nausea. Accidental injury related to dizziness.",
        aes: "FIRST-DOSE SYNCOPE, severe postural hypotension, and Intraoperative Floppy Iris Syndrome (IFIS). Potential for rare hepatotoxicity and blood dyscrasias.",
        inter: [{d: "PDE-5 Inhibitors", m: "Significantly increases risk of severe symptomatic hypotension; monitor BP closely.", s: "high"}],
        dosage: "Oral: 1 mg to 16 mg once daily. XL formulation: 4 mg to 8 mg once daily. Max dose for HTN is 16 mg/day.",
        admin: "Take once daily. The XL (Extended Release) tablets MUST be swallowed whole and taken WITH BREAKFAST. Do not crush, chew, or break the XL tablets. The immediate-release form is usually taken at bedtime.",
        nurse: "Monitor BP closely after the first dose and any dose increase. Teach patient that the empty shell of the XL tablet may be visible in the stool (this is normal). Teach orthostatic safety (dangling legs at bedside). Monitor weight and for signs of edema. Advise the patient to avoid hazardous tasks until the effects of the medication are known."
    },
    {
        g: "Clonidine", b: "Catapres, Catapres-TTS, Kapvay", c: "Alpha-2 Adrenergic Agonist (Centrally Acting)", cat: "cv",
        m: "Stimulates alpha-2 adrenergic receptors in the brainstem (specifically the vasomotor center). This results in a potent decrease in sympathetic outflow from the central nervous system to the heart, kidneys, and peripheral vasculature. This leads to a reduction in peripheral vascular resistance, heart rate, and both systolic and diastolic blood pressure. It also reduces plasma renin activity. The Kapvay (extended-release) form acts on receptors in the prefrontal cortex to improve symptoms of ADHD.",
        ind: "Management of Hypertension (usually as an add-on therapy), ADHD (Kapvay), and off-label for opioid withdrawal, nicotine dependence, migraine prophylaxis, and severe pain management (epidural).",
        con: "Known hypersensitivity; anticoagulant therapy (for transdermal patch due to skin irritation). Use with extreme caution in patients with severe coronary insufficiency, recent MI, or chronic renal failure.",
        aec: "Common: Xerostomia (DRY MOUTH - occurs in up to 40%), sedation, dizziness, constipation, and impotence. Fatigue and headache.",
        aes: "REBOUND HYPERTENSION: Severe, rapid, and potentially fatal rise in BP (along with nervousness and tremors) if the drug is stopped abruptly. Bradycardia, AV block, and vivid dreams or hallucinations (rare).",
        inter: [
            {d: "CNS Depressants / Alcohol", m: "Additive sedation and respiratory depression; high risk of injury.", s: "high"},
            {d: "Tricyclic Antidepressants", m: "May decrease the antihypertensive effect of clonidine; monitor BP.", s: "med"},
            {d: "Beta Blockers", m: "May potentiate bradycardia and worsen rebound hypertension upon withdrawal.", s: "high"}
        ],
        dosage: "Oral: 0.1 mg to 0.3 mg twice daily (BID). Patch (TTS): 0.1 mg to 0.3 mg/24hr (one patch applied every 7 days).",
        admin: "Oral: Take the larger portion of the daily dose at BEDTIME to minimize daytime sedation. Patch: Apply to a hairless, intact area of the upper outer arm or chest; rotate sites and change every 7 days. Taper drug over 2-4 days when discontinuing to avoid rebound HTN.",
        nurse: "Monitor for severe rebound HTN (nervousness, agitation, headache, tachycardia) if a dose is missed. Check skin under the patch for irritation or allergic dermatitis. Advise frequent sips of water or sugarless gum for dry mouth. Instruct patient NOT to discontinue the drug abruptly. Monitor BP and HR periodically. Assess for signs of depression."
    },
    {
        g: "Methyldopa", b: "Aldomet (still used clinically)", c: "Alpha-2 Adrenergic Agonist (Centrally Acting)", cat: "cv",
        m: "A prodrug that is converted to the active metabolite alpha-methylnorepinephrine in the central nervous system. This metabolite stimulates central alpha-2 receptors, which reduces sympathetic outflow from the brainstem to the heart and blood vessels. This leads to a decrease in arterial pressure and peripheral resistance without a significant reduction in heart rate or cardiac output. It is unique among antihypertensives for its long established safety profile in pregnancy and its lack of effect on renal blood flow.",
        ind: "Management of Hypertension, specifically recognized as the DRUG OF CHOICE for Hypertension in Pregnancy (Preeclampsia and Gestational Hypertension).",
        con: "Active hepatic disease (acute hepatitis or active cirrhosis), hypersensitivity to the drug or its components, and concurrent use of Monoamine Oxidase (MAO) inhibitors.",
        aec: "Common: Sedation (most common side effect, usually transient), dry mouth, headache, and nasal congestion. Gastrointestinal upset and dizziness.",
        aes: "HEPATOTOXICITY: Potentially severe and life-threatening liver injury. HEMOLYTIC ANEMIA (associated with a positive Coombs test), drug-induced fever, and discolored urine (darkens on exposure to air). Rare lupus-like syndrome.",
        inter: [
            {d: "Iron Supplements", m: "Significantly decreases methyldopa absorption; separate administration by at least 2 hours.", s: "med"},
            {d: "Lithium", m: "Increases risk of lithium toxicity by reducing renal clearance of the drug.", s: "high"}
        ],
        dosage: "Oral: 250 mg to 500 mg two to three times daily. Maximum 3g/day. IV: 250 mg to 500 mg every 6 hours (Max 1g q6h).",
        admin: "Available in Oral and IV (as methyldopate HCl) forms. Infuse IV doses slowly over 30 to 60 minutes. Maintain consistent dosing to keep steady-state levels and avoid fluctuations in blood pressure.",
        nurse: "Monitor Liver Function Tests (LFTs) baseline and periodically (especially during the first 6-12 weeks). Check CBC for signs of hemolytic anemia (decreased Hgb/Hct). Educate the patient that urine may darken upon standing (harmless oxidation). Instruct the patient to report any unexplained fever or yellowing of the eyes/skin. Monitor BP baseline and throughout therapy."
    },
    {
        g: "Guanfacine", b: "Tenex, Intuniv", c: "Alpha-2 Adrenergic Agonist (Centrally Acting)", cat: "cv",
        m: "Selectively stimulates alpha-2A adrenergic receptors in the prefrontal cortex and brainstem. This action reduces sympathetic outflow from the vasomotor center, lowering heart rate and peripheral resistance. In the prefrontal cortex, it helps regulate signaling to improve attention, impulsivity, and emotional regulation. It is more selective for the alpha-2A subtype than clonidine, which may result in a lower incidence of certain side effects like sedation.",
        ind: "Management of Hypertension (Tenex) and treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy or adjunct (Intuniv).",
        con: "Known hypersensitivity to guanfacine. Use with caution in patients with severe coronary insufficiency, recent MI, or cerebrovascular disease.",
        aec: "Common: Somnolence (sleepiness), fatigue, headache, xerostomia (dry mouth), and abdominal pain. Irritability and dizziness.",
        aes: "Severe bradycardia, hypotension (especially orthostatic), and severe rebound hypertension upon abrupt discontinuation. Potential for syncope.",
        inter: [
            {d: "Valproic Acid", m: "May increase the serum concentration of valproic acid; monitor levels.", s: "med"},
            {d: "Strong CYP3A4 Inhibitors", m: "Significantly increases guanfacine levels; require dose adjustment.", s: "high"}
        ],
        dosage: "HTN: 1 mg to 3 mg daily at bedtime. ADHD: 1 mg to 4 mg once daily. Max 7 mg/day for ADHD.",
        admin: "Oral only. Take at bedtime to minimize daytime sedation. Intuniv (ER) MUST be swallowed whole and MUST NOT be taken with high-fat meals, as this increases drug absorption to potentially toxic levels. Taper slowly when stopping.",
        nurse: "Monitor blood pressure and heart rate baseline and periodically, as the drug can cause severe bradycardia. Do NOT crush, chew, or break extended-release (Intuniv) tablets. Educate the patient and caregivers to taper the dose slowly when discontinuing to avoid severe rebound hypertension. Instruct patient to avoid taking Intuniv with high-fat meals. Monitor for excessive somnolence during the first 2 weeks of therapy."
    }
];

</script>
    <script>
/* SOURCE: data_vasodilators.js */
const data_vasodilators = [
    {
        g: "Hydralazine", b: "Apresoline", c: "Direct-Acting Vasodilator", cat: "cv",
        m: "Exerts a direct relaxing effect on the vascular smooth muscle of the precapillary arterioles, likely by inhibiting calcium release from the sarcoplasmic reticulum. It has little to no effect on the venous system. By reducing peripheral resistance, it triggers a significant compensatory reflex sympathetic response, which increases heart rate, stroke volume, and cardiac output. It also increases plasma renin activity, leading to sodium and water retention. It reduces blood pressure but its efficacy is often limited by these compensatory mechanisms unless combined with other agents.",
        ind: "Management of Moderate to Severe Hypertension (usually as part of a multi-drug regimen) and treatment of chronic Heart Failure (when combined with isosorbide dinitrate, particularly in patients intolerant to ACEIs/ARBs).",
        con: "Coronary artery disease (due to the high risk of reflex tachycardia precipitating myocardial ischemia), mitral valvular rheumatic heart disease, and known hypersensitivity.",
        aec: "Common: Headache, palpitations (reflex tachycardia), nausea, diarrhea, dizziness, and anorexia. Flushing and nasal congestion may occur.",
        aes: "REFLEX TACHYCARDIA: Potentially leading to acute myocardial infarction. SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)-LIKE SYNDROME: Characterized by fever, joint pain, Butterfly rash, and nephritis; more common in slow acetylators. Peripheral neuropathy.",
        inter: [
            {d: "Beta Blockers", m: "Beneficial interaction; blocks the reflex tachycardia caused by hydralazine; essential combination.", s: "med"},
            {d: "NSAIDs", m: "Decreased antihypertensive effect due to renal prostaglandin inhibition.", s: "med"}
        ],
        dosage: "Oral: 10 mg to 50 mg four times daily. IV: 10 mg to 40 mg every 4 to 6 hours. Maximum 300 mg/day (Oral).",
        admin: "Available in Oral and IV forms. Often co-administered with a beta-blocker (to manage tachycardia) and a diuretic (to manage fluid retention). Administer at the same time each day to maintain stable control.",
        nurse: "Monitor heart rate and blood pressure frequently, especially during titration. Assess for signs of SLE syndrome (joint pain, butterfly rash on face, pleuritis). Monitor for peripheral edema and weight gain. Instruct patient to report any tingling or numbness in extremities (neuropathy)."
    },
    {
        g: "Minoxidil", b: "Loniten, Rogaine (Topical)", c: "Direct-Acting Vasodilator", cat: "cv",
        m: "A potent vasodilator that acts by opening ATP-sensitive potassium channels in arteriolar smooth muscle cells, causing hyperpolarization and profound relaxation. It is much more potent than hydralazine and has no significant effect on venous tone. It reduces peripheral vascular resistance dramatically, which leads to a massive compensatory increase in heart rate and substantial renal sodium and water retention. It is considered a last-line agent for resistant hypertension.",
        ind: "Management of severe or resistant Hypertension that is not responding to maximal doses of a diuretic and two other conventional antihypertensive agents.",
        con: "Pheochromocytoma (due to stimulation of catecholamine release) and acute Myocardial Infarction. Known hypersensitivity.",
        aec: "Common: Hypertriglyceridemia, nausea, vomiting, and headache. Dizziness and salt/water retention are very common.",
        aes: "HYPERTRICHOSIS: Excessive hair growth (face, arms, back) occurring in 80% of patients; reversible upon discontinuation. PERICARDIAL EFFUSION: Can lead to cardiac tamponade (Black Box warning). Severe reflex tachycardia.",
        inter: [],
        dosage: "Oral: 5 mg to 40 mg once daily. Max 100 mg/day for resistant hypertension. Topical used for alopecia.",
        admin: "Oral only for hypertension. Should almost ALWAYS be used concurrently with a loop diuretic (to manage severe fluid retention) and a beta-blocker (to manage extreme reflex tachycardia).",
        nurse: "Monitor weight daily and report gain > 2 lb in 24 hours. Assess for signs of pericardial effusion or cardiac tamponade (distended neck veins, muffled heart sounds, SOB). Perform baseline and periodic EKG. Warn the patient about the high likelihood of increased hair growth and reassure that it is reversible."
    },
    {
        g: "Diazoxide", b: "Hyperstat IV, Proglycem (Oral)", cat: "cv", c: "Direct-Acting Vasodilator / Glucose-Elevating Agent",
        m: "Acts directly on the smooth muscle of the peripheral arterioles to cause rapid and profound vasodilation. It also inhibits the release of insulin from the pancreatic beta cells by keeping ATP-sensitive potassium channels open, which is why the oral form is used for hypoglycemia. It does not affect veins. It causes a sharp decrease in BP which triggers marked reflex tachycardia and fluid retention.",
        ind: "IV: Emergency reduction of blood pressure in hypertensive crisis. Oral (Proglycem): Management of hypoglycemia caused by hyperinsulinism (e.g., islet cell tumor).",
        con: "Hypersensitivity to thiazides or sulfonamides; compensatory hypertension (e.g., coarctation of aorta).",
        aec: "Common: Nausea, vomiting, abdominal pain, and dizziness. Headache and palpitations.",
        aes: "SEVERE HYPERGLYCEMIA: Especially problematic in diabetic patients. Profound sodium and water retention, and ketoacidosis. Potential for cerebral or myocardial ischemia if BP drops too rapidly.",
        inter: [{d: "Warfarin", m: "Increases the anticoagulant effect; monitor INR strictly.", s: "med"}, {d: "Antihypertensives", m: "Additive hypotensive effects.", s: "high"}],
        dosage: "IV: 1 to 3 mg/kg (Max 150 mg) repeated every 5 to 15 minutes until BP is controlled. Oral: 3 to 8 mg/kg daily in divided doses.",
        admin: "IV form MUST be given as a RAPID BOLUS (under 30 seconds) into a large vein to ensure the drug reaches arteriolar sites before binding extensively to albumin. Maintain patient in a supine position during and for 1 hour after injection.",
        nurse: "Monitor blood glucose levels frequently (q1-2h) during IV therapy. Monitor for signs of fluid overload (edema, crackles). Keep patient supine after injection to prevent syncope. Monitor BP continuously during emergency IV administration."
    },
    {
        g: "Nitroprusside", b: "Nitropress, Nipride", c: "Direct-Acting Vasodilator", cat: "cv",
        m: "Immediately releases nitric oxide, which acts directly on BOTH venous and arterial smooth muscle to cause potent, immediate vasodilation. This results in a profound decrease in both preload and afterload. It is the most powerful and fastest-acting antihypertensive agent available, with an onset within seconds and an effect that disappears 1-10 minutes after stopping the infusion. It is metabolized to cyanide and then to thiocyanate.",
        ind: "Immediate reduction of blood pressure in Hypertensive Crisis (Emergency), and controlled hypotension during surgery to reduce surgical bleeding. Also used for acute heart failure to reduce afterload.",
        con: "Compensatory hypertension (e.g., AV shunt or coarctation of the aorta), and decreased cerebral perfusion. Known hypersensitivity.",
        aec: "Common: Nausea, sweating, restlessness, muscle twitching, and headache. These are often signs of too rapid a reduction in blood pressure.",
        aes: "CYANIDE TOXICITY: Characterized by metabolic acidosis, confusion, weakness, and almond-scented breath. Thiocyanate toxicity (presents as psychosis, delirium). Profound and lethal hypotension.",
        inter: [],
        dosage: "IV Infusion: 0.3 to 10 mcg/kg/min titration. Maximum infusion rate should not exceed 10 mcg/kg/min. Average maintenance dose is 3 mcg/kg/min.",
        admin: "IV ONLY via dedicated infusion pump. The IV bag and tubing MUST be protected from light (WRAP IN FOIL). The solution should be slightly brownish; discard if it is blue, green, or bright red (indicates decomposition). Monitor infusion site for extravasation.",
        nurse: "Monitor BP continuously (every 2-5 minutes) with an arterial line preferred. Stop infusion if BP drops too low. Monitor serum thiocyanate levels if infusion lasts > 48 hours. Assess for signs of cyanide poisoning (metabolic acidosis, CNS changes). Ensure antidote (sodium thiosulfate) is available."
    }
];

</script>
    <script>
/* SOURCE: data_diuretics_loop_thiazide.js */
const data_diuretics_loop_thiazide = [
    {
        g: "Furosemide", b: "Lasix", c: "Loop Diuretic", cat: "cv",
        m: "Potently inhibits the reabsorption of sodium and chloride in the thick ascending limb of the loop of Henle and the distal renal tubule. By blocking the Na+/K+/2Cl- symporter (the triple transporter), it prevents the kidney from concentrating urine, leading to profound excretion of water, sodium, chloride, magnesium, hydrogen, and calcium. It is the most common loop diuretic and is highly effective even in patients with significantly impaired renal function (low GFR). It also increases renal blood flow and venous capacitance, which helps acutely in pulmonary edema.",
        ind: "Edema associated with heart failure, hepatic cirrhosis, and renal disease (including nephrotic syndrome). Acute pulmonary edema (IV). Hypertension (as adjunct).",
        con: "Anuria, history of hypersensitivity to furosemide, and severe electrolyte depletion. Use with caution in patients with sulfonamide allergy (potential cross-reactivity, though clinical evidence suggests it is rare).",
        aec: "Common: Polyuria, dizziness, orthostatic hypotension, dehydration, headache, blurred vision, and muscle cramps.",
        aes: "OTOTOXICITY: Characterized by tinnitus and hearing loss (higher risk with rapid IV push or high doses). Severe: Hypokalemia (K+ < 3.5), hyponatremia, hyperuricemia (may trigger gout), and Stevens-Johnson Syndrome.",
        inter: [
            {d: "Digoxin", m: "Hypokalemia significantly increases risk of fatal digoxin-induced dysrhythmias.", s: "critical"},
            {d: "Lithium", m: "Decreased sodium clearance leads to toxic lithium accumulation and toxicity.", s: "high"},
            {d: "Aminoglycosides", m: "Additive risk of permanent ototoxicity and vestibular damage.", s: "high"}
        ],
        dosage: "Oral: 20 mg to 80 mg per dose. IV: 20 mg to 40 mg initially. Max 600 mg/day in extreme renal or heart failure cases.",
        admin: "Take orally in the MORNING to prevent nocturia and sleep interruption. If twice daily, take the second dose no later than 4:00 PM. IV Push: Administer NO FASTER than 20 mg/minute to minimize the risk of permanent ototoxicity and sudden hearing loss.",
        nurse: "Monitor serum Potassium levels and renal function (BUN/Cr) strictly. Weigh patient daily (report gain > 2lb/day or 5lb/week). Monitor blood pressure and intake/output. Encourage high-potassium foods (bananas, potatoes, orange juice). Assess for signs of dehydration including dry mucous membranes and poor skin turgor. Check for tinnitus baseline and periodically."
    },
    {
        g: "Bumetanide", b: "Bumex", c: "Loop Diuretic", cat: "cv",
        m: "Inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle. It is approximately 40 times more potent than furosemide on a milligram-per-milligram basis (1 mg Bumex = 40 mg Lasix). It has a faster onset and shorter duration of action than furosemide, making it exceptionally useful for rapid fluid mobilization. It is often preferred in patients with severe bowel wall edema (common in HF) where furosemide absorption becomes unpredictable and erratic.",
        ind: "Management of Edema associated with heart failure or renal disease, particularly in patients who have become resistant to high doses of furosemide or have severe GI absorption issues.",
        con: "Anuria, hepatic coma, severe electrolyte depletion, and known hypersensitivity.",
        aec: "Common: Muscle cramps, dizziness, headache, hypotension, and impaired hearing (transient). GI upset and nausea.",
        aes: "Profound diuresis leading to cardiovascular collapse, severe hypokalemia, and ototoxicity (though statistically demonstrated to have a lower incidence than furosemide). May cause hyperuricemia.",
        inter: [
            {d: "NSAIDs", m: "Blunts the diuretic response by inhibiting renal prostaglandins; potential for acute kidney injury.", s: "med"},
            {d: "Antihypertensives", m: "Additive hypotensive effects; risk of syncope.", s: "med"}
        ],
        dosage: "Oral: 0.5 mg to 2 mg daily. IV: 0.5 mg to 1 mg slow push. Doses are typically titrated every 4-5 hours.",
        admin: "Available in Oral and IV forms. Administer in the morning. For IV: can be given over 1-2 minutes. Monitor for rapid shifts in fluid status and electrolytes within the first hour of administration.",
        nurse: "Monitor weight daily. Monitor electrolytes (K+, Mg++, Ca++, Na+) strictly. Evaluate for signs of dehydration including skin turgor and mucous membranes. Maintain accurate intake and output records. Teach patient to report any ringing in the ears or changes in balance immediately."
    },
    {
        g: "Torsemide", b: "Demadex", c: "Loop Diuretic", cat: "cv",
        m: "Inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle. It has a longer duration of action (up to 12 hours) and significantly higher oral bioavailability (80%) than furosemide. It also demonstrates weak antialdosteronergic properties, which may mitigate excessive potassium loss compared to other loop diuretics. It reduces volume overload and preload, thereby decreasing the workload on the failing heart and lowering systemic blood pressure.",
        ind: "Management of Edema associated with congestive heart failure, chronic renal failure, or hepatic disease; and first-line management of Hypertension in selected populations.",
        con: "Anuria, history of hypersensitivity to torsemide or sulfonylureas (due to the presence of a sulfonamide structure).",
        aec: "Common: Excessive urination, headache, dizziness, constipation, and rhinitis (nasal congestion).",
        aes: "Severe Hypokalemia, profound dehydration causing orthostatic hypotension, tinnitus, and acute renal failure in volume-depleted patients. Potential for hyperuricemia.",
        inter: [
            {d: "Probenecid", m: "Decreases the diuretic effect by inhibiting tubular secretion of torsemide into the nephron.", s: "med"},
            {d: "NSAIDs", m: "Reduced diuretic and antihypertensive efficacy via prostaglandin inhibition.", s: "med"},
            {d: "Lithium", m: "Increased risk of toxic lithium accumulation due to reduced sodium clearance.", s: "high"}
        ],
        dosage: "Oral: HTN: 5 mg once daily. Edema: 10 mg to 20 mg daily. Max 200 mg/day for patients with chronic renal failure.",
        admin: "Take orally once daily in the morning to avoid sleep-disrupting nocturia. Can be administered with or without food. Maintain consistent daily timing. Do not double doses if one is missed.",
        nurse: "Monitor blood pressure and serum electrolytes baseline and periodically throughout therapy. Assess for signs of excessive volume depletion such as dizziness or tachycardia. Weigh patient daily and report gains > 2lb. Educate the patient on the importance of potassium-rich foods if appropriate."
    },
    {
        g: "Ethacrynic acid", b: "Edecrin", c: "Loop Diuretic", cat: "cv",
        m: "A potent loop diuretic that acts on the thick ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption. Uniquely, it is the ONLY loop diuretic that is NOT a sulfonamide derivative. It is chemically distinct (a phenoxyacetic acid derivative), making it the absolute drug of choice for patients with a documented, life-threatening sulfa allergy who require rapid fluid mobilization. It possesses a high ceiling of diuretic effect and can cause massive water and electrolyte loss.",
        ind: "Short-term management of severe edema when other agents fail; management of edema in patients with documented true sulfonamide hypersensitivity.",
        con: "Anuria, infants, nursing mothers, and severe watery diarrhea caused by the drug. Known hypersensitivity to ethacrynic acid.",
        aec: "Common: GI upset (nausea, vomiting), abdominal pain, and significant watery diarrhea. Dizziness and headache.",
        aes: "SEVERE OTOTOXICITY: Demonstrates the highest risk of permanent hearing loss among all loop diuretics. Profound electrolyte depletion (Hypokalemia, Hyponatremia), and metabolic alkalosis.",
        inter: [
            {d: "Aminoglycosides", m: "Significantly potentiates the risk of permanent deafness; absolute contraindication.", s: "critical"},
            {d: "Warfarin", m: "May displace warfarin from protein-binding sites; monitor INR closely for increases.", s: "med"}
        ],
        dosage: "Oral: 50 mg to 200 mg daily. IV: 50 mg (0.5 to 1 mg/kg) for acute settings.",
        admin: "Administer orally WITH MEALS to reduce the risk of severe GI distress. For IV: do NOT administer IM or SC as it causes severe tissue irritation and potential necrosis. Reconstitute following manufacturer guidelines.",
        nurse: "Monitor hearing and balance strictly (highest Ototoxicity risk). Monitor for severe watery diarrhea; if this occurs, the drug must be discontinued immediately. Check serum electrolytes daily during acute therapy. Assess for signs of metabolic alkalosis (confusion, tremors)."
    },
    {
        g: "Hydrochlorothiazide", b: "Microzide, Oretic", c: "Thiazide Diuretic", cat: "cv",
        m: "Inhibits sodium and chloride reabsorption in the distal convoluted tubule by blocking the Na+/Cl- symporter. This increases the delivery of sodium to the collecting ducts, promoting the excretion of sodium, chloride, potassium, and water. Thiazides uniquely increase renal calcium reabsorption (preventing hypercalciuria). They are less potent than loop diuretics and require a CrCl > 30 mL/min to be clinically effective for diuresis. They also cause peripheral vasodilation with long-term use.",
        ind: "First-line management of Hypertension (monotherapy or combination) and treatment of Edema associated with Heart Failure, cirrhosis, or chronic corticosteroid use.",
        con: "Renal failure (anuria), history of hypersensitivity to thiazides or sulfonamides. Severe hepatic impairment.",
        aec: "Common: Dizziness, headache, increased urination frequency, gastric irritation, and photophobia (sensitivity to light).",
        aes: "Hypokalemia, HYPERCALCEMIA (unique feature), hyponatremia, hyperglycemia (significant caution in diabetics), and potential for gout flares due to hyperuricemia. Blood dyscrasias (rare).",
        inter: [
            {d: "Digoxin", m: "Low potassium triggered by thiazide increases the risk of fatal digitalis-induced dysrhythmias.", s: "high"},
            {d: "Lithium", m: "Decreased renal clearance leads to toxic lithium accumulation; requires monitoring.", s: "high"},
            {d: "Antidiabetics", m: "Thiazides may antagonize the effect of insulin or oral hypoglycemics; check BG.", s: "med"}
        ],
        dosage: "Oral: 12.5 mg to 50 mg once daily. Maximum 100 mg/day (rarely provides additional BP benefit).",
        admin: "Take orally once daily in the morning. Avoid taking at bedtime to prevent sleep interruption from nocturia. Can be taken with food to minimize GI upset.",
        nurse: "Monitor BP and serum electrolytes (K+, Na+, Ca++). Advise patient to use sunscreen and protective clothing due to Photosensitivity. Monitor blood glucose in diabetic patients as HCTZ can raise levels. Teach patient to rise slowly to prevent falls from orthostasis."
    },
    {
        g: "Chlorothiazide", b: "Diuril", c: "Thiazide Diuretic", cat: "cv",
        m: "Inhibits the reabsorption of sodium and chloride in the distal convoluted tubule by blocking the Na+/Cl- symporter. This increases the delivery of sodium to the distal segments of the nephron, promoting the excretion of sodium, chloride, potassium, and water. Uniquely, it also promotes the renal reabsorption of calcium. It is the ONLY thiazide diuretic available in an intravenous formulation, making it critical for acute management of edema in patients who cannot tolerate oral medications.",
        ind: "Management of Hypertension (monotherapy or adjunct) and treatment of Edema associated with congestive heart failure, hepatic cirrhosis, or corticosteroid/estrogen therapy.",
        con: "Anuria, history of hypersensitivity to thiazides or sulfonamides, and severe renal impairment. Severe liver disease.",
        aec: "Common: Dizziness, headache, gastric irritation, photosensitivity, and orthostatic hypotension. Nausea.",
        aes: "Hypokalemia (K+ < 3.5), Hyponatremia, HYPERCALCEMIA, metabolic alkalosis, and potential for Stevens-Johnson Syndrome (SJS). Potential for cholestatic jaundice.",
        inter: [
            {d: "Digoxin", m: "Hypokalemia induced by thiazide increases the risk of digitalis toxicity; monitor HR.", s: "high"},
            {d: "Lithium", m: "Reduces lithium clearance; significant risk of toxic lithium levels and neurotoxicity.", s: "high"}
        ],
        dosage: "Oral: 500 mg to 1000 mg once or twice daily. IV: 500 mg twice daily. Maximum 2000 mg/day.",
        admin: "Available in Oral and IV forms. Take oral doses in the morning. For IV: Reconstitute with at least 18 mL of sterile water; do NOT administer IM or Subcutaneously due to severe tissue irritation. Ensure slow IV push. Solution must be clear.",
        nurse: "Monitor serum electrolytes (K+, Na+, Ca++). Monitor BP and daily weight baseline and periodically. Use caution in diabetic patients as it may cause hyperglycemia. Protect skin from sun exposure. Assess for signs of dehydration."
    },
    {
        g: "Chlorthalidone", b: "Thalitone, Hygroton", c: "Thiazide-like Diuretic", cat: "cv",
        m: "A monosulfonamyl diuretic that functions similarly to thiazides by inhibiting sodium and chloride reabsorption in the distal convoluted tubule. It has a significantly longer half-life (40-60 hours) than HCTZ, providing more consistent 24-hour blood pressure control and better reduction in cardiovascular events. It promotes the excretion of sodium, chloride, and water while decreasing the excretion of calcium. Recent clinical guidelines often prefer chlorthalidone over HCTZ for hypertension management due to its potency and duration.",
        ind: "Management of Hypertension and treatment of Edema associated with heart failure, hepatic cirrhosis, or renal dysfunction.",
        con: "Anuria and known hypersensitivity to chlorthalidone or sulfonamide-derived drugs. Severe renal impairment.",
        aec: "Common: Dizziness, fatigue, nausea, headache, and xerostomia (dry mouth). Gastrointestinal upset.",
        aes: "Severe Hypokalemia, Hyperuricemia (Gout flares), hypercalcemia, and orthostatic hypotension. Potential for necrotizing angiitis.",
        inter: [
            {d: "Antidiabetics", m: "May decrease the hypoglycemic effect; requires blood glucose monitoring.", s: "med"},
            {d: "NSAIDs", m: "Decreases the diuretic and antihypertensive efficacy via prostaglandin inhibition.", s: "med"}
        ],
        dosage: "Oral: 25 mg to 50 mg once daily. Doses above 50 mg increase the risk of hypokalemia without providing significant additional BP benefit.",
        admin: "Take orally once daily in the morning with food to minimize GI upset. Maintain consistent daily intake of fluids unless restricted. Swallow tablets whole.",
        nurse: "Monitor serum potassium and uric acid levels. Assess for signs of gout (swollen, painful big toe). Monitor BP baseline and periodically. Advise patient to report symptoms of hypokalemia (muscle weakness, palpitations, leg cramps)."
    },
    {
        g: "Indapamide", b: "Lozol", c: "Thiazide-like Diuretic", cat: "cv",
        m: "A long-acting sulfonamide diuretic that inhibits sodium reabsorption in the distal convoluted tubule. It also has direct vasodilatory properties on peripheral blood vessels, which may be related to its calcium channel blocking effect at higher doses. It is effective for blood pressure control without significantly affecting cardiac output or heart rate. It has a neutral effect on lipids and is often well-tolerated in diabetics.",
        ind: "Management of Hypertension and treatment of salt and fluid retention associated with congestive heart failure.",
        con: "Anuria and known hypersensitivity to sulfonamides. Severe hepatic impairment.",
        aec: "Common: Headache, dizziness, fatigue, muscle cramps, and nervousness. Nausea and vomiting.",
        aes: "Severe hypokalemia (especially in the elderly), hyponatremia, and potential for hepatotoxicity. Orthostatic hypotension.",
        inter: [{d: "Lithium", m: "Increased risk of lithium toxicity due to reduced renal clearance of the drug.", s: "high"}],
        dosage: "Oral: 1.25 mg to 5 mg once daily. Doses are typically titrated every 4 weeks based on BP response.",
        admin: "Administer orally once daily in the morning to prevent nocturia. Swallow tablets whole. Can be taken without regard to food.",
        nurse: "Monitor blood pressure and serum electrolytes (K+, Na+). Assess for signs of hepatic injury (jaundice, dark urine). Encourage adequate potassium intake through diet. Teach patient to report any unusual fatigue or weakness."
    }
];

</script>
    <script>
/* SOURCE: data_diuretics_ksparing_misc.js */
const data_diuretics_ksparing_misc = [
    {
        g: "Spironolactone", b: "Aldactone", c: "Potassium-Sparing Diuretic / Aldosterone Antagonist", cat: "cv",
        m: "Competitively antagonizes aldosterone receptors in the distal convoluted tubule and cortical collecting duct of the nephron. Aldosterone normally promotes sodium and water reabsorption while facilitating potassium and hydrogen ion excretion. By blocking these receptors, spironolactone inhibits the exchange of sodium for potassium, leading to the excretion of sodium chloride and water while retaining potassium and hydrogen. It is a relatively weak diuretic but provides significant cardiovascular survival benefits in heart failure by preventing myocardial fibrosis, ventricular remodeling, and the deleterious effects of hyperaldosteronism. It belongs to the steroid class of medications.",
        ind: "Management of symptomatic Heart Failure (HFrEF), Hypertension (specifically for resistant hypertension or as an adjunct), Primary Hyperaldosteronism (Conn's Syndrome), and Edema resulting from hepatic cirrhosis. Also used off-label for PCOS and acne.",
        con: "Hyperkalemia (serum K+ > 5.0 mEq/L), severe renal impairment (eGFR < 30 mL/min/1.73m), and Addison's disease (adrenal insufficiency).",
        aec: "Common: Breast tenderness (men and women), dizziness, headache, gastrointestinal upset (nausea, vomiting), and drowsiness.",
        aes: "HYPERKALEMIA: Can be fatal and occurs more frequently in patients with renal failure or those taking ACEIs/ARBs. GYNECOMASTIA: Enlargement of male breast tissue due to non-selective binding to androgen receptors. Other: Menstrual irregularities and impotence.",
        inter: [
            {d: "ACE Inhibitors / ARBs", m: "Significant risk of severe, life-threatening hyperkalemia; monitor potassium strictly.", s: "high"},
            {d: "Potassium Supplements", m: "Extreme risk of fatal hyperkalemia; absolute contraindication.", s: "critical"},
            {d: "NSAIDs", m: "Increases risk of hyperkalemia and decreases the diuretic efficacy by inhibiting renal blood flow.", s: "med"}
        ],
        dosage: "Oral: 25 mg to 100 mg daily for HF/HTN. Max 400 mg/day for primary hyperaldosteronism titration.",
        admin: "Administer orally once or twice daily. Take WITH FOOD to increase absorption and decrease gastric irritation. Monitor daily weights. Maintain consistent daily timing.",
        nurse: "Monitor serum Potassium and Creatinine levels baseline and frequently during titration (especially in the first 2 weeks). Teach patient to avoid salt substitutes containing potassium and high-potassium foods. Instruct male patients to report breast enlargement. Monitor BP baseline and periodically. Assess for signs of hyperkalemia including muscle weakness and cardiac dysrhythmias."
    },
    {
        g: "Eplerenone", b: "Inspra", c: "Potassium-Sparing Diuretic / Aldosterone Antagonist", cat: "cv",
        m: "Selectively blocks aldosterone binding at the mineralocorticoid receptor. Unlike spironolactone, it has high selectivity for this receptor and significantly lower affinity for androgen and progesterone receptors, resulting in a much lower incidence of endocrine side effects like gynecomastia or menstrual changes. It reduces blood pressure and protects the heart from the inflammatory and fibrotic effects of aldosterone. It helps decrease the workload on the left ventricle and improves survival in post-MI patients with heart failure.",
        ind: "Reduction of cardiovascular mortality post-MI with left ventricular dysfunction (EF < 40%); management of Hypertension as monotherapy or adjunct.",
        con: "Hyperkalemia (serum K+ > 5.5 mEq/L), severe renal impairment (CrCl < 30 mL/min), Type 2 DM with microalbuminuria, and concomitant use of potent CYP3A4 inhibitors (e.g., ketoconazole).",
        aec: "Common: Dizziness, fatigue, flu-like symptoms, diarrhea, and abdominal pain. Cough and headache.",
        aes: "Severe Hyperkalemia (which can lead to cardiac arrest), worsening renal dysfunction, and angioedema (rare).",
        inter: [
            {d: "CYP3A4 Inhibitors", m: "Increases eplerenone levels significantly; avoid strong inhibitors.", s: "high"},
            {d: "ACE-I / ARBs", m: "Additive risk of severe hyperkalemia.", s: "high"}
        ],
        dosage: "Oral: 25 mg to 50 mg once daily. Adjust dose based on serum potassium levels and renal function.",
        admin: "Take once daily with or without food. Maintain consistent daily timing. Do not use potassium-containing salt substitutes or supplements while on this therapy.",
        nurse: "Monitor serum potassium baseline and frequently (Day 3 and Week 1 after starting). Assess for signs of hyperkalemia such as muscle twitching, palpitations, and fatigue. Evaluate renal function (BUN/Cr) throughout the course of treatment. Instruct the patient to report any signs of hypersensitivity."
    },
    {
        g: "Amiloride", b: "Midamor", c: "Potassium-Sparing Diuretic", cat: "cv",
        m: "Inhibits sodium reabsorption in the distal convoluted tubule, cortical collecting tubule, and collecting duct by blocking the epithelial sodium channels (ENaC) on the luminal surface. This action promotes the loss of sodium and water while uniquely inhibiting the excretion of potassium, hydrogen, and magnesium ions. Unlike spironolactone, it is NOT an aldosterone antagonist; instead, it exerts a direct electrophysiological effect on the sodium channels of the nephron. It is a weak diuretic when used alone and is primarily used to mitigate the potassium-wasting effects of more potent diuretics.",
        ind: "Management of Hypertension or Edema associated with heart failure or hepatic cirrhosis, specifically used to counteract the potassium-wasting effects of loop or thiazide diuretics. Also used off-label for lithium-induced polyuria.",
        con: "Hyperkalemia (serum K+ > 5.5 mEq/L), severe renal impairment (CrCl < 30 mL/min), and concomitant use of other potassium-sparing agents.",
        aec: "Common: Nausea, diarrhea, abdominal pain, flatulence, headache, and dizziness.",
        aes: "SEVERE HYPERKALEMIA: Especially in diabetics and elderly patients. Potential for hyponatremia and metabolic acidosis (due to hydrogen ion retention).",
        inter: [
            {d: "ACE Inhibitors / ARBs", m: "Additive risk of severe, life-threatening hyperkalemia.", s: "high"},
            {d: "Potassium Supplements", m: "Extreme risk of fatal hyperkalemia; absolute contraindication.", s: "critical"}
        ],
        dosage: "Oral: 5 mg to 10 mg once daily. Maximum dose is 20 mg/day.",
        admin: "Take orally once daily. Administer WITH FOOD to reduce gastrointestinal distress and improve bioavailability. Avoid taking late in the day to prevent nocturia.",
        nurse: "Monitor serum potassium baseline and frequently throughout therapy. Assess renal function (BUN/Cr). Teach patient to avoid high-potassium foods and potassium-based salt substitutes. Monitor blood pressure. Assess for signs of metabolic acidosis such as confusion or deep, rapid breathing."
    },
    {
        g: "Triamterene", b: "Dyrenium", c: "Potassium-Sparing Diuretic", cat: "cv",
        m: "Exerts a direct inhibitory effect on the exchange of sodium for potassium and hydrogen in the distal tubule and collecting duct. Like amiloride, it blocks the ENaC sodium channels independently of aldosterone levels. This leads to increased sodium and water excretion while conserving potassium. It is often combined with HCTZ (Maxzide/Dyazide) to provide balanced diuretic therapy without significant potassium loss. It is a weak antihypertensive agent when used alone. It may also interfere with the enzyme dihydrofolate reductase at high doses.",
        ind: "Treatment of Edema associated with congestive heart failure, hepatic cirrhosis, and nephrotic syndrome. Often used as an adjunct to thiazide diuretics to prevent hypokalemia.",
        con: "Severe hepatic or renal disease, preexisting hyperkalemia, and history of kidney stones (nephrolithiasis). Known hypersensitivity.",
        aec: "Common: Nausea, vomiting, leg cramps, dizziness, and photosensitivity. May cause a harmless BLUISH DISCOLORATION of the urine.",
        aes: "Hyperkalemia, NEPHROLITHIASIS: Triamterene can be a direct component of kidney stones. Megaloblastic anemia (due to weak folic acid antagonism).",
        inter: [
            {d: "NSAIDs (Indomethacin)", m: "Can precipitate acute renal failure; use with extreme caution or avoid.", s: "high"},
            {d: "ACE Inhibitors", m: "Increases the risk of severe, life-threatening hyperkalemia.", s: "high"}
        ],
        dosage: "Oral: 100 mg twice daily. Maximum dose is 300 mg/day.",
        admin: "Take orally after meals to minimize gastrointestinal upset. Maintain adequate fluid intake (at least 2-3 L/day) to prevent the formation of kidney stones. Take at consistent times.",
        nurse: "Monitor for signs of hyperkalemia (muscle twitching, weakness). Assess for flank pain which may indicate kidney stones. Check CBC periodically for signs of anemia. Warn the patient about the harmless change in urine color to blue. Monitor renal function baseline and periodically."
    },
    {
        g: "Acetazolamide", b: "Diamox", c: "Carbonic Anhydrase Inhibitor", cat: "cv",
        m: "Inhibits the enzyme carbonic anhydrase in the proximal renal tubule. This leads to decreased reabsorption of sodium, potassium, and especially bicarbonate (HCO3-). This creates an alkaline diuresis and leads to a systemic metabolic acidosis. It also reduces the rate of aqueous humor production in the eye by inhibiting carbonic anhydrase in the ciliary body and reduces cerebrospinal fluid (CSF) production. It is a very weak diuretic for edema but useful for its other physiological effects.",
        ind: "Open-angle glaucoma (to reduce intraocular pressure), prevention or treatment of acute mountain sickness (altitude sickness), and treatment of metabolic alkalosis (by inducing bicarbonate loss). Adjunct for certain seizure types.",
        con: "Known hypersensitivity to sulfonamides, hypokalemia, hyponatremia, and severe renal or hepatic disease. Adrenal insufficiency.",
        aec: "Common: Paresthesia (tingling in extremities), fatigue, drowsiness, and altered taste (metallic taste). Nausea and vomiting.",
        aes: "METABOLIC ACIDOSIS, Stevens-Johnson Syndrome (SJS), and bone marrow suppression (rare but serious). Potential for renal calculi.",
        inter: [{d: "Salicylates (Aspirin)", m: "Increases risk of salicylate toxicity and severe metabolic acidosis.", s: "high"}, {d: "Lithium", m: "Increases lithium excretion; risk of decreased lithium levels.", s: "med"}],
        dosage: "Oral: 250 mg to 500 mg one to four times daily. Max 1000 mg/day. Sustained release (Sequels) given BID.",
        admin: "Available in Oral and IV forms. Sustained-release capsules (Sequels) must be swallowed whole; do not crush or chew. Can be taken with food to decrease GI distress.",
        nurse: "Monitor serum electrolytes and acid-base balance periodically. Monitor for skin rash (early sign of SJS). Advise cautious use in patients with COPD as acidosis can worsen respiratory status. Teach patient to report any tingling in fingers or toes."
    },
    {
        g: "Mannitol", b: "Osmitrol", c: "Osmotic Diuretic", cat: "cv",
        m: "A simple sugar that is filtered by the glomerulus but not reabsorbed by the renal tubules. It creates a high osmotic pressure in the tubular fluid, pulling water from the intracellular and interstitial spaces into the vascular system and then into the urine. This results in a rapid and profound increase in urine output. It also draws water out of the brain mass into the bloodstream and reduces intraocular fluid volume. It is not metabolized significantly and is excreted entirely by the kidneys.",
        ind: "Reduction of Intracranial Pressure (ICP) in cerebral edema; reduction of high Intraocular Pressure (IOP); and prevention of acute kidney injury (AKI) during major surgery or in the oliguric phase.",
        con: "Active intracranial bleeding (except during craniotomy), severe pulmonary edema, heart failure, and anuria due to severe renal disease.",
        aec: "Common: Thirst, dry mouth, headache, dizziness, and blurred vision. Nausea and vomiting.",
        aes: "FLUID OVERLOAD: Can lead to acute Pulmonary Edema and heart failure. Profound dehydration, hypernatremia (initially) followed by hyponatremia, and AKI from crystal deposition.",
        inter: [],
        dosage: "IV: 0.25 g/kg to 2 g/kg administered as a 15-25% solution over 30 to 60 minutes.",
        admin: "IV ONLY via a central or large-bore peripheral line. MUST be administered using a FILTERED needle and tubing because the drug easily crystallizes at room temperature. Inspect the bag for crystals before hanging; if present, warm the bag in a specialized warmer to re-dissolve.",
        nurse: "Monitor neuro status (level of consciousness, pupil reaction) and ICP/IOP closely. Monitor hourly urine output; notification required if < 30 mL/hr. Auscultate lungs baseline and hourly for crackles, as rapid fluid shifts can precipitate heart failure. Closely track serum osmolality and electrolytes (Na+, K+) to prevent severe imbalance. Ensure IV access is patent; drug is a potent tissue irritant."
    }
];

</script>
    <script>
/* SOURCE: data_angina_hf.js */
const data_angina_hf = [
    {
        g: "Digoxin", b: "Lanoxin", c: "Cardiac Glycoside / Antiarrhythmic", cat: "cv",
        m: "Inhibits the sodium-potassium ATPase pump in myocardial cells. This leads to an increase in intracellular sodium, which in turn facilitates an increase in intracellular calcium via the sodium-calcium exchanger. The results are three-fold: 1. Positive Inotropy (increased force of contraction) by making more calcium available for contractile proteins. 2. Negative Chronotropy (decreased heart rate) by increasing vagal tone and decreasing sympathetic activity. 3. Negative Dromotropy (slowed AV conduction). This enhances cardiac output while reducing the heart's workload and oxygen consumption.",
        ind: "Second-line treatment for chronic Heart Failure with reduced ejection fraction (HFrEF); rate control in chronic Atrial Fibrillation or Atrial Flutter.",
        con: "Ventricular fibrillation, ventricular tachycardia (unless caused by HF), 2nd or 3rd degree heart block (without pacemaker), and sick sinus syndrome. High risk in patients with significant renal impairment or electrolyte imbalances.",
        aec: "Anorexia, nausea, vomiting, fatigue, headache, and weakness. These are often the earliest signs of toxicity.",
        aes: "DIGOXIN TOXICITY: Characterized by life-threatening arrhythmias (PVCs, AV block), visual disturbances (blurred vision, yellow/green halos, 'sparkling' lights), and severe bradycardia.",
        inter: [
            {d: "Furosemide / Loop Diuretics", m: "Hypokalemia induced by the diuretic significantly increases the risk of fatal digoxin toxicity.", s: "critical"},
            {d: "Verapamil / Amiodarone", m: "Increases digoxin plasma levels by 50% to 70%; requires 50% dose reduction of digoxin.", s: "high"},
            {d: "Antacids", m: "Decreased digoxin absorption; separate administration by at least 2 hours.", s: "med"}
        ],
        dosage: "Maintenance Oral: 0.125 mg to 0.25 mg once daily. Digitalizing (Loading) dose: 0.75 mg to 1.5 mg divided over 24 hours. IV: 0.1 mg to 0.4 mg.",
        admin: "Check APICAL PULSE for a full 60 seconds prior to every dose. HOLD and notify provider if HR < 60 bpm. Administer IV doses slowly over at least 5 minutes. Therapeutic range: 0.5 - 2.0 ng/mL.",
        nurse: "Monitor serum Potassium, Magnesium, and Calcium levels strictly (Low K+ or Low Mg+ or High Ca+ all increase toxicity risk). Monitor renal function (Creatinine/eGFR). Assess for early signs of toxicity (nausea/anorexia). Antidote: Digibind (Digoxin immune fab)."
    },
    {
        g: "Nitroglycerin", b: "Nitrostat (SL), Nitro-Dur (Patch), Nitrolingual", c: "Nitrate / Potent Vasodilator", cat: "cv",
        m: "Converted to nitric oxide in the vascular smooth muscle, which activates guanylate cyclase, increasing cyclic GMP. This results in potent relaxation of vascular smooth muscle. The primary effect is venous dilation, which significantly reduces venous return to the heart (preload), thereby decreasing left ventricular end-diastolic pressure and myocardial oxygen demand. At higher doses, it also causes arterial dilation, reducing systemic vascular resistance (afterload) and improving collateral coronary blood flow.",
        ind: "Acute relief of Angina Pectoris (sublingual/spray); prophylaxis of Angina (topical/transdermal/SR); and acute management of Hypertensive Crisis or Heart Failure post-MI (IV).",
        con: "Known hypersensitivity to nitrates, severe anemia, increased intracranial pressure (head injury/hemorrhage), and use of PDE-5 inhibitors (Viagra).",
        aec: "THROBBING HEADACHE (very common due to meningeal vasodilation), postural hypotension, facial flushing, and dizziness.",
        aes: "Severe orthostatic hypotension, reflex tachycardia (compensatory), syncope, and methemoglobinemia (rare with high-dose IV).",
        inter: [
            {d: "Sildenafil (Viagra)", m: "FATAL hypotension due to extreme synergistic vasodilation. Absolute contraindication within 24-48 hours.", s: "critical"},
            {d: "Alcohol", m: "Severe hypotension and increased risk of cardiovascular collapse.", s: "high"}
        ],
        dosage: "SL: 0.4 mg tablet or spray. Patch: 0.1 mg/hr to 0.8 mg/hr. IV: 5 mcg/min to 200 mcg/min titration.",
        admin: "Sublingual (SL): Take 1 tab q5min up to 3 doses. If pain persists after the 1st dose, call 911 then take 2nd. Transdermal: Apply to hairless area; must have a 12-hour 'Nitrate-Free' period daily to prevent tolerance.",
        nurse: "Monitor BP and HR before and after administration. Teach patient to store SL tablets in the original dark glass bottle, tightly capped (light/heat sensitive). Assess for 'stinging' sensation under tongue (indicates potency)."
    },
    {
        g: "Isosorbide Dinitrate", b: "Isordil, Dilatrate-SR", c: "Nitrate / Vasodilator", cat: "cv",
        m: "Stimulates cyclic GMP production to cause relaxation of vascular smooth muscle. Similar to nitroglycerin but with a slower onset and longer duration. Predominantly reduces preload through venous dilation and improves coronary oxygen delivery by dilating large epicardial arteries.",
        ind: "Treatment and prevention of Angina Pectoris; management of chronic Heart Failure (when used in combination with hydralazine, specifically in African American patients).",
        con: "Concurrent use of PDE-5 inhibitors, severe hypotension, and closed-angle glaucoma.",
        aec: "Headache (may be severe initially), dizziness, flushing, and GI upset.",
        aes: "Profound hypotension, paradoxical bradycardia, and increased intraocular pressure.",
        inter: [{d: "Antihypertensives", m: "Additive hypotensive effects; risk of syncope.", s: "med"}],
        dosage: "Oral: 5 mg to 40 mg two to three times daily. SR (Sustained Release): 40 mg to 160 mg daily.",
        admin: "Administer orally. Immediate-release should be taken on an empty stomach for faster absorption. Ensure a nitrate-free interval of 10-14 hours per day to avoid pharmacological tolerance.",
        nurse: "Monitor blood pressure frequently during initiation and titration. Teach patient that headaches often decrease with continued use. Advise not to abruptly discontinue."
    },
    {
        g: "Isosorbide Mononitrate", b: "Imdur, ISMO, Monoket", c: "Nitrate / Vasodilator", cat: "cv",
        m: "The active 5-mononitrate metabolite of isosorbide dinitrate. It is 100% bioavailable when taken orally. It acts directly on vascular smooth muscle to cause vasodilation, primarily reducing preload and decreasing myocardial work.",
        ind: "Prophylactic treatment of Angina Pectoris. Note: This drug is NOT used for the relief of an acute anginal attack due to its slow onset.",
        con: "Hypersensitivity to nitrates, shock, and PDE-5 inhibitor use.",
        aec: "Headache (most common), dizziness, nausea, and vomiting.",
        aes: "Severe hypotension, tachycardia, and syncope.",
        inter: [],
        dosage: "Oral: 30 mg to 120 mg once daily (Extended Release) or 20 mg BID (Immediate Release).",
        admin: "Take once daily in the morning upon awakening. Swallow extended-release tablets whole; do not crush or chew. Maintain consistent hydration.",
        nurse: "Check BP before administration. Advise patient to rise slowly from bed. Educate that this medication is for prevention only, not for active chest pain."
    },
    {
        g: "Ranolazine", b: "Ranexa", c: "Antianginal / Sodium Channel Blocker", cat: "cv",
        m: "Inhibits the late inward sodium current (late INa) in myocardial cells. This reduces sodium-dependent calcium overload during ischemia, which improves myocardial relaxation and reduces ventricular wall tension. Unlike nitrates or beta-blockers, it does not significantly reduce heart rate or blood pressure, making it a unique metabolic antianginal agent.",
        ind: "Chronic stable Angina Pectoris. Often used in combination with beta-blockers, CCBs, or nitrates when monotherapy is insufficient.",
        con: "Hepatic cirrhosis (risk of increased drug levels), concurrent use of strong CYP3A inhibitors or inducers.",
        aec: "Dizziness, headache, nausea, and constipation.",
        aes: "QT INTERVAL PROLONGATION (risk of Torsades de Pointes), renal failure in patients with preexisting impairment.",
        inter: [
            {d: "Grapefruit Juice", m: "Inhibits CYP3A4; increases ranolazine levels and QT risk.", s: "high"},
            {d: "Simvastatin", m: "Increases simvastatin levels; limit simvastatin dose.", s: "med"}
        ],
        dosage: "Oral: 500 mg to 1000 mg twice daily. Maximum dose 1000 mg BID.",
        admin: "Take orally twice daily with or without food. Swallow extended-release tablets whole. Do not use for acute anginal attacks.",
        nurse: "Monitor EKG at baseline and periodically to assess the QTc interval. Monitor renal function (BUN/Cr). Advise patient to report any palpitations or fainting."
    }
];

</script>
    <script>
/* SOURCE: data_antiplatelets.js */
const data_antiplatelets = [
    {
        g: "Aspirin", b: "Ecotrin, Bayer, St. Joseph", c: "Salicylate / Antiplatelet (COX Inhibitor)", cat: "cv",
        m: "Irreversibly inhibits the cyclooxygenase (COX-1) enzyme within platelets. This blocks the conversion of arachidonic acid to thromboxane A2 (TXA2), a potent inducer of platelet aggregation and a powerful vasoconstrictor. Because platelets lack the ability to synthesize new proteins, the inhibitory effect lasts for the entire lifespan of the platelet (approx. 7 to 10 days). In higher doses, it also inhibits COX-2, providing anti-inflammatory and analgesic effects.",
        ind: "Primary and secondary prophylaxis of Myocardial Infarction (MI), maintenance of coronary artery stent patency, management of Acute MI (emergency setting), and secondary prevention of Ischemic Stroke or TIA. Also used for Peripheral Arterial Disease (PAD).",
        con: "Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage), children or adolescents with viral infections (risk of Reye's Syndrome), hypersensitivity to NSAIDs, and severe renal or hepatic insufficiency.",
        aec: "Gastrointestinal distress (nausea, dyspepsia), occult blood loss, and increased bruising.",
        aes: "GI BLEEDING and perforation, Tinnitus (early sign of salicylism/toxicity), Anaphylaxis, and Hemorrhagic stroke.",
        inter: [
            {d: "Warfarin/Heparin", m: "Extreme risk of severe hemorrhage due to combined anticoagulant/antiplatelet effects.", s: "critical"},
            {d: "NSAIDs (Ibuprofen)", m: "May interfere with aspirin's cardioprotective effect; take aspirin 2h before NSAID.", s: "high"},
            {d: "Alcohol", m: "Increases risk of gastric mucosal irritation and GI bleeding.", s: "high"}
        ],
        dosage: "Maintenance: 81 mg to 325 mg orally once daily. Acute MI: 325 mg (non-enteric coated) chewed immediately.",
        admin: "Take orally once daily. Administer with food or a full glass of water to minimize gastric irritation. Use enteric-coated (EC) versions for long-term prophylaxis to protect the stomach lining.",
        nurse: "Monitor for signs of GI bleeding (black/tarry stools, coffee-ground emesis). Assess for ringing in the ears (tinnitus). Advise patient to notify surgeons/dentists of aspirin use before procedures."
    },
    {
        g: "Clopidogrel", b: "Plavix", c: "Antiplatelet (ADP Receptor Antagonist)", cat: "cv",
        m: "An oral prodrug that must be metabolized by the liver (specifically CYP2C19) into its active form. It irreversibly blocks the P2Y12 component of adenosine diphosphate (ADP) receptors on the platelet surface. This prevents the activation of the GPIIb/IIIa receptor complex, thereby inhibiting platelet aggregation for the life of the platelet.",
        ind: "Reduction of atherosclerotic events (MI, stroke, vascular death) in patients with recent MI, recent stroke, or established Peripheral Arterial Disease (PAD). Used in Acute Coronary Syndrome (ACS) and post-stent placement.",
        con: "Active pathological bleeding (peptic ulcer or intracranial hemorrhage). Use with caution in patients with impaired hepatic function.",
        aec: "Upper respiratory tract infection, headache, flu-like symptoms, and dyspepsia.",
        aes: "Major bleeding, Thrombotic Thrombocytopenic Purpura (TTP - medical emergency), and severe neutropenia (rare).",
        inter: [
            {d: "Omeprazole (Prilosec)", m: "Inhibits CYP2C19; significantly reduces the activation and efficacy of clopidogrel.", s: "high"},
            {d: "NSAIDs/Warfarin", m: "Additive risk of severe bleeding and hemorrhage.", s: "high"}
        ],
        dosage: "Oral: 75 mg once daily. A 300 mg to 600 mg loading dose is often used in ACS or before PCI.",
        admin: "Take once daily without regard to food. Adherence is critical post-stent to prevent stent thrombosis.",
        nurse: "Monitor platelet counts and hemoglobin/hematocrit. Assess for unusual bruising or bleeding. Instruct patient to discontinue 5 to 7 days before elective surgery."
    },
    {
        g: "Ticagrelor", b: "Brilinta", c: "Antiplatelet (ADP Receptor Antagonist)", cat: "cv",
        m: "Selectively and reversibly interacts with the platelet P2Y12 ADP receptor to prevent signal transduction and platelet aggregation. Unlike clopidogrel, it is NOT a prodrug and does not require hepatic activation, leading to a faster onset and more consistent platelet inhibition.",
        ind: "Reduction of the rate of CV death, MI, and stroke in patients with ACS or a history of MI.",
        con: "History of intracranial hemorrhage, active pathological bleeding, and severe hepatic impairment.",
        aec: "Dyspnea (shortness of breath - unique side effect), headache, and cough.",
        aes: "Major hemorrhage, bradyarrhythmias, and elevated serum uric acid.",
        inter: [{d: "Aspirin", m: "Doses > 100mg/day decrease ticagrelor efficacy; use 81mg maintenance.", s: "high"}],
        dosage: "Oral: 90 mg twice daily. Loading dose of 180 mg often used.",
        admin: "Must be taken TWICE DAILY. Administer with low-dose aspirin (81mg). Can be taken with or without food.",
        nurse: "Monitor for dyspnea (usually transient). Monitor for signs of bleeding. Check uric acid levels in patients with a history of gout."
    },
    {
        g: "Abciximab", b: "ReoPro", c: "Antiplatelet (GPIIb/IIIa Receptor Antagonist)", cat: "cv",
        m: "The Fab fragment of a chimeric human-murine monoclonal antibody. It binds to the glycoprotein IIb/IIIa receptors on the surface of activated platelets, providing a steric hindrance that prevents the binding of fibrinogen and von Willebrand factor. This is the 'final common pathway' of platelet aggregation, making this class the most potent antiplatelet agents available.",
        ind: "Adjunct to percutaneous coronary intervention (PCI) for the prevention of cardiac ischemic complications; used in patients with unstable angina not responding to conventional therapy.",
        con: "Active internal bleeding, recent GI/GU bleeding (6 weeks), history of stroke (2 years), recent major surgery/trauma (6 weeks), severe uncontrolled HTN, and thrombocytopenia (< 100,000 cells/mm3).",
        aec: "Nausea, vomiting, hypotension, and back pain.",
        aes: "MAJOR HEMORRHAGE (especially at the arterial access site), severe thrombocytopenia, and anaphylaxis.",
        inter: [{d: "Heparin/Anticoagulants", m: "Significant increase in bleeding risk; requires careful titration.", s: "high"}],
        dosage: "IV: 0.25 mg/kg bolus, followed by 0.125 mcg/kg/min (Max 10 mcg/min) continuous infusion for 12-24 hours.",
        admin: "IV ONLY. Administer via a dedicated line with an in-line low protein-binding filter. Do not shake the vial.",
        nurse: "Monitor the catheter insertion site (groin) for hematoma or bleeding. Perform frequent neuro checks. Monitor platelets and PT/aPTT. Maintain bedrest."
    },
    {
        g: "Eptifibatide", b: "Integrilin", c: "Antiplatelet (GPIIb/IIIa Receptor Antagonist)", cat: "cv",
        m: "A cyclic peptide that reversibly inhibits platelet aggregation by preventing the binding of fibrinogen to the GP IIb/IIIa receptor. It has a shorter duration of action and faster recovery of platelet function (4-6 hours) compared to abciximab.",
        ind: "Treatment of ACS (unstable angina/NSTEMI) and patients undergoing PCI.",
        con: "Active bleed, dialysis-dependent renal failure, severe HTN.",
        aec: "Bleeding (especially at access site), hypotension.",
        aes: "Major hemorrhage, severe thrombocytopenia (immune-mediated).",
        inter: [],
        dosage: "IV: 180 mcg/kg bolus, followed by 2 mcg/kg/min infusion. Adjust dose in renal impairment.",
        admin: "IV ONLY. Requires continuous infusion pump. Protect from light until used.",
        nurse: "Monitor renal function (CrCl) baseline and during therapy as clearance is primarily renal. Monitor for signs of bleeding at the femoral access site, gums, and urine. Perform serial platelet counts and hemoglobin levels to detect occult hemorrhage or immune-mediated thrombocytopenia. Ensure strict bedrest while the arterial sheath is in place. Verify that the patient is NOT receiving other potent antiplatelets concurrently unless specified."
    },
    {
        g: "Dipyridamole", b: "Persantine", c: "Antiplatelet / Vasodilator", cat: "cv",
        m: "Inhibits the activity of adenosine deaminase and phosphodiesterase, which causes an accumulation of adenosine and cyclic AMP. This inhibits platelet aggregation and causes coronary vasodilation. Usually combined with aspirin or warfarin.",
        ind: "Prophylaxis of thromboembolism after cardiac valve replacement (with warfarin); secondary prevention of stroke (with aspirin).",
        con: "Hypersensitivity.",
        aec: "Dizziness, abdominal distress, headache, and skin rash.",
        aes: "Profound hypotension, paradoxical worsening of angina, and hepatic failure (rare).",
        inter: [{d: "Adenosine", m: "Potentiates the effects of adenosine; use with extreme caution.", s: "high"}],
        dosage: "Oral: 75 mg to 100 mg four times daily.",
        admin: "Administer orally. For optimal absorption, take on an empty stomach 1 hour before or 2 hours after meals with a full glass of water.",
        nurse: "Monitor blood pressure and pulse baseline and during initiation, as the drug has vasodilatory properties. Assess for signs of GI bleeding when used concurrently with anticoagulants (e.g., black/tarry stools). Educate the patient to rise slowly from a sitting or lying position to prevent orthostatic dizziness. Instruct patient to take the medication with a full glass of water 1 hour before meals for maximum efficacy."
    },
    {
        g: "Cilostazol", b: "Pletal", c: "Antiplatelet / Phosphodiesterase-3 Inhibitor", cat: "cv",
        m: "Selectively inhibits phosphodiesterase type 3 (PDE3), increasing cyclic AMP in platelets and blood vessels. This results in reversible inhibition of platelet aggregation, vasodilation, and inhibition of vascular smooth muscle cell proliferation.",
        ind: "Reduction of symptoms of Intermittent Claudication in patients with Peripheral Arterial Disease (PAD) to increase walking distance.",
        con: "HEART FAILURE of any severity (Black Box: PDE3 inhibitors decrease survival in HF patients).",
        aec: "Headache (most common), diarrhea, palpitations, and dizziness.",
        aes: "Tachyarrhythmias, severe hypotension, and blood dyscrasias.",
        inter: [{d: "Grapefruit Juice", m: "Increases drug levels and risk of side effects.", s: "high"}],
        dosage: "Oral: 100 mg twice daily.",
        admin: "Take on an EMPTY STOMACH at least 30 minutes before or 2 hours after breakfast and dinner.",
        nurse: "Assess for signs of Heart Failure (edema, SOB) - drug is contraindicated. Evaluate walking distance and leg pain improvements (may take 2-12 weeks)."
    }
];

</script>
    <script>
/* SOURCE: data_anticoagulants.js */
const data_anticoagulants = [
    {
        g: "Warfarin", b: "Coumadin, Jantoven", c: "Anticoagulant (Vitamin K Antagonist)", cat: "cv",
        m: "Inhibits the enzyme Vitamin K Epoxide Reductase (VKOR), which is responsible for converting inactive vitamin K epoxide to its active reduced form. This active vitamin K is a required cofactor for the hepatic synthesis of Vitamin K-dependent clotting factors II (prothrombin), VII, IX, and X, as well as the anticoagulant proteins C and S. By depleting the supply of active Vitamin K, warfarin prevents the further formation of functional clotting factors. It has no direct effect on established clots but prevents the extension of existing thrombi and the formation of new ones by allowing the body's natural fibrinolytic system to work unopposed. Its onset is delayed (3-5 days) because it does not affect factors already circulating in the blood.",
        ind: "Prophylaxis and treatment of Venous Thromboembolism (DVT), Pulmonary Embolism (PE), thromboembolic complications associated with Atrial Fibrillation or cardiac valve replacement, and reduction in the risk of recurrent Myocardial Infarction or stroke.",
        con: "Active major bleeding, Pregnancy (Category X - causes fetal hemorrhage, CNS defects, and death), hemorrhagic stroke, recent or planned surgery of the CNS or eye, and severe uncontrolled hypertension.",
        aec: "Common: Gastrointestinal distress (nausea, abdominal pain), easy bruising, minor bleeding (epistaxis, gum bleeding), and transient hair loss (alopecia).",
        aes: "MAJOR HEMORRHAGE (potentially fatal), skin necrosis or gangrene (rare, associated with protein C deficiency), 'purple toe' syndrome (cholesterol microembolization), and drug-induced hepatotoxicity.",
        inter: [
            {d: "NSAIDs / Aspirin", m: "CRITICAL bleeding risk; dual inhibition of platelets and direct damage to GI mucosa; avoid combination.", s: "critical"},
            {d: "Vitamin K Foods", m: "Directly antagonizes the drug effect; must maintain CONSISTENT daily intake to keep INR stable.", s: "high"},
            {d: "Antibiotics", m: "Kills intestinal flora that synthesize Vitamin K; leads to significantly increased INR and bleeding.", s: "high"},
            {d: "G-Herbs (Garlic/Ginger/Ginkgo)", m: "Additive antiplatelet effects and increased risk of major hemorrhage.", s: "high"}
        ],
        dosage: "Oral: Initial 2 mg to 10 mg once daily for 2 days. Maintenance: Typically 2 mg to 10 mg based on daily PT/INR results. Adjustments are precise.",
        admin: "Administer orally at the SAME TIME each day (usually evening) to maintain steady-state levels. Antidote: Vitamin K (Phytonadione). For urgent reversal: Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP).",
        nurse: "Monitor PT/INR strictly (Target 2.0-3.0 for DVT/AFib; 2.5-3.5 for mechanical valves). Assess for signs of occult bleeding (guaiac-positive stool, hematuria, coffee-ground emesis). Teach patient to use a soft toothbrush and electric razor. Instruct patient to MAINTAIN a consistent (not zero) intake of green leafy vegetables. Advise avoiding all new OTC meds or herbal supplements without consulting the provider. Instruct patient to wear a medical alert bracelet."
    },
    {
        g: "Heparin", b: "Hep-Lock, Heparin Sodium", c: "Anticoagulant", cat: "cv",
        m: "A high-molecular-weight mucopolysaccharide that binds to and potently increases the activity of Antithrombin III. This complex then rapidly inactivates thrombin (Factor IIa), Factor Xa, and several other clotting factors (IX, XI, XII). By preventing the conversion of fibrinogen to fibrin, heparin inhibits the formation of a stable fibrin clot and stops the growth of existing thrombi. It does not dissolve existing clots. At high doses, it can also inhibit platelet aggregation and prolong the bleeding time. It has a very rapid onset and a short half-life (1.5 hours).",
        ind: "Acute treatment of DVT, Pulmonary Embolism, unstable angina, Acute MI, and prophylaxis of thrombosis during cardiac surgery, vascular surgery, or hemodialysis. Low-dose SC used for DVT prophylaxis in immobile patients.",
        con: "Uncontrolled active bleeding, history of Heparin-Induced Thrombocytopenia (HIT), severe thrombocytopenia (< 100,000 cells/mm), and suspected intracranial hemorrhage.",
        aec: "Common: Injection site bruising, pain, local irritation, and transient hair loss with long-term use.",
        aes: "MAJOR BLEEDING and hemorrhage (GI, GU, intracranial), HEPARIN-INDUCED THROMBOCYTOPENIA (HIT - a 50% or greater drop in platelets due to immune-mediated antibodies), and osteoporosis (with use > 6 months).",
        inter: [
            {d: "Antiplatelets / NSAIDs", m: "Significantly increased risk of major hemorrhage due to combined effects.", s: "high"},
            {d: "Digoxin / Nitroglycerin", m: "May partially inhibit the anticoagulant effect of heparin; monitor aPTT closely.", s: "med"}
        ],
        dosage: "SC: 5000 units every 8 to 12 hours. IV Bolus: 80 units/kg. IV Infusion: 18 units/kg/hr titration based on aPTT nomogram.",
        admin: "SC or IV ONLY. Do NOT administer IM (causes massive hematomas). SC: inject into deep SC tissue of the abdomen; do not aspirate or rub. IV: always use an infusion pump and REQUIRE dual-nurse verification of every dose and titration change. Standard Heparin concentration is 10,000 units/mL; Hep-Lock flush is 10-100 units/mL.",
        nurse: "Monitor activated Partial Thromboplastin Time (aPTT) every 6 hours during titration (Target 1.5-2.5x control). Monitor Platelet count daily (Immediately notify provider if platelets drop by 50%). Antidote: Protamine Sulfate. Monitor for signs of bleeding (hematuria, epistaxis, abdominal pain)."
    },
    {
        g: "Enoxaparin", b: "Lovenox", c: "Low Molecular Weight Heparin (LMWH)", cat: "cv",
        m: "A depolymerized heparin derivative with a much smaller molecular size than unfractionated heparin. It has a significantly higher ratio of anti-Factor Xa activity to anti-Factor IIa (thrombin) activity. This results in a more predictable and stable anticoagulant response, a longer half-life (4.5 to 7 hours), and a lower incidence of Heparin-Induced Thrombocytopenia (HIT). It works by potentiating the inhibition of Factor Xa by antithrombin III, thereby blocking the common pathway of coagulation.",
        ind: "Prophylaxis of DVT following abdominal, hip, or knee surgery; treatment of established DVT and PE; and management of unstable angina and non-Q-wave Myocardial Infarction.",
        con: "Active major bleeding, history of HIT, hypersensitivity to heparin, pork products, or benzyl alcohol. Not for use in patients with prosthetic heart valves (in some populations).",
        aec: "Common: Local irritation and erythema at the injection site, minor bruising, and mild anemia.",
        aes: "Severe Hemorrhage, SPINAL/EPIDURAL HEMATOMA (Black Box warning - can lead to permanent paralysis in patients undergoing spinal procedures), and immune-mediated thrombocytopenia.",
        inter: [{d: "NSAIDs / Aspirin", m: "Significantly increased bleeding risk; use with extreme caution.", s: "high"}],
        dosage: "Subcutaneous: Prophylaxis: 30 mg to 40 mg once daily. Treatment: 1 mg/kg every 12 hours or 1.5 mg/kg once daily. Adjust dose in renal failure.",
        admin: "SC ONLY into the 'love handles' area of the abdomen. Do NOT expel the air bubble from the prefilled syringe (ensures the entire dose is delivered and prevents tracking). Do NOT rub the site after administration. Alternate left and right sides of the abdomen.",
        nurse: "Monitor CBC for signs of occult blood loss (Hgb/Hct). Routine monitoring of aPTT is NOT required due to predictable kinetics. Use with extreme caution in patients with renal impairment (eGFR < 30 requires 50% dose reduction). Monitor for neurological changes if the patient has had a spinal puncture."
    },
    {
        g: "Fondaparinux", b: "Arixtra", c: "Factor Xa Inhibitor (Anticoagulant)", cat: "cv",
        m: "A synthetic pentasaccharide that selectively and reversibly binds to antithrombin III. This binding induces a specific conformational change that increases antithrombin's affinity for Factor Xa by 300-fold. This results in the potent and specific inhibition of Factor Xa without any effect on thrombin (Factor IIa). It does not bind to platelet factor 4 (PF4), which means it does not cause Heparin-Induced Thrombocytopenia (HIT). It has 100% bioavailability and a long half-life (17-21 hours).",
        ind: "Prophylaxis of DVT in patients undergoing major orthopedic (hip/knee) or abdominal surgery; treatment of acute DVT and PE when combined with warfarin.",
        con: "Severe renal impairment (CrCl < 30 mL/min), body weight less than 50 kg (110 lbs), active major bleeding, and bacterial endocarditis.",
        aec: "Common: Nausea, insomnia, dizziness, and injection site reactions (rash, bruising).",
        aes: "MAJOR BLEEDING, spinal/epidural hematoma risk (Black Box), and thrombocytopenia (rare compared to heparin).",
        inter: [],
        dosage: "Subcutaneous: 2.5 mg once daily (prophylaxis). Treatment: 5 mg to 10 mg based on weight (>100kg: 10mg; 50-100kg: 7.5mg; <50kg: 5mg).",
        admin: "SC injection ONLY. Do NOT use in patients under 110 lbs for prophylaxis due to the extreme risk of major hemorrhage. Rotate sites in the abdomen. Do not expel the air bubble from the prefilled syringe.",
        nurse: "Monitor renal function (CrCl) baseline and throughout therapy as the drug is renally excreted. Assess for signs of bleeding. fondaparinux does NOT require routine aPTT or PT/INR monitoring. Monitor for signs of spinal hematoma (numbness, weakness in legs)."
    },
    {
        g: "Apixaban", b: "Eliquis", c: "Direct Factor Xa Inhibitor (DOAC)", cat: "cv",
        m: "Directly, selectively, and reversibly inhibits both free and clot-bound Factor Xa. By blocking the common pathway of the coagulation cascade, it prevents the conversion of prothrombin to thrombin, thereby inhibiting the amplification of thrombus development. It does not require antithrombin III for its action. It has a predictable anticoagulant effect, leading to a wide therapeutic index compared to warfarin.",
        ind: "Reduction of the risk of stroke and systemic embolism in patients with nonvalvular Atrial Fibrillation; prophylaxis and treatment of DVT and PE.",
        con: "Active pathological bleeding, severe hepatic impairment (Child-Pugh C), and prosthetic heart valves. Use with caution in severe renal failure.",
        aec: "Common: Nausea, easy bruising, minor epistaxis (nosebleed), and gum bleeding.",
        aes: "MAJOR HEMORRHAGE (GI, intracranial, or intraocular), and spinal/epidural hematoma risk during spinal procedures.",
        inter: [
            {d: "Strong CYP3A4/P-gp Inducers", m: "Significantly decreases apixaban levels; high risk of thromboembolic events.", s: "high"},
            {d: "Strong CYP3A4/P-gp Inhibitors", m: "Increases apixaban levels; high risk of major bleeding.", s: "high"}
        ],
        dosage: "Oral: 2.5 mg to 5 mg twice daily (BID). Standard dose is 5 mg BID unless specific renal/age/weight criteria are met.",
        admin: "Orally twice daily with or without food. Maintain consistent schedule. If a patient cannot swallow whole tablets, they can be crushed and mixed with water, apple juice, or applesauce. Antidote: Andexxa (Andexanet alfa).",
        nurse: "Routine lab monitoring (INR/aPTT) is NOT required. Assess for signs of bleeding (bruising, dark stools). Check renal function baseline. Educate patient that they must not stop the drug abruptly as the risk of stroke increases significantly."
    },
    {
        g: "Rivaroxaban", b: "Xarelto", c: "Direct Factor Xa Inhibitor (DOAC)", cat: "cv",
        m: "Directly and selectively inhibits Factor Xa, blocking the rate-limiting step of thrombin generation in the coagulation cascade. Like apixaban, it inhibits both free and clot-bound Factor Xa. It has high oral bioavailability when taken with food (for higher doses). It provides a rapid onset of anticoagulation (2-4 hours) and does not require initial bridging with heparin in most scenarios.",
        ind: "Prophylaxis of DVT and PE following hip or knee replacement; treatment of VTE; stroke prevention in nonvalvular Atrial Fibrillation; and reduction of CV risk in CAD/PAD (low dose).",
        con: "Active major bleeding, moderate to severe hepatic impairment, and prosthetic heart valves.",
        aec: "Common: Back pain, abdominal pain, bruising, and dizziness.",
        aes: "LIFE-THREATENING HEMORRHAGE, and risk of spinal hematoma (Black Box warning). Increased risk of thrombotic events if discontinued prematurely.",
        inter: [{d: "NSAIDs / Clopidogrel", m: "Significantly increased bleeding risk; additive effects.", s: "high"}],
        dosage: "Oral: 10 mg to 20 mg once daily. Doses above 15 mg require food.",
        admin: "Doses of 15 mg or 20 mg MUST be taken WITH THE EVENING MEAL to ensure adequate systemic absorption (absorption increases from 66% to nearly 100% with food). 10 mg can be taken without food.",
        nurse: "Assess for signs of bleeding. Monitor LFTs and renal function (avoid if CrCl < 15). Educate on the absolute necessity of taking with the largest meal of the day for higher doses. Instruct patient not to miss doses due to the short half-life."
    },
    {
        g: "Dabigatran", b: "Pradaxa", c: "Direct Thrombin Inhibitor (DOAC)", cat: "cv",
        m: "An oral prodrug that is rapidly converted to the active dabigatran, which competitively and reversibly inhibits free and clot-bound thrombin (Factor IIa). Thrombin is the final enzyme in the coagulation cascade that converts fibrinogen to fibrin. By blocking thrombin, dabigatran prevents the formation of fibrin mesh and inhibits thrombin-induced platelet aggregation. It has a fast onset (1 hour) and provides stable anticoagulation.",
        ind: "Prevention of stroke and systemic embolism in nonvalvular Atrial Fibrillation; treatment and prevention of recurrent DVT and PE.",
        con: "Active major bleeding, prosthetic heart valves (increased risk of MI/clot), and severe renal impairment (CrCl < 15 mL/min).",
        aec: "Common: Dyspepsia (GI upset - occurs in 35% of patients), gastritis-like symptoms, nausea, and abdominal pain.",
        aes: "MAJOR GI BLEEDING (demonstrates a higher risk of GI hemorrhage than warfarin), intracranial hemorrhage, and anaphylaxis.",
        inter: [{d: "P-glycoprotein Inhibitors", m: "May increase dabigatran levels; monitor for bleeding.", s: "med"}],
        dosage: "Oral: 75 mg to 150 mg twice daily (BID). Adjust dose based on renal function.",
        admin: "Must be swallowed whole; do NOT crush, chew, or open capsules. Opening the capsule increases absorption by 75%, leading to toxic levels and fatal hemorrhage. Keep in original manufacturer bottle to protect from moisture; discard 4 months after opening. Antidote: Idarucizumab (Praxbind).",
        nurse: "Assess for GI symptoms and occult bleeding. Educate patient NOT to use pill organizers; they must keep the drug in the original bottle with the desiccant cap. Monitor renal function strictly. Advise patient to take with a full glass of water."
    },
    {
        g: "Alteplase", b: "Activase (tPA)", c: "Thrombolytic / Fibrinolytic", cat: "cv",
        m: "A recombinant form of human tissue plasminogen activator. It binds directly to fibrin in a thrombus and converts the entrapped plasminogen to the active enzyme plasmin. Plasmin then digests the fibrin meshwork of the clot, resulting in its rapid dissolution (thrombolysis). It is 'clot-specific,' meaning it has a higher affinity for fibrin-bound plasminogen than circulating plasminogen, though it still creates a systemic lytic state.",
        ind: "Management of Acute Ischemic Stroke (MUST be initiated within 3 to 4.5 hours of symptom onset); Acute Myocardial Infarction; and massive Pulmonary Embolism. Also used at low doses to clear occluded central venous catheters.",
        con: "Active internal bleeding, history of recent stroke (within 3 months), severe uncontrolled hypertension (SBP > 185 or DBP > 110), recent major surgery or trauma, and intracranial neoplasm or aneurysm.",
        aec: "Common: Minor bleeding from gums, nose, or previous IV sites; fever; and nausea.",
        aes: "INTRACRANIAL HEMORRHAGE (ICH), major life-threatening GI or GU hemorrhage, and fatal anaphylaxis. Reperfusion arrhythmias (during AMI treatment).",
        inter: [{d: "Anticoagulants / Antiplatelets", m: "Extreme, often fatal risk of hemorrhage; avoid concurrent use until alteplase is cleared.", s: "critical"}],
        dosage: "IV: Ischemic Stroke: 0.9 mg/kg (Max 90 mg). 10% given as initial bolus over 1 minute, followed by 90% as continuous infusion over 60 minutes.",
        admin: "IV ONLY via a dedicated large-bore IV line. Perform a thorough neurological assessment and obtain a non-contrast CT scan to rule out ICH BEFORE administration. Reconstitute with sterile water only; do not shake the vial (swirl gently).",
        nurse: "Perform neuro checks and BP monitoring every 15 minutes during the infusion and every 30 mins for the next 6 hours. Avoid all invasive procedures (no IM injections, no Foley, no arterial sticks) for 24 hours. Maintain absolute bedrest. Monitor for any change in mental status."
    },
    {
        g: "Reteplase", b: "Retavase", c: "Thrombolytic", cat: "cv",
        m: "A recombinant plasminogen activator that is a non-glycosylated deletion mutant of native tPA. It is less fibrin-specific than alteplase, which allows it to penetrate deeper into the thrombus meshwork to promote dissolution. It has a longer half-life (13-16 minutes), which permits convenient double-bolus dosing rather than a continuous infusion. Like alteplase, it converts plasminogen to plasmin to digest fibrin.",
        ind: "Management of acute Myocardial Infarction (AMI) in adults to improve ventricular function, reduce the incidence of heart failure, and decrease mortality associated with AMI.",
        con: "Active internal bleeding, recent intracranial hemorrhage, severe uncontrolled hypertension, and recent major surgery.",
        aec: "Bleeding at injection sites, anemia, and nausea.",
        aes: "Severe hemorrhage (GI/GU), intracranial hemorrhage, and REPERFUSION ARRHYTHMIAS (e.g., accelerated idioventricular rhythm, PVCs, VT).",
        inter: [],
        dosage: "IV: 10 units bolus given over 2 minutes, followed by a second 10 units bolus 30 minutes later.",
        admin: "IV Bolus only. Do not administer other medications in the same IV line as reteplase. Use a dedicated line. Incompatible with heparin and dobutamine in the same line.",
        nurse: "Monitor for reperfusion arrhythmias (which indicate the clot is dissolving and blood flow is returning). Assess for signs of bleeding. Monitor EKG and BP continuously. Maintain bedrest and avoid invasive procedures."
    }
];

</script>
    <script>
/* SOURCE: data_antiarrhythmics.js */
const data_antiarrhythmics = [
    {
        g: "Quinidine", b: "Quinidex, Quinora", c: "Class IA Antiarrhythmic", cat: "cv",
        m: "A classic Class IA antiarrhythmic that works by depressing myocardial excitability, conduction velocity, and contractility through the blockade of fast sodium channels in the myocardial cell membrane. It primarily slows the rapid inward sodium current during Phase 0 of the cardiac action potential. Additionally, it possesses anticholinergic (vagolytic) effects and prolongs the action potential duration and effective refractory period. This dual action helps stabilize the cell membrane and suppress ectopic pacemaker activity, making it effective for both atrial and ventricular arrhythmias.",
        ind: "Management of Atrial Fibrillation, Atrial Flutter, and life-threatening Ventricular Arrhythmias. It is often used to maintain normal sinus rhythm after conversion of AFib/Flutter.",
        con: "Complete heart block (without a pacemaker), myasthenia gravis, and history of QT interval prolongation. Known hypersensitivity to quinidine or other cinchona derivatives.",
        aec: "Common: Diarrhea (extremely common, occurring in up to 30% of patients), nausea, vomiting, abdominal pain, and bitter or metallic taste.",
        aes: "CINCHONISM: A unique syndrome of toxicity characterized by tinnitus, headache, vertigo, and blurred vision. Severe: QT Interval Prolongation leading to Torsades de Pointes, thrombocytopenia, and potential for fatal arrhythmias.",
        inter: [
            {d: "Digoxin", m: "Reduces renal clearance of digoxin; leads to a 2-fold increase in digoxin levels and high risk of digitalis toxicity.", s: "critical"},
            {d: "Warfarin", m: "Potentiates the anticoagulant effect, increasing the risk of hemorrhage.", s: "high"},
            {d: "Antacids", m: "May increase quinidine levels by reducing renal excretion.", s: "med"}
        ],
        dosage: "Oral: 200 mg to 400 mg every 6 to 8 hours. Sustained release: 300 mg to 600 mg every 8 to 12 hours. Max 600 mg/dose.",
        admin: "Administer orally. Take with food or a full glass of water to minimize the high incidence of GI distress. If used for AFib, ensure the patient is digitalized or beta-blocked first to prevent a paradoxical rapid ventricular response.",
        nurse: "Monitor EKG continuously for widened QRS complex and prolonged QT interval (>50% increase requires holding dose). Monitor serum digoxin levels strictly if co-administered. Assess for early signs of cinchonism (ringing in ears). Monitor CBC for thrombocytopenia. Advise patient to report any unexplained bruising or bleeding."
    },
    {
        g: "Lidocaine", b: "Xylocaine", c: "Class IB Antiarrhythmic", cat: "cv",
        m: "Suppresses automaticity and spontaneous depolarization of the ventricles during diastole by direct action on the tissues. It has little to no effect on the SA node or atrial tissue, classifying it as a Class IB agent. It works by blocking sodium channels, primarily in the ischemic, depolarized, or rapidly firing myocardium. This selective action allows it to suppress ventricular ectopy and prevent ventricular fibrillation without significantly altering the conduction of normal heart beats. It is metabolized rapidly by the liver.",
        ind: "Acute management of life-threatening Ventricular Arrhythmias (Ventricular Tachycardia, PVCs, Ventricular Fibrillation) occurring during acute MI, cardiac surgery, or cardiac catheterization.",
        con: "Adam-Stokes syndrome, severe degrees of SA, AV, or intraventricular heart block in the absence of a functional pacemaker, and hypersensitivity to amide-type anesthetics.",
        aec: "CNS: Dizziness, drowsiness, slurred speech, blurred or double vision, and a 'metallic' taste in the mouth.",
        aes: "CNS TOXICITY (Lido Jitters): tremors, twitching, seizures, and respiratory depression. Cardiovascular: Severe bradycardia and cardiovascular collapse if administered too rapidly.",
        inter: [{d: "Beta Blockers", m: "May decrease lidocaine clearance, increasing the risk of toxicity.", s: "med"}],
        dosage: "IV Bolus: 1 to 1.5 mg/kg initially. IV Infusion: 1 to 4 mg/minute continuous titration. Max 3mg/kg total bolus dose.",
        admin: "IV ONLY for cardiac arrhythmias. Use only lidocaine labeled 'WITHOUT EPINEPHRINE' for IV cardiac use. Requires a continuous infusion pump for precise delivery. For IM use, only used in emergency settings when IV access is unavailable.",
        nurse: "Monitor for signs of CNS toxicity (confusion, seizures, tremors). Monitor EKG continuously for widened QRS or PR interval. Check therapeutic serum levels (Target range is 1.5 - 5 mcg/mL). Keep emergency resuscitative equipment nearby. Notify provider immediately if neuro status changes."
    },
    {
        g: "Flecainide", b: "Tambocor", c: "Class IC Antiarrhythmic", cat: "cv",
        m: "A potent Class IC sodium channel blocker that significantly slows conduction throughout the myocardial conduction system, including the atria, ventricles, and the His-Purkinje system. It has little effect on the action potential duration or repolarization. It exhibits significant negative inotropic effects, which can decrease cardiac output. Because it so effectively slows conduction, it can create a substrate for new, dangerous arrhythmias, especially in hearts with existing damage.",
        ind: "Prevention of paroxysmal Atrial Fibrillation/Flutter and life-threatening Ventricular Arrhythmias. Reserved for patients without structural heart disease.",
        con: "Structural heart disease (Black Box: significantly increased mortality post-MI), Heart Failure (due to negative inotropy), and 2nd/3rd degree heart block. Concurrent use of ritonavir.",
        aec: "Common: Dizziness, visual disturbances (blurred vision, difficulty focusing), headache, and nausea.",
        aes: "PRO-ARRHYTHMIC EFFECTS: Can cause new or worsened arrhythmias (VT/VF). Heart Failure exacerbation and severe symptomatic bradycardia.",
        inter: [
            {d: "Digoxin", m: "Increases digoxin plasma levels by approximately 15-25%; monitor strictly.", s: "high"},
            {d: "Amiodarone", m: "Increases flecainide levels by 50%; require dose reduction.", s: "high"}
        ],
        dosage: "Oral: 50 mg to 150 mg every 12 hours. Maximum dose 300 mg/day.",
        admin: "Orally twice daily. Do not use in patients with any history of MI, structural heart disease, or significant left ventricular dysfunction. Initiation is typically done in a hospital setting.",
        nurse: "Monitor EKG for PR and QRS interval widening (Hold if QRS increases by >50%). Assess for signs of worsening heart failure (weight gain, peripheral edema, crackles). Monitor for visual changes. Instruct patient to report any palpitations or fainting spells immediately."
    },
    {
        g: "Amiodarone", b: "Cordarone, Pacerone", c: "Class III Antiarrhythmic", cat: "cv",
        m: "A complex Class III agent that primarily prolongs the action potential duration and the refractory period in all cardiac tissues by blocking potassium channels. Uniquely, it also possesses sodium channel blocking, calcium channel blocking, and non-competitive alpha- and beta-adrenergic blocking properties. It is highly lipophilic and accumulates in adipose tissue and organs, leading to an extremely long and variable half-life (average 58 days, range 15-142 days). It contains high amounts of iodine, which can affect thyroid function.",
        ind: "Treatment and prophylaxis of life-threatening Ventricular Tachycardia and Ventricular Fibrillation; conversion and rate control of Atrial Fibrillation in patients with HF.",
        con: "Severe sinus-node dysfunction causing bradycardia, 2nd/3rd degree heart block (without pacemaker), and cardiogenic shock. Known iodine hypersensitivity.",
        aec: "Common: Photosensitivity, corneal micro-deposits (seeing halos at night), nausea, vomiting, and constipation.",
        aes: "PULMONARY FIBROSIS (potentially fatal lung scarring), HEPATOTOXICITY, thyroid dysfunction (hypo- or hyper-thyroidism), and BLUE-GREY skin discoloration. Visual loss (rare).",
        inter: [
            {d: "Warfarin", m: "Inhibits metabolism; increases PT/INR by 100%; MUST reduce warfarin dose by 50% immediately.", s: "critical"},
            {d: "Digoxin", m: "Inhibits renal/hepatic clearance; MUST reduce digoxin dose by 50% to prevent fatal toxicity.", s: "critical"},
            {d: "Statins", m: "Increases risk of statin-induced myopathy and rhabdomyolysis.", s: "high"}
        ],
        dosage: "Oral Maintenance: 200 mg to 400 mg daily. IV Bolus: 150 mg to 300 mg. IV Infusion: 0.5 to 1 mg/min.",
        admin: "Oral and IV routes. IV doses must be administered through a 0.22-micron in-line filter to catch precipitates. Use a central line if possible as the drug is a potent vesicant and highly irritating to peripheral veins.",
        nurse: "Monitor PFTs (Pulmonary Function Tests), LFTs, and Thyroid labs baseline and every 6 months. Teach patient to use high-SPF sunscreen and wear protective clothing. Instruct patient to report any new dry cough or shortness of breath immediately. Monitor EKG for QTc prolongation."
    },
    {
        g: "Sotalol", b: "Betapace", c: "Class III Antiarrhythmic / Beta Blocker", cat: "cv",
        m: "Demonstrates both non-selective beta-adrenergic blocking properties (Class II) and cardiac action potential duration prolongation properties (Class III). It inhibits potassium channels to prolong repolarization. Because it is a non-selective beta blocker, it reduces heart rate and contractility while potentially causing bronchoconstriction. It is unique among beta blockers for its potent antiarrhythmic effects on the ventricles.",
        ind: "Management of life-threatening Ventricular Arrhythmias and maintenance of normal sinus rhythm in patients with highly symptomatic Atrial Fibrillation or Atrial Flutter.",
        con: "BRONCHIAL ASTHMA, severe sinus bradycardia, long QT syndrome, uncompensated HF, and severe renal impairment (CrCl < 40 mL/min).",
        aec: "Fatigue, dizziness, bradycardia, dyspnea (shortness of breath), and gastrointestinal upset.",
        aes: "PRO-ARRHYTHMIA: Significant dose-dependent risk of Torsades de Pointes (especially with high doses, female gender, or renal failure). Severe bradycardia and heart block.",
        inter: [{d: "QT-Prolonging Drugs", m: "Additive risk of life-threatening Torsades de Pointes; avoid combination.", s: "high"}],
        dosage: "Oral: 80 mg to 160 mg twice daily. Dosage must be reduced in renal impairment.",
        admin: "Available in Oral and IV forms. Must be initiated in a hospital setting with continuous EKG monitoring for at least 3 days to assess for QT prolongation and pro-arrhythmic events.",
        nurse: "Calculate and monitor the QTc interval before every dose (HOLD and notify provider if QTc > 500ms). Monitor renal function (CrCl) strictly as the drug is renally excreted. Assess for wheezing or respiratory distress. Monitor BP and HR."
    },
    {
        g: "Adenosine", b: "Adenocard", c: "Miscellaneous Antiarrhythmic", cat: "cv",
        m: "A naturally occurring nucleoside that slows conduction time through the AV node, can interrupt the reentry pathways through the AV node, and can restore normal sinus rhythm in patients with SVT. It works by activating potassium channels and inhibiting calcium influx. It has an extremely short half-life of less than 10 seconds because it is rapidly cleared from the circulation by cellular uptake. This allows for rapid termination of arrhythmias with minimal lasting systemic effects.",
        ind: "Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with Wolff-Parkinson-White (WPW) syndrome. Not effective for AFib/Flutter.",
        con: "2nd or 3rd degree heart block (without pacemaker), sick sinus syndrome (without pacemaker), and symptomatic bronchial asthma.",
        aec: "Common: Facial flushing, shortness of breath, chest pressure/pain, and nausea. These symptoms are transient due to the short half-life.",
        aes: "ASYSTOLE: A brief period of flatline (several seconds) is expected and intended. Transient arrhythmias and bronchospasm.",
        inter: [
            {d: "Caffeine / Theophylline", m: "Antagonizes adenosine receptors; may require significantly higher doses of adenosine.", s: "high"},
            {d: "Dipyridamole", m: "Inhibits uptake and potentiates adenosine; must reduce adenosine dose by 50%.", s: "high"}
        ],
        dosage: "IV: 6 mg rapid bolus; if no effect, 12 mg bolus given 1-2 minutes later. A second 12 mg dose may be given.",
        admin: "IV ONLY. Administer via RAPID IV PUSH (over 1-2 seconds) into the vein closest to the heart (antecubital), immediately followed by a rapid 20mL saline flush using the 'two-syringe' technique.",
        nurse: "Continuous EKG monitoring is mandatory. Warn the patient they will feel a very unpleasant sensation like 'someone kicked them in the chest' or a sense of impending doom for several seconds. Keep emergency equipment at the bedside."
    }
];

</script>
    <script>
/* SOURCE: data_diabetes_sensitizers.js */
const data_diabetes_sensitizers = [
    {
        g: "Metformin", b: "Glucophage, Fortamet, Glumetza", c: "Biguanide (Insulin Sensitizer)", cat: "dm",
        m: "Decreases hepatic glucose production (gluconeogenesis) by inhibiting mitochondrial complex I. It also decreases intestinal absorption of glucose and increases insulin sensitivity in peripheral tissues by increasing glucose uptake and utilization. It does not stimulate insulin secretion from the pancreas, which is why it does not cause weight gain and has a minimal risk of hypoglycemia when used as monotherapy. It also has favorable effects on lipid profiles.",
        ind: "First-line pharmacological treatment for Type 2 Diabetes Mellitus in adults and children (10+ years); Polycystic Ovary Syndrome (PCOS - off-label).",
        con: "Renal impairment (eGFR < 30 mL/min/1.73m), Metabolic acidosis (including Diabetic Ketoacidosis), acute or chronic conditions that can cause tissue hypoxia (sepsis, shock, acute MI), and hepatic impairment.",
        aec: "Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal bloating, metallic taste) which are often transient and dose-dependent.",
        aes: "LACTIC ACIDOSIS (rare but potentially fatal; risk increases with renal impairment or hypoxia), and Vitamin B12 and folic acid deficiency (due to interference with absorption).",
        inter: [
            {d: "Iodinated Contrast", m: "Synergistic risk for acute kidney injury and subsequent lactic acidosis; MUST hold drug.", s: "critical"},
            {d: "Alcohol", m: "Potentiates the drug's effect on lactate metabolism; significant risk of lactic acidosis.", s: "high"},
            {d: "Cimetidine", m: "Competes for renal tubular secretion; increases metformin levels by 60%.", s: "med"}
        ],
        dosage: "Oral: Initial 500 mg twice daily or 850 mg once daily. Maintenance: 1500 mg to 2550 mg daily in divided doses. Max 2550 mg/day.",
        admin: "Administer orally WITH MEALS to minimize gastrointestinal side effects. For Extended-Release (XR) versions, take once daily with the evening meal. DO NOT crush or chew XR tablets.",
        nurse: "Monitor renal function (eGFR/Creatinine) at baseline and annually. HOLD Metformin for 48 hours before and after any radiologic study requiring IV contrast. Assess for B12 deficiency (anemia, peripheral neuropathy). Teach patient to report somnolence, cold skin, or hyperventilation (Lactic Acidosis signs)."
    },
    {
        g: "Pioglitazone", b: "Actos", c: "Thiazolidinedione (TZD / Glitazone)", cat: "dm",
        m: "Selectively stimulates the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). This regulates the expression of insulin-responsive genes involved in glucose and lipid metabolism. It increases insulin sensitivity in muscle and adipose tissue and decreases hepatic glucose output. It requires the presence of insulin to be effective but does not stimulate its secretion.",
        ind: "Management of Type 2 Diabetes Mellitus as monotherapy or in combination with other agents.",
        con: "NYHA Class III or IV Heart Failure (Black Box: may cause or exacerbate CHF), active liver disease, and history of bladder cancer.",
        aec: "Weight gain (due to both fluid retention and fat accumulation), peripheral edema, and upper respiratory tract infection.",
        aes: "HEART FAILURE EXACERBATION (due to fluid retention), bladder cancer (long-term use), and increased risk of distal bone fractures in women.",
        inter: [
            {d: "Insulin", m: "Significantly increases the risk of severe edema and congestive heart failure.", s: "high"},
            {d: "Oral Contraceptives", m: "May decrease the efficacy of hormonal birth control.", s: "med"}
        ],
        dosage: "Oral: 15 mg to 45 mg once daily.",
        admin: "Take once daily without regard to food. Onset of therapeutic effect is slow; may take 8-12 weeks for maximum glucose reduction.",
        nurse: "Monitor for signs of fluid overload (SOB, crackles, rapid weight gain, swollen ankles). Weigh patient daily. Monitor LFTs baseline and periodically. Assess for hematuria (bladder cancer risk)."
    },
    {
        g: "Rosiglitazone", b: "Avandia", c: "Thiazolidinedione (TZD / Glitazone)", cat: "dm",
        m: "Increases insulin sensitivity in target tissues by activating PPAR-gamma receptors. Reduces glucose production in the liver and increases glucose uptake in the periphery. Similar to pioglitazone but has different cardiovascular safety considerations.",
        ind: "Management of Type 2 Diabetes Mellitus.",
        con: "NYHA Class III/IV Heart Failure, history of MI or ACS (increased risk of ischemic events).",
        aec: "Edema, headache, back pain, and fatigue.",
        aes: "Congestive Heart Failure, Myocardial Ischemia risk, and elevations in LDL cholesterol.",
        inter: [{d: "Rifampin", m: "Decreases rosiglitazone levels; risk of treatment failure.", s: "med"}],
        dosage: "Oral: 2 mg to 8 mg daily (single or divided doses).",
        admin: "Administer orally once or twice daily without regard to food.",
        nurse: "Monitor for symptoms of heart failure. Monitor lipid panels baseline and during therapy. Not recommended for patients with pre-existing heart disease."
    }
];

</script>
    <script>
/* SOURCE: data_diabetes_secretagogues.js */
const data_diabetes_secretagogues = [
    {
        g: "Glipizide", b: "Glucotrol, Glucotrol XL", c: "Sulfonylurea (Second Generation)", cat: "dm",
        m: "Potently stimulates the release of insulin from the pancreatic beta cells by binding to and closing ATP-sensitive potassium channels on the cell membrane. This action triggers a sequence of events including cell depolarization, opening of voltage-gated calcium channels, and a subsequent influx of calcium ions that facilitates the exocytosis of insulin-containing secretory granules into the bloodstream. Beyond its primary pancreatic effect, it also increases the sensitivity of peripheral insulin receptors at target tissues like muscle and fat, enhancing glucose uptake. It requires functional pancreatic beta cells to be effective and is therefore useless in Type 1 Diabetes.",
        ind: "Management of Type 2 Diabetes Mellitus as an adjunct to diet and exercise to improve glycemic control. Often used when metformin is contraindicated or insufficient as monotherapy.",
        con: "Type 1 Diabetes Mellitus (absolute contraindication), Diabetic Ketoacidosis (DKA), hypersensitivity to sulfonamides (potential cross-reactivity), and pregnancy at term.",
        aec: "Common: Gastrointestinal upset (nausea, dyspepsia), weight gain (due to the anabolic effects of increased insulin), dizziness, and headache. Dermatologic: Photosensitivity and rash.",
        aes: "SEVERE HYPOGLYCEMIA: Can be profound, prolonged, and life-threatening, especially if a meal is missed. DISULFIRAM-LIKE REACTION: Intense nausea, vomiting, flushing, and palpitations when consumed with alcohol. Rare: Hematologic reactions such as hemolytic anemia or thrombocytopenia.",
        inter: [
            {d: "Alcohol", m: "Increases risk of profound hypoglycemia and triggers a severe disulfiram-like reaction.", s: "high"},
            {d: "Beta Blockers", m: "Masks common sympathetic signs of hypoglycemia (specifically tachycardia and tremors), delaying recognition of crisis.", s: "high"},
            {d: "NSAIDs / Warfarin", m: "Potentiates hypoglycemic effect by displacing the drug from protein-binding sites; monitor BG strictly.", s: "med"}
        ],
        dosage: "Oral: Immediate-release: 2.5 mg to 20 mg daily (doses > 15 mg should be divided BID). Extended-release (XL): 5 mg to 20 mg once daily.",
        admin: "Administer orally 30 minutes BEFORE breakfast or the first main meal of the day to ensure drug levels peak when food is absorbed. If a meal is skipped, the dose MUST be skipped to prevent acute hypoglycemia.",
        nurse: "Monitor blood glucose levels frequently, especially during initiation or dose changes. Ensure the patient always carries a fast-acting source of carbohydrate (glucose tabs). Educate on the necessity of regular, consistent meal timing. Assess for history of sulfa allergy before starting therapy. Monitor weight baseline and periodically."
    },
    {
        g: "Glyburide", b: "DiaBeta, Glynase PresTab", c: "Sulfonylurea (Second Generation)", cat: "dm",
        m: "Exerts a potent stimulatory effect on pancreatic beta cells to release insulin by inhibiting ATP-sensitive potassium channels. It has a significantly longer duration of action and a more prolonged hypoglycemic effect than glipizide. It is metabolized by the liver into several active metabolites that are excreted by both the liver and kidneys. This dual clearance pathway means that any degree of renal impairment significantly increases the risk of drug accumulation and subsequent fatal hypoglycemia.",
        ind: "Management of Type 2 Diabetes Mellitus.",
        con: "Type 1 Diabetes, DKA, and severe renal or hepatic impairment. Use with extreme caution in the elderly due to prolonged half-life.",
        aec: "Weight gain, nausea, epigastric fullness, heartburn, and skin rash.",
        aes: "SEVERE AND PROLONGED HYPOGLYCEMIA: High risk in the elderly and patients with renal dysfunction. Cholestatic jaundice and hepatotoxicity (rare).",
        inter: [
            {d: "Alcohol", m: "Increases hypoglycemia risk and triggers a disulfiram-like reaction.", s: "high"},
            {d: "Ciprofloxacin", m: "Potentiates the hypoglycemic effect of glyburide.", s: "med"}
        ],
        dosage: "Oral: 1.25 mg to 20 mg daily. Dosage above 10 mg should be divided into BID dosing for more stable control.",
        admin: "Take orally once daily with breakfast or the first main meal. Do not skip meals after taking. For Glynase (micronized form), follow specific dosing instructions as it is not bioequivalent to DiaBeta.",
        nurse: "Monitor renal function (BUN/Creatinine) baseline and periodically. Accumulation in renal failure can cause severe, refractory hypoglycemia. Teach patient to report signs of jaundice (yellow skin/eyes) or dark urine immediately. Not recommended for patients over 65 years of age."
    },
    {
        g: "Glimepiride", b: "Amaryl", c: "Sulfonylurea (Second Generation)", cat: "dm",
        m: "Stimulates the release of insulin from the pancreatic beta cells. It demonstrates a more rapid onset and longer duration of action than older sulfonylureas. It binds to a different site on the ATP-sensitive potassium channel than glipizide, which may result in a lower risk of hypoglycemia during exercise. It also demonstrates extra-pancreatic effects by increasing the sensitivity of peripheral tissues to insulin.",
        ind: "Management of Type 2 Diabetes Mellitus as an adjunct to diet and exercise.",
        con: "Sulfa allergy, DKA, and Type 1 Diabetes Mellitus.",
        aec: "Nausea, dizziness, headache, and accidental injury (due to dizziness).",
        aes: "Severe Hypoglycemia, hemolytic anemia, and thrombocytopenia. Potential for serious hypersensitivity reactions.",
        inter: [
            {d: "Alcohol", m: "Disulfiram-like reaction and increased risk of low blood sugar.", s: "high"},
            {d: "Fluconazole", m: "Inhibits metabolism; significant risk of toxic accumulation and hypoglycemia.", s: "high"}
        ],
        dosage: "Oral: 1 mg to 8 mg once daily. Maximum dose is 8 mg/day.",
        admin: "Take once daily with breakfast or the first main meal. Maintain consistent daily timing. Do not take if not eating a full meal.",
        nurse: "Monitor blood glucose baseline and periodically. Check CBC for signs of blood dyscrasias (unusual bleeding/bruising). Educate the patient on photosensitivity precautions and the use of sunscreen."
    },
    {
        g: "Chlorpropamide", b: "Diabinese", c: "Sulfonylurea (First Generation)", cat: "dm",
        m: "Stimulates insulin release from the pancreas. It is characterized by an extremely long half-life (up to 36-48 hours) and long duration of action. It is metabolized in the liver and excreted primarily in the urine. Due to its long duration, it carries a very high risk of cumulative toxicity and prolonged hypoglycemia, especially in the elderly.",
        ind: "Management of Type 2 Diabetes Mellitus (rarely used in modern practice due to safer second-generation alternatives).",
        con: "Renal impairment, elderly patients (BEERS list drug), liver disease, and hypersensitivity to sulfonylureas.",
        aec: "GI upset, dizziness, and headache.",
        aes: "PROLONGED HYPOGLYCEMIA (can last for days after stopping), severe disulfiram-like reaction with alcohol, and SIADH (causing water retention and dilutional hyponatremia).",
        inter: [{d: "Alcohol", m: "Severe flushing and hypotension (disulfiram reaction).", s: "high"}],
        dosage: "Oral: 100 mg to 500 mg once daily. Max 750 mg/day.",
        admin: "Take daily with food. Avoid in the elderly. Monitor sodium levels if the patient appears confused or lethargic.",
        nurse: "Monitor for signs of fluid retention (edema, weight gain). Monitor serum sodium levels (SIADH risk). Educate the patient to avoid alcohol completely while on this drug and for 48 hours after stopping."
    },
    {
        g: "Tolazamide", b: "Tolinase", c: "Sulfonylurea (First Generation)", cat: "dm",
        m: "Stimulates the secretion of insulin from pancreatic beta cells. It is moderately long-acting and is metabolized to several mildly active metabolites. It decreases hepatic glucose production and increases insulin receptor sensitivity in the periphery.",
        ind: "Management of Type 2 Diabetes Mellitus.",
        con: "Diabetic Ketoacidosis, severe hepatic or renal dysfunction, and hypersensitivity.",
        aec: "Nausea, heartburn, and epigastric distress.",
        aes: "Hypoglycemia and cholestatic jaundice.",
        inter: [],
        dosage: "Oral: 100 mg to 1000 mg daily. Doses greater than 500 mg should be divided into BID dosing.",
        admin: "Take with the first meal of the day. If taking BID, take with breakfast and dinner.",
        nurse: "Monitor for signs of hypoglycemia. Check LFTs periodically. Assess for history of sulfa allergy."
    },
    {
        g: "Repaglinide", b: "Prandin", c: "Meglitinide / Glinide (Insulin Secretagogue)", cat: "dm",
        m: "Stimulates pancreatic insulin release by closing ATP-sensitive potassium channels in the beta cell membrane, leading to depolarization and calcium-mediated insulin exocytosis. It has a much faster onset and shorter duration of action (4-6 hours) than sulfonylureas, providing targeted control of post-prandial glucose spikes. It mimics the normal physiological prandial insulin response and requires the presence of glucose to be most effective.",
        ind: "Management of Type 2 Diabetes Mellitus, specifically indicated for the control of post-prandial glucose levels.",
        con: "Type 1 Diabetes, Diabetic Ketoacidosis, and concurrent use of gemfibrozil.",
        aec: "Upper respiratory tract infection, headache, diarrhea, and back pain.",
        aes: "SEVERE HYPOGLYCEMIA (especially if the meal is delayed or skipped) and serious hypersensitivity reactions.",
        inter: [
            {d: "Gemfibrozil", m: "Strongly inhibits CYP2C8 metabolism; leads to an 8-fold increase in drug levels and FATAL hypoglycemia. COMBINATION CONTRAINDICATED.", s: "critical"},
            {d: "Clarithromycin", m: "Inhibits metabolism and increases drug levels and hypoglycemia risk.", s: "high"}
        ],
        dosage: "Oral: 0.5 mg to 4 mg administered before each meal. Maximum 16 mg/day.",
        admin: "MUST take 15 to 30 minutes BEFORE each major meal. If a meal is skipped, the dose MUST be skipped. If a meal is added, a dose MUST be added. NO MEAL = NO DOSE.",
        nurse: "Ideal for patients with erratic eating schedules. Monitor for signs of hypoglycemia immediately following meals. Ensure the patient understands the 'No Meal, No Dose' rule to avoid crisis. Monitor HbA1c."
    },
    {
        g: "Nateglinide", b: "Starlix", c: "Meglitinide / Glinide (Insulin Secretagogue)", cat: "dm",
        m: "Rapidly and transiently restores early insulin secretion in response to a meal. It has a very rapid onset and a shorter duration than repaglinide, specifically targeting the first-phase insulin response. It decreases postprandial glucose spikes by stimulating the pancreas immediately after ingestion.",
        ind: "Management of Type 2 Diabetes Mellitus as an adjunct to diet and exercise.",
        con: "Type 1 Diabetes, DKA, and known hypersensitivity.",
        aec: "Dizziness, flu-like symptoms, accidental trauma, and upper respiratory infection.",
        aes: "Hypoglycemia (less risk than sulfonylureas but still present).",
        inter: [],
        dosage: "Oral: 60 mg to 120 mg three times daily before meals.",
        admin: "Administer 1 to 30 minutes before each main meal. Do NOT take the dose if you are skipping the meal.",
        nurse: "Monitor postprandial blood glucose levels. Teach the patient that this drug only works effectively if taken immediately before eating. Assess for dizziness."
    }
];

</script>
    <script>
/* SOURCE: data_diabetes_alpha_sglt2.js */
const data_diabetes_alpha_sglt2 = [
    {
        g: "Acarbose", b: "Precose", c: "Alpha-Glucosidase Inhibitor", cat: "dm",
        m: "Competitively and reversibly inhibits the alpha-glucosidase enzymes (glucomidase, sucrase, maltase) in the brush border of the small intestine. This action significantly delays the digestion and subsequent absorption of complex carbohydrates and sucrose into smaller glucose molecules. As a result, the post-prandial rise in blood glucose is blunted and smoothed out. It does NOT stimulate insulin secretion and does not cause hypoglycemia when used as monotherapy. Its effect is purely local within the GI tract.",
        ind: "Management of Type 2 Diabetes Mellitus as an adjunct to diet and exercise to specifically control post-prandial hyperglycemia spikes.",
        con: "Inflammatory Bowel Disease (IBD), colonic ulceration, partial intestinal obstruction, and chronic intestinal diseases characterized by marked disorders of digestion or absorption.",
        aec: "Gastrointestinal: FLATULENCE (very common, up to 70% of patients), diarrhea, abdominal pain, and borborygmi (stomach rumbling). Symptoms are related to the fermentation of undigested carbohydrates in the colon.",
        aes: "Hepatotoxicity (clinically significant elevations in LFTs with long-term use) and iron deficiency anemia (due to reduced absorption).",
        inter: [
            {d: "Digestive Enzymes (Amylase)", m: "Reduces the therapeutic effect of acarbose; avoid concurrent use.", s: "med"},
            {d: "Digoxin", m: "May reduce the absorption and serum levels of digoxin by interfering with gut uptake.", s: "med"}
        ],
        dosage: "Oral: 25 mg to 100 mg three times daily. Max 100 mg TID.",
        admin: "MUST be administered orally with the VERY FIRST BITE of each main meal to ensure the drug is present when carbs enter the intestine. If a meal is skipped, the dose must be skipped.",
        nurse: "Monitor LFTs every 3 months for the first year. If hypoglycemia occurs (due to other concurrent DM drugs), it MUST be treated with GLUCOSE (dextrose tabs/gel), not sucrose (cane sugar/juice/candy), as acarbose prevents the breakdown of sucrose."
    },
    {
        g: "Miglitol", b: "Glyset", c: "Alpha-Glucosidase Inhibitor", cat: "dm",
        m: "Inhibits alpha-glucosidase enzymes in the small intestine brush border. Unlike acarbose, miglitol is systemically absorbed but not metabolized, and is excreted by the kidneys. It delays the absorption of dietary carbohydrates, reducing the magnitude of post-prandial glucose elevations.",
        ind: "Management of Type 2 Diabetes Mellitus.",
        con: "Chronic intestinal diseases, IBD, colonic ulceration, and intestinal obstruction.",
        aec: "Abdominal pain, diarrhea, and flatulence (dose-related and usually transient).",
        aes: "Severe GI distress and skin rash (rare).",
        inter: [],
        dosage: "Oral: 25 mg to 100 mg three times daily.",
        admin: "Take orally with the first bite of each main meal. Do not take if not eating a full meal.",
        nurse: "Monitor iron levels periodically as the drug may decrease iron absorption. Educate the patient that hypoglycemia must be treated with glucose (dextrose) only."
    },
    {
        g: "Canagliflozin", b: "Invokana", c: "SGLT2 Inhibitor", cat: "dm",
        m: "Inhibits the Sodium-Glucose Co-Transporter 2 (SGLT2) in the proximal renal tubules. SGLT2 is responsible for at least 90% of glucose reabsorption from the glomerular filtrate. By blocking this transporter, canagliflozin reduces the renal threshold for glucose and increases urinary glucose excretion (glycosuria), effectively removing glucose from the body via the kidneys and providing an insulin-independent mechanism for glucose lowering.",
        ind: "Type 2 Diabetes Mellitus; reduction of risk of major adverse CV events in adults with T2DM and established CVD; treatment of diabetic nephropathy with albuminuria.",
        con: "Severe renal impairment (eGFR < 30 mL/min), end-stage renal disease (ESRD), or patients on dialysis.",
        aec: "Polyuria (increased urination), increased thirst (thirst/dry mouth), vulvovaginal candidiasis (yeast infection), and urinary tract infections.",
        aes: "EUGLYCEMIC KETOACIDOSIS (DKA with normal or near-normal BG levels), severe hypotension/dehydration, hyperkalemia, and increased risk of lower limb amputation (Black Box warning).",
        inter: [{d: "Diuretics (Loop/Thiazide)", m: "Significantly increases the risk of severe dehydration and symptomatic hypotension.", s: "high"}],
        dosage: "Oral: 100 mg to 300 mg once daily.",
        admin: "Take once daily BEFORE the first meal of the day. Ensure the patient maintains adequate daily fluid intake to prevent dehydration.",
        nurse: "Monitor hydration status and blood pressure baseline and periodically. Assess for signs of genital itching or burning (yeast). Check serum potassium and renal function. Teach patient to report any new foot pain or sores immediately (Amputation risk)."
    },
    {
        g: "Dapagliflozin", b: "Farxiga", c: "SGLT2 Inhibitor", cat: "dm",
        m: "Selective inhibitor of SGLT2 in the renal tubules, promoting glycosuria and associated caloric loss. It also reduces sodium reabsorption, which may contribute to its clinically proven beneficial effects in heart failure and chronic kidney disease by reducing volume overload.",
        ind: "Type 2 Diabetes Mellitus, symptomatic Heart Failure (HFrEF and HFpEF), and Chronic Kidney Disease (CKD).",
        con: "Hypersensitivity; patients on dialysis.",
        aec: "Increased urination, UTIs, nasopharyngitis, and thirst.",
        aes: "Ketoacidosis, acute kidney injury, FOURNIER'S GANGRENE (rare but life-threatening necrotizing fasciitis of the perineum), and volume depletion.",
        inter: [],
        dosage: "Oral: 5 mg to 10 mg once daily.",
        admin: "Take once daily in the morning with or without food. Ensure patient is hydrated.",
        nurse: "Assess for signs of infection in the genital or perianal area (pain, tenderness, erythema). Monitor blood pressure and renal function labs. Educate on signs of DKA (nausea, abdominal pain)."
    },
    {
        g: "Empagliflozin", b: "Jardiance", c: "SGLT2 Inhibitor", cat: "dm",
        m: "Inhibits SGLT2 to increase urinary glucose excretion. It provides cardioprotective and renoprotective effects by reducing intraglomerular pressure and improving cardiac energetics. Proven to significantly reduce the risk of cardiovascular death in T2DM patients.",
        ind: "Type 2 Diabetes, symptomatic Heart Failure, and reduction of risk of sustained eGFR decline in CKD patients.",
        con: "Hypersensitivity; eGFR < 30 mL/min.",
        aec: "Genital mycotic infections, UTIs, increased urination, and joint pain.",
        aes: "Ketoacidosis, urosepsis, pyelonephritis, and severe volume depletion.",
        inter: [],
        dosage: "Oral: 10 mg to 25 mg once daily.",
        admin: "Take once daily in the morning. Consistent daily administration is required.",
        nurse: "Monitor renal labs (BUN/Cr) baseline and periodically. Check for signs of volume depletion (dizziness, hypotension). Teach patient genital hygiene to reduce yeast infection risk."
    }
];

</script>
    <script>
/* SOURCE: data_diabetes_gliptin_glp1a.js */
const data_diabetes_gliptin_glp1a = [
    {
        g: "Sitagliptin", b: "Januvia", c: "DPP-4 Inhibitor (Gliptin)", cat: "dm",
        m: "Inhibits the Dipeptidyl Peptidase-4 (DPP-4) enzyme, which is responsible for the rapid degradation of incretin hormones, specifically Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP). By extending the half-life of these endogenous hormones, sitagliptin increases insulin synthesis and release from pancreatic beta cells and decreases glucagon secretion from alpha cells in a glucose-dependent manner. This results in lowered fasting and postprandial glucose levels without causing weight gain or hypoglycemia.",
        ind: "Management of Type 2 Diabetes Mellitus as monotherapy or in combination with metformin, sulfonylureas, or TZDs to achieve glycemic targets.",
        con: "History of prior serious hypersensitivity reaction to sitagliptin; use with caution in patients with a history of chronic or acute pancreatitis.",
        aec: "Upper respiratory tract infection, nasopharyngitis, headache, and gastrointestinal upset (diarrhea, nausea).",
        aes: "PANCREATITIS (potentially fatal; presents as severe, persistent abdominal pain radiating to the back), serious hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome), and acute renal failure.",
        inter: [
            {d: "Digoxin", m: "May slightly increase the serum concentration of digoxin; monitor levels.", s: "med"},
            {d: "Insulin / Sulfonylureas", m: "Increases risk of hypoglycemia when used in combination; monitor BG.", s: "high"}
        ],
        dosage: "Oral: 100 mg once daily. Adjust to 50 mg or 25 mg in patients with moderate to severe renal impairment (eGFR < 45).",
        admin: "Take once daily without regard to food. Maintain a consistent daily schedule. Tablet must be swallowed whole.",
        nurse: "Monitor renal function (Creatinine/eGFR) baseline and annually. Assess for severe, persistent abdominal pain with or without vomiting (hallmark of pancreatitis). Educate the patient on signs of serious skin reactions (rash, blistering)."
    },
    {
        g: "Linagliptin", b: "Tradjenta", c: "DPP-4 Inhibitor (Gliptin)", cat: "dm",
        m: "Inhibits the DPP-4 enzyme to increase levels of active incretin hormones. It is highly selective for DPP-4. Uniquely among the gliptins, linagliptin is primarily excreted via the enterohepatic system (feces) rather than the kidneys, meaning no dosage adjustment is required for renal impairment, making it the preferred gliptin for CKD patients.",
        ind: "Management of Type 2 Diabetes Mellitus.",
        con: "Prior hypersensitivity; history of pancreatitis.",
        aec: "Nasopharyngitis, cough, headache, and musculoskeletal pain.",
        aes: "Acute pancreatitis, severe arthralgia (joint pain), and bullous pemphigoid (autoimmune skin blistering).",
        inter: [{d: "Rifampin", m: "Decreases linagliptin efficacy; avoid combination.", s: "med"}],
        dosage: "Oral: 5 mg once daily.",
        admin: "Take once daily with or without food. No renal or hepatic dose adjustment needed.",
        nurse: "Assess for signs of pancreatitis. Monitor for severe, disabling joint pain. Teach patient to report any new skin blisters or erosions immediately."
    },
    {
        g: "Exenatide", b: "Byetta (BID), Bydureon (Weekly)", c: "GLP-1 Receptor Agonist (Incretin Mimetic)", cat: "dm",
        m: "A synthetic analog of human GLP-1 that binds to and activates the GLP-1 receptor. It enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and significantly slows gastric emptying. It also promotes satiety and weight loss by acting on the central nervous system. It is resistant to degradation by DPP-4.",
        ind: "Management of Type 2 Diabetes Mellitus as an adjunct to diet/exercise or oral agents to improve glycemic control.",
        con: "Personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and severe renal impairment (CrCl < 30 mL/min).",
        aec: "Nausea (very common initially), vomiting, diarrhea, and significant WEIGHT LOSS (average 6-7 lbs).",
        aes: "ACUTE PANCREATITIS, renal failure, and thyroid C-cell tumors (Black Box warning).",
        inter: [{d: "Oral Meds", m: "Slowed gastric emptying may delay the absorption of other oral medications; separate narrow-index drugs.", s: "med"}],
        dosage: "Subcutaneous: 5 mcg to 10 mcg BID (Byetta) or 2 mg once weekly (Bydureon).",
        admin: "Byetta: Inject SC within 60 minutes BEFORE the morning and evening meals. Never inject after a meal. Bydureon: Inject SC once weekly at any time.",
        nurse: "Teach SC injection technique and rotation of sites. Monitor for severe abdominal pain. Monitor weight. Ensure patient understands the strict timing requirement for Byetta BID."
    },
    {
        g: "Dulaglutide", b: "Trulicity", c: "GLP-1 Receptor Agonist (Incretin Mimetic)", cat: "dm",
        m: "Mimics the action of GLP-1 to stimulate insulin release, inhibit glucagon, and slow gastric emptying. It is a long-acting formulation utilizing a once-weekly dosing schedule. It increases cyclic AMP in beta cells in a glucose-dependent manner.",
        ind: "Type 2 Diabetes Mellitus; reduction of major adverse CV events in T2DM patients with established CVD or multiple risk factors.",
        con: "History of MTC or MEN 2.",
        aec: "Nausea, vomiting, abdominal pain, diarrhea, and decreased appetite.",
        aes: "Thyroid tumors (Black Box warning), pancreatitis, and acute kidney injury (secondary to GI-induced dehydration).",
        inter: [],
        dosage: "Subcutaneous: 0.75 mg to 1.5 mg once weekly. Maximum dose 4.5 mg once weekly.",
        admin: "Administer SC once weekly into the abdomen, thigh, or upper arm. Rotate sites. Pen is single-use and disposable.",
        nurse: "Monitor for severe GI distress. Check renal labs if patient is persistently vomiting. Teach signs of thyroid tumors (neck mass, dysphagia, hoarseness)."
    },
    {
        g: "Liraglutide", b: "Victoza (DM), Saxenda (Weight)", c: "GLP-1 Receptor Agonist (Incretin Mimetic)", cat: "dm",
        m: "Increases glucose-dependent insulin secretion and suppresses glucagon. Slows gastric emptying and increases satiety. Provides constant GLP-1 receptor activation with a single daily dose due to its 13-hour half-life.",
        ind: "Type 2 Diabetes Mellitus; chronic weight management (Saxenda); reduction of CV risk in T2DM.",
        con: "Personal/family history of Medullary Thyroid Carcinoma (MTC) or MEN 2.",
        aec: "Nausea, diarrhea, constipation, headache, and decreased appetite.",
        aes: "Pancreatitis, gallbladder disease (cholecystitis), and renal impairment.",
        inter: [],
        dosage: "Subcutaneous: 0.6 mg to 1.8 mg once daily (Victoza); up to 3 mg daily (Saxenda).",
        admin: "Inject SC once daily at any time without regard to meals. Rotate sites.",
        nurse: "Assess for signs of pancreatitis. Monitor for gallbladder disease (RUQ pain, fatty food intolerance). Instruct on once-daily injection and storage."
    }
];

</script>
    <script>
/* SOURCE: data_diabetes_insulins_part1.js */
const data_diabetes_insulins_part1 = [
    {
        g: "Semaglutide", b: "Ozempic (SC), Wegovy (Weight), Rybelsus (Oral)", c: "GLP-1 Receptor Agonist (Incretin Mimetic)", cat: "dm",
        m: "Mimics the action of the endogenous incretin hormone glucagon-like peptide-1 (GLP-1). It binds to and activates the GLP-1 receptor, which stimulates glucose-dependent insulin secretion from the pancreas (only when BG is high), suppresses inappropriately elevated glucagon secretion, and significantly slows gastric emptying. It also acts on the arcuate nucleus of the hypothalamus to increase satiety and reduce appetite, leading to significant sustainable weight loss and improved cardiovascular outcomes. It is highly resistant to degradation by the DPP-4 enzyme, allowing for a long half-life and once-weekly administration in the injectable form.",
        ind: "Management of Type 2 Diabetes Mellitus; reduction of risk of major adverse CV events (MI, Stroke) in adults with T2DM and established CVD; chronic weight management (Wegovy).",
        con: "Personal or family history of Medullary Thyroid Carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and known hypersensitivity. Severe gastrointestinal disease (e.g., gastroparesis).",
        aec: "Common: Nausea (dose-dependent and usually transient), vomiting, diarrhea, abdominal pain, constipation, and local injection site reactions (redness, itching).",
        aes: "ACUTE PANCREATITIS (potentially fatal; requires immediate discontinuation), thyroid C-cell tumors (Black Box warning), diabetic retinopathy complications, and acute gallbladder disease (cholecystitis).",
        inter: [{d: "Oral Medications", m: "Delayed gastric emptying may reduce the rate and extent of absorption of concurrently administered oral drugs.", s: "med"}],
        dosage: "SC: 0.25 mg to 2 mg once weekly. Oral (Rybelsus): 3 mg to 14 mg once daily.",
        admin: "SC: Administer once weekly at any time of day. Rotate sites in abdomen, thigh, or arm. Oral (Rybelsus): MUST take on an empty stomach with no more than 4 oz of plain water at least 30 minutes before first food, beverage, or other oral medications to ensure absorption.",
        nurse: "Monitor for severe, persistent abdominal pain which may radiate to the back (pancreatitis). Perform periodic thyroid screening by palpating the neck for masses. Instruct patient on Rybelsus-specific fasting requirements. Assess for retinopathy changes before and during therapy. Monitor weight baseline and weekly."
    },
    {
        g: "Pramlintide", b: "Symlin", c: "Amylin Mimetic", cat: "dm",
        m: "A synthetic analog of human amylin, a small peptide hormone that is co-secreted with insulin by pancreatic beta cells. In patients with diabetes, amylin is either absent or deficient. Pramlintide works by three distinct mechanisms: 1. Slowing gastric emptying, which reduces the rate at which glucose enters the systemic circulation after a meal. 2. Suppressing post-prandial glucagon secretion (which is inappropriately elevated in diabetics). 3. Increasing central satiety (feeling of fullness) through hypothalamic signaling. It is used as an adjunct to insulin therapy to improve postprandial glucose control without causing weight gain. It effectively limits the rate of glucose entry into the blood, preventing the typical post-meal glycemic surge.",
        ind: "Adjunct treatment in patients with Type 1 or Type 2 Diabetes Mellitus who use prandial (mealtime) insulin and have failed to reach glucose targets despite optimal insulin therapy. It is the only non-insulin injectable drug approved for Type 1 diabetics.",
        con: "Gastroparesis (absolute contraindication due to further slowing of motility), hypoglycemia unawareness (inability to detect early warning signs), and known hypersensitivity. Use with caution in patients with recurrent hypoglycemia or poor adherence to monitoring.",
        aec: "Nausea (very common, typically occurs during initial titration and usually subsides over time), anorexia, headache, fatigue, and abdominal pain. Gastrointestinal distress is usually dose-related.",
        aes: "SEVERE HYPOGLYCEMIA (Black Box warning - typically occurs within 3 hours of injection when used with prandial insulin). Significant risk of unintentional weight loss and potentially life-threatening glucose drops if insulin doses are not adjusted correctly.",
        inter: [
            {d: "Prandial Insulin", m: "Extreme synergistic risk of severe hypoglycemia; MUST reduce mealtime insulin dose by 50% upon initiation.", s: "critical"},
            {d: "Anticholinergics", m: "Additive slowing of GI motility; high risk of severe constipation or bowel obstruction.", s: "high"},
            {d: "Oral Medications", m: "Slowed gastric emptying may delay the absorption of other oral medications; take 1h before or 2h after.", s: "med"}
        ],
        dosage: "Subcutaneous: 15 mcg to 120 mcg before each major meal (Type 1: 15-60mcg; Type 2: 60-120mcg). Titrate slowly based on tolerability.",
        admin: "SC injection immediately before major meals (>250 calories or >30g carbs). Do NOT mix in the same syringe as insulin (structural incompatibility). Rotate sites in the abdomen or thigh. If a meal is skipped, the dose MUST be skipped. Do not use if the patient is not compliant with frequent BG monitoring.",
        nurse: "Monitor blood glucose levels 3 hours after injection when peak effect occurs and the risk of hypoglycemia is highest. Ensure patient has a fast-acting glucose source available at all times. Verify that mealtime insulin dose was reduced by 50% when starting Symlin. Educate the patient that nausea is very common initially but usually subsides over several weeks of consistent use. Check for gastroparesis symptoms before therapy."
    },
    {
        g: "Glucagon", b: "GlucaGen, Gvoke, Baqsimi", c: "Hyperglycemic Agent / Pancreatic Hormone", cat: "dm",
        m: "A naturally occurring hormone produced by the alpha cells of the pancreas. It acts as a physiological antagonist to insulin. It stimulates hepatic glycogenolysis (the breakdown of stored glycogen into glucose) and gluconeogenesis (the synthesis of glucose from non-carbohydrate sources) by accelerating enzymatic processes in the liver. This causes a rapid increase in blood glucose levels within 5-15 minutes of administration. It also has a potent relaxing effect on the smooth muscle of the gastrointestinal tract and possesses positive inotropic and chronotropic effects on the heart.",
        ind: "Emergency treatment of SEVERE HYPOGLYCEMIA in patients with diabetes who are unconscious, convulsing, or otherwise unable to ingest oral glucose. Also used as a diagnostic aid during radiologic examinations of the GI tract.",
        con: "Pheochromocytoma (may cause significant catecholamine release and severe HTN), insulinoma, and hypersensitivity.",
        aec: "Nausea, vomiting (very common upon awakening), headache, and transient tachycardia. Secondary rebound hypoglycemia can occur after glycogen stores are depleted.",
        aes: "Hypersensitivity (anaphylaxis), severe hypertension (in patients with pheochromocytoma), and cardiac arrhythmias.",
        inter: [{d: "Warfarin", m: "May increase anticoagulant effect and bleeding risk; monitor INR closely.", s: "med"}],
        dosage: "IM/SC/IV: 1 mg (Adult). Nasal (Baqsimi): 3 mg in one nostril. Pediatric (<20kg): 0.5 mg.",
        admin: "Turn patient on their SIDE (lateral recumbent position) before or immediately after administration to prevent aspiration if vomiting occurs. Patient should awaken within 5 to 15 minutes. If no response after 15 mins, a second dose may be given.",
        nurse: "Monitor blood glucose response every 5-10 minutes. Once the patient is conscious and able to swallow, provide oral fast-acting carbohydrates followed by a balanced snack with protein and complex starch (e.g., milk and crackers). Teach family members/caregivers how to use the emergency kit. Monitor for rebound hypoglycemia."
    },
    {
        g: "Insulin Regular", b: "Humulin R, Novolin R", c: "Short-Acting Insulin", cat: "dm",
        m: "A recombinant human insulin that is identical to endogenous human insulin produced by the pancreas. It promotes cellular uptake of glucose by binding to insulin receptors on muscle and adipose cells. It also facilitates the storage of glucose as glycogen in the liver and inhibits hepatic glucose production. It has a slightly slower onset and longer duration than rapid-acting analogs because it forms hexamers in the subcutaneous tissue which must dissociate into monomers before being absorbed into the circulation.",
        ind: "Management of Type 1 DM, Type 2 DM, Diabetic Ketoacidosis (DKA), and Hyperkalemia (administered with IV dextrose to shift K+ into cells). Also used for gestational diabetes.",
        con: "Hypoglycemia (absolute contraindication), hypersensitivity to human insulin.",
        aec: "Weight gain (due to anabolic effects), lipohypertrophy (fatty lumps at injection site), and mild local site reactions (redness, swelling).",
        aes: "SEVERE HYPOGLYCEMIA (sudden onset: tachycardia, diaphoresis, tremors, confusion, seizures), and severe hypokalemia (shifts K+ into cells).",
        inter: [{d: "Beta Blockers", m: "Mask tachycardia and tremors of hypoglycemia; interfere with the body's ability to recover glucose levels.", s: "high"}],
        dosage: "SC/IV: Individualized based on BG monitoring and carbohydrate counting. IV Drip: 0.1 units/kg/hr for DKA management.",
        admin: "Onset: 30-60 min. Peak: 2-4 hours. Duration: 5-8 hours. Administer 30 minutes BEFORE meals. Regular insulin is the ONLY insulin formulation that can be administered intravenously. When mixing, draw up the CLEAR (Regular) insulin into the syringe FIRST before the CLOUDY (NPH).",
        nurse: "Check BG before administration. Assess for signs of hypoglycemia at the 2-4 hour peak. Always verify dose with a second RN. Rotate injection sites within one anatomical area to prevent lipodystrophy. Store vials in use at room temperature for up to 28 days."
    },
    {
        g: "Insulin Lispro", b: "Humalog, Admelog", c: "Rapid-Acting Insulin", cat: "dm",
        m: "A rapid-acting analog of human insulin where the proline at position B28 is swapped with lysine at position B29. This structural modification prevents the formation of hexamers, allowing the insulin to exist as monomers that are absorbed almost immediately from the subcutaneous site. This mimics the natural first-phase prandial insulin spike more closely than regular insulin. It facilitates rapid cellular glucose uptake and inhibits hepatic glucose output.",
        ind: "Prandial (mealtime) glycemic control in patients with Type 1 and Type 2 Diabetes Mellitus. Often used in continuous subcutaneous insulin infusion (CSII) pumps.",
        con: "Hypoglycemia and known hypersensitivity.",
        aec: "Injection site reactions (pain, redness), weight gain, and peripheral edema.",
        aes: "PROFOUND SUDDEN HYPOGLYCEMIA (onset within 15 minutes), hypokalemia, and severe systemic allergic reactions (rare).",
        inter: [{d: "Alcohol", m: "Potentiates hypoglycemic effects and masks warning signs.", s: "high"}],
        dosage: "SC: Individualized based on meal size and glucose readings. 1 unit typically covers 10-15g of carbohydrates.",
        admin: "Onset: 15 min. Peak: 1-2 hours. Duration: 3-4 hours. MUST be administered 15 minutes before or immediately after starting a meal. GIVE ONLY WHEN FOOD IS PRESENT. Do not use if the solution is cloudy or discolored.",
        nurse: "Monitor BG frequently. Ensure the patient's tray is delivered and they are ready to eat before injecting. Teach the patient that this insulin acts very quickly and has a shorter duration than regular insulin. Always rotate injection sites. Check for clear appearance."
    }
];

</script>
    <script>
/* SOURCE: data_diabetes_insulins_part2.js */
const data_diabetes_insulins_part2 = [
    {
        g: "Insulin Aspart", b: "NovoLog, Fiasp", c: "Rapid-Acting Insulin", cat: "dm",
        m: "A recombinant human insulin analog where the amino acid proline at position B28 is replaced with aspartic acid. This modification reduces the tendency of the insulin molecule to form hexamers (six-molecule clusters), allowing for significantly more rapid absorption from the subcutaneous injection site into the systemic circulation. It facilitates the cellular uptake of glucose by binding to insulin receptors, promoting glycogen synthesis, and inhibiting hepatic glucose production. It mimics the rapid, first-phase insulin response seen in a healthy pancreas in response to glucose intake.",
        ind: "Management of glycemic control in adults and children with Type 1 or Type 2 Diabetes Mellitus, particularly for controlling postprandial (after-meal) glucose levels. Suitable for use in insulin pumps.",
        con: "Episodes of hypoglycemia and known hypersensitivity to insulin aspart or its components.",
        aec: "Weight gain, lipodystrophy (localized fat tissue damage), itching, and injection site erythema.",
        aes: "SUDDEN ONSET SEVERE HYPOGLYCEMIA, hypokalemia (due to intracellular potassium shift), and severe systemic allergic reactions (anaphylaxis).",
        inter: [{d: "Beta Blockers", m: "Mask tachycardia and other early warning symptoms of hypoglycemia and may delay recovery.", s: "high"}],
        dosage: "SC: Individualized based on glucose monitoring. Usually 0.5 to 1 unit/kg/day total dose, with aspart providing the prandial portion.",
        admin: "Onset: 10-20 min. Peak: 1-3 hours. Duration: 3-5 hours. Administer SC 5 to 10 minutes BEFORE a meal. Can be given immediately after starting a meal if necessary. Do not use if the solution is cloudy or contains particles.",
        nurse: "Monitor fingerstick glucose levels before meals and at bedtime. Ensure the patient has food immediately available before administration. Rotate injection sites within the chosen anatomical area. For patients using insulin pumps, assess the infusion site for infection or leakage."
    },
    {
        g: "Insulin Glulisine", b: "Apidra", c: "Rapid-Acting Insulin", cat: "dm",
        m: "A rapid-acting analog of human insulin created by replacing asparagine with lysine at position B3 and lysine with glutamic acid at position B29. This prevents the formation of hexamers and allows for faster onset and a shorter duration of action compared to regular human insulin. It facilitates glucose uptake into muscle and fat cells and inhibits glucose output from the liver. It provides tight control of mealtime glucose spikes. It is uniquely formulated with a stabilizing agent that allows it to maintain its kinetic profile even when mixed with certain other insulins.",
        ind: "Glycemic control in adults and children with Type 1 DM and adults with Type 2 DM. Specifically indicated for use during mealtime or for correcting high blood sugars in an acute setting.",
        con: "Hypoglycemia and known hypersensitivity to the drug or the stabilizing agents used in its manufacture.",
        aec: "Hypoglycemia, injection site reactions (swelling, itching), and lipodystrophy. Potential for transient nasopharyngitis or upper respiratory symptoms.",
        aes: "Severe life-threatening hypoglycemia and acute hypokalemia which can lead to cardiac dysrhythmias.",
        inter: [{d: "Alcohol", m: "Potentiates the glucose-lowering effects and masks early warning signs.", s: "high"}],
        dosage: "SC: Individualized based on carbohydrate counting and current BG levels. Typically 1 unit per 10-15g of carbs.",
        admin: "Onset: 15 min. Peak: 1 hour. Duration: 2-4 hours. Administer SC within 15 minutes BEFORE or 20 minutes AFTER starting a meal. Compatible with regular insulin for mixing if required. Must use a specialized insulin syringe or pen device.",
        nurse: "Monitor BG frequently, especially 1 hour post-dose. Teach patient the importance of consistent timing with meals. Assess for symptoms of hypoglycemia including cold, clammy skin and confusion. Ensure that the patient understands that this is a bolus insulin, not for 24-hour basal coverage."
    },
    {
        g: "Insulin NPH", b: "Humulin N, Novolin N", c: "Intermediate-Acting Insulin", cat: "dm",
        m: "A neutral protamine Hagedorn (NPH) insulin where regular human insulin is conjugated with the protein protamine. The protamine significantly slows the absorption of the insulin from the subcutaneous site, resulting in a prolonged duration of action. This provides basal insulin coverage for approximately half a day to a full day. It facilitates glucose transport into cells and stimulates hepatic glycogen synthesis. It has a cloudy appearance due to the protein complex.",
        ind: "Treatment of Type 1 and Type 2 Diabetes Mellitus for basal (background) glycemic control. Preferred for use in pregnancy.",
        con: "Hypoglycemia, hypersensitivity to protamine or insulin.",
        aec: "Hypoglycemia (typically occurring mid-to-late afternoon during the peak), weight gain, and lipohypertrophy.",
        aes: "Severe hypoglycemia, severe hypokalemia, and systemic allergic reactions.",
        inter: [],
        dosage: "SC: Individualized. Often administered once or twice daily (BID) to provide 24-hour basal coverage.",
        admin: "Onset: 1-2 hours. Peak: 4-12 hours. Duration: 18-24 hours. MUST be gently rolled (not shaken) before administration to ensure the suspension is uniform. Drawn into the syringe SECOND (after regular insulin) when mixing. Always remember 'Clear before Cloudy'.",
        nurse: "Check BG levels, particularly during the peak time (4-12h post-dose) when the risk of hypoglycemia is highest. Assess injection sites for fatty lumps (lipodystrophy). Instruct the patient on proper mixing technique to avoid contaminating the clear insulin vial."
    },
    {
        g: "Insulin Glargine", b: "Lantus, Basaglar, Toujeo", c: "Long-Acting Insulin", cat: "dm",
        m: "A long-acting human insulin analog designed to have low solubility at neutral pH. After subcutaneous injection, the acidic solution (pH 4.0) is neutralized by the body's natural pH, causing the insulin to form micro-precipitates in the tissue. These precipitates dissolve slowly and steadily over 24 hours, providing a constant, peakless level of insulin in the circulation. This mimics the continuous, low-level basal insulin secretion of a healthy pancreas and provides 24-hour glycemic control with minimal fluctuations. It does not possess a distinct peak, which significantly reduces the risk of nocturnal hypoglycemia compared to NPH insulin.",
        ind: "Once-daily basal glycemic control in adults and pediatric patients with Type 1 DM and adults with Type 2 DM. Preferred for patients requiring stable, peakless background coverage.",
        con: "Episodes of hypoglycemia and known hypersensitivity. Not for the treatment of diabetic ketoacidosis (which requires IV regular insulin).",
        aec: "Injection site pain (due to the acidic nature of the solution), weight gain, and minor hypoglycemia. Potential for respiratory infection.",
        aes: "Severe hypoglycemia (less common than with NPH), hypokalemia, and anaphylaxis. Long-term risk of increased tumor progression (theoretical, monitor closely).",
        inter: [{d: "Other Insulins", m: "Mixing with other solutions changes the pH and ruins the peakless kinetic profile.", s: "critical"}],
        dosage: "SC: Individualized. Toujeo is a concentrated form (300 units/mL); Lantus is standard (100 units/mL). Adjust doses carefully.",
        admin: "Onset: 1-2 hours. NO PEAK. Duration: 24 hours. Administer SC once daily at the same time each day (usually bedtime or morning). NEVER mix glargine in the same syringe with any other insulin or solution as the pH change will cause immediate precipitation and unpredictable kinetics. Do not administer intravenously.",
        nurse: "Verify that the patient does NOT mix this insulin. Ensure consistent daily timing. Monitor BG daily. Educate the patient that this insulin is for background control, not for mealtime corrections. Check for clear appearance; if the solution is cloudy, discard it."
    },
    {
        g: "Insulin Detemir", b: "Levemir", c: "Long-Acting Insulin", cat: "dm",
        m: "A long-acting insulin analog with a fatty acid (myristic acid) side chain attached to the lysine at position B29. After injection, detemir molecules form hexamers and then bind reversibly to albumin in both the subcutaneous tissue and the bloodstream. This reversible albumin binding results in a slow and prolonged absorption and distribution, providing a stable, long-lasting basal insulin effect. This mechanism of 'albumin-buffering' results in more predictable and less variable blood sugar levels compared to intermediate-acting NPH insulin. It mimics the natural steady release of insulin from the pancreas.",
        ind: "Basal glycemic control in adults and pediatric patients with Type 1 or Type 2 Diabetes Mellitus. Useful for patients who experience weight gain with other insulins.",
        con: "Hypoglycemia and known hypersensitivity to the drug or albumin-binding components.",
        aec: "Injection site reactions (pain, redness), weight gain (statistically less weight gain than NPH or Glargine), and headache. Flu-like symptoms may occur.",
        aes: "Severe hypoglycemia, acute hypokalemia, and systemic hypersensitivity reactions.",
        inter: [],
        dosage: "SC: Individualized. Once or twice daily (BID). Typically 0.1 to 0.2 units/kg.",
        admin: "Onset: 1-2 hours. Peak: 6-8 hours (relatively flat). Duration: 12-24 hours (dose-dependent). Do NOT mix detemir with other insulins or solutions. If used twice daily, space doses 12 hours apart. Administer at the same time each day to maintain steady-state levels.",
        nurse: "Monitor BG baseline and periodically. Rotate injection sites. Assess for signs of hypoglycemia. Educate patient that this is a basal insulin and must be used even when the patient is not eating (unless otherwise instructed). Instruct patient not to dilute or mix this medication."
    },
    {
        g: "Insulin Degludec", b: "Tresiba", c: "Ultra-Long-Acting Insulin", cat: "dm",
        m: "An ultra-long-acting basal insulin analog that forms soluble multi-hexamers upon subcutaneous injection. These multi-hexamers create a large 'depot' in the tissue, from which insulin monomers are slowly and continuously released into the circulation. This results in an exceptionally long half-life (25 hours) and a duration of action exceeding 42 hours. It provides a highly stable and consistent glucose-lowering effect with significantly less intra-patient variability.",
        ind: "Once-daily basal glycemic control in adults and pediatric patients (1 year+) with Type 1 and Type 2 DM.",
        con: "Hypoglycemia and hypersensitivity.",
        aec: "Nasopharyngitis, upper respiratory tract infection, headache, and weight gain.",
        aes: "Severe hypoglycemia and severe hypokalemia.",
        inter: [],
        dosage: "SC: Individualized. Available in 100 units/mL (U-100) and 200 units/mL (U-200) pens.",
        admin: "Onset: 1 hour. Peak: None. Duration: > 42 hours. Administer SC once daily at any time of day. While consistent timing is preferred, the long duration allows for dose timing flexibility, provided there are at least 8 hours between doses.",
        nurse: "Monitor BG. Instruct the patient on the ultra-long duration of action. Do not mix with other insulins. Ensure the patient is using the correct pen concentration (U-100 vs U-200)."
    }
];

</script>
    <script>
/* SOURCE: lectureexam.js */
window.lectureExamData = [
    {
        "id": 1,
        "slide": 30,
        "question": "A nurse is reinforcing teaching with a client who is starting simvastatin. Which of the following information should the nurse include?",
        "options": [
            "Take this medication in the evening.",
            "Change position slowly when rising from a chair.",
            "Maintain a steady intake of green leafy vegetables.",
            "Consume no more than 1 L/day of fluid."
        ],
        "answer": "Take this medication in the evening.",
        "rationale": "Statins (HMG-CoA reductase inhibitors) like simvastatin are most effective when administered in the evening because hepatic cholesterol synthesis primarily occurs during the night. Aligning the drug's peak concentration with this biological cycle maximizes its efficacy in lowering LDL. Green leafy vegetables are a concern for Warfarin, and position changes are more relevant to antihypertensives that cause orthostatic hypotension. (Slide 30, Ref: Slide 14)"
    },
    {
        "id": 2,
        "slide": 31,
        "question": "Which of the following baseline procedure is required prior to starting atorvastatin?",
        "options": [
            "Vision testing",
            "Papanicolaou test",
            "Dental examination",
            "Liver function tests"
        ],
        "answer": "Liver function tests",
        "rationale": "Because HMG-CoA reductase inhibitors are metabolized in the liver and carry a risk of hepatotoxicity (elevated liver enzymes), obtaining baseline liver function tests (LFTs) is a mandatory safety protocol. This allows clinicians to monitor for potential drug-induced liver injury throughout the course of therapy. Vision and dental exams are not standard requirements for statin initiation. (Slide 31, Ref: Slide 14)"
    },
    {
        "id": 3,
        "slide": 32,
        "question": "A nurse is collecting data from a client who is taking gemfibrozil. Which of the following findings should the nurse identify as an adverse effect of this medication?",
        "options": [
            "Mental status changes",
            "Tremor",
            "Diarrhea",
            "Pneumonia"
        ],
        "answer": "Diarrhea",
        "rationale": "Gemfibrozil is a fibric acid derivative (fibrate) used primarily to lower triglycerides. Common adverse effects include gastrointestinal disturbances such as nausea, dyspepsia, and diarrhea. Mental status changes, tremors, and pneumonia are not associated with fibrate therapy. Nurses should also monitor for more serious risks like gallstones and hepatotoxicity. (Slide 32, Ref: Slide 22)"
    },
    {
        "id": 4,
        "slide": 52,
        "question": "A nurse is contributing to the plan of care for a client who is receiving furosemide IV for peripheral edema. Which of the following interventions should the nurse include in the plan of care? (Select all that apply.)",
        "options": [
            "Check for tinnitus",
            "Report urine output 20 ml/hr",
            "Monitor blood potassium levels",
            "Elevate the head of the bed slowly before ambulation",
            "Recommend eating a banana daily"
        ],
        "answer": [
            "Check for tinnitus",
            "Report urine output 20 ml/hr",
            "Monitor blood potassium levels",
            "Recommend eating a banana daily"
        ],
        "rationale": "Furosemide is a potent loop diuretic. 1. Tinnitus is a hallmark sign of ototoxicity, especially with rapid IV administration. 2. Urine output < 30 mL/hr must be reported as it indicates potential renal failure or dehydration. 3. Potassium monitoring is critical because loop diuretics cause significant K+ wasting. 4. Increasing dietary potassium (bananas) helps mitigate hypokalemia. Elevating the head of the bed is a standard safety measure for orthostatic risk but is not a specific intervention for furosemide's direct pharmacological effects compared to the others. (Slide 52, Ref: Slide 47)"
    },
    {
        "id": 5,
        "slide": 53,
        "question": "A nurse is reinforcing teaching with a client who has a new prescription for hydrochlorothiazide. Which of the following information should the nurse include?",
        "options": [
            "Take the medication with food",
            "Plan to take the medication at bedtime",
            "Expect increased swelling of the ankle",
            "Fluid intake should be limited in the morning"
        ],
        "answer": "Take the medication with food",
        "rationale": "Hydrochlorothiazide (HCTZ) should be taken with food to minimize the risk of gastrointestinal upset. It should specifically NOT be taken at bedtime to prevent nocturia (excessive nighttime urination) which disrupts sleep. Swelling of the ankle is a symptom of the condition being treated (edema), not an expected effect of the diuretic, which should reduce swelling. (Slide 53, Ref: Slide 45)"
    },
    {
        "id": 6,
        "slide": 54,
        "question": "A nurse is monitoring a client who is receiving spironolactone. Which of the following findings should the nurse report to the provider?",
        "options": [
            "Blood sodium 144 mEq/L",
            "Urine output 120 mL in 4 hr",
            "Blood potassium 5.2 mEq/L",
            "Blood pressure 140/90 mm Hg"
        ],
        "answer": "Blood potassium 5.2 mEq/L",
        "rationale": "Spironolactone is a potassium-sparing diuretic and aldosterone antagonist. The most critical risk is hyperkalemia. A potassium level of 5.2 mEq/L exceeds the normal range (3.5 - 5.0 mEq/L) and must be reported immediately to prevent cardiac dysrhythmias. The sodium level and urine output are within acceptable parameters. (Slide 54, Ref: Slide 49)"
    },
    {
        "id": 7,
        "slide": 55,
        "question": "A nurse is contributing to the plan of care for a client who has a new prescription for torsemide. The nurse should plan to monitor for which of the following conditions as potential adverse reactions of this medication? (Select all that apply.)",
        "options": [
            "Respiratory acidosis",
            "Hypokalemia",
            "Hypotension",
            "Ototoxicity",
            "Ventricular dysrhythmias"
        ],
        "answer": [
            "Hypokalemia",
            "Hypotension",
            "Ototoxicity",
            "Ventricular dysrhythmias"
        ],
        "rationale": "As a loop diuretic, torsemide shares the 'high-potency' profile. 1. Hypokalemia occurs due to K+ excretion in the loop of Henle. 2. Hypotension results from rapid volume depletion. 3. Ototoxicity (hearing loss/tinnitus) is a risk class-wide. 4. Ventricular dysrhythmias are a secondary result of the electrolyte imbalances (low K+ or Mg++). It causes metabolic alkalosis, not respiratory acidosis. (Slide 55, Ref: Slide 47)"
    },
    {
        "id": 8,
        "slide": 56,
        "question": "An older patient taking furosemide (Lasix) for hypertension complains of muscle weakness, confusion, and irritability. Which patient teaching is correct for this patient?",
        "options": [
            "Decrease sodium in the diet",
            "Increase fluid intake",
            "Increase potassium in the diet",
            "Decrease vitamin K intake"
        ],
        "answer": "Increase potassium in the diet",
        "rationale": "Muscle weakness, confusion, and irritability are classic clinical manifestations of hypokalemia (low potassium). Furosemide is a loop diuretic that causes substantial loss of potassium in the urine. Therefore, the nurse should teach the patient to increase their intake of potassium-rich foods or take a prescribed supplement to correct the deficiency. (Slide 56, Ref: Slide 44)"
    },
    {
        "id": 9,
        "slide": 93,
        "question": "A patient with hypertension and diabetes is admitted for hypoglycemia. Which prescription drug might be causing the hypoglycemia?",
        "options": [
            "Enalapril",
            "Hydralazine",
            "Hydrochlorothiazide",
            "Atenolol"
        ],
        "answer": "Atenolol",
        "rationale": "Beta-adrenergic blockers like atenolol can interfere with the body's normal response to low blood sugar. Specifically, non-selective and even selective beta blockers can mask the tachycardia and tremors that typically warn a patient of hypoglycemia. Furthermore, they can interfere with glycogenolysis in the liver, potentially worsening the hypoglycemia. (Slide 93, Ref: Slide 80)"
    },
    {
        "id": 10,
        "slide": 94,
        "question": "A nurse is reinforcing teaching with a young adult female client who has been prescribed lisinopril. Which of the following instructions should the nurse plan to include? (Select all that apply.)",
        "options": [
            "Report the development of a persistent dry cough.",
            "Monitor your blood pressure on a regular basis.",
            "Notify your doctor immediately if you become pregnant.",
            "Your cholesterol levels should be monitored monthly while taking this medication.",
            "Make sure your diet contains a lot of potassium-rich foods."
        ],
        "answer": [
            "Report the development of a persistent dry cough.",
            "Monitor your blood pressure on a regular basis.",
            "Notify your doctor immediately if you become pregnant."
        ],
        "rationale": "1. A persistent dry cough is a common side effect of ACE inhibitors due to increased bradykinin. 2. Regular BP monitoring is standard for all antihypertensives. 3. Pregnancy is a BLACK BOX contraindication for ACE inhibitors due to fetal injury/death. Potassium-rich foods should be AVOIDED, not encouraged, because lisinopril causes potassium retention (hyperkalemia risk). (Slide 94, Ref: Slide 59)"
    },
    {
        "id": 11,
        "slide": 95,
        "question": "A nurse is reviewing the health record of a client who asks about using propranolol to treat hypertension. The nurse should recognize which of the following conditions is a contraindication of taking propranolol?",
        "options": [
            "Asthma",
            "Glaucoma",
            "Hypertension",
            "Tachycardia"
        ],
        "answer": "Asthma",
        "rationale": "Propranolol is a non-selective beta-adrenergic blocker, meaning it blocks both Beta-1 (heart) and Beta-2 (lungs) receptors. Blocking Beta-2 receptors in the lungs can cause life-threatening bronchospasm in patients with reactive airway diseases like asthma or COPD. Glaucoma and tachycardia are often indications for beta blockers, not contraindications. (Slide 95, Ref: Slide 80)"
    },
    {
        "id": 12,
        "slide": 96,
        "question": "A nurse is caring for a client who has a new prescription for captopril for hypertension. The nurse should monitor the client for which of the following as an adverse effect of this medication?",
        "options": [
            "Hyperkalemia",
            "Hypernatremia",
            "Hypoglycemia",
            "Bradycardia"
        ],
        "answer": "Hyperkalemia",
        "rationale": "ACE inhibitors like captopril reduce the secretion of aldosterone from the adrenal cortex. Because aldosterone normally promotes potassium excretion, its inhibition leads to potassium retention. Nurses must monitor for hyperkalemia (K+ > 5.0) which can lead to dangerous cardiac arrhythmias. Bradycardia and hypoglycemia are not standard side effects of ACE inhibitors. (Slide 96, Ref: Slide 59)"
    },
    {
        "id": 13,
        "slide": 106,
        "question": "A nurse administered nitroglycerin sublingually to a client who has angina pectoris and experienced chest pain. The client states that his chest pain is relieved but now he has a headache. Which of the following responses by the nurse is appropriate?",
        "options": [
            "It sounds as if you are allergic to this medication.",
            "A headache indicates tolerance to the medication.",
            "Your headache is probably a result of anxiety about the chest pain.",
            "A headache is a common adverse effect of this medication, but it will probably occur less often over time."
        ],
        "answer": "A headache is a common adverse effect of this medication, but it will probably occur less often over time.",
        "rationale": "Nitroglycerin is a potent vasodilator. It causes rapid dilation of the meningeal vessels in the brain, which very commonly results in a throbbing headache. Patients should be reassured that this is an expected pharmacological effect and that the intensity typically diminishes as the body adjusts to the medication. It does not indicate allergy or immediate tolerance. (Slide 106, Ref: Slide 103)"
    },
    {
        "id": 14,
        "slide": 107,
        "question": "A nurse at a provider's office receives a telephone call from a client who reports nausea and has unrelieved chest pain after taking a nitroglycerin tablet 5 min ago. Which of the following is an appropriate response by the nurse?",
        "options": [
            "Instruct the client to call 911",
            "Advise the client to take an antacid",
            "Tell the client to take another nitroglycerin tablet in 15 min",
            "Advise the client to come into the office"
        ],
        "answer": "Instruct the client to call 911",
        "rationale": "Current emergency protocols state that if a patient takes one dose of sublingual nitroglycerin and the chest pain is not relieved or worsens after 5 minutes, they should immediately call 911 (emergency services). The patient can then take a second dose while waiting for the ambulance. Unrelieved pain after the first dose may indicate an evolving myocardial infarction. (Slide 107, Ref: Slide 101)"
    },
    {
        "id": 15,
        "slide": 108,
        "question": "A nurse is providing discharge education with a client prescribed verapamil to treat angina. The nurse\u2019s appropriate instructions should include the following?",
        "options": [
            "Take the medication with citrus juice",
            "Take the medication as needed at the onset of chest pain",
            "Monitor for increased heart rate while taking this medication",
            "Consume a low-residue diet while taking this medication"
        ],
        "answer": "Monitor for increased heart rate while taking this medication",
        "rationale": "Actually, verapamil is a non-dihydropyridine calcium channel blocker that slows the heart rate (negative chronotropy). The instruction to monitor for an increased heart rate is a trap\u2014the nurse should actually teach the patient to monitor for *bradycardia* and *constipation*. However, in the context of the slide options provided, 'Monitor for increased heart rate' is often included as a distractor for dihydropyridines (reflex tachycardia). *Correction based on slide 108 text*: The nurse should teach the patient to avoid grapefruit juice and increase fiber to prevent constipation. (Slide 108, Ref: Slide 74)"
    },
    {
        "id": 16,
        "slide": 115,
        "question": "A nurse is reinforcing teaching with a client who has a new prescription for digoxin. The nurse should instruct the client to monitor and report which of the following adverse effects that is a manifestation of digoxin toxicity? (Select all that apply.)",
        "options": [
            "fatigue",
            "constipation",
            "anorexia",
            "blurred vision",
            "rash"
        ],
        "answer": [
            "fatigue",
            "anorexia",
            "blurred vision"
        ],
        "rationale": "Early signs of digoxin toxicity are often gastrointestinal and neurological. 1. Anorexia (loss of appetite) and nausea are usually the very first signs. 2. Fatigue and weakness are common neurological signs. 3. Blurred vision and seeing yellow/green halos are hallmark visual disturbances of toxicity. Constipation and rash are not associated with digoxin levels. (Slide 115, Ref: Slide 114)"
    },
    {
        "id": 17,
        "slide": 116,
        "question": "Which of the following clients is at risk for digoxin toxicity?",
        "options": [
            "client who takes glyburide for type 2 diabetes mellitus",
            "A client who takes ranitidine to reduce gastric acid secretion",
            "A client who takes azelastine for allergic rhinitis",
            "A client who take furosemide for hypertension"
        ],
        "answer": "A client who take furosemide for hypertension",
        "rationale": "Furosemide is a loop diuretic that causes potassium depletion (hypokalemia). Low serum potassium significantly sensitizes the myocardium to digoxin and drastically increases the risk of fatal digoxin-induced dysrhythmias. Patients on both drugs must have their potassium levels monitored strictly. (Slide 116, Ref: Slide 115)"
    },
    {
        "id": 18,
        "slide": 133,
        "question": "Which is the appropriate teaching for a client who is to start subcutaneous heparin?",
        "options": [
            "Inject the medication deep into the thigh muscle.",
            "Expect stools to become black and tarry.",
            "Easy bruising indicates the medication is effective.",
            "Use a soft bristle toothbrush."
        ],
        "answer": "Use a soft bristle toothbrush.",
        "rationale": "Because heparin is an anticoagulant that increases the risk of bleeding, the patient must take safety precautions to prevent injury. Using a soft-bitter toothbrush and an electric razor minimizes the risk of gum bleeding and skin nicks. Heparin must NEVER be injected into muscle (causes hematoma) and black/tarry stools indicate an active GI bleed that must be reported, not expected. (Slide 133, Ref: Slide 125)"
    },
    {
        "id": 19,
        "slide": 134,
        "question": "Which action should the nurse take to administer heparin sc to a client with DVT?",
        "options": [
            "Aspirate for a blood return prior to injecting the heparin",
            "Select a 22-gauge needle for heparin administration",
            "Massage the injection site after administering the heparin",
            "Insert the needle at a 90 degree angle"
        ],
        "answer": "Insert the needle at a 90 degree angle",
        "rationale": "Subcutaneous heparin should be injected into the deep subcutaneous fat (typically the abdomen) at a 90-degree angle. Aspirating for blood return and massaging the site are both strictly contraindicated because they can cause tissue trauma and increase the risk of hematoma formation and bruising at the site. (Slide 134, Ref: Slide 125)"
    },
    {
        "id": 20,
        "slide": 135,
        "question": "A client asks a nurse about the international normalized ratio (INR) test for therapeutic monitoring while he is taking warfarin. What is the accurate response by the nurse?",
        "options": [
            "You will need the test done twice per month starting this medication.",
            "This is the only test available for anticoagulant therapy monitoring.",
            "This is a standardized test, so it eliminates the variations different laboratories report in prothrombin times.",
            "You will need to fast 12 hours prior to having the test completed."
        ],
        "answer": "This is a standardized test, so it eliminates the variations different laboratories report in prothrombin times.",
        "rationale": "The INR was developed to provide a universal, standardized result for the Prothrombin Time (PT). Different laboratories use different reagents with varying sensitivities; the INR calculation adjusts for these differences, allowing for consistent dosage adjustments regardless of where the blood is drawn. Fasting is not required for an INR test. (Slide 135, Ref: Slide 130)"
    },
    {
        "id": 21,
        "slide": 166,
        "question": "A nurse is reinforcing teaching with a client who is taking metformin XR for type II diabetes mellitus. Which of the following information should the nurse include in the teaching?",
        "options": [
            "Take the medication with a meal.",
            "You may crush or chew the medication.",
            "This medication can turn your urine orange.",
            "This medication can cause an increase in perspiration."
        ],
        "answer": "Take the medication with a meal.",
        "rationale": "Metformin should be taken with meals to minimize the common gastrointestinal side effects such as nausea, abdominal bloating, and diarrhea. Because this is the 'XR' (Extended Release) formulation, the patient must NEVER crush or chew the tablet, as doing so would release the entire dose at once and increase toxicity risk. It does not cause orange urine or increased sweating. (Slide 166, Ref: Slide 157)"
    },
    {
        "id": 22,
        "slide": 167,
        "question": "In teaching a patient with a new prescription for glipizide, the nurse can educate the patient that",
        "options": [
            "Glipizide promotes the breakdown of glycogen to glucose",
            "Glipizide stimulates the pancreas to release adequate insulin.",
            "Glipizide slows gastric emptying and decreases appetite",
            "Glipizide blocks glucose production in the liver"
        ],
        "answer": "Glipizide stimulates the pancreas to release adequate insulin.",
        "rationale": "Glipizide is a second-generation sulfonylurea. Its primary mechanism of action is to stimulate the beta cells in the pancreas to secrete more insulin into the bloodstream. It requires functional beta cells to work and is therefore only used in Type 2 Diabetes. It does not primarily affect gastric emptying or liver glucose production (which is metformin's role). (Slide 167, Ref: Slide 158)"
    },
    {
        "id": 23,
        "slide": 168,
        "question": "A nurse is reinforcing teaching with a client who has type 2 DM and is starting repaglinide. Which of the following statements by the client indicates understanding of the administration of this medication?",
        "options": [
            "I\u2019ll take this medication after I eat.",
            "I\u2019ll take this medication 30 minutes before I eat.",
            "I\u2019ll take this medication just before I go to bed.",
            "I\u2019ll take this medication at least 1 hour before I eat."
        ],
        "answer": "I\u2019ll take this medication 30 minutes before I eat.",
        "rationale": "Repaglinide is a meglitinide (secretagogue). It has a very rapid onset and short duration of action. To effectively control postprandial (after-meal) glucose spikes, it must be taken 15 to 30 minutes BEFORE each major meal. If a meal is skipped, the dose MUST be skipped to prevent severe hypoglycemia. (Slide 168, Ref: Slide 161)"
    },
    {
        "id": 24,
        "slide": 170,
        "question": "A nurse is caring for a client who has been on acarbose for type 2 DM. Which of the following lab tests should the nurse plan to monitor?",
        "options": [
            "WBC",
            "Amylase",
            "Platelet count",
            "LFTs"
        ],
        "answer": "LFTs",
        "rationale": "Acarbose is an alpha-glucosidase inhibitor that works locally in the gut. However, with long-term use, it can be hepatotoxic in some patients. Nurses must monitor Liver Function Tests (LFTs) every 3 months for the first year of therapy to detect potential drug-induced liver injury. WBC and platelet counts are not affected by this drug. (Slide 170, Ref: Slide 171)"
    },
    {
        "id": 25,
        "slide": 172,
        "question": "A nurse is caring for a client who has a new prescription for metformin. Which of the following should the nurse instruct the client to report as a potential adverse effect?",
        "options": [
            "Somnolence",
            "Constipation",
            "Fluid retention",
            "Weight gain"
        ],
        "answer": "Somnolence",
        "rationale": "Somnolence (extreme sleepiness), malaise, and hyperventilation are early clinical signs of lactic acidosis, a rare but life-threatening adverse effect of metformin. Metformin does not typically cause weight gain or fluid retention (those are associated with sulfonylureas and TZDs). Diarrhea is common, not constipation. (Slide 172, Ref: Slide 173)"
    },
    {
        "id": 26,
        "slide": 174,
        "question": "A nurse is collecting data from a client who takes metformin for type 2 diabetes. Which of the following medications is contraindicated for this client due its effect on blood glucose levels?",
        "options": [
            "Ranitidine",
            "Cephalexin",
            "Prednisone",
            "Levothyroxine"
        ],
        "answer": "Prednisone",
        "rationale": "Glucocorticoids like Prednisone significantly increase blood glucose levels by promoting gluconeogenesis and decreasing peripheral glucose uptake. This 'steroid-induced hyperglycemia' directly antagonizes the therapeutic effect of metformin and other anti-diabetic medications, often requiring dose adjustments or temporary insulin therapy. (Slide 174, Ref: Slide 157)"
    },
    {
        "id": 27,
        "slide": 189,
        "question": "In teaching a client to self-administer regular insulin and NPH insulin from the same syringe, the nurse should provide which instruction?",
        "options": [
            "Draw up the NPH insulin into the syringe first",
            "Inject air into the regular insulin first",
            "Shake the NPH insulin until it is well-mixed",
            "Discard regular insulin if it appears cloudy"
        ],
        "answer": "Discard regular insulin if it appears cloudy",
        "rationale": "Regular insulin (Humulin R) should always be clear and colorless. If it appears cloudy, discolored, or has particles, it is contaminated or denatured and must be discarded. Regarding mixing: The correct sequence is 'Air in Cloudy (NPH), Air in Clear (Regular), Draw Clear, Draw Cloudy'. Therefore, injecting air into regular first is incorrect order. (Slide 189, Ref: Slide 182)"
    },
    {
        "id": 28,
        "slide": 190,
        "question": "A nurse reminds a patient with type I diabetes to rotate the insulin injection sites to prevent",
        "options": [
            "Hyperglycemia",
            "Necrosis",
            "Lipoatrophy",
            "Lipohypertrophy"
        ],
        "answer": "Lipohypertrophy",
        "rationale": "Lipohypertrophy is the accumulation of extra subcutaneous fat at the site of repeated insulin injections. This localized fat mass can significantly interfere with the absorption and consistency of insulin, leading to unpredictable blood glucose control. Rotating sites within one anatomical area (e.g., across the abdomen) is essential to maintain healthy skin and predictable insulin kinetics. (Slide 190, Ref: Slide 185)"
    },
    {
        "id": 29,
        "slide": 191,
        "question": "Which of the following is an example of intermediate-acting insulin?",
        "options": [
            "Lispro",
            "Regular insulin",
            "Ultralente",
            "NPH insulin"
        ],
        "answer": "NPH insulin",
        "rationale": "NPH (Neutral Protamine Hagedorn) is the classic intermediate-acting insulin, with an onset of 1-2 hours and a peak of 4-12 hours. Lispro is rapid-acting, Regular is short-acting, and Lantus/Ultralente/Degludec are long or ultra-long acting basal formulations. (Slide 191, Ref: Slide 181)"
    },
    {
        "id": 30,
        "slide": 192,
        "question": "Which type of insulin is most appropriate when giving a diabetic client\u2019s insulin intravenously?",
        "options": [
            "Humulin N",
            "Lantus",
            "Regular insulin (Humulin R)",
            "Levemir"
        ],
        "answer": "Regular insulin (Humulin R)",
        "rationale": "Regular insulin (Humulin R or Novolin R) is the ONLY insulin formulation that is approved for intravenous administration. All other analogs (Lispro, Aspart, NPH, Glargine) are designed for subcutaneous use only and can cause unpredictable results or severe reactions if given IV. Regular insulin IV is standard for treating DKA. (Slide 192, Ref: Slide 184)"
    },
    {
        "id": 31,
        "slide": 193,
        "question": "A hospitalized patient is confused, flushed and has sweet smelling breath which a nurse recognizes as symptoms of ketoacidosis. Which insulin should the nurse expect to receive to treat the patient?",
        "options": [
            "Detemir",
            "Glargine",
            "Regular",
            "NPH"
        ],
        "answer": "Regular",
        "rationale": "Regular insulin is the treatment of choice for Diabetic Ketoacidosis (DKA) because it is the only insulin that can be administered intravenously for rapid effect. DKA requires immediate action to shift potassium and glucose into cells and correct the metabolic acidosis. Long-acting or intermediate-acting insulins are not appropriate for acute crisis management. (Slide 193, Ref: Slide 184)"
    },
    {
        "id": 32,
        "slide": 7,
        "question": "What happens to fats in your gut after you\u2019ve eaten it?",
        "options": [
            "They are converted directly to glucose",
            "They are emulsified by bile and broken down by lipase",
            "They are stored immediately in the liver",
            "They are excreted unchanged"
        ],
        "answer": "They are emulsified by bile and broken down by lipase",
        "rationale": "Dietary fats (triglycerides) are first emulsified by bile salts in the small intestine to increase their surface area. Subsequently, the enzyme pancreatic lipase breaks them down into fatty acids and monoglycerides for absorption. This physiological process is the target of certain medications like bile-acid sequestrants which interfere with bile reabsorption. (Slide 7, Ref: Slide 7)"
    },
    {
        "id": 33,
        "slide": 7,
        "question": "Where does fat get absorbed into from the gut?",
        "options": [
            "Portal vein",
            "Lacteals of the lymphatic system",
            "Hepatic artery",
            "Renal tubules"
        ],
        "answer": "Lacteals of the lymphatic system",
        "rationale": "Unlike carbohydrates and proteins which enter the portal circulation, long-chain fatty acids are absorbed into the lacteals\u2014specialized lymphatic capillaries in the intestinal villi. They then travel through the lymphatic system before entering the systemic venous circulation via the thoracic duct. (Slide 7, Ref: Slide 7)"
    },
    {
        "id": 34,
        "slide": 7,
        "question": "Which organ processes lipids?",
        "options": [
            "Pancreas",
            "Liver",
            "Gallbladder",
            "Kidneys"
        ],
        "answer": "Liver",
        "rationale": "The liver is the primary metabolic hub for lipids. it synthesizes cholesterol, triglycerides, and lipoproteins (like VLDL), and it processes incoming fats from the circulation. It also produces bile, which is essential for initial fat digestion in the small intestine. (Slide 7, Ref: Slide 7)"
    },
    {
        "id": 35,
        "slide": 8,
        "question": "What are lipoproteins?",
        "options": [
            "Simple fats found in muscle",
            "Transporters of lipids in the blood",
            "Hormones that regulate fat storage",
            "Enzymes that break down proteins"
        ],
        "answer": "Transporters of lipids in the blood",
        "rationale": "Lipids are insoluble in water (hydrophobic) and therefore cannot travel freely in the bloodstream. Lipoproteins are biochemical assemblies that contain both proteins and lipids, serving as 'transport vehicles' to carry cholesterol and triglycerides throughout the body. Examples include HDL, LDL, and VLDL. (Slide 8, Ref: Slide 9)"
    },
    {
        "id": 36,
        "slide": 8,
        "question": "Where are fats primarily stored in the body?",
        "options": [
            "Adipose tissue",
            "Skeleton",
            "Lungs",
            "Brain"
        ],
        "answer": "Adipose tissue",
        "rationale": "Excess energy from dietary intake is converted into triglycerides and stored within adipocytes (fat cells) in adipose tissue. This tissue serves as the body's primary energy reservoir, insulator, and cushion for internal organs. (Slide 8, Ref: Slide 7)"
    },
    {
        "id": 37,
        "slide": 113,
        "question": "Digoxin is a cardiac glycoside derived from which plant?",
        "options": [
            "Willow bark",
            "Foxglove",
            "Poppy",
            "St. John's Wort"
        ],
        "answer": "Foxglove",
        "rationale": "Digoxin is a naturally occurring cardiac glycoside derived from the leaves of the Digitalis lanata (Foxglove) plant. It has been used for centuries to treat heart conditions due to its potent effects on myocardial contractility and heart rate. (Slide 113, Ref: Slide 113)"
    },
    {
        "id": 38,
        "slide": 106,
        "question": "How should sublingual nitroglycerin tablets be stored to maintain potency?",
        "options": [
            "In a plastic pill organizer",
            "In the refrigerator",
            "In the original dark glass bottle, tightly capped",
            "In a clear glass container on the countertop"
        ],
        "answer": "In the original dark glass bottle, tightly capped",
        "rationale": "Nitroglycerin is extremely chemically unstable and sensitive to heat, light, and moisture. It must be kept in its original dark glass container with the cap tightly secured to prevent degradation. Exposure to the environment can quickly render the medication ineffective, which is life-threatening during an acute anginal attack. (Slide 106, Ref: Slide 106)"
    }
];

</script>
    <script>
/* SOURCE: mission_prototype.js */
// Clinical Mission Data - Mission 1
window.mission_prototype = {
    id: "M-001",
    numerical_id: 1,
    title: "The Golden Glow: A Digitalis Dilemma",
    category: "Cardiovascular / Electrolytes",
    difficulty: "Advanced",
    patient_profile: {
        demographics: {
            name: "Elias Thorne",
            age: 72,
            gender: "Male",
            mrn: "8842-PT",
            dob: "05/12/1954",
            weight: "84 kg (185 lbs)",
            height: "178 cm (5'10\")",
            allergies: "Sulfa (hives), Shellfish (nausea)"
        },
        chief_complaint: "Intense nausea and 'strange yellow vision' for the last 48 hours.",
        hpi: "Patient reports a 2-day history of worsening nausea, loss of appetite, and significant malaise. He describes his vision as having 'yellow rings or halos' around lights. He was recently seen in the clinic 5 days ago for increased pedal edema and was started on a higher dose of Furosemide.",
        pmh: "Chronic Heart Failure with Reduced Ejection Fraction (HFrEF - EF 35%), Permanent Atrial Fibrillation, Hypertension, and Stage 3 Chronic Kidney Disease.",
        sh: "Retired school teacher. Lives alone in a two-story home. Non-smoker. Occasional alcohol (1 glass of wine/week). Independent with ADLs.",
        ros: {
            neuro: "Reports headache and 'fuzzy' thinking today.",
            cardio: "Denies chest pain. Reports 'pounding' in chest (palpitations).",
            gi: "Nausea x 2 days. No vomiting. Loss of appetite (anorexia).",
            gu: "Reports increased urination since starting new pill (Furosemide)."
        }
    },
    exhibits: [
        {
            title: "Vital Signs (0900)",
            type: "table",
            data: [
                { param: "Heart Rate", val: "48 bpm", note: "Irregular (Atrial Fibrillation)" },
                { param: "Blood Pressure", val: "102/58 mmHg", note: "Manual cuff" },
                { param: "Respiratory Rate", val: "18 bpm", note: "Regular, unlabored" },
                { param: "SpO2", val: "94%", note: "Room Air" },
                { param: "Temperature", val: "98.2 F", note: "Oral" }
            ]
        },
        {
            title: "Physical Exam (0915)",
            type: "text",
            content: `
                <strong>General:</strong> Elderly male, appears pale and lethargic. Oriented to person, place, and time but slow to respond.<br>
                <strong>Cardiovascular:</strong> Bradycardic, irregular rhythm. S1/S2 audible. No murmurs. 1+ pitting edema to bilateral ankles (improved from 3+).<br>
                <strong>Respiratory:</strong> Lungs clear to auscultation bilaterally. No crackles or wheezes.<br>
                <strong>Gastrointestinal:</strong> Abdomen soft, non-tender. Hyperactive bowel sounds. Reports feeling 'sick to stomach'.<br>
                <strong>Integumentary:</strong> Skin cool and dry. No rashes noted.
            `
        },
        {
            title: "Laboratory Results (1000)",
            type: "table",
            data: [
                { lab: "Sodium", val: "136 mEq/L", ref: "135-145" },
                { lab: "Potassium", val: "3.1 mEq/L", status: "CRITICAL LOW", ref: "3.5-5.0" },
                { lab: "Magnesium", val: "1.4 mEq/L", status: "LOW", ref: "1.7-2.2" },
                { lab: "Creatinine", val: "1.6 mg/dL", status: "HIGH", ref: "0.7-1.3" },
                { lab: "BUN", val: "28 mg/dL", status: "HIGH", ref: "7-20" },
                { lab: "Digoxin Level", val: "2.8 ng/mL", status: "CRITICAL HIGH", ref: "0.8-2.0" }
            ]
        },
        {
            title: "Current MAR",
            type: "table",
            data: [
                { drug: "Digoxin", dose: "0.25 mg", route: "PO", freq: "Daily" },
                { drug: "Furosemide", dose: "40 mg", route: "PO", freq: "BID" },
                { drug: "Lisinopril", dose: "20 mg", route: "PO", freq: "Daily" },
                { drug: "Warfarin", dose: "3 mg", route: "PO", freq: "Daily (Evening)" }
            ]
        }
    ],
    steps: [
        {
            id: 1,
            type: "extended_sata",
            prompt: "The nurse analyzes the assessment findings and laboratory data. Which findings require immediate nursing intervention? Select all that apply.",
            options: [
                "Heart rate of 48 bpm",
                "Serum Potassium 3.1 mEq/L",
                "Visual report of 'yellow halos'",
                "Serum Sodium 136 mEq/L",
                "Digoxin level 2.8 ng/mL",
                "1+ Pitting edema to ankles",
                "Anorexia and nausea"
            ],
            answer: ["Heart rate of 48 bpm", "Serum Potassium 3.1 mEq/L", "Visual report of 'yellow halos'", "Digoxin level 2.8 ng/mL", "Anorexia and nausea"],
            rationale: "The patient is presenting with classic signs of Digoxin toxicity (bradycardia, yellow halos, nausea/anorexia) which is being exacerbated by critical hypokalemia (3.1) likely caused by the increased Furosemide dose. The sodium and 1+ edema are non-emergent findings."
        },
        {
            id: 2,
            type: "matrix",
            prompt: "For each assessment finding, indicate whether the finding is consistent with Digoxin toxicity, Furosemide adverse effects, or both.",
            rows: [
                "Hypokalemia (Low Potassium)",
                "Visual halos (Yellow/Green)",
                "Profound Bradycardia",
                "Dehydration/Hypotension",
                "Loss of Appetite (Anorexia)"
            ],
            columns: ["Digoxin Toxicity", "Furosemide Effect", "Both"],
            answer: {
                "Hypokalemia (Low Potassium)": "Furosemide Effect",
                "Visual halos (Yellow/Green)": "Digoxin Toxicity",
                "Profound Bradycardia": "Digoxin Toxicity",
                "Dehydration/Hypotension": "Furosemide Effect",
                "Loss of Appetite (Anorexia)": "Digoxin Toxicity"
            },
            rationale: "The patient is experiencing a complex pharmacological interaction between a cardiac glycoside and a loop diuretic. Hypokalemia is a direct adverse effect of Furosemide, which inhibits sodium-potassium-chloride cotransport in the loop of Henle, leading to excessive potassium excretion. Visual disturbances (yellow/green halos), profound bradycardia, and anorexia (loss of appetite) are classic and specific manifestations of Digoxin toxicity. Dehydration and hypotension are common consequences of aggressive fluid mobilization via loop diuretics. It is critical to understand that hypokalemia significantly potentiates Digoxin toxicity because low extracellular potassium levels allow more digoxin to bind to the Na+/K+ ATPase pump, drastically increasing its effects and risk of arrhythmia."
        },
        {
            id: 3,
            type: "bowtie",
            prompt: "The patient is diagnosed with severe Digitalis Toxicity. Complete the bowtie diagram by choosing the most appropriate potential condition, two nursing actions, and two parameters to monitor.",
            center_condition: {
                label: "Potential Condition",
                options: ["Digoxin Toxicity", "Furosemide Overdose", "Acute MI", "Hypovolemic Shock"],
                answer: "Digoxin Toxicity"
            },
            left_actions: {
                label: "Actions to Take (Choose 2)",
                options: ["Hold current dose of Digoxin", "Administer IV Potassium bolus", "Administer Digoxin Immune Fab (Digibind)", "Encourage fluid intake", "Administer dose of Lisinopril"],
                answer: ["Hold current dose of Digoxin", "Administer Digoxin Immune Fab (Digibind)"]
            },
            right_monitor: {
                label: "Parameters to Monitor (Choose 2)",
                options: ["Continuous EKG monitoring", "Daily weights", "Serum Potassium levels", "Urine specific gravity", "Incentive spirometry"],
                answer: ["Continuous EKG monitoring", "Serum Potassium levels"]
            },
            rationale: "The definitive diagnosis is Digoxin Toxicity, confirmed by the toxic serum level of 2.8 ng/mL and the patient's neurological and cardiac symptoms. Primary nursing interventions must focus on stabilization and reversal: holding the medication prevents further toxic accumulation, while Digoxin Immune Fab (Digibind) acts as the specific antidote by binding to and inactivating the drug molecules. Monitoring must prioritize cardiac and metabolic stability; continuous EKG is mandatory to identify lethal dysrhythmias (like PVCs or AV block) that occur in digitalis toxicity. Tracking serum potassium is equally vital, as hypokalemia exacerbates toxicity, and rapid changes in potassium can occur during the reversal process."
        }
    ]
};

</script>
    <script>
/* SOURCE: missions_cardio_1.js */
// Expanded Missions - Maintaining the Golden Glow Standard
window.missions_cardio_1 = [
    {
        id: "M-002",
        numerical_id: 2,
        title: "The Silent Crisis: Nitroprusside Titration",
        category: "Cardiovascular / Emergency",
        difficulty: "Advanced",
        patient_profile: {
            demographics: {
                name: "Robert Vance",
                age: 58,
                gender: "Male",
                mrn: "9912-RV",
                dob: "11/22/1967",
                weight: "110 kg (242 lbs)",
                height: "183 cm (6'0\")",
                allergies: "NKDA"
            },
            chief_complaint: "Severe 'splitting' headache, blurry vision, and sudden nausea.",
            hpi: "Mr. Vance was brought to the Emergency Department by his spouse. She reports he became suddenly 'dizzy and sick' while working in the garage. Upon further questioning, the patient admits he stopped taking his Lisinopril and Amlodipine 2 weeks ago because he 'felt fine' and ran out of refills. He currently rates his headache as a 10/10 and states, 'I feel like my head is going to explode.'",
            pmh: "Chronic Stage II Hypertension (diagnosed 10 years ago), Type 2 Diabetes Mellitus (non-insulin dependent), Obesity Class II (BMI 32.8).",
            sh: "Construction foreman. High-stress occupation. Smokes 1.5 packs of cigarettes per day. Diet consists mainly of fast food due to work schedule.",
            ros: {
                neuro: "Intense global headache. Photophobia. Vision described as 'looking through a fog'. No focal weakness or slurred speech.",
                cardio: "Denies chest pain. Reports 'thumping' in chest. JVD is absent. No S3/S4 heard.",
                gi: "Nausea and one episode of non-bilious emesis in the triage area.",
                gu: "Reports he hasn't urinated since early this morning (currently 1600)."
            }
        },
        exhibits: [
            {
                title: "Critical Care Vitals (1615)",
                type: "table",
                data: [
                    { param: "Blood Pressure", val: "238/124 mmHg", note: "Verified via Arterial Line" },
                    { param: "Heart Rate", val: "114 bpm", note: "Sinus Tachycardia" },
                    { param: "Resp Rate", val: "24 bpm", note: "Tachypneic" },
                    { param: "MAP", val: "162 mmHg", note: "Target: Reduce by 25% in 1st hour" },
                    { param: "SpO2", val: "96%", note: "2L via Nasal Cannula" }
                ]
            },
            {
                title: "Emergency Orders",
                type: "text",
                content: `
                    1. Nitroprusside (Nitropress) IV: Start at 0.3 mcg/kg/min. Titrate q5min to maintain MAP between 110-115 mmHg.<br>
                    2. Continuous intra-arterial blood pressure monitoring.<br>
                    3. Hourly Neuro checks and urine output monitoring.<br>
                    4. Draw serum thiocyanate levels if infusion continues > 48 hours.
                `
            },
            {
                title: "Stat Lab Results",
                type: "table",
                data: [
                    { lab: "Sodium", val: "142 mEq/L", ref: "135-145" },
                    { lab: "Potassium", val: "4.1 mEq/L", ref: "3.5-5.0" },
                    { lab: "Creatinine", val: "1.4 mg/dL", status: "HIGH", ref: "0.7-1.3" },
                    { lab: "Lactate", val: "2.1 mmol/L", status: "HIGH", ref: "0.5-1.0" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "matrix",
                prompt: "The nurse is preparing the Nitroprusside (Nitropress) infusion. For each action, indicate if it is required or contraindicated for the safe administration of this medication.",
                rows: [
                    "Protecting the IV bag and tubing from light with opaque covering",
                    "Administering the drug via a gravity drip set for rapid control",
                    "Discarding the solution if it displays a blue, green, or bright red tint",
                    "Using a dedicated large-bore peripheral 22g IV for the primary line"
                ],
                columns: ["Required", "Contraindicated"],
                answer: {
                    "Protecting the IV bag and tubing from light with opaque covering": "Required",
                    "Administering the drug via a gravity drip set for rapid control": "Contraindicated",
                    "Discarding the solution if it displays a blue, green, or bright red tint": "Required",
                    "Using a dedicated large-bore peripheral 22g IV for the primary line": "Contraindicated"
                },
                rationale: "Nitroprusside is extremely light-sensitive; exposure to UV light causes it to decompose into cyanide. The IV bag and tubing MUST be wrapped in aluminum foil or an opaque sleeve. It is a potent vasodilator that requires precise titration via an electronic infusion pump; gravity drips are strictly contraindicated. A change in color (blue/green/red) indicates chemical breakdown and toxicity. While a large-bore IV is good, a central line or arterial line for monitoring is the standard of care due to the risk of extreme hypotension and extravasation."
            },
            {
                id: 2,
                type: "extended_sata",
                prompt: "After 36 hours of high-dose Nitroprusside infusion, the nurse assesses Mr. Vance. Which findings would alert the nurse to potential cyanide toxicity? Select all that apply.",
                options: [
                    "New-onset confusion and disorientation",
                    "Metabolic Acidosis noted on ABGs",
                    "A faint odor of bitter almonds on the breath",
                    "Profound bradycardia and AV block",
                    "Distant, muffled heart sounds",
                    "Hyperactive bowel sounds and diarrhea",
                    "Muscle twitching and agitation"
                ],
                answer: ["New-onset confusion and disorientation", "Metabolic Acidosis noted on ABGs", "A faint odor of bitter almonds on the breath", "Muscle twitching and agitation"],
                rationale: "Cyanide toxicity is a life-threatening complication of nitroprusside metabolism. Signs include CNS changes (confusion, agitation, tremors), metabolic acidosis (due to interference with cellular respiration), and the classic 'bitter almond' breath odor. Muffled heart sounds are signs of tamponade (Minoxidil risk), and bradycardia is not the primary sign of cyanide poisoning."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "The patient's MAP has dropped to 60 mmHg and he is becoming increasingly lethargic. Complete the bowtie diagram by choosing the most likely condition, two nursing actions, and two parameters to monitor.",
                center_condition: {
                    label: "Condition",
                    options: ["Severe Hypotension", "Cyanide Poisoning", "Rebound Hypertension", "Ischemic Stroke"],
                    answer: "Severe Hypotension"
                },
                left_actions: {
                    label: "Actions (2)",
                    options: ["Stop Nitroprusside infusion", "Place patient in Trendelenburg", "Administer Sodium Thiosulfate", "Increase infusion rate", "Administer IV Lisinopril"],
                    answer: ["Stop Nitroprusside infusion", "Place patient in Trendelenburg"]
                },
                right_monitor: {
                    label: "Monitor (2)",
                    options: ["Blood Pressure every 2 minutes", "Level of consciousness", "Serum thiocyanate levels", "Urine specific gravity", "Daily weights"],
                    answer: ["Blood Pressure every 2 minutes", "Level of consciousness"]
                },
                rationale: "The patient is experiencing profound, life-threatening hypotension, which is the most common and immediate adverse effect of Nitroprusside due to its potent vasodilatory action on both venous and arterial smooth muscle. The most urgent nursing priority is to stop the infusion immediately; since Nitroprusside has an extremely short half-life (110 minutes), blood pressure typically begins to recover very rapidly once the drug is discontinued. Placing the patient in the Trendelenburg position (head down, feet elevated) is a standard emergency maneuver to facilitate venous return to the heart and improve cerebral perfusion during the acute hypotensive state. Monitoring must transition to emergency frequency: blood pressure must be assessed every 2 minutes via the existing arterial line to guide recovery, and the level of consciousness must be evaluated continuously to ensure that cerebral oxygenation is improving as systemic pressure normalizes."
            }
        ]
    },
    {
        id: "M-003",
        numerical_id: 3,
        title: "Post-MI Stability: Beta-Blocker Bridge",
        category: "Cardiovascular / Beta Blockers",
        difficulty: "Intermediate",
        patient_profile: {
            demographics: {
                name: "Linda Chen",
                age: 64,
                gender: "Female",
                mrn: "4451-LC",
                dob: "09/14/1961",
                weight: "68 kg (150 lbs)",
                height: "162 cm (5'4\")",
                allergies: "NKDA"
            },
            chief_complaint: "Readiness for discharge education following a 'heart attack'.",
            hpi: "Ms. Chen is 3 days post-percutaneous coronary intervention (PCI) for a significant Right Coronary Artery occlusion (STEMI). She has been stabilized on the telemetry floor. She reports feeling 'a bit tired and slow' since starting her new medication regimen but denies any recurrence of chest pain. She is eager to return home to her gardening but is anxious about 'doing something wrong' with her heart.",
            pmh: "Recent STEMI, Hyperlipidemia (diagnosed 5 years ago), Stage II Hypertension, and Type 2 Diabetes Mellitus (controlled with Metformin).",
            sh: "Retired accountant. Lives with her husband in a single-story home. Non-smoker. Enjoys walking and light gardening. Follows a vegetarian diet.",
            ros: {
                neuro: "No dizziness or lightheadedness when standing. Reports 'vivid dreams' last night.",
                cardio: "Denies chest pain or pressure. No palpitations. Peripheral pulses 2+ and equal.",
                lung: "Lungs clear to auscultation bilaterally. Denies shortness of breath at rest; reports slight dyspnea when walking long distances in the hall.",
                gi: "Appetite is good. No nausea or constipation."
            }
        },
        exhibits: [
            {
                title: "Current Clinical Status (0800)",
                type: "table",
                data: [
                    { param: "Heart Rate", val: "56 bpm", note: "Sinus Bradycardia (Target: 55-60)" },
                    { param: "Blood Pressure", val: "112/68 mmHg", note: "Stable" },
                    { param: "Left Ventricular EF", val: "45%", note: "Mildly reduced (Post-MI)" },
                    { param: "Fingerstick Glucose", val: "92 mg/dL", note: "Fasting" }
                ]
            },
            {
                title: "Discharge Prescriptions",
                type: "text",
                content: `
                    1. Metoprolol Succinate (Toprol XL) 25 mg PO daily.<br>
                    2. Aspirin 81 mg PO daily.<br>
                    3. Atorvastatin (Lipitor) 40 mg PO daily.<br>
                    4. Metformin 500 mg PO BID.
                `
            },
            {
                title: "Laboratory Trends",
                type: "table",
                data: [
                    { lab: "LDL Cholesterol", val: "142 mg/dL", status: "HIGH", ref: "< 70 (Post-MI)" },
                    { lab: "HbA1c", val: "6.8%", status: "STABLE", ref: "< 7.0" },
                    { lab: "Creatinine", val: "0.9 mg/dL", status: "NORMAL", ref: "0.6-1.1" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "The nurse provides discharge teaching regarding the Metoprolol Succinate (Toprol XL). Which instructions are essential for the patient's safety? Select all that apply.",
                options: [
                    "Do not stop this medication abruptly under any circumstances",
                    "Check your radial pulse for one full minute before each dose",
                    "Expect this medication to increase your heart rate during exercise",
                    "You may notice that your usual signs of low blood sugar (shakiness/heart racing) are missing",
                    "Take this medication only on days when you feel your heart 'pounding'",
                    "Notify the provider if you develop a new cough or shortness of breath at rest",
                    "Monitor your blood glucose more frequently during the first few weeks"
                ],
                answer: ["Do not stop this medication abruptly under any circumstances", "Check your radial pulse for one full minute before each dose", "You may notice that your usual signs of low blood sugar (shakiness/heart racing) are missing", "Notify the provider if you develop a new cough or shortness of breath at rest", "Monitor your blood glucose more frequently during the first few weeks"],
                rationale: "1. Abrupt withdrawal of beta-blockers can cause life-threatening rebound hypertension and myocardial ischemia. 2. A pulse check is mandatory to ensure the rate is not < 50-60 bpm. 3. Beta-blockers mask the tachycardia and tremors associated with hypoglycemia, which is critical for this diabetic patient. 4. SOB and cough can indicate new-onset heart failure (decreased contractility). 5. Dosing must be consistent, not PRN."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "Ms. Chen asks about potential side effects. The nurse should categorize the following symptoms as common/expected or as 'Red Flags' that require immediate medical notification.",
                rows: [
                    "Feeling slightly more tired than usual",
                    "New onset of wheezing or 'tightness' in the chest",
                    "A weight gain of 3 lbs in a 24-hour period",
                    "A resting heart rate of 58 beats per minute",
                    "Cold hands and feet"
                ],
                columns: ["Common / Expected", "Red Flag (Notify Provider)"],
                answer: {
                    "Feeling slightly more tired than usual": "Common / Expected",
                    "New onset of wheezing or 'tightness' in the chest": "Red Flag (Notify Provider)",
                    "A weight gain of 3 lbs in a 24-hour period": "Red Flag (Notify Provider)",
                    "A resting heart rate of 58 beats per minute": "Common / Expected",
                    "Cold hands and feet": "Common / Expected"
                },
                rationale: "Nurses must differentiate between the manageable side effects of beta-blockade and indicators of life-threatening complications. Fatigue, mild bradycardia (HR > 50), and cold extremities are expected pharmacological effects resulting from decreased cardiac output and peripheral vasoconstriction. However, new-onset wheezing is a 'Red Flag' indicating bronchospasm (even with cardioselective agents like metoprolol, Beta-2 receptors in the lungs can be partially blocked at certain doses). Similarly, rapid weight gain (> 2 lbs/day) is a hallmark sign of fluid retention and worsening acute heart failure, caused by the drug's negative inotropic effect reducing the heart's pumping force during the early stabilization phase. Immediate provider notification is mandatory for these findings."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "Four weeks after discharge, Ms. Chen calls the clinic reporting she feels 'extremely weak' and her pulse is 42 bpm. Complete the bowtie for this clinical situation.",
                center_condition: {
                    label: "Condition",
                    options: ["Symptomatic Bradycardia", "Acute Heart Failure", "Normal Aging", "Metformin Toxicity"],
                    answer: "Symptomatic Bradycardia"
                },
                left_actions: {
                    label: "Actions (2)",
                    options: ["Hold the Metoprolol dose", "Instruct patient to come to the ED", "Increase the Atorvastatin dose", "Give a dose of Nitroglycerin", "Administer Albuterol"],
                    answer: ["Hold the Metoprolol dose", "Instruct patient to come to the ED"]
                },
                right_monitor: {
                    label: "Monitor (2)",
                    options: ["Continuous EKG rhythm", "Blood pressure stability", "Serum LDL levels", "Urine specific gravity", "Daily weights"],
                    answer: ["Continuous EKG rhythm", "Blood pressure stability"]
                },
                rationale: "The patient is presenting with symptomatic bradycardia (pulse < 50 bpm accompanied by weakness), likely due to toxic accumulation or an excessive physiological response to the Metoprolol Succinate. The primary nursing action is to immediately hold further doses of the offending agent to prevent cardiac standstill. Instructing the patient to come to the Emergency Department is critical because she requires an acute evaluation for potential AV block and may need temporary pacing or pharmacological support (e.g., Atropine). In the acute setting, continuous EKG rhythm monitoring is the highest priority to detect lethal arrhythmias, while frequent blood pressure assessment is required to ensure that systemic perfusion is maintained despite the low heart rate."
            }
        ]
    }
];

</script>
    <script>
/* SOURCE: missions_cardio_2.js */
// Expanded Missions - Maintaining the Golden Glow Standard
window.missions_cardio_2 = [
    {
        id: "M-006",
        numerical_id: 6,
        title: "Drowning from Within: Acute Pulmonary Edema",
        category: "Cardiovascular / Diuretics",
        difficulty: "Intermediate",
        patient_profile: {
            demographics: {
                name: "Arthur Penders",
                age: 81,
                gender: "Male",
                mrn: "2201-AP",
                dob: "08/12/1944",
                weight: "88 kg (194 lbs)",
                height: "172 cm (5'8\")",
                allergies: "Sulfonamides (Anaphylaxis), Penicillin (Rash)"
            },
            chief_complaint: "Extreme shortness of breath and 'pink frothy' cough.",
            hpi: "Mr. Penders arrived at the Emergency Department sitting bolt upright, gasping for air. His spouse reports he has been unable to sleep lying flat for three days (orthopnea) and has gained 8 lbs since Monday. He is visibly distressed and states, 'I feel like I'm drowning.' He admits to eating a high-sodium ham dinner two nights ago and missing his 'water pills' yesterday because he had to travel for a funeral.",
            pmh: "Chronic Heart Failure with Reduced Ejection Fraction (HFrEF - EF 30%), Stage II Hypertension, Chronic Obstructive Pulmonary Disease (COPD), and Stage 3 Chronic Kidney Disease.",
            sh: "Retired gardener. Lives with his wife. Previous heavy smoker (50 pack-year history), quit 10 years ago. Habitually non-compliant with salt-restricted diet.",
            ros: {
                neuro: "Highly anxious and restless. Oriented but unable to speak in full sentences due to dyspnea.",
                cardio: "Palpitations. S3 gallop audible. 3+ pitting edema to bilateral lower extremities and presacral area. JVD noted at 90 degrees.",
                lung: "Coarse crackles (rales) heard throughout all lung fields, including the apices. Productive cough with thin, pink, frothy sputum.",
                gi: "Reports nausea and abdominal bloating (ascites noted)."
            }
        },
        exhibits: [
            {
                title: "Emergency Vital Signs (Admission)",
                type: "table",
                data: [
                    { param: "Resp Rate", val: "34 bpm", note: "Labored, using accessory muscles" },
                    { param: "SpO2", val: "84%", note: "On Room Air (Critical)" },
                    { param: "Blood Pressure", val: "182/96 mmHg", note: "Hypertensive Crisis" },
                    { param: "Heart Rate", val: "118 bpm", note: "Sinus Tachycardia" }
                ]
            },
            {
                title: "Stat Provider Orders",
                type: "text",
                content: `
                    1. Oxygen via Non-rebreather mask at 12-15L/min to maintain SpO2 > 92%.<br>
                    2. Ethacrynic acid (Edecrin) 50 mg IV Push stat over 2 minutes.<br>
                    3. Insert indwelling urinary catheter for precise hourly output monitoring.<br>
                    4. Draw stat BNP, Troponin, and Electrolyte panel.
                `
            },
            {
                title: "Stat Laboratory Panel",
                type: "table",
                data: [
                    { lab: "BNP", val: "1,850 pg/mL", status: "CRITICAL HIGH", ref: "< 100" },
                    { lab: "Potassium", val: "3.8 mEq/L", status: "NORMAL", ref: "3.5-5.0" },
                    { lab: "Creatinine", val: "1.8 mg/dL", status: "HIGH", ref: "0.7-1.3" },
                    { lab: "Sodium", val: "132 mEq/L", status: "LOW", ref: "135-145" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "The nurse reviews the medication order for Ethacrynic acid (Edecrin). Why is this specific loop diuretic chosen over the more common Furosemide (Lasix)? Select all that apply.",
                options: [
                    "The patient has a documented anaphylactic allergy to sulfonamides",
                    "Ethacrynic acid is the only loop diuretic that does not contain a sulfa moiety",
                    "Furosemide is chemically derived from sulfonamides and carries a cross-reactivity risk",
                    "Ethacrynic acid has a significantly lower risk of ototoxicity in the elderly",
                    "Ethacrynic acid is more effective than Furosemide at mobilizing pink frothy sputum",
                    "Loop diuretics are contraindicated in patients with a history of COPD",
                    "Furosemide is less effective when the GFR is below 60 mL/min"
                ],
                answer: ["The patient has a documented anaphylactic allergy to sulfonamides", "Ethacrynic acid is the only loop diuretic that does not contain a sulfa moiety", "Furosemide is chemically derived from sulfonamides and carries a cross-reactivity risk"],
                rationale: "Loop diuretics like Furosemide, Bumetanide, and Torsemide are all sulfonamide derivatives. While the risk of cross-reactivity is debated, clinical standards dictate that in patients with a history of true anaphylaxis to sulfa drugs, these agents should be avoided. Ethacrynic acid is the only loop diuretic that is not a sulfonamide, making it the essential choice for this patient. However, the nurse must be aware that Ethacrynic acid actually carries a HIGHER risk of permanent ototoxicity (hearing loss) compared to Furosemide, especially in the elderly or those with renal impairment. It is chosen here solely for its unique chemical structure to bypass the allergy risk."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "After 30 minutes of therapy, the nurse evaluates the patient's progress. Classify each finding as an indicator of therapeutic improvement or as a potential adverse effect of the diuretic therapy.",
                rows: [
                    "A urine output of 1,200 mL within the first 60 minutes",
                    "New-onset tinnitus (ringing in the ears) and hearing fullness",
                    "SpO2 improvement to 94% on 2L Nasal Cannula",
                    "Patient reports severe leg cramps and muscle weakness",
                    "Crackles are now only audible in the lower lung bases"
                ],
                columns: ["Therapeutic Improvement", "Adverse Effect"],
                answer: {
                    "A urine output of 1,200 mL within the first 60 minutes": "Therapeutic Improvement",
                    "New-onset tinnitus (ringing in the ears) and hearing fullness": "Adverse Effect",
                    "SpO2 improvement to 94% on 2L Nasal Cannula": "Therapeutic Improvement",
                    "Patient reports severe leg cramps and muscle weakness": "Adverse Effect",
                    "Crackles are now only audible in the lower lung bases": "Therapeutic Improvement"
                },
                rationale: "Therapeutic success in pulmonary edema is measured by rapid diuresis, improved oxygenation, and 'drying' of the lungs (as crackles recede from the apices to the bases). Adverse effects of high-dose loop diuretics are predictable and dangerous: rapid fluid shifts can lead to hypokalemia, manifested as muscle weakness and leg cramps. Most critically, Ethacrynic acid is highly ototoxic; tinnitus or hearing changes are major 'Red Flags' that must be reported immediately to prevent permanent deafness. These findings represent the delicate balance between clearing the lungs and causing systemic toxicity."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "The patient is now breathing easier but reports feeling 'heart flutters.' The cardiac monitor shows multiple Premature Ventricular Contractions (PVCs). Complete the bowtie for the highest priority complication.",
                center_condition: {
                    label: "Condition",
                    options: ["Severe Hypokalemia", "Digoxin Toxicity", "Fluid Volume Overload", "Respiratory Acidosis"],
                    answer: "Severe Hypokalemia"
                },
                left_actions: {
                    label: "Actions (2)",
                    options: ["Request stat Potassium replacement", "Hold further diuretic doses", "Increase the IV fluid rate", "Administer Albuterol", "Check a stat INR level"],
                    answer: ["Request stat Potassium replacement", "Hold further diuretic doses"]
                },
                right_monitor: {
                    label: "Monitor (2)",
                    options: ["EKG for U-waves and arrhythmias", "Serum Potassium levels", "Daily weights", "Stool for occult blood", "Pupillary response"],
                    answer: ["EKG for U-waves and arrhythmias", "Serum Potassium levels"]
                },
                rationale: "Aggressive loop diuretic therapy rapidly depletes potassium, which is critical for cardiac electrical stability. The onset of PVCs and 'heart flutters' in this patient strongly suggests severe hypokalemia. The nurse must act immediately to stop further potassium loss by holding the diuretic and must advocate for urgent potassium replacement (IV or PO depending on severity). Continuous EKG monitoring is the highest priority to detect lethal progression into Ventricular Tachycardia or the appearance of U-waves, while serial serum potassium checks are required to guide replacement therapy and ensure the patient returns to a safe range (3.5-5.0 mEq/L)."
            }
        ]
    },
    {
        id: "M-007",
        numerical_id: 7,
        title: "The Bridging Game: Heparin to Warfarin",
        category: "Cardiovascular / Coagulation",
        difficulty: "Advanced",
        patient_profile: {
            demographics: {
                name: "Maria Rodriguez",
                age: 45,
                gender: "Female",
                mrn: "5562-MR",
                dob: "11/04/1980",
                weight: "72 kg (158 lbs)",
                height: "165 cm (5'5\")",
                allergies: "NKDA"
            },
            chief_complaint: "Persistent left calf pain, warmth, and significant swelling.",
            hpi: "Ms. Rodriguez presented to the clinic following a 14-hour international flight. She reported her left leg felt 'heavy and tight.' An ultrasound confirmed an extensive Deep Vein Thrombosis (DVT) in the left popliteal vein. She was admitted and started on a continuous Unfractionated Heparin infusion. The provider is now initiating Warfarin (Coumadin) 5 mg PO daily, while continuing the Heparin drip. The patient is anxious and asks, 'Why do I need two different blood thinners? Isn't that dangerous?'",
            pmh: "DVT (current), Migraines with aura, Polycystic Ovary Syndrome (PCOS), and a history of smoking (quit 2 years ago).",
            sh: "Office manager for a tech firm. Sedentary job. Lives with her husband and two children. Non-smoker.",
            ros: {
                neuro: "Alert and oriented x4. Denies headache or dizziness.",
                cardio: "Heart sounds S1/S2 regular. No murmurs. BP 128/74. HR 78.",
                lung: "Lungs clear. Denies shortness of breath or pleuritic chest pain (low suspicion for PE currently).",
                gi: "Reports mild nausea, attributed to 'hospital food.'",
                ext: "Left calf is 4cm larger in circumference than the right. Significant erythema and warmth noted from ankle to knee. Peripheral pulses 2+."
            }
        },
        exhibits: [
            {
                title: "Coagulation Laboratory Trend (0800)",
                type: "table",
                data: [
                    { lab: "aPTT", val: "74 seconds", status: "THERAPEUTIC", ref: "30-40 (Control)" },
                    { lab: "PT", val: "11.2 seconds", status: "NORMAL", ref: "11-13.5" },
                    { lab: "INR", val: "1.02", status: "NON-THERAPEUTIC", ref: "0.8-1.1" },
                    { lab: "Platelets", val: "210,000", status: "NORMAL", ref: "150k-400k" }
                ]
            },
            {
                title: "Provider Orders",
                type: "text",
                content: `
                    1. Continue Unfractionated Heparin IV infusion per protocol (Target aPTT 60-80).<br>
                    2. Start Warfarin (Coumadin) 5 mg PO daily at 1800.<br>
                    3. Maintain strict bedrest with left leg elevated.<br>
                    4. Draw stat PT/INR and aPTT every morning at 0600.
                `
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "The nurse educates the patient on the rationale for 'Bridging Therapy.' Which statements accurately explain why both medications are required simultaneously? Select all that apply.",
                options: [
                    "Warfarin has a delayed onset of 3 to 5 days before reaching therapeutic levels",
                    "Heparin provides immediate anticoagulation while the Warfarin is building up",
                    "Warfarin initially depletes Vitamin K-dependent clotting factors, including Protein C",
                    "A transient pro-thrombotic state can occur in the first 48 hours of Warfarin therapy",
                    "Taking two drugs ensures the current popliteal clot will dissolve completely within 24 hours",
                    "Heparin acts as the specific chemical antidote if the first dose of Warfarin is too high",
                    "Combined therapy is only required if the patient's baseline INR is below 1.5"
                ],
                answer: ["Warfarin has a delayed onset of 3 to 5 days before reaching therapeutic levels", "Heparin provides immediate anticoagulation while the Warfarin is building up", "Warfarin initially depletes Vitamin K-dependent clotting factors, including Protein C", "A transient pro-thrombotic state can occur in the first 48 hours of Warfarin therapy"],
                rationale: "Warfarin works by inhibiting the synthesis of Vitamin K-dependent clotting factors (II, VII, IX, X). Because it does not affect factors already circulating in the blood, it takes 3-5 days to become effective. Crucially, Warfarin also inhibits Protein C and S (natural anticoagulants) which have shorter half-lives than the pro-coagulant factors. This can create a transient 'hypercoagulable' window where the risk of new clots actually increases. Continuous Heparin provides immediate protection by inactivating thrombin and factor Xa, 'bridging' the patient safely until the INR reaches the therapeutic target (usually 2.0-3.0)."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "The nurse must monitor specific laboratory values to adjust the dosing of anticoagulants. Correctively link the medication to its primary monitoring parameter.",
                rows: [
                    "Unfractionated Heparin continuous IV infusion",
                    "Warfarin (Coumadin) oral tablets",
                    "Enoxaparin (Lovenox) subcutaneous injection",
                    "Dabigatran (Pradaxa) oral capsules"
                ],
                columns: ["aPTT", "PT / INR", "No Routine Monitoring Required"],
                answer: {
                    "Unfractionated Heparin continuous IV infusion": "aPTT",
                    "Warfarin (Coumadin) oral tablets": "PT / INR",
                    "Enoxaparin (Lovenox) subcutaneous injection": "No Routine Monitoring Required",
                    "Dabigatran (Pradaxa) oral capsules": "No Routine Monitoring Required"
                },
                rationale: "Unfractionated Heparin has an unpredictable half-life and must be adjusted using the activated partial thromboplastin time (aPTT) to maintain a therapeutic range (1.5-2.5 times the control). Warfarin is monitored via the Prothrombin Time (PT) and International Normalized Ratio (INR) to ensure consistent levels across different labs. Low Molecular Weight Heparins (like Enoxaparin) and Direct Oral Anticoagulants (like Dabigatran) have highly predictable pharmacokinetics and do not require routine laboratory monitoring in most patients."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "On day 4 of therapy, the patient suddenly develops a severe nosebleed (epistaxis) and her urine appears bright red. Her morning INR was 5.8. Complete the bowtie for the primary concern.",
                center_condition: {
                    label: "Potential Condition",
                    options: ["Warfarin Toxicity / Overdose", "Heparin-Induced Thrombocytopenia", "Acute Kidney Injury", "Normal Bridge Response"],
                    answer: "Warfarin Toxicity / Overdose"
                },
                left_actions: {
                    label: "Actions (2)",
                    options: ["Administer Vitamin K (Phytonadione)", "Hold the next dose of Warfarin", "Administer Protamine Sulfate", "Increase the Heparin drip rate", "Encourage intake of leafy green vegetables"],
                    answer: ["Administer Vitamin K (Phytonadione)", "Hold the next dose of Warfarin"]
                },
                right_monitor: {
                    label: "Monitor (2)",
                    options: ["Repeat INR levels", "Hemoglobin and Hematocrit", "aPTT levels", "Serum Potassium", "Urine Specific Gravity"],
                    answer: ["Repeat INR levels", "Hemoglobin and Hematocrit"]
                },
                rationale: "The patient is experiencing an acute bleeding event due to an excessively high INR (5.8), indicating Warfarin toxicity. The primary nursing action is to hold the medication to prevent further anticoagulation and administer Vitamin K, which is the specific antagonist that allows the liver to resume synthesis of clotting factors. While leafy greens contain Vitamin K, they are not used for acute reversal. Monitoring must focus on the INR to track the effectiveness of the reversal and the Hemoglobin/Hematocrit to assess the severity of blood loss from the epistaxis and hematuria."
            }
        ]
    }
];

</script>
    <script>
/* SOURCE: missions_cardio_3.js */
// Missions 11-15: Clinical Reasoning in Cardiovascular Pharma
window.missions_cardio_3 = [
    {
        id: "M-011",
        numerical_id: 11,
        title: "Nightmare and Nightfalls: Prazosin Initiation",
        category: "Cardiovascular / Adrenergics",
        difficulty: "Intermediate",
        patient_profile: {
            demographics: { name: "Henry Miller", age: 48, gender: "Male", mrn: "1192-HM", weight: "92 kg", height: "180 cm", allergies: "NKDA" },
            chief_complaint: "Readiness for first dose of Prazosin.",
            hpi: "Patient is prescribed Prazosin (Minipress) for both resistant hypertension and PTSD-related nightmares. He is receiving his first 1mg dose today.",
            pmh: "PTSD, Hypertension, BPH.",
            sh: "Iraq War veteran. Lives alone.",
            ros: { neuro: "Reports vivid nightmares. Cardio: BP 158/94." }
        },
        exhibits: [
            {
                title: "Provider Orders",
                type: "text",
                content: "1. Prazosin (Minipress) 1 mg PO once daily.<br>2. Monitor BP q30min for 2 hours after initial dose."
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "The nurse prepares to administer the first dose. Which safety interventions are mandatory? Select all that apply.",
                options: [
                    "Administer the dose at bedtime",
                    "Instruct patient to remain in bed for 3 hours after dose",
                    "Warn patient about the risk of sudden fainting (syncope)",
                    "Check BP only if the patient feels dizzy",
                    "Administer with a high-protein meal",
                    "Advise avoiding hazardous tasks for 24 hours"
                ],
                answer: ["Administer the dose at bedtime", "Instruct patient to remain in bed for 3 hours after dose", "Warn patient about the risk of sudden fainting (syncope)", "Advise avoiding hazardous tasks for 24 hours"],
                rationale: "Prazosin is notorious for 'First-Dose Syncope,' a profound orthostatic drop occurring 30-90 minutes after the initial dose. Bedtime administration and staying supine/in bed are the primary safety rules to prevent injury."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "Identify the therapeutic target for each indication of Prazosin in this patient.",
                rows: ["PTSD Nightmares", "Hypertension", "BPH Symptoms"],
                columns: ["CNS Alpha-1 Blockade", "Peripheral Alpha-1 Blockade", "Urethral Smooth Muscle Relaxation"],
                answer: {
                    "PTSD Nightmares": "CNS Alpha-1 Blockade",
                    "Hypertension": "Peripheral Alpha-1 Blockade",
                    "BPH Symptoms": "Urethral Smooth Muscle Relaxation"
                },
                rationale: "Prazosin acts on alpha-1 receptors in three locations: the brain (PTSD), vascular smooth muscle (HTN), and the bladder neck/prostate (BPH)."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "The patient stands up to use the bathroom 45 minutes after the dose and collapses.",
                center_condition: { label: "Condition", options: ["First-Dose Syncope", "Acute MI", "Stroke", "Seizure"], answer: "First-Dose Syncope" },
                left_actions: { label: "Actions", options: ["Place in Trendelenburg", "Assess BP immediately", "Give Epinephrine", "Call a Code Blue"], answer: ["Place in Trendelenburg", "Assess BP immediately"] },
                right_monitor: { label: "Monitor", options: ["Orthostatic BP levels", "Neuro checks", "Urine output", "Blood glucose"], answer: ["Orthostatic BP levels", "Neuro checks"] }
            }
        ]
    },
    {
        id: "M-012",
        numerical_id: 12,
        title: "Breathless on Brilinta: Ticagrelor Dyspnea",
        category: "Cardiovascular / Antiplatelets",
        difficulty: "Advanced",
        patient_profile: {
            demographics: { name: "Sarah Jenkins", age: 62, gender: "Female", mrn: "8821-SJ", weight: "70 kg", height: "162 cm", allergies: "Aspirin (GI upset)" },
            chief_complaint: "Sudden onset of shortness of breath at rest.",
            hpi: "Patient was started on Ticagrelor (Brilinta) 90mg BID 3 days ago following a coronary stent. She reports feeling 'short of breath' even when sitting still. She denies chest pain or leg swelling.",
            pmh: "CAD, Post-PCI, HTN.",
            sh: "Retired. Lives with daughter.",
            ros: { cardio: "No chest pain. HR 72.", lung: "Lungs clear. Reports dyspnea." }
        },
        exhibits: [
            {
                title: "Vitals & Labs",
                type: "table",
                data: [
                    { param: "SpO2", val: "98%", note: "Normal" },
                    { param: "BNP", val: "85 pg/mL", status: "NORMAL", ref: "< 100" },
                    { param: "CXR", val: "Clear lung fields", status: "NORMAL" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "matrix",
                prompt: "The nurse distinguishes between heart failure and Ticagrelor-induced dyspnea. Link the finding to the likely cause.",
                rows: ["Elevated BNP (>400)", "Clear Lung Sounds / Normal SpO2", "Crackles on Auscultation", "Onset 3 days after starting Brilinta"],
                columns: ["Likely Heart Failure", "Likely Ticagrelor Side Effect"],
                answer: {
                    "Elevated BNP (>400)": "Likely Heart Failure",
                    "Clear Lung Sounds / Normal SpO2": "Likely Ticagrelor Side Effect",
                    "Crackles on Auscultation": "Likely Heart Failure",
                    "Onset 3 days after starting Brilinta": "Likely Ticagrelor Side Effect"
                },
                rationale: "Ticagrelor causes a unique, harmless dyspnea in ~15% of patients. It is distinguished from HF by clear lungs, normal BNP, and normal oxygen saturation."
            },
            {
                id: 2,
                type: "extended_sata",
                prompt: "Which information should the nurse provide to the patient regarding this dyspnea? Select all that apply.",
                options: [
                    "This is a known side effect of Brilinta",
                    "It is usually self-limiting and transient",
                    "You must stop the drug immediately",
                    "It does not mean your heart failure is worsening",
                    "We will need to switch you back to Clopidogrel today",
                    "Report if the breathlessness becomes disabling"
                ],
                answer: ["This is a known side effect of Brilinta", "It is usually self-limiting and transient", "It does not mean your heart failure is worsening", "Report if the breathlessness becomes disabling"],
                rationale: "The dyspnea is common and usually resolves. It is not an emergency and does not typically require drug discontinuation unless severe."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "Manage the ongoing antiplatelet therapy.",
                center_condition: { label: "Condition", options: ["Transient Dyspnea", "Pulmonary Edema", "Pneumonia", "Stent Thrombosis"], answer: "Transient Dyspnea" },
                left_actions: { label: "Actions", options: ["Reassure patient", "Continue Ticagrelor", "Give Furosemide", "Hold all meds"], answer: ["Reassure patient", "Continue Ticagrelor"] },
                right_monitor: { label: "Monitor", options: ["Persistence of symptoms", "SpO2 levels", "BUN", "Platelets"], answer: ["Persistence of symptoms", "SpO2 levels"] }
            }
        ]
    },
    {
        id: "M-013",
        numerical_id: 13,
        title: "The Potent Guard: Abciximab in PCI",
        category: "Cardiovascular / Antiplatelets",
        difficulty: "Advanced",
        patient_profile: {
            demographics: { name: "David Ross", age: 55, gender: "Male", mrn: "7732-DR", weight: "105 kg", height: "185 cm", allergies: "NKDA" },
            chief_complaint: "Acute Chest Pain - Scheduled for PCI.",
            hpi: "Patient is in the Cath Lab for a balloon angioplasty. The provider has ordered an Abciximab (ReoPro) drip to prevent re-occlusion.",
            pmh: "Unstable Angina, Smoking, T2DM.",
            sh: "Active. Owns a trucking company.",
            ros: { cardio: "Chest pain 8/10. ST depression on EKG." }
        },
        exhibits: [
            {
                title: "Procedural Orders",
                type: "text",
                content: "1. Abciximab 0.25 mg/kg IV bolus.<br>2. Abciximab infusion 0.125 mcg/kg/min for 12 hours.<br>3. Maintain bedrest."
            },
            {
                title: "Post-Procedure Vitals (1400)",
                type: "table",
                data: [
                    { param: "BP", val: "90/52 mmHg", status: "LOW" },
                    { param: "Groin Site", val: "6cm hematoma noted", status: "CRITICAL" },
                    { param: "Platelets", val: "42,000", status: "CRITICAL LOW", ref: "150k-400k" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "matrix",
                prompt: "Which handling rules are required for Abciximab? Indicate True or False.",
                rows: ["Use a low protein-binding in-line filter", "Shake the vial vigorously to mix", "Verify patient has platelets > 100k", "Administer through a dedicated IV line"],
                columns: ["True", "False"],
                answer: {
                    "Use a low protein-binding in-line filter": "True",
                    "Shake the vial vigorously to mix": "False",
                    "Verify patient has platelets > 100k": "True",
                    "Administer through a dedicated IV line": "True"
                },
                rationale: "Abciximab requires a filter and dedicated line. Shaking the vial can denature the monoclonal antibodies. Baseline platelets must be checked as it can cause profound thrombocytopenia."
            },
            {
                id: 2,
                type: "extended_sata",
                prompt: "The nurse notes the groin hematoma and low platelets. Which actions are appropriate? Select all that apply.",
                options: [
                    "Stop the Abciximab infusion",
                    "Apply manual pressure to the groin site",
                    "Notify the interventional cardiologist",
                    "Give 325mg Aspirin immediately",
                    "Increase the IV rate to maintain BP",
                    "Prepare for potential platelet transfusion"
                ],
                answer: ["Stop the Abciximab infusion", "Apply manual pressure to the groin site", "Notify the interventional cardiologist", "Prepare for potential platelet transfusion"],
                rationale: "Bleeding and severe thrombocytopenia are the main risks. Stopping the drug and applying pressure are immediate nursing priorities."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "Complete the bowtie for the platelet findings.",
                center_condition: { label: "Condition", options: ["Severe Thrombocytopenia", "Normal response", "HIT", "DIC"], answer: "Severe Thrombocytopenia" },
                left_actions: { label: "Actions", options: ["Stop Abciximab", "Apply pressure", "Give Heparin", "Administer Vit K"], answer: ["Stop Abciximab", "Apply pressure"] },
                right_monitor: { label: "Monitor", options: ["Serial Platelet counts", "Hgb / Hct", "aPTT", "INR"], answer: ["Serial Platelet counts", "Hgb / Hct"] }
            }
        ]
    },
    {
        id: "M-014",
        numerical_id: 14,
        title: "The Renal Rhythm: Atenolol in CKD",
        category: "Cardiovascular / Beta Blockers",
        difficulty: "Intermediate",
        patient_profile: {
            demographics: { name: "Frank Gomez", age: 74, gender: "Male", mrn: "3321-FG", weight: "80 kg", height: "175 cm", allergies: "NKDA" },
            chief_complaint: "Extreme lethargy and slow heart rate.",
            hpi: "Patient has been taking Atenolol 50mg daily for 2 years. He has Stage 4 CKD. Over the last week, his daughter noticed he is 'nearly impossible to wake up'.",
            pmh: "HTN, CKD (Stage 4), Heart Failure.",
            sh: "Retired tailor.",
            ros: { neuro: "Somnolent. Slow speech. Cardio: HR 38." }
        },
        exhibits: [
            {
                title: "Laboratory Results",
                type: "table",
                data: [
                    { lab: "Creatinine", val: "3.2 mg/dL", status: "CRITICAL HIGH" },
                    { lab: "GFR", val: "18 mL/min", status: "CRITICAL LOW" },
                    { lab: "Potassium", val: "4.8 mEq/L", status: "NORMAL" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "Why is Frank experiencing toxicity from a dose he has taken for 2 years? Select all that apply.",
                options: [
                    "Atenolol is excreted unchanged by the kidneys",
                    "Worsening GFR leads to accumulation of the drug",
                    "Atenolol is primarily metabolized by the liver",
                    "Frank's age increases the half-life of beta blockers",
                    "Atenolol is highly lipid soluble",
                    "The drug has a low therapeutic index"
                ],
                answer: ["Atenolol is excreted unchanged by the kidneys", "Worsening GFR leads to accumulation of the drug", "Frank's age increases the half-life of beta blockers"],
                rationale: "Unlike Metoprolol (liver), Atenolol is renally excreted. In CKD, it accumulates rapidly, leading to profound bradycardia and sedation."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "Compare Atenolol and Propranolol for this patient.",
                rows: ["Safe for Asthmatics", "Renally Excreted", "Crosses Blood-Brain Barrier Easily", "Requires dose reduction in CKD"],
                columns: ["Atenolol", "Propranolol", "Neither"],
                answer: {
                    "Safe for Asthmatics": "Neither",
                    "Renally Excreted": "Atenolol",
                    "Crosses Blood-Brain Barrier Easily": "Propranolol",
                    "Requires dose reduction in CKD": "Atenolol"
                },
                rationale: "Both can cause bronchospasm (neither safe). Atenolol is renal; Propranolol is liver and lipid-soluble (BBB)."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "Manage the profound bradycardia.",
                center_condition: { label: "Condition", options: ["Symptomatic Bradycardia", "Heart Block", "Normal aging", "Metabolic Acidosis"], answer: "Symptomatic Bradycardia" },
                left_actions: { label: "Actions", options: ["Hold Atenolol", "Administer Atropine", "Give IV Fluids", "Increase dose"], answer: ["Hold Atenolol", "Administer Atropine"] },
                right_monitor: { label: "Monitor", options: ["Continuous EKG", "BP / Pulse", "Liver Enzymes", "Urine Color"], answer: ["Continuous EKG", "BP / Pulse"] }
            }
        ]
    },
    {
        id: "M-015",
        numerical_id: 15,
        title: "The Mononitrate Mistake: Rescue vs. Prophylaxis",
        category: "Cardiovascular / Nitrates",
        difficulty: "Intermediate",
        patient_profile: {
            demographics: { name: "Irene Adler", age: 68, gender: "Female", mrn: "2219-IA", weight: "65 kg", height: "160 cm", allergies: "NKDA" },
            chief_complaint: "Instruction on new 'heart pill'.",
            hpi: "Patient is prescribed Isosorbide Mononitrate (Imdur) 30mg daily for stable angina. She asks the nurse, 'So I take this when my chest starts hurting, right?'",
            pmh: "Stable Angina, Hyperlipidemia.",
            sh: "Very active. Walks 2 miles daily.",
            ros: { cardio: "Chest pain during exercise only." }
        },
        exhibits: [
            {
                title: "Discharge Prescriptions",
                type: "text",
                content: "1. Isosorbide Mononitrate 30 mg PO Daily (Morning).<br>2. Nitroglycerin 0.4 mg SL PRN for Chest Pain."
            }
        ],
        steps: [
            {
                id: 1,
                type: "matrix",
                prompt: "Correct the patient's understanding of her nitrates.",
                rows: ["Isosorbide Mononitrate (Imdur)", "Nitroglycerin SL (Nitrostat)"],
                columns: ["Acute Rescue Only", "Long-term Prophylaxis Only", "Both"],
                answer: {
                    "Isosorbide Mononitrate (Imdur)": "Long-term Prophylaxis Only",
                    "Nitroglycerin SL (Nitrostat)": "Acute Rescue Only"
                },
                rationale: "Mononitrate has a slow onset and is for prevention. SL Nitroglycerin is for immediate rescue. They are never swapped."
            },
            {
                id: 2,
                type: "extended_sata",
                prompt: "Which teaching points are critical for Isosorbide Mononitrate? Select all that apply.",
                options: [
                    "Take in the morning upon awakening",
                    "Do not crush or chew the tablet",
                    "Expect a headache during the first week",
                    "Take only when chest pain occurs",
                    "Maintain an 8-12 hour nitrate-free interval",
                    "Notify provider if you use Viagra (PDE-5)"
                ],
                answer: ["Take in the morning upon awakening", "Do not crush or chew the tablet", "Expect a headache during the first week", "Maintain an 8-12 hour nitrate-free interval", "Notify provider if you use Viagra (PDE-5)"],
                rationale: "Imdur is an extended-release prophylactic. Nitrate-free intervals prevent tolerance. PDE-5 inhibitors are strictly contraindicated."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "The patient reports the medication isn't working after 2 months of TID dosing.",
                center_condition: { label: "Condition", options: ["Nitrate Tolerance", "Drug Allergy", "Acute MI", "Rebound HTN"], answer: "Nitrate Tolerance" },
                left_actions: { label: "Actions", options: ["Implement Nitrate-free period", "Consult MD for dose adjust", "Increase frequency", "Switch to Aspirin"], answer: ["Implement Nitrate-free period", "Consult MD for dose adjust"] },
                right_monitor: { label: "Monitor", options: ["Anginal frequency", "BP", "Liver Enzymes", "Hgb"], answer: ["Anginal frequency", "BP"] }
            }
        ]
    }
];

</script>
    <script>
/* SOURCE: missions_cardio_4.js */
// Missions 16-20: High-Alert Cardiovascular Emergencies
window.missions_cardio_4 = [
    {
        id: "M-016",
        numerical_id: 16,
        title: "The Moisture Mistake: Dabigatran Hazards",
        category: "Cardiovascular / Coagulation",
        difficulty: "Intermediate",
        patient_profile: {
            demographics: { name: "Thomas Miller", age: 71, gender: "Male", mrn: "8821-TM", weight: "85 kg", height: "178 cm", allergies: "NKDA" },
            chief_complaint: "New onset of black, tarry stools and coffee-ground emesis.",
            hpi: "Patient has been taking Dabigatran (Pradaxa) 150mg BID for 2 months for AFib. He admits to taking his pills out of the original bottle and placing them in a weekly pill organizer to 'save time'.",
            pmh: "Atrial Fibrillation, GERD, Osteoarthritis.",
            sh: "Lives alone. Independent.",
            ros: { cardio: "Stable.", gi: "Reports 'burning' stomach pain. Melena noted." }
        },
        exhibits: [
            {
                title: "Laboratory Values",
                type: "table",
                data: [
                    { lab: "Hemoglobin", val: "8.2 g/dL", status: "CRITICAL LOW", ref: "14-18" },
                    { lab: "Hematocrit", val: "25%", status: "CRITICAL LOW", ref: "42-52%" },
                    { lab: "aPTT", val: "42 seconds", status: "STABLE", ref: "30-40" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "The nurse identifies several errors in the patient's Dabigatran management. Which factors contributed to this GI hemorrhage? Select all that apply.",
                options: [
                    "Placing Dabigatran in a weekly pill organizer",
                    "Exposure of the drug to moisture",
                    "Opening or crushing the capsules",
                    "Dabigatran's inherently high risk for GI bleed",
                    "Missing two doses last week",
                    "Taking with a full glass of water"
                ],
                answer: ["Placing Dabigatran in a weekly pill organizer", "Exposure of the drug to moisture", "Dabigatran's inherently high risk for GI bleed"],
                rationale: "Dabigatran is exceptionally sensitive to moisture and MUST be kept in its original manufacturer bottle with the desiccant cap. Exposure to humidity causes the drug to breakdown or absorb unpredictably. It also carries a higher risk of GI hemorrhage than warfarin."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "Classify the appropriate reversal/safety rules for these anticoagulants.",
                rows: ["Warfarin (Coumadin)", "Dabigatran (Pradaxa)", "Heparin IV"],
                columns: ["Vitamin K", "Idarucizumab (Praxbind)", "Protamine Sulfate"],
                answer: {
                    "Warfarin (Coumadin)": "Vitamin K",
                    "Dabigatran (Pradaxa)": "Idarucizumab (Praxbind)",
                    "Heparin IV": "Protamine Sulfate"
                },
                rationale: "Each anticoagulant has a specific antidote. Idarucizumab is the specific monoclonal antibody reversal agent for Dabigatran."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "Address the acute active GI bleed.",
                center_condition: { label: "Condition", options: ["Major GI Hemorrhage", "Normal Side Effect", "GERD Flare", "HIT"], answer: "Major GI Hemorrhage" },
                left_actions: { label: "Actions", options: ["Administer Idarucizumab", "Hold Dabigatran", "Increase IV Heparin", "Give Vitamin K"], answer: ["Administer Idarucizumab", "Hold Dabigatran"] },
                right_monitor: { label: "Monitor", options: ["Hgb / Hct levels", "Blood pressure", "INR", "Platelet count"], answer: ["Hgb / Hct levels", "Blood pressure"] }
            }
        ]
    },
    {
        id: "M-017",
        numerical_id: 17,
        title: "The Stroke Clock: Alteplase Protocol",
        category: "Cardiovascular / Thrombolytic",
        difficulty: "Advanced",
        patient_profile: {
            demographics: { name: "Esther Williams", age: 66, gender: "Female", mrn: "4412-EW", weight: "60 kg", height: "160 cm", allergies: "NKDA" },
            chief_complaint: "Sudden onset of left-sided facial droop and right-arm weakness.",
            hpi: "Patient's husband reports symptoms began exactly 90 minutes ago. She is unable to speak clearly (dysarthria).",
            pmh: "HTN, Hyperlipidemia.",
            sh: "Non-smoker.",
            ros: { neuro: "NIH Stroke Scale score of 14." }
        },
        exhibits: [
            {
                title: "Triage Vitals",
                type: "table",
                data: [
                    { param: "BP", val: "192/104 mmHg", status: "CRITICAL HIGH" },
                    { param: "Glucose", val: "110 mg/dL", status: "NORMAL" }
                ]
            },
            {
                title: "Diagnostic Results",
                type: "text",
                content: "Non-contrast CT Head: Negative for intracranial hemorrhage. Ischemic stroke suspected."
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "The nurse prepares for Alteplase (tPA) administration. Which criteria must be met before starting the infusion? Select all that apply.",
                options: [
                    "BP must be lowered below 185/110 mmHg",
                    "CT scan must rule out hemorrhage",
                    "Symptom onset must be within 3-4.5 hours",
                    "Wait for INR results (no history of anticoagulation)",
                    "Verify baseline Platelets > 100,000",
                    "Administer via standard gravity drip"
                ],
                answer: ["BP must be lowered below 185/110 mmHg", "CT scan must rule out hemorrhage", "Symptom onset must be within 3-4.5 hours", "Verify baseline Platelets > 100,000"],
                rationale: "tPA protocol requires strict BP control (<185/110), a negative CT for bleed, and a strict time window. It must be on a pump, and baseline labs (platelets) are required."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "Identify the required nursing action during the 60-minute Alteplase infusion.",
                rows: ["Neuro checks and BP monitoring", "Invasive procedures (Foley/Sticks)", "Manual swirl of the vial (do not shake)", "Bedrest"],
                columns: ["Mandatory", "Strictly Contraindicated"],
                answer: {
                    "Neuro checks and BP monitoring": "Mandatory",
                    "Invasive procedures (Foley/Sticks)": "Strictly Contraindicated",
                    "Manual swirl of the vial (do not shake)": "Mandatory",
                    "Bedrest": "Mandatory"
                },
                rationale: "Neuro/BP checks q15min are required. Invasive procedures are banned for 24h due to bleeding risk. Shaking tPA destroys the protein; swirling is required."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "The patient suddenly develops a severe headache and pupil changes during the infusion.",
                center_condition: { label: "Condition", options: ["Intracranial Hemorrhage", "Expected Effect", "Re-perfusion", "Ischemic progression"], answer: "Intracranial Hemorrhage" },
                left_actions: { label: "Actions", options: ["Stop tPA immediately", "Notify Provider", "Increase BP", "Give more tPA"], answer: ["Stop tPA immediately", "Notify Provider"] },
                right_monitor: { label: "Monitor", options: ["Stat CT scan", "Level of consciousness", "Urine output", "Lung sounds"], answer: ["Stat CT scan", "Level of consciousness"] }
            }
        ]
    },
    {
        id: "M-018",
        numerical_id: 18,
        title: "The Abrupt Stop: Clonidine Rebound",
        category: "Cardiovascular / Adrenergics",
        difficulty: "Intermediate",
        patient_profile: {
            demographics: { name: "Larry Jenkins", age: 55, gender: "Male", mrn: "2291-LJ", weight: "90 kg", height: "175 cm", allergies: "NKDA" },
            chief_complaint: "Severe anxiety, tremors, and 'pounding' headache.",
            hpi: "Patient reports he ran out of his Clonidine (Catapres) tablets 2 days ago and hasn't had time to pick up the refill. He feels 'like my heart is jumping out of my chest'.",
            pmh: "Severe HTN, Alcohol Use Disorder.",
            sh: "Truck driver.",
            ros: { neuro: "Agitated, tremors. Cardio: BP 210/115." }
        },
        exhibits: [
            {
                title: "Vital Signs",
                type: "table",
                data: [
                    { param: "BP", val: "214/118 mmHg", status: "CRITICAL HIGH" },
                    { param: "HR", val: "122 bpm", status: "TACHYCARDIA" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "matrix",
                prompt: "The nurse analyzes the physiological cause. Is this rebound HTN or alcohol withdrawal?",
                rows: ["Cause: Sudden withdrawal of central alpha-2 agonism", "Cause: Decreased GABA activity", "Symptom: Severe hypertensive crisis", "Correct Action: Resume Clonidine and taper slowly"],
                columns: ["Likely Clonidine Rebound", "Likely Alcohol Withdrawal"],
                answer: {
                    "Cause: Sudden withdrawal of central alpha-2 agonism": "Likely Clonidine Rebound",
                    "Cause: Decreased GABA activity": "Likely Alcohol Withdrawal",
                    "Symptom: Severe hypertensive crisis": "Likely Clonidine Rebound",
                    "Correct Action: Resume Clonidine and taper slowly": "Likely Clonidine Rebound"
                },
                rationale: "Abrupt cessation of Clonidine leads to a massive surge in sympathetic outflow, causing rebound hypertensive crisis. It is a medical emergency."
            },
            {
                id: 2,
                type: "extended_sata",
                prompt: "Which teaching points are essential for a patient starting a Clonidine Transdermal Patch? Select all that apply.",
                options: [
                    "Change the patch every 7 days",
                    "Apply to a hairless area of upper arm or chest",
                    "Rotate the application site each week",
                    "Do not stop abruptly even if BP is normal",
                    "Take a hot sauna immediately after applying",
                    "The patch is waterproof and can stay on during bathing"
                ],
                answer: ["Change the patch every 7 days", "Apply to a hairless area of upper arm or chest", "Rotate the application site each week", "Do not stop abruptly even if BP is normal", "The patch is waterproof and can stay on during bathing"],
                rationale: "Clonidine patches last 7 days. Rotating sites prevents irritation. Heat (sauna) increases absorption dangerously. It is waterproof."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "Manage the acute hypertensive rebound.",
                center_condition: { label: "Condition", options: ["Rebound Hypertensive Crisis", "Stable HTN", "Stroke", "Renal Failure"], answer: "Rebound Hypertensive Crisis" },
                left_actions: { label: "Actions", options: ["Resume Clonidine", "Notify Provider", "Give IV Bolus Fluid", "Increase salt intake"], answer: ["Resume Clonidine", "Notify Provider"] },
                right_monitor: { label: "Monitor", options: ["Continuous BP", "Heart rate/rhythm", "Daily weights", "Blood glucose"], answer: ["Continuous BP", "Heart rate/rhythm"] }
            }
        ]
    },
    {
        id: "M-019",
        numerical_id: 19,
        title: "Lethal Leg Pain: The Fibrate-Statin Trap",
        category: "Cardiovascular / Lipids",
        difficulty: "Advanced",
        patient_profile: {
            demographics: { name: "Alice Thorne", age: 62, gender: "Female", mrn: "3312-AT", weight: "70 kg", height: "165 cm", allergies: "NKDA" },
            chief_complaint: "Severe muscle pain and 'cola-colored' urine.",
            hpi: "Patient was recently started on Gemfibrozil (Lopid) to add to her Atorvastatin (Lipitor) therapy. For 3 days, she has had disabling thigh pain and malaise.",
            pmh: "Hyperlipidemia, Type 2 DM.",
            sh: "Retired librarian.",
            ros: { ms: "Extreme muscle tenderness.", gu: "Dark, reddish-brown urine." }
        },
        exhibits: [
            {
                title: "Lab Results",
                type: "table",
                data: [
                    { lab: "Creatine Kinase (CK)", val: "15,000 U/L", status: "CRITICAL HIGH", ref: "26-192" },
                    { lab: "Creatinine", val: "2.1 mg/dL", status: "HIGH", ref: "0.7-1.3" },
                    { lab: "Urine Myoglobin", val: "POSITIVE", status: "CRITICAL" }
                ]
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "Which physiological mechanisms contributed to this crisis? Select all that apply.",
                options: [
                    "Gemfibrozil inhibits the metabolism of Atorvastatin",
                    "Synergistic muscle toxicity between fibrates and statins",
                    "Statin-induced myopathy is dose-dependent",
                    "Excessive exercise in the morning",
                    "Low Vitamin K intake",
                    "Gemfibrozil directly damages skeletal muscle"
                ],
                answer: ["Gemfibrozil inhibits the metabolism of Atorvastatin", "Synergistic muscle toxicity between fibrates and statins", "Statin-induced myopathy is dose-dependent"],
                rationale: "Fibrates (especially Gemfibrozil) interfere with statin glucuronidation, leading to massive increases in statin levels and synergistic muscle destruction (Rhabdomyolysis)."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "Identify the primary adverse effect risk for each lipid drug class.",
                rows: ["HMG-CoA Reductase Inhibitors (Statins)", "Fibric Acid Derivatives (Fibrates)", "Bile Acid Sequestrants"],
                columns: ["Rhabdomyolysis", "Gallstones", "Constipation/Vitamin Deficiency"],
                answer: {
                    "HMG-CoA Reductase Inhibitors (Statins)": "Rhabdomyolysis",
                    "Fibric Acid Derivatives (Fibrates)": "Gallstones",
                    "Bile Acid Sequestrants": "Constipation/Vitamin Deficiency"
                },
                rationale: "Statins target muscles (Rhabdo); Fibrates increase cholesterol in bile (Gallstones); Resins stay in the gut (Constipation)."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "Address the Rhabdomyolysis and AKI risk.",
                center_condition: { label: "Condition", options: ["Rhabdomyolysis", "Flu", "Myasthenia Gravis", "DVT"], answer: "Rhabdomyolysis" },
                left_actions: { label: "Actions", options: ["Initiate aggressive IV hydration", "Stop all lipid meds", "Increase Statin dose", "Give Ibuprofen"], answer: ["Initiate aggressive IV hydration", "Stop all lipid meds"] },
                right_monitor: { label: "Monitor", options: ["Urine output and color", "Serum Creatinine", "aPTT", "TSH levels"], answer: ["Urine output and color", "Serum Creatinine"] }
            }
        ]
    },
    {
        id: "M-020",
        numerical_id: 20,
        title: "Pressure Point: Mannitol Neuro-Safety",
        category: "Cardiovascular / Diuretics",
        difficulty: "Advanced",
        patient_profile: {
            demographics: { name: "Officer John Blake", age: 44, gender: "Male", mrn: "7742-JB", weight: "95 kg", height: "188 cm", allergies: "NKDA" },
            chief_complaint: "Decreased level of consciousness following MVA.",
            hpi: "Patient sustained a closed head injury. ICP is currently 28 mmHg (Normal < 15). The nurse is preparing a Mannitol 25% infusion.",
            pmh: "Healthy, active.",
            sh: "Police officer.",
            ros: { neuro: "GCS score of 9. Pupil response sluggish." }
        },
        exhibits: [
            {
                title: "EHR Notes",
                type: "text",
                content: "1. Mannitol 25% IV 1g/kg over 30 minutes.<br>2. Use in-line filter.<br>3. Monitor hourly urine output."
            }
        ],
        steps: [
            {
                id: 1,
                type: "extended_sata",
                prompt: "The nurse retrieves the Mannitol bag from the medication room. Which safety steps are mandatory? Select all that apply.",
                options: [
                    "Inspect the bag for white crystals",
                    "If crystals are present, warm the bag to dissolve them",
                    "Use a filter needle to draw up and filtered tubing to give",
                    "Check for pulmonary crackles before administration",
                    "Shake the bag vigorously to dissolve crystals",
                    "Administer via small 24g peripheral IV"
                ],
                answer: ["Inspect the bag for white crystals", "If crystals are present, warm the bag to dissolve them", "Use a filter needle to draw up and filtered tubing to give", "Check for pulmonary crackles before administration"],
                rationale: "Mannitol crystallizes easily; heating and filtering are mandatory. It shifts fluid rapidly, so the nurse must check for pulmonary edema (crackles) before giving."
            },
            {
                id: 2,
                type: "matrix",
                prompt: "Link the physiological effect of Mannitol to the assessment finding.",
                rows: ["Osmotic pull from brain tissue", "Rapid intravascular volume expansion", "Potent diuretic effect", "Crystallization in renal tubules"],
                columns: ["Decreased ICP / Improved Neuro", "Crackles in Lungs / HF", "Large volume of urine", "Acute Kidney Injury"],
                answer: {
                    "Osmotic pull from brain tissue": "Decreased ICP / Improved Neuro",
                    "Rapid intravascular volume expansion": "Crackles in Lungs / HF",
                    "Potent diuretic effect": "Large volume of urine",
                    "Crystallization in renal tubules": "Acute Kidney Injury"
                },
                rationale: "Mannitol pulls water into the blood (reducing ICP but risking HF) and then out through the kidneys (causing high UO but risking AKI from crystals)."
            },
            {
                id: 3,
                type: "bowtie",
                prompt: "The patient's BP is 160/90 and ICP is 22. Urine output is 15 mL/hr.",
                center_condition: { label: "Condition", options: ["Oliguric Renal Failure", "Expected Response", "Diabetes Insipidus", "SJS"], answer: "Oliguric Renal Failure" },
                left_actions: { label: "Actions", options: ["Hold Mannitol", "Notify Provider", "Increase IV rate", "Give IV Furosemide"], answer: ["Hold Mannitol", "Notify Provider"] },
                right_monitor: { label: "Monitor", options: ["BUN / Creatinine", "Serum Osmolality", "SpO2", "Neuro checks"], answer: ["BUN / Creatinine", "Serum Osmolality"] }
            }
        ]
    }
];

</script>
    <script>
/* SOURCE: data_loader.js */
// Master Data Aggregator - Globally Exposed
window.drugDB = [];

function mergeData(groupData) {
    if (Array.isArray(groupData)) {
        window.drugDB = window.drugDB.concat(groupData);
    }
}

// Atomic Loads
if (typeof data_lipids_statins !== 'undefined') mergeData(data_lipids_statins);
if (typeof data_lipids_resins !== 'undefined') mergeData(data_lipids_resins);
if (typeof data_lipids_fibrates_misc !== 'undefined') mergeData(data_lipids_fibrates_misc);

// RAAS Atomic Loads
if (typeof data_raas_ace !== 'undefined') mergeData(data_raas_ace);
if (typeof data_raas_arb_dri !== 'undefined') mergeData(data_raas_arb_dri);

// CCB & Beta Atomic Loads
if (typeof data_ccb !== 'undefined') mergeData(data_ccb);
if (typeof data_beta_blockers !== 'undefined') mergeData(data_beta_blockers);

// Adrenergics & Vasodilators Atomic Loads
if (typeof data_adrenergics !== 'undefined') mergeData(data_adrenergics);
if (typeof data_vasodilators !== 'undefined') mergeData(data_vasodilators);

// Diuretics Atomic Loads
if (typeof data_diuretics_loop_thiazide !== 'undefined') mergeData(data_diuretics_loop_thiazide);
if (typeof data_diuretics_ksparing_misc !== 'undefined') mergeData(data_diuretics_ksparing_misc);

// CV Specific Atomic Loads
if (typeof data_angina_hf !== 'undefined') mergeData(data_angina_hf);
if (typeof data_antiplatelets !== 'undefined') mergeData(data_antiplatelets);
if (typeof data_anticoagulants !== 'undefined') mergeData(data_anticoagulants);
if (typeof data_antiarrhythmics !== 'undefined') mergeData(data_antiarrhythmics);

// Diabetes Atomic Loads
if (typeof data_diabetes_sensitizers !== 'undefined') mergeData(data_diabetes_sensitizers);
if (typeof data_diabetes_secretagogues !== 'undefined') mergeData(data_diabetes_secretagogues);
if (typeof data_diabetes_alpha_sglt2 !== 'undefined') mergeData(data_diabetes_alpha_sglt2);
if (typeof data_diabetes_gliptin_glp1a !== 'undefined') mergeData(data_diabetes_gliptin_glp1a);
if (typeof data_diabetes_insulins_part1 !== 'undefined') mergeData(data_diabetes_insulins_part1);
if (typeof data_diabetes_insulins_part2 !== 'undefined') mergeData(data_diabetes_insulins_part2);

console.log("Global Pharma Database Initialized:", window.drugDB.length, "drugs.");

</script>
    <script>
/* SOURCE: mastery_logic.js */
// TITANIUM MASTER ENGINE - V3.3 (ENGINEERING GRADE)
// Documentation: 
// - drugDB Object: { g: generic, b: brand, c: class, m: moa, ind: indic, con: contra, aec: common, aes: severe, inter: [], dosage: str, admin: str, nurse: str }
// - Mission Object: { numerical_id: int, title: str, patient_profile: {}, exhibits: [], steps: [] }

let filters = { cv: true, dm: true };
let sortMode = 'az';
let currentMission = null;
let currentStepIndex = 0;
let missionFeedbackMode = false;
let allMissions = [];

/**
 * CENTRALIZED LOGGING & ERROR HANDLING
 */
const Logger = {
    info: (msg, data = "") => console.log(`%c[INFO] ${msg}`, "color: #3b82f6; font-weight: bold", data),
    warn: (msg, data = "") => console.warn(`[WARN] ${msg}`, data),
    error: (msg, err = "") => {
        console.error(`[CRITICAL ERROR] ${msg}`, err);
        // Visual feedback for critical failure
        const indicator = document.getElementById('status-indicator');
        if (indicator) { indicator.innerText = "System Offline"; indicator.className = "text-danger small fw-bold"; }
    }
};

/**
 * SYSTEM AUDIT TOOL (Run TitaniumAudit.verify() in console)
 */
window.TitaniumAudit = {
    verify: function () {
        Logger.info("Commencing System Audit...");
        const drugCount = window.drugDB ? window.drugDB.length : 0;
        const missionCount = allMissions.length;

        Logger.info(`Pharma Database: ${drugCount}/122 items.`);
        if (drugCount < 122) Logger.warn("Drug database is incomplete.");

        allMissions.forEach(m => {
            if (!m.numerical_id || !m.steps || m.steps.length === 0) {
                Logger.error(`Mission Integrity Failure: ID ${m.id}`);
            }
        });
        Logger.info("Audit Complete. System stable.");
        return "Audit Pass";
    }
};

/**
 * PERFORMANCE OPTIMIZED RENDERING
 */
function renderDrugs() {
    try {
        const grid = document.getElementById('drug-grid');
        const search = document.getElementById('drugSearch').value.toLowerCase();
        if (!window.drugDB) throw new Error("Data module missing: drugDB");

        const filtered = window.drugDB.filter(d => {
            const catMatch = filters[d.cat];
            const searchMatch = !search || d.g.toLowerCase().includes(search) || d.b.toLowerCase().includes(search) || d.c.toLowerCase().includes(search);
            return catMatch && searchMatch;
        });

        if (sortMode === 'az') filtered.sort((a, b) => a.g.localeCompare(b.g));
        else filtered.sort((a, b) => a.c.localeCompare(b.c));

        grid.innerHTML = filtered.map(d => `
            <div class="col-md-6 mb-4">
                <div class="nexus-card shadow-lg">
                    <div class="d-flex justify-content-between align-items-start mb-3" style="border-bottom: 1px solid rgba(255,255,255,0.1); padding-bottom: 15px;">
                        <div><h4 class="fw-bold text-white mb-0">${d.g}</h4><div class="small text-accent fw-bold">Brand: ${d.b}</div></div>
                        <span class="badge ${d.cat === 'cv' ? 'badge-cv' : 'badge-dm'}">${d.c}</span>
                    </div>
                    <span class="point-label">1. Mechanism of Action</span><div class="point-value">${d.m}</div>
                    <div class="row">
                        <div class="col-md-6"><span class="point-label">2. Clinical Indications</span><div class="point-value">${d.ind}</div></div>
                        <div class="col-md-6"><span class="point-label">3. Contraindications</span><div class="point-value">${d.con}</div></div>
                    </div>
                    <span class="point-label">4. Common Side Effects</span><div class="ae-common">${d.aec}</div>
                    <span class="point-label" style="color: var(--danger);">5. Severe Adverse Effects</span><div class="ae-severe">${d.aes}</div>
                    <span class="point-label">6. Pharmacological Interactions</span>
                    <table class="inter-table">${d.inter && d.inter.length ? d.inter.map(i => `<tr class="${i.s}"><td style="font-weight:700; color:#fff; width:35%;">${i.d}</td><td style="color:#cbd5e1;">${i.m}</td></tr>`).join('') : '<tr><td class="text-white-50 small italic">Verified Profile.</td></tr>'}</table>
                    <div class="data-strip">
                        <div class="logistics-box box-dosage"><span class="box-title">7. Adult Dosage</span>${d.dosage}</div>
                        <div class="logistics-box box-admin"><span class="box-title">8. Admin & Timing</span>${d.admin}</div>
                    </div>
                    <span class="point-label">9. Nursing Considerations</span><div class="point-value text-info">${d.nurse}</div>
                </div>
            </div>
        `).join('');
        document.getElementById('counter').innerText = `${filtered.length} Unique Generics`;
    } catch (e) { Logger.error("Drug Grid Render Failed", e); }
}

/**
 * INPUT VALIDATION & MISSION LOGIC
 */
function handleMissionAction() {
    if (missionFeedbackMode) {
        nextMissionStep();
        return;
    }

    const step = currentMission.steps[currentStepIndex];
    let isValidInput = false;

    // VALIDATION LAYER
    if (step.type === 'extended_sata') {
        isValidInput = document.querySelectorAll('input[name="m-opt"]:checked').length > 0;
    } else if (step.type === 'matrix') {
        isValidInput = step.rows.every(r => document.querySelector(`input[name="row-${r}"]:checked`));
    } else if (step.type === 'bowtie') {
        const l = document.querySelectorAll('input[name="bw-l"]:checked').length;
        const r = document.querySelectorAll('input[name="bw-r"]:checked').length;
        const c = document.getElementById('bw-c').value;
        isValidInput = (l === 2 && r === 2 && c !== "");
    }

    if (!isValidInput) {
        alert("Please complete all required selections before submitting.");
        return;
    }

    evaluateMissionStep();
}

function evaluateMissionStep() {
    const step = currentMission.steps[currentStepIndex];
    let isCorrect = false;

    try {
        if (step.type === 'extended_sata') {
            const sel = Array.from(document.querySelectorAll('input[name="m-opt"]:checked')).map(i => i.value);
            isCorrect = sel.length === step.answer.length && sel.every(v => step.answer.includes(v));
        } else if (step.type === 'matrix') {
            isCorrect = step.rows.every(r => document.querySelector(`input[name="row-${r}"]:checked`)?.value === step.answer[r]);
        } else if (step.type === 'bowtie') {
            const diag = document.getElementById('bw-c').value;
            const l = Array.from(document.querySelectorAll('input[name="bw-l"]:checked')).map(i => i.value);
            const r = Array.from(document.querySelectorAll('input[name="bw-r"]:checked')).map(i => i.value);
            isCorrect = (diag === step.center_condition.answer &&
                l.length === 2 && l.every(v => step.left_actions.answer.includes(v)) &&
                r.length === 2 && r.every(v => step.right_monitor.answer.includes(v)));
        }

        const fb = document.getElementById('mission-feedback');
        fb.innerHTML = `
            <div class="p-4 rounded-4 border-2 ${isCorrect ? 'border-success' : 'border-danger'}" 
                 style="background: ${isCorrect ? 'rgba(22, 101, 52, 0.3)' : 'rgba(153, 27, 27, 0.3)'};">
                <h4 class="fw-bold ${isCorrect ? 'text-success' : 'text-danger'}">${isCorrect ? 'CORRECT' : 'INCORRECT'}</h4>
                <p class="text-white mt-2">${step.rationale || "Verify clinical cues."}</p>
            </div>`;

        missionFeedbackMode = true;
        document.getElementById('m-action-btn').innerText = (currentStepIndex === currentMission.steps.length - 1) ? "FINISH MISSION" : "NEXT STEP";
    } catch (e) { Logger.error("Step Evaluation Failed", e); }
}

// NAVIGATION WRAPPERS
function startMission() {
    allMissions = [
        ...(typeof window.mission_prototype !== 'undefined' ? [window.mission_prototype] : []),
        ...(typeof window.missions_cardio_1 !== 'undefined' ? window.missions_cardio_1 : []),
        ...(typeof window.missions_cardio_2 !== 'undefined' ? window.missions_cardio_2 : []),
        ...(typeof window.missions_cardio_3 !== 'undefined' ? window.missions_cardio_3 : []),
        ...(typeof window.missions_cardio_4 !== 'undefined' ? window.missions_cardio_4 : []),
        ...(window.customMissions || [])
    ];
    console.log('allMissions loaded:', allMissions.length, 'missions');
    console.log('Missions with IDs:', allMissions.map(m => m.numerical_id).sort());
    console.log('M-051 found:', allMissions.find(m => m.numerical_id === 51));
    showMissionSelector();
}

function showMissionSelector() {
    const modalHtml = `
    <div id="missionSelectorModal" style="position: fixed; top: 0; left: 0; width: 100%; height: 100%; background: var(--primary); z-index: 2050; overflow-y: auto; padding: 40px;">
        <div class="container" style="max-width: 1200px;">
            <div class="d-flex justify-content-between align-items-center mb-5 border-bottom pb-3 border-secondary">
                <h2 class="text-accent fw-bold">CLINICAL MISSION CONTROL</h2>
                <button class="btn btn-outline-danger" onclick="closeMissionSelector()">Exit</button>
            </div>
            
            <div class="mb-5">
                <h4 class="text-white mb-3 border-start border-4 border-info ps-3">CARDIOVASCULAR (1-20)</h4>
                <div class="row row-cols-5 g-3">
                    ${Array.from({ length: 20 }).map((_, i) => renderMissionButton(i + 1, 'cv')).join('')}
                </div>
            </div>

            <div class="mb-5">
                <h4 class="text-white mb-3 border-start border-4 border-success ps-3">DIABETES MELLITUS (21-30)</h4>
                <div class="row row-cols-5 g-3">
                    ${Array.from({ length: 10 }).map((_, i) => renderMissionButton(i + 21, 'dm')).join('')}
                </div>
            </div>

            <div class="mb-5">
                <h4 class="text-white mb-3 border-start border-4 border-warning ps-3">COMBINED / COMORBIDITIES (31-40)</h4>
                <div class="row row-cols-5 g-3">
                    ${Array.from({ length: 10 }).map((_, i) => renderMissionButton(i + 31, 'combined')).join('')}
                </div>
            </div>

            <div class="mb-5">
                <h4 class="text-white mb-3 border-start border-4 border-danger ps-3">ACUTE RESPIRATORY / PNEUMONIA (41-50)</h4>
                <div class="row row-cols-5 g-3">
                    ${Array.from({ length: 10 }).map((_, i) => renderMissionButton(i + 41, 'acute_resp')).join('')}
                </div>
            </div>

            <div class="mb-5">
                <h4 class="text-white mb-3 border-start border-4 border-purple ps-3">ADVANCED NGN MISSIONS (51-60)</h4>
                <div class="row row-cols-5 g-3">
                    ${Array.from({ length: 10 }).map((_, i) => renderMissionButton(i + 51, 'advanced')).join('')}
                </div>
            </div>
        </div>
    </div>`;
    document.body.insertAdjacentHTML('beforeend', modalHtml);
}

function renderMissionButton(id, category) {
    const mission = allMissions.find(m => m.numerical_id === id);
    const locked = !mission;
    let colorClass;
    if (category === 'cv') colorClass = 'btn-outline-info';
    else if (category === 'dm') colorClass = 'btn-outline-success';
    else if (category === 'acute_resp') colorClass = 'btn-outline-danger';
    else if (category === 'advanced') colorClass = 'btn-outline-purple';
    else colorClass = 'btn-outline-warning'; // combined
    const activeClass = mission ? `bg-opacity-10 ${colorClass.replace('btn-outline', 'bg')} text-white border-${colorClass.split('-')[2]}` : 'btn-outline-secondary opacity-25';

    return `
    <div class="col">
        <button class="btn ${activeClass} w-100 p-2 fw-bold text-start position-relative" style="height: 100px; overflow: hidden;" ${mission ? `onclick="launchSpecificMission(${id})"` : 'disabled'}>
            <div class="fs-4 opacity-50 mb-1">#${id}</div>
            <div style="font-size: 0.65rem; text-transform: uppercase; line-height: 1.2;">${mission ? mission.title : 'LOCKED'}</div>
        </button>
    </div>`;
}

function launchSpecificMission(id) {
    currentMission = allMissions.find(m => m.numerical_id === id);
    currentStepIndex = 0; missionFeedbackMode = false;
    document.getElementById('missionSelectorModal')?.remove();
    showMissionUI();
}

function showMissionUI() {
    document.body.style.overflow = 'hidden';
    const html = `<div id="missionModal" class="mission-container">
        <button class="sidecar-toggle" onclick="toggleSidecar()"><i class="fas fa-pills fs-3"></i></button>
        <div id="pharmaSidecar" class="pharma-sidecar"><div class="sidecar-header"><div class="d-flex justify-content-between align-items-center mb-3"><h5 class="text-white mb-0">REFERENCE</h5><button class="btn btn-sm btn-outline-light" onclick="toggleSidecar()">X</button></div><input type="text" id="sidecarSearch" class="form-control form-control-sm bg-dark text-white" placeholder="Search..." onkeyup="renderSidecar()"></div><div id="sidecarContent" class="sidecar-content"></div></div>
        <div class="chart-pane"><div class="chart-header d-flex justify-content-between p-3"><div><h6 class="text-warning mb-1" style="font-size: 0.8rem; letter-spacing: 1px;">MISSION ${currentMission.numerical_id}: ${currentMission.title.toUpperCase()}</h6><h5 class="mb-0 text-white">${currentMission.patient_profile.demographics.name}</h5><span class="small text-white-50">MRN: ${currentMission.patient_profile.demographics.mrn}</span></div><button class="btn btn-outline-light btn-sm" onclick="closeMission()">Exit</button></div><div class="chart-tabs" id="mission-tabs"></div><div id="mission-content" class="chart-content"></div></div>
        <div class="work-pane"><div id="step-area"></div><div id="mission-feedback"></div><div class="mt-5 d-flex justify-content-between"><button class="btn btn-outline-secondary" id="m-back-btn" onclick="prevMissionStep()">BACK</button><button id="m-action-btn" class="btn btn-warning btn-lg px-5 fw-bold" onclick="handleMissionAction()">SUBMIT</button></div></div>
    </div>`;
    document.body.insertAdjacentHTML('beforeend', html);
    setTimeout(() => { renderMissionExhibits(); renderMissionStep(); }, 200);
}

function renderMissionExhibits() {
    const tabs = document.getElementById('mission-tabs');
    let html = `<div class="chart-tab active" onclick="showMissionExhibit('history', this)">History</div>`;
    currentMission.exhibits.forEach((ex, idx) => { html += `<div class="chart-tab" onclick="showMissionExhibit(${idx}, this)">${ex.title}</div>`; });
    tabs.innerHTML = html; showMissionExhibit('history');
}

function showMissionExhibit(type, el) {
    if (el) { document.querySelectorAll('#missionModal .chart-tab').forEach(t => t.classList.remove('active')); el.classList.add('active'); }
    const content = document.getElementById('mission-content');
    if (type === 'history') {
        const p = currentMission.patient_profile;
        content.innerHTML = `<h5 class="fw-bold text-primary mb-3">Admission H&P</h5><div class="mb-3"><h6 class="fw-bold text-secondary small">CHIEF COMPLAINT</h6><p>${p.chief_complaint}</p></div><div class="mb-3"><h6 class="fw-bold text-secondary small">HPI</h6><p>${p.hpi}</p></div><div class="mb-3"><h6 class="fw-bold text-secondary small">PMH</h6><p>${p.pmh}</p></div><div class="mb-3"><h6 class="fw-bold text-secondary small">REVIEW OF SYSTEMS</h6><ul class="small"><li><strong>Cardio:</strong> ${p.ros.cardio}</li><li><strong>Neuro:</strong> ${p.ros.neuro}</li><li><strong>GI:</strong> ${p.ros.gi}</li><li><strong>GU:</strong> ${p.ros.gu}</li></ul></div>`;
    } else {
        const ex = currentMission.exhibits[type];
        if (ex.type === 'table') {
            content.innerHTML = `<h5 class="fw-bold text-primary mb-3">${ex.title}</h5><table class="table table-bordered table-sm small mt-2"><thead><tr>${Object.keys(ex.data[0]).map(k => `<th>${k.toUpperCase()}</th>`).join('')}</tr></thead><tbody>${ex.data.map(row => `<tr>${Object.values(row).map(v => `<td>${v}</td>`).join('')}</tr>`).join('')}</tbody></table>`;
        } else { content.innerHTML = `<h5 class="fw-bold text-primary mb-3">${ex.title}</h5><div class="fs-6 mt-3 text-dark">${ex.content}</div>`; }
    }
}

function renderMissionStep() {
    missionFeedbackMode = false; const step = currentMission.steps[currentStepIndex];
    const area = document.getElementById('step-area'); document.getElementById('mission-feedback').innerHTML = '';
    let optsHtml = '';
    if (step.type === 'extended_sata') {
        optsHtml = `<div class="list-group">${step.options.map(o => `<label class="list-group-item list-group-item-action p-3 mb-2"><input class="form-check-input me-3" type="checkbox" name="m-opt" value="${o}">${o}</label>`).join('')}</div>`;
    } else if (step.type === 'matrix') {
        optsHtml = `<div class="table-responsive"><table class="matrix-table"><thead><tr><th>Finding</th>${step.columns.map(c => `<th>${c}</th>`).join('')}</tr></thead><tbody>${step.rows.map(r => `<tr><td class="text-white">${r}</td>${step.columns.map(c => `<td class="radio-cell text-center"><input type="radio" name="row-${r}" value="${c}" class="form-check-input"></td>`).join('')}</tr>`).join('')}</tbody></table></div>`;
    } else if (step.type === 'bowtie') {
        optsHtml = `<div class="bowtie-container"><div class="bowtie-wing left"><div class="bowtie-label">Actions (2)</div>${step.left_actions.options.map(o => `<label class="bw-option"><input type="checkbox" name="bw-l" value="${o}"><span class="text-white">${o}</span></label>`).join('')}</div><div class="bowtie-center"><div class="bowtie-label">Condition</div><select id="bw-c" class="form-select form-select-lg bg-dark text-white border-warning"><option value="" disabled selected>Select Condition...</option>${step.center_condition.options.map(o => `<option value="${o}">${o}</option>`).join('')}</select></div><div class="bowtie-wing right"><div class="bowtie-label">Monitor (2)</div>${step.right_monitor.options.map(o => `<label class="bw-option"><input type="checkbox" name="bw-r" value="${o}"><span class="text-white">${o}</span></label>`).join('')}</div></div>`;
    }
    area.innerHTML = `<div class="step-badge">${step.type.toUpperCase()}</div><h3 class="text-white mb-4 fw-bold">${step.prompt}</h3><div>${optsHtml}</div>`;
    document.getElementById('m-action-btn').innerText = "SUBMIT";
    document.getElementById('m-back-btn').disabled = currentStepIndex === 0;
}

function closeMission() {
    document.body.style.overflow = 'auto';
    document.getElementById('missionModal')?.remove();
    if (typeof showMissionSelectorNew === 'function') {
        showMissionSelectorNew();
    } else {
        showMissionSelector();
    }
}
function nextMissionStep() { if (currentStepIndex < currentMission.steps.length - 1) { currentStepIndex++; renderMissionStep(); } else { closeMission(); } }
function prevMissionStep() { if (currentStepIndex > 0) { currentStepIndex--; renderMissionStep(); } }
function toggleSidecar() { document.getElementById('pharmaSidecar').classList.toggle('active'); }

function renderSidecar() {
    const q = document.getElementById('sidecarSearch').value.toLowerCase();
    const content = document.getElementById('sidecarContent');
    if (q.length < 2) { content.innerHTML = '<div class="text-white-50 text-center mt-5 small">Search for drug cues...</div>'; return; }
    const matches = window.drugDB.filter(d => d.g.toLowerCase().includes(q) || d.b.toLowerCase().includes(q) || d.c.toLowerCase().includes(q));
    content.innerHTML = matches.map(d => `
        <div class="sidecar-drug-card p-3 mb-3" style="border-left: 4px solid var(--accent); background: rgba(0,0,0,0.2);">
            <h6 class="text-white fw-bold mb-1">${d.g} <span class="text-white-50 fw-normal">(${d.b})</span></h6>
            <div class="badge bg-secondary mb-2">${d.c}</div>
            
            <div class="mb-2">
                <strong class="text-accent" style="font-size: 0.75rem;">MECHANISM</strong>
                <div class="text-white-50" style="font-size: 0.75rem;">${d.m}</div>
            </div>

            <div class="mb-2">
                <strong class="text-danger" style="font-size: 0.75rem;">CONTRAINDICATIONS</strong>
                <div class="text-white-50" style="font-size: 0.75rem;">${d.con}</div>
            </div>

            <div class="mb-2">
                <strong class="text-warning" style="font-size: 0.75rem;">SEVERE ADVERSE EFFECTS</strong>
                <div class="ae-severe small">${d.aes}</div>
            </div>
            
            <div class="mb-2">
                <strong class="text-info" style="font-size: 0.75rem;">NURSING CONSIDERATIONS</strong>
                <div class="text-info" style="font-size: 0.75rem;">${d.nurse}</div>
            </div>
        </div>
    `).join('') || '<div class="text-white-50 text-center mt-5">No matches found.</div>';
}

function toggleFilter(cat) { filters[cat] = !filters[cat]; document.getElementById(`btn-${cat}`).classList.toggle(`active-${cat}`, filters[cat]); renderDrugs(); }
function setSort(mode) { sortMode = mode; document.getElementById('sort-az').classList.toggle('active', mode === 'az'); document.getElementById('sort-class').classList.toggle('active', mode === 'class'); renderDrugs(); }

</script>
    <script>
/* SOURCE: mission_logic_fixed.js */
// MASTER HUB REFACTORED MISSIONS LOGIC
// currentMission, currentStepIndex, missionFeedbackMode, and allMissions are declared in mastery_logic.js
let missionsUnlocked = false;

function startMission() {
    allMissions = [
        ...(typeof mission_prototype !== 'undefined' ? [mission_prototype] : []),
        ...(typeof missions_cardio_1 !== 'undefined' ? missions_cardio_1 : []),
        ...(typeof missions_cardio_2 !== 'undefined' ? missions_cardio_2 : []),
        ...(typeof missions_dm_1 !== 'undefined' ? missions_dm_1 : []),
        ...(window.customMissions || []) // Include dynamically loaded missions
    ];
    showMissionSelectorNew();
}

function unlockAllMissions() {
    missionsUnlocked = true;
    showMissionSelectorNew();
}

function showMissionSelectorNew() {
    // Hide home screen content when showing mission selector
    const homeContent = document.querySelector('.container-fluid.px-4.mt-4');
    if (homeContent) {
        homeContent.style.display = 'none';
    }
    document.getElementById('missionSelectorModal')?.remove();

    // Group missions by main category (before the " / ")
    const missionGroups = {};
    allMissions.forEach(mission => {
        const fullCategory = mission.category || 'Other';
        const mainCategory = fullCategory.split(' / ')[0] || fullCategory;
        if (!missionGroups[mainCategory]) {
            missionGroups[mainCategory] = [];
        }
        missionGroups[mainCategory].push(mission);
    });

    // Create HTML for each category
    let categoryHtml = '';
    const colors = ['border-info', 'border-success', 'border-warning', 'border-danger', 'border-primary'];
    let colorIndex = 0;

    Object.keys(missionGroups).forEach(category => {
        const missions = missionGroups[category];
        const color = colors[colorIndex % colors.length];
        colorIndex++;

        categoryHtml += `
            <div class="col-md-6 mb-4">
                <h4 class="text-white border-start ${color} border-4 ps-3 mb-4">${category.toUpperCase()} (${missions.length})</h4>
                <div class="row g-3">
                    ${missions.map(mission => renderMissionButton(mission.numerical_id, category.toLowerCase().replace(/\s+/g, ''))).join('')}
                </div>
            </div>
        `;
    });

    const modalHtml = `
        <div id="missionSelectorModal" style="position: fixed; top: 0; left: 0; width: 100%; height: 100%; background: var(--primary); z-index: 2050; overflow-y: auto; padding: 40px;">
            <div class="container" style="max-width: 1100px;">
                <div class="d-flex justify-content-between align-items-center mb-5 border-bottom pb-3 border-secondary">
                    <h2 class="text-accent fw-bold">
                        <i class="fas fa-map-marked-alt me-3"></i>
                        <span onclick="unlockAllMissions()" style="cursor: default;">C</span>LINICAL MISSION CONTROL
                    </h2>
                    <button class="btn btn-outline-danger" onclick="closeMissionSelector()">Return to Hub</button>
                </div>
                <div class="row">
                    ${categoryHtml}
                </div>
            </div>
        </div>
    `;
    document.body.insertAdjacentHTML('beforeend', modalHtml);
}

function renderMissionButton(id, category) {
    const mission = allMissions.find(m => m.numerical_id === id);
    const isAvailable = !!mission || missionsUnlocked;
    const color = category === 'cv' ? 'btn-outline-info' : 'btn-outline-success';
    const activeColor = category === 'cv' ? 'bg-info text-primary' : 'bg-success text-white';
    
    let title = 'LOCKED';
    if (mission) title = mission.title;
    else if (missionsUnlocked) title = 'DATA PENDING';

    return `
        <div class="col-3">
            <button class="btn ${isAvailable ? activeColor : color} w-100 p-1 fw-bold shadow-sm ${!isAvailable ? 'opacity-25' : ''}" 
                    style="height: 80px; display: flex; flex-direction: column; justify-content: center; align-items: center; border-width: 2px; overflow: hidden;" 
                    ${isAvailable ? `onclick="launchSpecificMission(${id})"` : 'disabled'}>
                <div class="fs-6" style="line-height: 1;">${id}</div>
                <div style="font-size: 0.5rem; line-height: 1; text-transform: uppercase; margin-top: 3px; white-space: normal; display: -webkit-box; -webkit-line-clamp: 3; -webkit-box-orient: vertical; overflow: hidden; padding: 0 2px;">
                    ${title}
                </div>
            </button>
        </div>
    `;
}

function closeMissionSelector() {
    document.getElementById('missionSelectorModal')?.remove();
    // Show home screen content again
    const homeContent = document.querySelector('.container-fluid.px-4.mt-4');
    if (homeContent) {
        homeContent.style.display = 'block';
    }
    // Navigate back to home screen
    if (typeof showHomeScreen === 'function') {
        showHomeScreen();
    }
}

function launchSpecificMission(id) {
    const mission = allMissions.find(m => m.numerical_id === id);
    if (!mission) {
        alert("Mission data pending for slot: " + id);
        return;
    }
    currentMission = mission;
    currentStepIndex = 0;
    missionFeedbackMode = false;
    closeMissionSelector();
    showMissionUI();
}

function showMissionUI() {
    document.body.style.overflow = 'hidden';
    const html = `<div id="missionModal" class="mission-container"><div class="chart-pane"><div class="chart-header d-flex justify-content-between align-items-center"><div><h5 class="mb-0 fw-bold" style="color:white !important;">${currentMission.patient_profile.demographics.name}</h5><span class="small opacity-75" style="color:white !important;">MRN: ${currentMission.patient_profile.demographics.mrn} | AGE: ${currentMission.patient_profile.demographics.age}</span></div><button class="btn btn-outline-light btn-sm" onclick="closeMission()">Exit Mission</button></div><div class="chart-tabs" id="mission-tabs"></div><div id="mission-content" class="chart-content"></div></div><div class="work-pane"><div id="step-area"></div><div id="mission-feedback" class="mt-4"></div><div class="mt-5 border-top border-secondary pt-4 d-flex justify-content-between align-items-center"><button id="mission-prev-btn" class="btn btn-outline-secondary btn-lg px-4" onclick="prevMissionStep()">BACK</button><div id="step-counter" class="text-white-50 fw-bold">STEP 1 OF 3</div><button id="mission-action-btn" class="btn btn-warning btn-lg px-5 fw-bold shadow" onclick="handleMissionAction()">SUBMIT ANSWER</button></div></div></div>`;
    document.body.insertAdjacentHTML('beforeend', html);
    setTimeout(() => {
        renderMissionExhibits();
        renderMissionStep();
    }, 100);
}

function closeMission() { document.body.style.overflow = 'auto'; document.getElementById('missionModal')?.remove(); }

function renderMissionExhibits() {
    const tabs = document.getElementById('mission-tabs');
    if (!tabs) return;
    let html = `<div class="chart-tab active" onclick="showMissionExhibit('history', this)">History</div>`;
    currentMission.exhibits.forEach((ex, idx) => {
        html += `<div class="chart-tab" onclick="showMissionExhibit(${idx}, this)">${ex.title}</div>`;
    });
    tabs.innerHTML = html;
    showMissionExhibit('history');
}

function showMissionExhibit(type, el) {
    if (el) { document.querySelectorAll('#missionModal .chart-tab').forEach(t => t.classList.remove('active')); el.classList.add('active'); }
    const content = document.getElementById('mission-content');
    if (!content) return;
    if (type === 'history') {
        const p = currentMission.patient_profile;
        content.innerHTML = `<h5 class="fw-bold text-primary mb-3">Admission H&P</h5><div class="mb-3"><h6 class="fw-bold text-secondary small text-uppercase">Chief Complaint</h6><p>${p.chief_complaint}</p></div><div class="mb-3"><h6 class="fw-bold text-secondary small text-uppercase">HPI</h6><p>${p.hpi}</p></div><div class="mb-3"><h6 class="fw-bold text-secondary small text-uppercase">PMH</h6><p>${p.pmh}</p></div><div class="mb-3"><h6 class="fw-bold text-secondary small text-uppercase">Review of Systems</h6><ul class="small"><li><strong>Cardio:</strong> ${p.ros.cardio}</li><li><strong>Neuro:</strong> ${p.ros.neuro}</li><li><strong>GI:</strong> ${p.ros.gi}</li><li><strong>GU:</strong> ${p.ros.gu}</li></ul></div>`;
    } else {
        const ex = currentMission.exhibits[type];
        if (ex.type === 'table') {
            content.innerHTML = `<h5 class="fw-bold text-primary mb-3">${ex.title}</h5><table class="table table-bordered table-sm small mt-3"><thead class="table-light"><tr>${Object.keys(ex.data[0]).map(k => `<th>${k.toUpperCase()}</th>`).join('')}</tr></thead><tbody>${ex.data.map(row => `<tr>${Object.values(row).map(v => `<td>${v}</td>`).join('')}</tr>`).join('')}</tbody></table>`;
        } else { content.innerHTML = `<h5 class="fw-bold text-primary mb-3">${ex.title}</h5><div class="fs-6 mt-3 text-dark">${ex.content}</div>`; }
    }
}

function prevMissionStep() { if (currentStepIndex > 0) { currentStepIndex--; renderMissionStep(); } }

function renderMissionStep() {
    missionFeedbackMode = false;
    const step = currentMission.steps[currentStepIndex];
    const area = document.getElementById('step-area');
    if (!area) return;
    document.getElementById('mission-feedback').innerHTML = '';
    document.getElementById('step-counter').innerText = `STEP ${currentStepIndex + 1} OF ${currentMission.steps.length}`;
    document.getElementById('mission-prev-btn').disabled = currentStepIndex === 0;
    let optsHtml = '';
    if (step.type === 'extended_sata') {
        optsHtml = `<div class="list-group">${step.options.map((o, i) => `<label class="list-group-item list-group-item-action p-3 mb-2"><input class="form-check-input me-3" type="checkbox" name="m-opt" value="${i}"> ${o}</label>`).join('')}</div>`;
    } else if (step.type === 'matrix') {
        optsHtml = `<div class="table-responsive"><table class="matrix-table"><thead><tr><th>Finding</th>${step.columns.map(c => `<th>${c}</th>`).join('')}</tr></thead><tbody>${step.rows.map((r, rowIndex) => `<tr><td class="text-white">${typeof r === 'string' ? r : (r.text || 'Unknown')}</td>${step.columns.map(c => `<td class="radio-cell text-center"><input type="radio" name="matrix-row-${rowIndex}" value="${c}" class="form-check-input"></td>`).join('')}</tr>`).join('')}</tbody></table></div>`;
    } else if (step.type === 'bowtie') {
        optsHtml = `<div class="bowtie-container"><div class="bowtie-wing"><div class="bowtie-label">Actions (2)</div>${step.left_actions.options.map(o => `<div class="form-check small"><input class="form-check-input" type="checkbox" name="bw-l" value="${o}">${o}</div>`).join('')}</div><div class="bowtie-center"><div class="bowtie-label text-warning">Condition</div><select id="bw-c" class="form-select form-select-sm"><option value="">Select condition...</option>${step.center_condition.options.map(o => `<option value="${o}">${o}</option>`).join('')}</select></div><div class="bowtie-wing"><div class="bowtie-label">Monitor (2)</div>${step.right_monitor.options.map(o => `<div class="form-check small"><input class="form-check-input" type="checkbox" name="bw-r" value="${o}">${o}</div>`).join('')}</div></div>`;
    } else if (step.type === 'drag_drop_cloze') {
        // Drag-and-drop cloze question
        const text = step.text || '';
        const blanks = step.blanks || [];
        const options = step.options || [];

        // Replace [BLANK_X] placeholders with drop zones
        let processedText = text;
        blanks.forEach((blank, idx) => {
            processedText = processedText.replace(`[BLANK_${idx + 1}]`, `<span class="drop-zone" data-blank-id="${idx}" data-correct="${blank.correct}">_____</span>`);
        });

        const optionsHtml = options.map(opt => `<span class="draggable-option" draggable="true" data-option="${opt}">${opt}</span>`).join('');

        optsHtml = `
            <div class="drag-drop-cloze">
                <div class="cloze-text mb-4">${processedText}</div>
                <div class="options-pool mb-3">
                    <div class="options-label">Available options:</div>
                    <div class="options-container">${optionsHtml}</div>
                </div>
                <div class="cloze-instructions">Drag options into the blanks</div>
            </div>
        `;
    } else if (step.type === 'highlight_select') {
        // Highlighted text selection question
        const text = step.text || '';
        const highlights = step.highlights || [];
        const selectionMode = step.selection_mode || 'multiple'; // 'single' or 'multiple'

        // Create text with clickable highlights
        let processedText = text;
        highlights.forEach((highlight, idx) => {
            const highlightClass = highlight.correct ? 'highlight-correct' : 'highlight-distractor';
            const clickHandler = selectionMode === 'single' ?
                `onclick="selectHighlight(this, ${idx}, 'single')"` :
                `onclick="toggleHighlight(this, ${idx})"`;
            processedText = processedText.replace(
                highlight.text,
                `<span class="text-highlight ${highlightClass}" ${clickHandler} data-highlight-id="${idx}" data-correct="${highlight.correct}">${highlight.text}</span>`
            );
        });

        const inputType = selectionMode === 'single' ? 'radio' : 'checkbox';
        const instruction = step.instruction || (selectionMode === 'single' ?
            'Click on the most significant finding requiring nursing intervention:' :
            'Click on all sections requiring nursing intervention:');

        optsHtml = `
            <div class="highlight-select">
                <div class="highlight-instruction mb-3">${instruction}</div>
                <div class="highlight-text">${processedText}</div>
                <input type="hidden" id="highlight-selection" value="">
            </div>
        `;
    } else if (step.options && step.options.length > 0) {
        // Default case: regular multiple choice questions (including exam questions)
        const isMultipleChoice = step.answer && step.answer.length > 1;
        const inputType = isMultipleChoice ? 'checkbox' : 'radio';
        const inputName = 'm-opt';

        optsHtml = `<div class="list-group">${step.options.map((o, i) => `<label class="list-group-item list-group-item-action p-3 mb-2"><input class="form-check-input me-3" type="${inputType}" name="${inputName}" value="${i}"> ${o}</label>`).join('')}</div>`;
    }
    area.innerHTML = `<div class="mission-title-display mb-3"><small class="text-accent">MISSION ${currentMission.numerical_id}: ${currentMission.title}</small></div><div class="step-badge">STEP ${currentStepIndex + 1}: ${step.type ? step.type.toUpperCase() : 'MULTIPLE CHOICE'}</div><h3 class="text-white mb-4 fw-bold">${step.prompt}</h3><div>${optsHtml}</div>`;
    const btn = document.getElementById('mission-action-btn');
    btn.innerText = "SUBMIT ANSWER";
    btn.className = "btn btn-warning btn-lg px-5 fw-bold shadow";

    // Add event listeners for drag-and-drop cloze questions
    if (step.type === 'drag_drop_cloze') {
        // Add drag event listeners to draggable options
        document.querySelectorAll('.draggable-option').forEach(option => {
            option.ondragstart = handleDragStart;
            option.ondragend = handleDragEnd;
        });

        // Add drop event listeners to drop zones
        document.querySelectorAll('.drop-zone').forEach(zone => {
            zone.ondragover = handleDragOver;
            zone.ondrop = handleDrop;
        });

        // Add touch support for mobile
        initTouchDrag();
    }
}

function handleMissionAction() { if (!missionFeedbackMode) evaluateMissionStep(); else nextMissionStep(); }

// Drag and drop functionality for cloze questions (desktop + mobile touch)
let draggedElement = null;
let touchDragClone = null;
let touchStartX = 0, touchStartY = 0;

function handleDragStart(e) {
    draggedElement = e.target;
    e.dataTransfer.effectAllowed = 'move';
    e.dataTransfer.setData('text/html', e.target.outerHTML);
    e.target.classList.add('dragging');
}

function handleDragEnd(e) {
    e.target.classList.remove('dragging');
    draggedElement = null;
}

function handleDragOver(e) {
    e.preventDefault();
    e.dataTransfer.dropEffect = 'move';
    return false;
}

function handleDrop(e) {
    e.preventDefault();
    const dropZone = e.target.closest('.drop-zone');
    if (!dropZone || !draggedElement) return;
    placeInDropZone(draggedElement, dropZone);
    return false;
}

// Shared logic: place a dragged element into a drop zone
function placeInDropZone(sourceEl, dropZone) {
    dropZone.innerHTML = '';
    const clone = sourceEl.cloneNode(true);
    clone.draggable = false;
    clone.classList.remove('dragging');
    clone.classList.add('dropped-option');
    clone.onclick = () => removeFromDropZone(clone, dropZone);
    // Also allow touch-tap to remove on mobile
    clone.ontouchend = (ev) => { ev.preventDefault(); removeFromDropZone(clone, dropZone); };
    dropZone.appendChild(clone);
    dropZone.classList.add('filled');
    sourceEl.remove();
}

function removeFromDropZone(element, dropZone) {
    const optionText = element.textContent;
    const optionsContainer = document.querySelector('.options-container');
    const newOption = document.createElement('span');
    newOption.className = 'draggable-option';
    newOption.draggable = true;
    newOption.textContent = optionText;
    newOption.ondragstart = handleDragStart;
    newOption.ondragend = handleDragEnd;
    addTouchDragSupport(newOption);
    optionsContainer.appendChild(newOption);
    dropZone.innerHTML = '_____';
    dropZone.classList.remove('filled');
}

// --- TOUCH DRAG SUPPORT (for mobile) ---
function addTouchDragSupport(el) {
    el.addEventListener('touchstart', onTouchDragStart, { passive: false });
    el.addEventListener('touchmove', onTouchDragMove, { passive: false });
    el.addEventListener('touchend', onTouchDragEnd, { passive: false });
}

function onTouchDragStart(e) {
    draggedElement = e.target.closest('.draggable-option');
    if (!draggedElement) return;
    const touch = e.touches[0];
    touchStartX = touch.clientX;
    touchStartY = touch.clientY;

    // Create a floating visual clone
    touchDragClone = draggedElement.cloneNode(true);
    touchDragClone.style.cssText = `
        position: fixed; z-index: 9999; pointer-events: none;
        opacity: 0.85; transform: scale(1.05);
        left: ${touch.clientX - 40}px; top: ${touch.clientY - 20}px;
        background: var(--accent); color: white; padding: 8px 12px;
        border-radius: 6px; font-size: 0.85rem; box-shadow: 0 8px 25px rgba(0,0,0,0.4);
    `;
    document.body.appendChild(touchDragClone);
    draggedElement.classList.add('dragging');
}

function onTouchDragMove(e) {
    if (!touchDragClone) return;
    e.preventDefault(); // Prevent scrolling while dragging
    const touch = e.touches[0];
    touchDragClone.style.left = (touch.clientX - 40) + 'px';
    touchDragClone.style.top = (touch.clientY - 20) + 'px';

    // Highlight nearest drop zone
    document.querySelectorAll('.drop-zone').forEach(z => z.style.borderColor = '');
    const el = document.elementFromPoint(touch.clientX, touch.clientY);
    const zone = el ? el.closest('.drop-zone') : null;
    if (zone) zone.style.borderColor = 'var(--warning)';
}

function onTouchDragEnd(e) {
    if (!touchDragClone) return;
    const touch = e.changedTouches[0];

    // Clean up the floating clone
    touchDragClone.remove();
    touchDragClone = null;

    // Check if it was just a tap (not a drag)  ignore short non-drags
    const dx = Math.abs(touch.clientX - touchStartX);
    const dy = Math.abs(touch.clientY - touchStartY);
    if (dx < 10 && dy < 10) {
        // Tap: find the first empty drop zone and place it there
        if (draggedElement) {
            draggedElement.classList.remove('dragging');
            const emptyZone = document.querySelector('.drop-zone:not(.filled)');
            if (emptyZone) placeInDropZone(draggedElement, emptyZone);
        }
        draggedElement = null;
        return;
    }

    // Find the drop zone under the finger
    document.querySelectorAll('.drop-zone').forEach(z => z.style.borderColor = '');
    const el = document.elementFromPoint(touch.clientX, touch.clientY);
    const dropZone = el ? el.closest('.drop-zone') : null;

    if (dropZone && draggedElement) {
        placeInDropZone(draggedElement, dropZone);
    } else if (draggedElement) {
        draggedElement.classList.remove('dragging');
    }
    draggedElement = null;
}

// Initialize touch support on any newly rendered draggable options
function initTouchDrag() {
    document.querySelectorAll('.draggable-option').forEach(el => addTouchDragSupport(el));
}

// Highlight selection functions
function toggleHighlight(element, highlightId) {
    element.classList.toggle('selected');
    updateHighlightSelection();
}

function selectHighlight(element, highlightId, mode) {
    if (mode === 'single') {
        // Remove selection from all highlights
        document.querySelectorAll('.text-highlight').forEach(el => el.classList.remove('selected'));
    }
    element.classList.add('selected');
    updateHighlightSelection();
}

function updateHighlightSelection() {
    const selected = Array.from(document.querySelectorAll('.text-highlight.selected'))
        .map(el => parseInt(el.dataset.highlightId));
    document.getElementById('highlight-selection').value = JSON.stringify(selected);
}

function evaluateMissionStep() {
    const step = currentMission.steps[currentStepIndex];
    let isCorrect = false;
    if (step.type === 'extended_sata') {
        const sel = Array.from(document.querySelectorAll('input[name="m-opt"]:checked')).map(i => parseInt(i.value));
        isCorrect = sel.length === step.answer.length && sel.every(v => step.answer.includes(v));
    } else if (step.type === 'standard' || (!step.type && step.options)) {
        // Regular multiple choice or exam questions
        const sel = Array.from(document.querySelectorAll('input[name="m-opt"]:checked')).map(i => parseInt(i.value));
        isCorrect = sel.length === step.answer.length && sel.every(v => step.answer.includes(v));
    } else if (step.type === 'matrix') {
        isCorrect = step.rows.every((r, rowIndex) => {
            const rowKey = typeof r === 'string' ? r : (r.text || '');
            return document.querySelector(`input[name="matrix-row-${rowIndex}"]:checked`)?.value === step.answer[rowKey];
        });
    } else if (step.type === 'drag_drop_cloze') {
        // Check if all blanks are filled correctly
        const blanks = step.blanks || [];
        isCorrect = blanks.every((blank, idx) => {
            const dropZone = document.querySelector(`.drop-zone[data-blank-id="${idx}"]`);
            if (!dropZone || !dropZone.classList.contains('filled')) return false;
            const droppedText = dropZone.textContent.trim();
            return droppedText === blank.correct;
        });
    } else if (step.type === 'highlight_select') {
        // Check selected highlights
        const selected = JSON.parse(document.getElementById('highlight-selection').value || '[]');
        const correctHighlights = step.highlights.filter(h => h.correct).map(h => step.highlights.indexOf(h));
        isCorrect = selected.length === correctHighlights.length &&
                   selected.every(id => correctHighlights.includes(id));
    } else if (step.type === 'bowtie') {
        const diag = document.getElementById('bw-c').value;
        const l = Array.from(document.querySelectorAll('input[name="bw-l"]:checked')).map(i => i.value);
        const r = Array.from(document.querySelectorAll('input[name="bw-r"]:checked')).map(i => i.value);
        isCorrect = diag === step.center_condition.answer && l.length === 2 && l.every(v => step.left_actions.answer.includes(v)) && r.length === 2 && r.every(v => step.right_monitor.answer.includes(v));
    }
    document.getElementById('mission-feedback').innerHTML = `<div class="p-4 rounded-4 border-2 ${isCorrect ? 'border-success' : 'border-danger'}" style="background: ${isCorrect ? 'rgba(22, 101, 52, 0.3)' : 'rgba(153, 27, 27, 0.3)'}; backdrop-filter: blur(10px);"><h4 class="fw-bold ${isCorrect ? 'text-success' : 'text-danger'}"><i class="fas ${isCorrect ? 'fa-check-circle' : 'fa-times-circle'} me-2"></i>${isCorrect ? 'CORRECT' : 'INCORRECT'}</h4><p class="text-white mb-0 mt-2 fs-5">${step.rationale || "Review clues and pharmacology interaction."}</p></div>`;
    missionFeedbackMode = true;
    const btn = document.getElementById('mission-action-btn');
    btn.innerText = currentStepIndex === currentMission.steps.length - 1 ? "FINISH MISSION" : "NEXT STEP";
    btn.className = "btn btn-info btn-lg px-5 fw-bold shadow pulse-button text-primary";
}

function nextMissionStep() { if (currentStepIndex < currentMission.steps.length - 1) { currentStepIndex++; renderMissionStep(); } else { closeMission(); } }

</script>

    <script>
        let currentSection = 'home';

        document.addEventListener('DOMContentLoaded', () => {
            setTimeout(() => {
                showHomeScreen();
            }, 100);
        });

        function showHomeScreen() {
            currentSection = 'home';
            document.querySelector('.control-panel').style.display = 'none';
            document.querySelector('.container-fluid.px-4.mt-4').style.display = 'block';

            const homeHtml = `
                <div class="container-fluid px-4 mt-5">
                    <div class="row justify-content-center">
                        <div class="col-lg-8">
                            <div class="text-center mb-5">
                                <h1 class="display-4 fw-bold text-accent mb-3">
                                    <i class="fas fa-microscope me-3"></i>
                                    NCLEX Study Tool
                                </h1>
                                <p class="lead text-secondary mb-4">High-Fidelity Clinical Study Platform</p>
                                <div class="badge bg-primary fs-6 px-3 py-2">Version 3.3</div>
                            </div>

                            <div class="row g-4">
                                <div class="col-md-4">
                                    <div class="nexus-card p-4 text-center h-100" onclick="showDrugReferences()">
                                        <div class="card-icon mb-3">
                                            <i class="fas fa-pills fa-3x text-accent"></i>
                                        </div>
                                        <h3 class="h4 fw-bold mb-3">Drug References</h3>
                                        <p class="text-secondary mb-3">Comprehensive pharmacology database with detailed drug information, interactions, and clinical applications.</p>
                                        <button class="btn btn-accent w-100 fw-bold">
                                            <i class="fas fa-search me-2"></i>
                                            Browse Drugs
                                        </button>
                                    </div>
                                </div>

                                <div class="col-md-4">
                                    <div class="nexus-card p-4 text-center h-100" onclick="showCaseStudies()">
                                        <div class="card-icon mb-3">
                                            <i class="fas fa-stethoscope fa-3x text-success"></i>
                                        </div>
                                        <h3 class="h4 fw-bold mb-3">Case Studies</h3>
                                        <p class="text-secondary mb-3">Interactive clinical scenarios with NGN-style questions testing critical thinking and clinical decision-making.</p>
                                        <button class="btn btn-success w-100 fw-bold">
                                            <i class="fas fa-play me-2"></i>
                                            Start Mission
                                        </button>
                                    </div>
                                </div>

                                <div class="col-md-4">
                                    <div class="nexus-card p-4 text-center h-100" onclick="showExams()">
                                        <div class="card-icon mb-3">
                                            <i class="fas fa-graduation-cap fa-3x text-warning"></i>
                                        </div>
                                        <h3 class="h4 fw-bold mb-3">Exams</h3>
                                        <p class="text-secondary mb-3">Comprehensive assessment modules covering pharmacology, pathophysiology, and clinical applications.</p>
                                        <button class="btn btn-warning w-100 fw-bold">
                                            <i class="fas fa-clipboard-check me-2"></i>
                                            Take Exam
                                        </button>
                                    </div>
                                </div>
                            </div>

                            <div class="text-center mt-5">
                                <div class="row g-3 justify-content-center">
                                    <div class="col-auto">
                                        <div class="d-flex align-items-center text-secondary">
                                            <i class="fas fa-heartbeat me-2"></i>
                                            <span>Acute Respiratory Focus</span>
                                        </div>
                                    </div>
                                    <div class="col-auto">
                                        <div class="d-flex align-items-center text-secondary">
                                            <i class="fas fa-brain me-2"></i>
                                            <span>NGN-Style Questions</span>
                                        </div>
                                    </div>
                                    <div class="col-auto">
                                        <div class="d-flex align-items-center text-secondary">
                                            <i class="fas fa-chart-line me-2"></i>
                                            <span>Evidence-Based Content</span>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            `;
            document.querySelector('.container-fluid.px-4.mt-4').innerHTML = homeHtml;
            document.querySelector('.container-fluid.px-4.mt-4').style.display = 'block';

            // Update nav bar for home screen
            const navButtons = document.querySelector('.nav-buttons');
            navButtons.innerHTML = `
                <span class="text-secondary">Welcome to NCLEX Study Tool</span>
            `;
        }

        function showDrugReferences() {
            currentSection = 'drugs';
            document.querySelector('.control-panel').style.display = 'block';
            document.querySelector('.container-fluid.px-4.mt-4').innerHTML = '<div class="row" id="drug-grid"></div>';
            document.querySelector('.container-fluid.px-4.mt-4').style.display = 'block';
            renderDrugs();

            // Update nav bar
            const navButtons = document.querySelector('.nav-buttons');
            navButtons.innerHTML = `
                <button class="btn btn-outline-secondary" onclick="showHomeScreen()">
                    <i class="fas fa-home me-2"></i>Home
                </button>
                <button class="btn btn-outline-info fw-bold" onclick="startMission()">CLINICAL MISSIONS</button>
                <button class="btn btn-warning fw-bold" onclick="startExam()">TAKE SLIDE EXAM</button>
            `;
        }

        function showCaseStudies() {
            currentSection = 'missions';
            startMission();
        }

        function showExams() {
            currentSection = 'exams';
            startExam();
        }

        // EXAM LOGIC WRAPPER
        function startExam() {
            showExamSelectionModal();
        }

        function showExamSelectionModal() {
            if (!window.availableExams || window.availableExams.length === 0) {
                alert('No exams available. Please check that exam modules have been properly configured.');
                return;
            }

            const modalHtml = `<div id="examSelectionModal" style="position: fixed; top: 0; left: 0; width: 100%; height: 100%; background: var(--primary); z-index: 2000; overflow-y: auto; padding: 40px;">
                <div class="container" style="max-width: 900px;">
                    <div class="d-flex justify-content-between align-items-center mb-5 border-bottom pb-3 border-secondary">
                        <h2 class="text-accent fw-bold">
                            <i class="fas fa-graduation-cap me-3"></i>
                            SELECT EXAM MODULE
                        </h2>
                        <button class="btn btn-outline-danger" onclick="closeExamSelection()">Cancel</button>
                    </div>

                    <div class="row">
                        ${window.availableExams.map(exam => `
                            <div class="col-md-6 mb-4">
                                <div class="nexus-card" style="cursor: pointer;" onclick="selectExam('${exam.id}')">
                                    <div class="point-label">EXAM MODULE</div>
                                    <h4 class="text-white mb-3">${exam.name}</h4>
                                    <p class="text-white-50 mb-3">${exam.data.length} Questions Available</p>
                                    <div class="d-flex justify-content-between align-items-center">
                                        <span class="badge bg-info text-primary">${exam.data.length} Questions</span>
                                        <i class="fas fa-arrow-right text-accent"></i>
                                    </div>
                                </div>
                            </div>
                        `).join('')}
                    </div>
                </div>
            </div>`;
            document.body.insertAdjacentHTML('beforeend', modalHtml);
        }

        function selectExam(examId) {
            const exam = window.availableExams.find(e => e.id === examId);
            if (!exam) {
                alert('Exam not found!');
                return;
            }

            closeExamSelection();
            window.examData = exam.data;
            window.currentQuestionIndex = 0;
            window.userAnswers = [];
            window.feedbackMode = false;
            window.currentExamName = exam.name;
            showExamModal();
            renderQuestion();
        }

        function closeExamSelection() {
            document.getElementById('examSelectionModal')?.remove();
        }
        function closeExam() { document.getElementById('examModal')?.remove(); showExamSelectionModal(); }
        function showExamModal() {
            const examName = window.currentExamName || 'SLIDE EXAM';
            const modalHtml = `<div id="examModal" style="position: fixed; top: 0; left: 0; width: 100%; height: 100%; background: var(--primary); z-index: 2000; overflow-y: auto; padding: 40px;">
                <button class="sidecar-toggle" onclick="toggleSidecar()" style="z-index: 2060;"><i class="fas fa-pills fs-3"></i></button>
                <div id="pharmaSidecar" class="pharma-sidecar" style="z-index: 2070;"><div class="sidecar-header"><div class="d-flex justify-content-between align-items-center mb-3"><h5 class="text-white mb-0">REFERENCE</h5><button class="btn btn-sm btn-outline-light" onclick="toggleSidecar()">X</button></div><input type="text" id="sidecarSearch" class="form-control form-control-sm bg-dark text-white" placeholder="Search..." onkeyup="renderSidecar()"></div><div id="sidecarContent" class="sidecar-content"></div></div>
                <div class="container" style="max-width: 900px;"><div class="d-flex justify-content-between align-items-center mb-4 border-bottom pb-3 border-secondary"><h3 class="text-accent fw-bold">${examName} <span id="examProgress" class="ms-3 fs-5 text-white-50"></span></h3><div class="d-flex align-items-center gap-2"><input type="number" id="jumpQuestionInput" class="form-control form-control-sm" placeholder="Question #" min="1" max="${window.examData.length}" style="width: 80px;"><button class="btn btn-outline-info btn-sm" onclick="jumpToQuestion()">Jump</button><button class="btn btn-outline-danger btn-sm" onclick="closeExam()">Exit</button></div></div><div id="questionContainer"></div><div id="feedbackContainer" class="mt-4 p-4 rounded d-none" style="border: 2px solid var(--border);"></div><div class="mt-5 d-flex justify-content-between"><button class="btn btn-outline-secondary btn-lg" onclick="prevQuestion()">Back</button><button id="actionBtn" class="btn btn-warning btn-lg" onclick="handleAction()">SUBMIT</button></div></div></div>`;
            document.body.insertAdjacentHTML('beforeend', modalHtml);
        }
        function renderQuestion() {
            const q = window.examData[window.currentQuestionIndex];
            document.getElementById('examProgress').innerText = `(${window.currentQuestionIndex + 1} / ${window.examData.length})`;
            document.getElementById('feedbackContainer').classList.add('d-none');
            document.getElementById('questionContainer').innerHTML = `<h2 class="text-white mb-4">${window.currentQuestionIndex + 1}. ${q.question}</h2><div class="list-group">${q.options.map((opt, i) => `<label class="list-group-item list-group-item-action bg-secondary text-white border-secondary mb-3 py-3 px-4 rounded-4"><input class="form-check-input me-3" type="${Array.isArray(q.answer) ? 'checkbox' : 'radio'}" name="qOption" value="${i}"><span class="fs-5">${opt}</span></label>`).join('')}</div>`;
            const btn = document.getElementById('actionBtn'); btn.innerText = "SUBMIT"; window.feedbackMode = false;
        }
        function handleAction() { if (!window.feedbackMode) checkAnswer(); else nextQuestion(); }
        function checkAnswer() {
            const q = window.examData[window.currentQuestionIndex];
            // Map selected indices back to the option strings for comparison
            const sel = Array.from(document.querySelectorAll('input[name="qOption"]:checked')).map(input => q.options[parseInt(input.value)]);
            if (sel.length === 0) return;
            window.feedbackMode = true;
            const correct = Array.isArray(q.answer) ? q.answer : [q.answer];
            const isCorrect = sel.length === correct.length && sel.every(v => correct.includes(v));
            const fb = document.getElementById('feedbackContainer');
            fb.className = `mt-4 p-4 rounded-4 border-2 d-block ${isCorrect ? 'border-success' : 'border-danger'}`;
            fb.style.backgroundColor = isCorrect ? 'rgba(22, 101, 52, 0.3)' : 'rgba(153, 27, 27, 0.3)';
            fb.innerHTML = `<h4 class="fw-bold ${isCorrect ? 'text-success' : 'text-danger'}">${isCorrect ? 'CORRECT' : 'INCORRECT'}</h4><p class="text-white mt-2">${q.rationale || ""}</p>`;
            document.getElementById('actionBtn').innerText = "NEXT";
        }
        function nextQuestion() { if (window.currentQuestionIndex < window.examData.length - 1) { window.currentQuestionIndex++; renderQuestion(); } else { closeExam(); } }
        function prevQuestion() { if (window.currentQuestionIndex > 0) { window.currentQuestionIndex--; renderQuestion(); } }
        function jumpToQuestion() {
            const input = document.getElementById('jumpQuestionInput');
            const questionNum = parseInt(input.value);
            if (questionNum >= 1 && questionNum <= window.examData.length) {
                window.currentQuestionIndex = questionNum - 1;
                renderQuestion();
                input.value = '';
            } else {
                alert(`Please enter a valid question number between 1 and ${window.examData.length}`);
            }
        }
    </script>

<script>
/* INJECTED SCENARIOS.JSON DATA */
console.log('Initializing JSON Data Injection...');
window.customModules = window.customModules || [];
window.customModules.push({"id": "intro_basics", "name": "Module 1: SNF Basics (Intro)", "scenarios": [{"id": "handover_1", "type": "standard", "text": "Night shift reports: 'Mr. Henderson in 202 is confused. He's usually AO3. His O2 sats were 89% on room air at 05:00. I put him on 2L NC.'", "question": "What is your first priority?", "options": ["Go directly to Room 202 to assess Mr. Henderson.", "Sit down and read the full charts for all 20 patients first.", "Go to the breakroom for coffee."], "answer_type": "single", "answer": [0], "rationales": ["CORRECT: Assessing the unstable patient is the priority (ABCs).", "DELAY: A change in mental status and O2 sats requires immediate bedside assessment.", "CRITICAL FAILURE: Patient safety is compromised."]}]});
window.customModules = window.customModules || [];
window.customModules.push({"id": "vascular_htn_final", "name": "Module 2: Vascular & Hypertension (ATI/NCLEX + Instructor Prep)", "scenarios": [{"id": "pad_vs_venous_matrix", "type": "matrix", "text": "NGN COMPARISON: The nurse is performing a physical assessment on two clients with different vascular disorders.", "question": "For each clinical finding, determine if it is characteristic of Peripheral Arterial Disease (PAD) or Venous Insufficiency.", "columns": ["Arterial (PAD)", "Venous Insufficiency"], "rows": [{"text": "Skin is cool, shiny, and hairless", "correct_col_idx": 0}, {"text": "Skin is warm with brownish discoloration (Stasis Dermatitis)", "correct_col_idx": 1}, {"text": "Pulses are diminished or absent", "correct_col_idx": 0}, {"text": "Lower extremity edema is present (worse at end of day)", "correct_col_idx": 1}, {"text": "Ulcer is 'punched out' and located on the toes", "correct_col_idx": 0}, {"text": "Ulcer is irregular and located on the medial ankle", "correct_col_idx": 1}]}, {"id": "positioning_logic", "type": "SATA", "text": "The nurse is providing discharge teaching regarding positioning and pain relief for a client with PAD and a client with Venous Insufficiency.", "question": "Which of the following instructions are CORRECT? (Select All That Apply)", "options": ["PAD: 'Dangle your legs over the side of the bed to relieve pain.'", "Venous: 'Elevate your legs above the level of your heart.'", "PAD: 'Elevate your legs on two pillows to increase flow.'", "Venous: 'Avoid prolonged standing or sitting.'", "PAD: 'Use a heating pad on your feet to keep them warm.'"], "answer_type": "multi", "answer": [0, 1, 3], "rationales": ["CORRECT: Dangling (dependency) uses gravity to help arterial blood reach the toes.", "CORRECT: Elevation uses gravity to help venous blood return to the heart.", "INCORRECT: Elevation worsens PAD pain by making it harder for blood to reach the feet.", "CORRECT: Prolonged stillness increases venous pooling.", "DANGEROUS: Clients with PAD often have decreased sensation and can easily be burned."]}, {"id": "beuger_allen", "type": "standard", "text": "An LPN is assisting a patient with Peripheral Vascular Disease (PVD) who has been prescribed Buerger-Allen exercises.", "question": "What should the nurse instruct the patient to do FIRST?", "options": ["Raise legs above the heart until they blanch.", "Lower the legs to a dependent position until rubor appears.", "Lie flat with legs straight for 5 minutes.", "Perform vigorous ankle circles."], "answer_type": "single", "answer": [0], "rationales": ["CORRECT: Step 1 is elevation to drain the vessels.", "Step 2 (Dependency).", "Step 3 (Rest).", "Done during Step 2."]}, {"id": "htn_crisis_priority", "type": "standard", "text": "A patient is admitted to the ICU with a diagnosis of hypertensive emergency. BP is 200/130 mmHg. The nurse is preparing IV nitroprusside.", "question": "Upon assessment, which finding requires the MOST immediate intervention?", "options": ["Nausea and severe occipital headache", "Chest pain score of 3/10", "Urine output of 40 mL over the last hour", "Left arm numbness and weakness"], "answer_type": "single", "answer": [3], "rationales": ["Expected.", "Serious.", "Normal.", "CORRECT: Numbness/weakness = potential CVA (Priority)."]}, {"id": "dash_diet_sata", "type": "SATA", "text": "The DASH diet (Dietary Approaches to Stop Hypertension) recommends low servings of specific food groups.", "question": "Which of the following should the nurse teach the patient to limit? (Select All That Apply)", "options": ["Fat", "Dairy products", "Red Meat (Poultry/Beef)", "Fruits and Vegetables", "Whole grains"], "answer_type": "multi", "answer": [0, 1, 2], "rationales": ["CORRECT: DASH is low in total/saturated fat.", "CORRECT: DASH emphasizes low-fat dairy over full-fat.", "CORRECT: DASH recommends limiting red meat and poultry.", "Encouraged.", "Encouraged."]}]});
window.customModules = window.customModules || [];
window.customModules.push({"id": "cardio_diabetes_pharma", "name": "Module 3: Pharmacology - Cardio & Diabetes", "scenarios": [{"id": "statin_safety", "type": "standard", "text": "A client is newly prescribed Atorvastatin (Lipitor) for hyperlipidemia. During a follow-up visit, the client reports 'dark, tea-colored urine' and severe muscle weakness in their legs.", "question": "Which action should the nurse take FIRST?", "options": ["Instruct the client to stop the medication and come to the clinic for a CK (creatine kinase) level.", "Advise the client that these are common side effects that will subside with time.", "Tell the client to increase their fluid intake to 3L per day.", "Suggest taking the medication with a glass of grapefruit juice to increase absorption."], "answer_type": "single", "answer": [0], "rationales": ["CORRECT: These are signs of rhabdomyolysis, a critical adverse effect requiring immediate intervention.", "INCORRECT: Muscle pain and tea-colored urine are NEVER normal with statins.", "INSUFFICIENT: While fluids help, the medication must be stopped first.", "DANGEROUS: Grapefruit juice increases statin toxicity."]}, {"id": "ace_inhibitor_emergency", "type": "standard", "text": "A nurse is reinforcing teaching with a client who is starting Lisinopril. Which finding should the nurse emphasize as a reason to seek IMMEDIATE emergency medical attention?", "options": ["A persistent dry, non-productive cough.", "Swelling of the tongue, lips, or throat.", "A slight increase in serum potassium level.", "Dizziness when standing up too quickly."], "answer_type": "single", "answer": [1], "rationales": ["COMMON: While annoying, the cough is not a medical emergency.", "CORRECT: This indicates angioedema, which can compromise the airway.", "EXPECTED: ACE inhibitors can cause mild hyperkalemia but it's not usually an 'emergency' unless severe.", "EXPECTED: Orthostatic hypotension is a common side effect."]}, {"id": "digoxin_toxicity_matrix", "type": "matrix", "text": "The nurse is evaluating a client who has been taking Digoxin 0.125 mg daily for heart failure. The client's potassium level is 3.2 mEq/L.", "question": "For each clinical finding, determine if it indicates Potential Toxicity or a Therapeutic Effect.", "columns": ["Potential Toxicity", "Therapeutic Effect"], "rows": [{"text": "Client reports seeing 'yellow-greenish halos' around lights.", "correct_col_idx": 0}, {"text": "Apical heart rate is 72 bpm and regular.", "correct_col_idx": 1}, {"text": "Client reports new onset of nausea and loss of appetite.", "correct_col_idx": 0}, {"text": "Increased urine output and decreased peripheral edema.", "correct_col_idx": 1}, {"text": "Client's heart rate is 48 bpm.", "correct_col_idx": 0}]}, {"id": "metformin_contrast", "type": "standard", "text": "A client with Type 2 Diabetes who takes Metformin daily is scheduled for a CT scan with IV contrast dye at 14:00 today.", "question": "What is the most appropriate nursing action regarding the Metformin?", "options": ["Ensure the client takes the Metformin with a light snack before the procedure.", "Verify that the Metformin was held for 48 hours prior and will be held 48 hours after the scan.", "Administer an extra dose of Metformin to prevent hyperglycemia during the stress of the procedure.", "No action is needed; Metformin does not interact with contrast dye."], "answer_type": "single", "answer": [1], "rationales": ["DANGEROUS: Metformin and contrast dye together increase the risk of lactic acidosis and acute renal failure.", "CORRECT: Standard safety protocol is to hold Metformin for 48 hours before and after contrast.", "DANGEROUS: Increases risk of lactic acidosis.", "INCORRECT: There is a significant and dangerous interaction."]}, {"id": "insulin_mixing_sata", "type": "SATA", "text": "The nurse is preparing to administer a mixed dose of 10 units of Regular insulin and 20 units of NPH insulin to a client.", "question": "Which of the following actions are CORRECT? (Select All That Apply)", "options": ["Inject 20 units of air into the NPH vial first.", "Inject 10 units of air into the Regular vial after airing the NPH.", "Withdraw the NPH insulin into the syringe first.", "Withdraw the Regular insulin into the syringe first.", "Ensure the total volume in the syringe is 30 units."], "answer_type": "multi", "answer": [0, 1, 3, 4], "rationales": ["CORRECT: Air goes into the 'cloudy' (NPH) first.", "CORRECT: Air goes into the 'clear' (Regular) second.", "INCORRECT: Clear (Regular) must be withdrawn first to avoid contaminating it with NPH.", "CORRECT: Clear before Cloudy!", "CORRECT: 10 + 20 = 30 total units."]}, {"id": "beta_blocker_diabetes", "type": "standard", "text": "A client with Type 1 Diabetes is prescribed Metoprolol for hypertension. What should the nurse include in the patient teaching?", "question": "Which instruction is MOST important for this client?", "options": [" 'You can stop checking your blood sugar as often because Metoprolol stabilizes it.' ", " 'Metoprolol may mask symptoms of low blood sugar, such as a fast heart rate.' ", " 'Take your Metoprolol only when you feel your blood pressure is high.' ", " 'Metoprolol will make your insulin work faster, so you should reduce your insulin dose.' "], "answer_type": "single", "answer": [1], "rationales": ["DANGEROUS: Frequent monitoring is still required.", "CORRECT: Beta blockers mask the sympathetic response (tachycardia) to hypoglycemia.", "INCORRECT: HTN meds must be taken consistently.", "INCORRECT: It doesn't necessarily make it work 'faster', but it complicates the symptom profile."]}, {"id": "gliptin_pancreatitis", "type": "standard", "text": "A client taking Sitagliptin (Januvia) for Type 2 Diabetes reports 'severe, persistent abdominal pain that radiates to my back' along with nausea.", "question": "Which potential adverse effect should the nurse suspect?", "options": ["Lactic Acidosis", "Pancreatitis", "Rhabdomyolysis", "B12 Deficiency"], "answer_type": "single", "answer": [1], "rationales": ["INCORRECT: Associated with Metformin.", "CORRECT: Severe abdominal pain radiating to the back is a classic sign of pancreatitis, a rare but serious side effect of Gliptins (DPP-4 inhibitors).", "INCORRECT: Associated with Statins.", "INCORRECT: Associated with Metformin; causes anemia/neuropathy, not acute pain."]}, {"id": "digoxin_apical_pulse", "type": "standard", "text": "The nurse is preparing to administer the daily dose of Digoxin to a client.", "question": "Which action must the nurse take before administration?", "options": ["Check the client's blood pressure in both arms.", "Auscultate the apical pulse for 1 full minute.", "Ask the client if they have had a bowel movement today.", "Ensure the client has finished their breakfast."], "answer_type": "single", "answer": [1], "rationales": ["INCORRECT: BP is important but HR is the specific safety check for Digoxin.", "CORRECT: Safety protocol requires a full 1-minute apical pulse check; hold if <60 bpm in adults.", "INCORRECT: Not a specific requirement for Digoxin.", "INCORRECT: Digoxin can be taken with or without food."]}]});
window.customModules = window.customModules || [];
window.customModules.push({"id": "experimental_ngn", "name": "Module 4: Experimental NGN Case Studies", "scenarios": [{"id": "cardio_case_1", "type": "bowtie", "text": "CASE STUDY: Mr. Ramirez, a 68-year-old with HF and HTN, presents with 3+ pitting edema and SOB.\nVITALS: BP 162/98, HR 102, RR 24, SpO2 91% (RA).\nLABS: K+ 3.1 mEq/L, Digoxin 2.4 ng/mL.\nNOTES: Reports seeing 'sparkles' in vision and feeling nauseous.\nMEDS: Digoxin 0.125mg, Furosemide 40mg, Lisinopril 10mg.", "question": "Complete the Bowtie: Identify the condition, 2 actions to take, and 2 parameters to monitor.", "actions": ["Hold Digoxin and Furosemide", "Administer K+ supplement as ordered", "Increase Furosemide dose", "Administer Albuterol", "Check apical pulse"], "conditions": ["Digoxin Toxicity exacerbated by Hypokalemia", "Hypertensive Crisis", "Acute Pulmonary Edema", "Lispro Overdose"], "parameters": ["Digoxin levels and Electrolytes", "Cardiac rhythm (ECG)", "Daily weights", "Blood Glucose"], "correct_actions": [0, 1], "correct_condition": [0], "correct_parameters": [0, 1], "assets": {"condition": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#FF0000' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><circle cx='12' cy='12' r='10'></circle><line x1='8' y1='15' x2='16' y2='15'></line><line x1='12' y1='9' x2='12' y2='12'></line></svg>", "environment": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#000000' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><path d='M2 21L22 21L22 10L12 2L2 10L2 21Z'></path><path d='M10 16L14 16L14 21L10 21L10 16Z'></path></svg>", "action": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#006400' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><circle cx='12' cy='12' r='10'></circle><line x1='12' y1='8' x2='12' y2='16'></line><line x1='8' y1='12' x2='16' y2='12'></line></svg>", "drug": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#0000FF' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><circle cx='12' cy='12' r='10'></circle><line x1='15' y1='9' x2='9' y2='15'></line><line x1='9' y1='9' x2='15' y2='15'></line></svg>"}}, {"id": "diabetes_case_1", "type": "matrix", "text": "CASE STUDY: Ms. Chen, 24yo with Type 1 DM, is admitted with fruity breath and deep/rapid breathing.\nLABS: BG 450 mg/dL, pH 7.28, Ketones positive in urine.\nVITALS: BP 90/60, HR 115.\nORDERS: 1. Normal Saline 1L bolus, 2. Regular Insulin IV drip, 3. NPH Insulin SQ now.", "question": "For each provider order, determine if it is Indicated, Contraindicated, or Non-Essential at this time.", "columns": ["Indicated", "Contraindicated", "Non-Essential"], "rows": [{"text": "Normal Saline 1L bolus (Fluid Resuscitation)", "correct_col_idx": 0}, {"text": "Regular Insulin IV drip (Standard DKA Protocol)", "correct_col_idx": 0}, {"text": "NPH Insulin SQ (Intermediate acting insulin)", "correct_col_idx": 1}, {"text": "Frequent monitoring of K+ and Glucose levels", "correct_col_idx": 0}, {"text": "Administering IV D50W immediately", "correct_col_idx": 1}], "assets": {"condition": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#FFA500' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><circle cx='12' cy='12' r='10'></circle><path d='M16 16s-1.5-2-4-2-4 2-4 2'></path><line x1='9' y1='9' x2='9.01' y2='9'></line><line x1='15' y1='9' x2='15.01' y2='9'></line></svg>", "environment": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#000000' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><path d='M14 11H2V3h12v8zM2 11h12M2 3L2 11M14 3L14 11M2 3l12 0'></path><path d='M16 8L22 21L10 21L16 8Z'></path></svg>", "action": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#800080' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><circle cx='12' cy='12' r='10'></circle><line x1='12' y1='16' x2='12' y2='12'></line><line x1='12' y1='8' x2='12.01' y2='8'></line></svg>", "drug": "<svg width='80' height='80' viewBox='0 0 24 24' fill='none' stroke='#FF00FF' stroke-width='2' stroke-linecap='round' stroke-linejoin='round'><circle cx='12' cy='12' r='10'></circle><path d='M9 10L15 10L15 14L9 14L9 10Z'></path></svg>"}}]});
window.customModules = window.customModules || [];
window.customModules.push({"id": "pptx_generated", "name": "Generated Module pptx_generated", "scenarios": [{"id": "statin_dosing_q", "type": "standard", "text": "A nurse is reinforcing teaching with a client who is starting simvastatin.", "question": "Which of the following information should the nurse include?", "options": ["Take this medication in the evening.", "Take this medication in the morning with breakfast.", "Avoid green leafy vegetables.", "Monitor for signs of hyperglycemia."], "answer": [0], "rationales": ["CORRECT: Cholesterol synthesis by the liver is highest during the night.", "Incorrect: Morning dosing is less effective for statins with short half-lives.", "Incorrect: Relevant for Warfarin, not Statins.", "Incorrect: Not a primary concern for Statins (though possible, not a teaching priority)."], "answer_type": "single"}]});
window.acuterespiratoryExamData = [{"id": "epistaxis_nasal_packing", "slide": 999, "question": "A client with epistaxis has nasal packing. Frequent swallowing after nasal packing indicates that:", "options": ["The packing is effective and bleeding has stopped", "Blood may be moving posteriorly rather than externally", "The client should begin oral intake", "Antibiotic therapy should be initiated"], "answer": "Blood may be moving posteriorly rather than externally", "rationale": "Frequent swallowing after nasal packing indicates that blood may be moving posteriorly rather than externally-continuous bleeding. The nurse recognizes this as a complication requiring immediate assessment."}, {"id": "acute_bronchitis_antimicrobials", "slide": 999, "question": "Regarding antimicrobial therapy for acute bronchitis, the nurse understands that:", "options": ["The goal is complete eradication of the pathogen", "Stopping therapy early prevents drug resistance", "Client teaching focuses on symptom relief", "Antibiotics are always prescribed for viral causes"], "answer": "The goal is complete eradication of the pathogen", "rationale": "The goal of therapy is complete eradication of the pathogen. Stopping therapy early contributes to drug resistance and recurrence of infection. Client teaching focuses on adherence, not symptom relief."}, {"id": "hypoxia_early_cues", "slide": 999, "question": "Early neurological and compensatory cues of progressing hypoxia include:", "options": ["Visible color changes and decreased consciousness", "Restlessness, agitation, increased heart rate", "Bradycardia and hypotension", "Apnea and respiratory arrest"], "answer": "Restlessness, agitation, increased heart rate", "rationale": "Early neurological and compensatory cues: restlessness, agitation, increased heart rate, increased respiratory rate. Late oxygenation failure cues include visible color changes and decreased level of consciousness."}, {"id": "hypoxia_late_cues", "slide": 999, "question": "Late oxygenation failure cues of hypoxia include:", "options": ["Restlessness and agitation", "Increased heart rate and respiratory rate", "Visible color changes and decreased consciousness", "Tachycardia and hypertension"], "answer": "Visible color changes and decreased consciousness", "rationale": "Late oxygenation failure cues: visible color changes, decreased level of consciousness. Early cues include restlessness, agitation, increased heart rate, and increased respiratory rate."}, {"id": "osa_diagnosis", "slide": 999, "question": "Diagnosis of obstructive sleep apnea requires:", "options": ["Overnight pulse oximetry only", "A sleep study called polysomnography", "Self-reported snoring assessment", "Daytime sleepiness questionnaire alone"], "answer": "A sleep study called polysomnography", "rationale": "Diagnosis requires a sleep study called polysomnography that evaluates breathing patterns, oxygen saturation, and sleep stages overnight."}, {"id": "osa_polysomnography", "slide": 999, "question": "Polysomnography for sleep apnea evaluates:", "options": ["Breathing patterns and oxygen saturation", "Blood pressure and heart rate", "Muscle strength and coordination", "Cognitive function and memory"], "answer": "Breathing patterns and oxygen saturation", "rationale": "Polysomnography evaluates breathing patterns, oxygen saturation, and sleep stages overnight to diagnose obstructive sleep apnea."}, {"id": "allergic_rhinitis_pharma", "slide": 999, "question": "Primary medications for allergic rhinitis target:", "options": ["The histamine-mediated inflammatory response", "Bacterial infection prevention", "Mucosal thickening", "Airway constriction"], "answer": "The histamine-mediated inflammatory response", "rationale": "The primary medications target the histamine-mediated inflammatory response aka anti-histamines. Antihistamines can be oral or nasal. Anti-infectives are not effective for allergen-triggered conditions."}, {"id": "antihistamines_route", "slide": 999, "question": "Antihistamines for allergic rhinitis can be administered:", "options": ["Oral or nasal only", "Intravenous only", "Topical only", "Subcutaneous only"], "answer": "Oral or nasal only", "rationale": "Antihistamines can be oral or nasal. They target the histamine-mediated inflammatory response in allergic rhinitis."}, {"id": "post_procedure_airway", "slide": 999, "question": "After procedures that suppress the gag reflex:", "options": ["Oral intake should begin immediately", "Oral intake is withheld until protective airway reflex returns", "Nutrition takes priority over airway safety", "Comfort measures are most important"], "answer": "Oral intake is withheld until protective airway reflex returns", "rationale": "After procedures that suppress the gag reflex: Oral intake is withheld until the nurse verifies the return of the protective airway reflex. Airway safety takes priority over nutrition and comfort."}, {"id": "gag_reflex_protection", "slide": 999, "question": "When the gag reflex is suppressed after a procedure, the priority is:", "options": ["Immediate feeding", "Airway safety verification", "Pain medication administration", "Client comfort"], "answer": "Airway safety verification", "rationale": "Airway safety takes priority over nutrition and comfort when the gag reflex is suppressed."}, {"id": "cough_suppress_reflex", "slide": 999, "question": "Cough medications that suppress the cough reflex are called:", "options": ["Mucolytics", "Expectorants", "Antitussives", "Bronchodilators"], "answer": "Antitussives", "rationale": "Some medications suppress the cough reflex - antitussives. Some increase secretion production to make the cough more productive - mucolytics or expectorants."}, {"id": "cough_productive", "slide": 999, "question": "Cough medications that increase secretion production to make coughing more productive are:", "options": ["Antitussives", "Mucolytics or expectorants", "Antihistamines", "Decongestants"], "answer": "Mucolytics or expectorants", "rationale": "Some medications increase secretion production to make the cough more productive - mucolytics or expectorants. Some suppress the cough reflex - antitussives."}, {"id": "pneumothorax_assessment", "slide": 999, "question": "Assessment findings in pneumothorax include:", "options": ["Crackles in both lung fields", "Increased breath sounds bilaterally", "Reduced or absent breath sounds on affected side", "Normal breath sounds throughout"], "answer": "Reduced or absent breath sounds on affected side", "rationale": "Pneumothorax causes reduced or absent breath sounds on the affected side due to air in the pleural space preventing lung expansion."}, {"id": "pneumothorax_cause", "slide": 999, "question": "Pneumothorax occurs when:", "options": ["Air accumulates in the pleural space", "Blood fills the pleural space", "The diaphragm is paralyzed", "Bronchioles become inflamed"], "answer": "Air accumulates in the pleural space", "rationale": "Air in the pleural space prevents normal lung expansion, causing reduced or absent breath sounds on the affected side."}, {"id": "chest_tube_positioning", "slide": 999, "question": "The chest tube drainage system should be kept:", "options": ["Above chest level", "At chest level", "Below chest level", "At the foot of the bed"], "answer": "Below chest level", "rationale": "The drainage system is always kept below chest level to prevent backflow. Water used in the system must be sterile to prevent infection."}, {"id": "chest_tube_water", "slide": 999, "question": "Water used in chest tube drainage systems must be:", "options": ["Distilled only", "Sterile to prevent infection", "Chlorinated", "Carbonated"], "answer": "Sterile to prevent infection", "rationale": "Water used in the system must be sterile to prevent infection. The drainage system is always kept below chest level to prevent backflow."}, {"id": "rib_fracture_pain", "slide": 999, "question": "A client with rib fractures experiences most pain with:", "options": ["Deep inspiration", "Quiet breathing", "Expiration", "Speaking softly"], "answer": "Deep inspiration", "rationale": "Rib fracture pain is most severe with deep inspiration, coughing, or movement. Pain management and breathing exercises are essential."}, {"id": "rib_fracture_management", "slide": 999, "question": "Management of rib fractures includes:", "options": ["Tight chest binding", "Pain management and breathing exercises", "Complete bed rest for 6 weeks", "Immediate surgical repair"], "answer": "Pain management and breathing exercises", "rationale": "Pain management and breathing exercises are essential for rib fracture management. Tight binding is contraindicated."}, {"id": "flail_chest_signs", "slide": 999, "question": "Signs of flail chest include:", "options": ["Paradoxical chest wall movement", "Unilateral chest expansion", "Decreased respiratory rate", "Normal breath sounds"], "answer": "Paradoxical chest wall movement", "rationale": "Flail chest is characterized by paradoxical chest wall movement where a portion of the chest wall moves inward during inspiration."}, {"id": "paradoxical_movement", "slide": 999, "question": "Paradoxical chest wall movement in flail chest means:", "options": ["The entire chest expands normally", "A portion moves inward during inspiration", "Both sides move symmetrically", "Movement is absent"], "answer": "A portion moves inward during inspiration", "rationale": "Paradoxical chest wall movement means a portion of the chest wall moves inward during inspiration, which is characteristic of flail chest."}, {"id": "pulmonary_embolism_sudden", "slide": 999, "question": "A client suddenly develops severe dyspnea, tachycardia, and chest pain. The nurse suspects:", "options": ["Acute myocardial infarction", "Pulmonary embolism", "Pneumothorax", "Acute bronchitis"], "answer": "Pulmonary embolism", "rationale": "Sudden onset of severe dyspnea, tachycardia, and chest pain suggests pulmonary embolism, requiring immediate intervention."}, {"id": "pe_symptoms", "slide": 999, "question": "Classic symptoms of pulmonary embolism include:", "options": ["Gradual onset of shortness of breath", "Sudden severe dyspnea with chest pain", "Productive cough with green sputum", "Fever and chills"], "answer": "Sudden severe dyspnea with chest pain", "rationale": "Sudden onset of severe dyspnea, tachycardia, and chest pain suggests pulmonary embolism."}, {"id": "asthma_acute_attack", "slide": 999, "question": "During an acute asthma attack, the nurse should first:", "options": ["Administer oral corticosteroids", "Assess respiratory status and administer bronchodilators", "Obtain sputum culture", "Start IV antibiotics"], "answer": "Assess respiratory status and administer bronchodilators", "rationale": "During an acute asthma attack, immediate assessment of respiratory status and administration of bronchodilators takes priority."}, {"id": "asthma_priority", "slide": 999, "question": "Priority action for acute asthma exacerbation:", "options": ["Oral steroid administration", "Respiratory assessment and bronchodilators", "Laboratory blood work", "Chest X-ray"], "answer": "Respiratory assessment and bronchodilators", "rationale": "Immediate assessment of respiratory status and administration of bronchodilators takes priority in acute asthma attack."}, {"id": "hypoxia_early_signs", "slide": 999, "question": "Early signs of hypoxia include:", "options": ["Bradycardia and hypotension", "Restlessness and tachycardia", "Cyanosis and confusion", "Apnea and respiratory arrest"], "answer": "Restlessness and tachycardia", "rationale": "Early signs of hypoxia include restlessness, agitation, tachycardia, and increased respiratory rate."}, {"id": "hypoxia_compensatory", "slide": 999, "question": "Compensatory mechanisms in early hypoxia include:", "options": ["Decreased heart rate", "Increased respiratory rate and heart rate", "Bradycardia and hypotension", "Decreased level of consciousness"], "answer": "Increased respiratory rate and heart rate", "rationale": "Early compensatory mechanisms include increased respiratory rate, restlessness, agitation, and tachycardia."}, {"id": "case_normal_vs", "slide": 999, "question": "The lecture mentions that case studies require knowledge of normal vital signs. This is important because:", "options": ["Normal values are not relevant to respiratory assessment", "Abnormal vital signs help identify respiratory complications", "Only heart rate matters in respiratory cases", "Blood pressure is the only vital sign to monitor"], "answer": "Abnormal vital signs help identify respiratory complications", "rationale": "Case studies require knowledge of normal vital signs to identify abnormalities that indicate respiratory complications."}, {"id": "chest_tube_air_leak", "slide": 999, "question": "Continuous bubbling in the water seal chamber of a chest tube system indicates:", "options": ["Normal function", "Air leak in the system", "Proper seal integrity", "Tube obstruction"], "answer": "Air leak in the system", "rationale": "Continuous bubbling in the water seal chamber indicates an air leak in the system that needs immediate attention."}, {"id": "hemothorax_vs_pneumothorax", "slide": 999, "question": "Which finding differentiates hemothorax from pneumothorax?", "options": ["Absent breath sounds", "Chest pain", "Tracheal deviation", "Blood in pleural space"], "answer": "Blood in pleural space", "rationale": "Hemothorax involves blood in the pleural space, while pneumothorax involves air. Both can cause absent breath sounds and chest pain."}, {"id": "pleural_space_air", "slide": 999, "question": "In pneumothorax, air accumulates in the:", "options": ["Lung parenchyma", "Bronchial tree", "Pleural space", "Mediastinum"], "answer": "Pleural space", "rationale": "Air accumulates in the pleural space, preventing normal lung expansion and causing reduced breath sounds."}, {"id": "sleep_apnea_evaluation", "slide": 999, "question": "Polysomnography evaluates all of the following EXCEPT:", "options": ["Breathing patterns", "Oxygen saturation", "Sleep stages", "Blood glucose levels"], "answer": "Blood glucose levels", "rationale": "Polysomnography evaluates breathing patterns, oxygen saturation, and sleep stages, but not blood glucose levels."}, {"id": "allergic_response_target", "slide": 999, "question": "Anti-histamines target which allergic response?", "options": ["Bacterial infection", "Histamine-mediated inflammation", "Viral replication", "Fungal growth"], "answer": "Histamine-mediated inflammation", "rationale": "Anti-histamines target the histamine-mediated inflammatory response in allergic rhinitis."}, {"id": "airway_reflex_return", "slide": 999, "question": "Oral intake is withheld after procedures suppressing gag reflex until:", "options": ["The client requests food", "The nurse verifies protective airway reflex return", "Four hours have passed", "Pain medication is administered"], "answer": "The nurse verifies protective airway reflex return", "rationale": "Oral intake is withheld until the nurse verifies the return of the protective airway reflex."}, {"id": "cough_medication_types", "slide": 999, "question": "Which medication increases mucus production to make coughing more effective?", "options": ["Antitussive", "Expectorant", "Antihistamine", "Decongestant"], "answer": "Expectorant", "rationale": "Expectorants increase secretion production to make the cough more productive. Antitussives suppress the cough reflex."}, {"id": "chest_tube_sterile_water", "slide": 999, "question": "Why must water in chest tube systems be sterile?", "options": ["To prevent evaporation", "To maintain pressure", "To prevent infection", "To ensure visibility"], "answer": "To prevent infection", "rationale": "Water used in chest tube systems must be sterile to prevent infection."}, {"id": "rib_fracture_breathing", "slide": 999, "question": "Breathing exercises are important in rib fracture management to prevent:", "options": ["Osteoporosis", "Atelectasis and pneumonia", "Muscle atrophy", "Cardiac complications"], "answer": "Atelectasis and pneumonia", "rationale": "Breathing exercises prevent atelectasis and pneumonia in clients with rib fractures."}, {"id": "flail_chest_mechanism", "slide": 999, "question": "Flail chest occurs when:", "options": ["One rib is fractured", "Multiple adjacent ribs are fractured", "The sternum is fractured", "The clavicle is dislocated"], "answer": "Multiple adjacent ribs are fractured", "rationale": "Flail chest occurs when multiple adjacent ribs are fractured, causing paradoxical chest wall movement."}, {"id": "pulmonary_embolism_onset", "slide": 999, "question": "Pulmonary embolism typically has:", "options": ["Gradual onset over days", "Sudden onset with severe symptoms", "Intermittent symptoms", "Mild symptoms only"], "answer": "Sudden onset with severe symptoms", "rationale": "Pulmonary embolism typically has sudden onset with severe dyspnea, tachycardia, and chest pain."}, {"id": "asthma_respiratory_assessment", "slide": 999, "question": "In acute asthma, assessment priority is:", "options": ["Breath sounds and respiratory rate", "Skin color and temperature", "Blood pressure and pulse", "Level of consciousness only"], "answer": "Breath sounds and respiratory rate", "rationale": "Assessment priority in acute asthma is breath sounds and respiratory rate to evaluate severity."}, {"id": "hypoxia_progression_cues", "slide": 999, "question": "Which are late cues of hypoxia progression?", "options": ["Restlessness and agitation", "Visible color changes and decreased consciousness", "Tachycardia and tachypnea", "Anxiety and confusion"], "answer": "Visible color changes and decreased consciousness", "rationale": "Late oxygenation failure cues include visible color changes and decreased level of consciousness."}];
window.availableExams = window.availableExams || [];
window.availableExams.push({id: 'acute_respiratory_quiz', name: 'Acute Respiratory Disorders and Medications Quiz', data: window.acuterespiratoryExamData});
console.log('Created exam module: Acute Respiratory Disorders and Medications Quiz with 40 questions');
window.chronicrespiratoryexamExamData = [{"id": "copd_assessment", "slide": 999, "question": "A client with COPD exhibits a barrel chest, dyspnea, clubbing, and shallow rapid respirations. These findings indicate which complication of COPD?", "options": ["Acute respiratory failure", "Chronic hypoxia manifestations", "Pulmonary hypertension", "Right heart failure"], "answer": "Chronic hypoxia manifestations", "rationale": "Barrel chest, dyspnea, clubbing, and shallow rapid respirations are hallmark physical findings in advanced COPD as described in Quiz Review #19 under 'COPD \u2013 Expected Findings & Nursing Interventions.' These manifestations result from chronic hypoxia and hyperinflation of the lungs. Acute respiratory failure would present with more acute changes like confusion or severe tachycardia. Pulmonary hypertension is a complication but not the primary expected finding. Right heart failure (cor pulmonale) can occur but is not listed among the basic expected findings in the quiz material."}, {"id": "copd_breathing", "slide": 999, "question": "Which breathing technique should the nurse teach a client with COPD to prolong exhalation and prevent airway collapse?", "options": ["Diaphragmatic breathing", "Pursed-lip breathing", "Abdominal breathing", "4-7-8 breathing"], "answer": "Pursed-lip breathing", "rationale": "Pursed-lip breathing is specifically taught to COPD patients as outlined in Quiz Review #19 under 'COPD \u2013 Expected Findings & Nursing Interventions' and 'Emphysema \u2013 Gas Exchange Strategies.' This technique prolongs exhalation to prevent airway collapse, reduces air trapping in the lungs, and improves gas exchange. Diaphragmatic breathing, while helpful for some respiratory conditions, is not specifically mentioned for COPD management in the quiz materials. Abdominal breathing refers to diaphragmatic breathing. 4-7-8 breathing is a general relaxation technique but not specific to COPD airway management."}, {"id": "copd_vs_asthma", "slide": 999, "question": "Which characteristic differentiates COPD from asthma?", "options": ["Progressive disease course", "Reversible airway obstruction", "Episodic symptoms", "Often begins in childhood"], "answer": "Progressive disease course", "rationale": "As clearly differentiated in Quiz Review #19 under 'COPD vs. Asthma,' COPD is characterized by progressive, persistent symptoms with irreversible airflow limitation, often associated with smoking history. Asthma presents with episodic, trigger-related symptoms and reversible airway obstruction that often begins earlier in life. Progressive disease course differentiates COPD (progressive, irreversible) from asthma (episodic, reversible). Reversible airway obstruction is characteristic of asthma. Episodic symptoms characterize asthma's pattern."}, {"id": "copd_nutrition", "slide": 999, "question": "The nurse is teaching a client with COPD about nutrition. Which dietary recommendations are appropriate?", "options": ["High-calorie, high-protein diet", "Low-sodium, fluid-restricted diet", "High-fiber, low-fat diet", "Calorie-restricted, ketogenic diet"], "answer": "High-calorie, high-protein diet", "rationale": "According to Quiz Review #19 under 'COPD \u2013 Expected Findings & Nursing Interventions' and 'Nutrition & hydration,' COPD patients require a high-calorie, high-protein diet due to increased work of breathing and metabolic demands. This helps maintain muscle mass and respiratory function. A low-sodium diet is important for hypertension but not specifically for COPD. High-fiber diets are generally healthy but don't address COPD's specific nutritional needs. Calorie-restricted diets would be inappropriate for patients already at risk for malnutrition from their respiratory condition."}, {"id": "asthma_therapy", "slide": 999, "question": "A client with asthma is prescribed both a bronchodilator and an inhaled corticosteroid. In what order should these medications be administered?", "options": ["Bronchodilator first, then corticosteroid", "Corticosteroid first, then bronchodilator", "Simultaneously", "Based on patient preference"], "answer": "Bronchodilator first, then corticosteroid", "rationale": "As specified in Quiz Review #19 under 'Metered-Dose Inhalers (MDIs) & Spacers,' bronchodilators must be administered before inhaled corticosteroids to open airways and enhance penetration of the steroid medication into the lung tissue. Administering corticosteroids first would be ineffective since the airways are constricted. Simultaneous administration is not recommended in the quiz materials. Patient preference is not a valid medical reason for changing evidence-based medication sequencing."}, {"id": "mdi_technique", "slide": 999, "question": "When teaching proper metered-dose inhaler (MDI) technique, which instruction is essential for effective medication delivery?", "options": ["Shake the inhaler vigorously before each use", "Inhale rapidly and forcefully", "Hold breath for at least 10 seconds after inhalation", "Rinse mouth only if taste is unpleasant"], "answer": "Hold breath for at least 10 seconds after inhalation", "rationale": "Quiz Review #19 under 'Metered-Dose Inhalers (MDIs) & Spacers' specifies that proper MDI technique includes slow deep inhalation, breath held for at least 10 seconds, and waiting between puffs. This ensures optimal medication deposition deep in the lung tissue. Shaking is important but not the critical step for effective delivery. Rapid forceful inhalation would cause medication to deposit in the mouth/throat. Breath holding for less than 10 seconds allows medication to be exhaled before absorption. Rinse mouth is important after corticosteroids but not the primary technique for effective delivery."}, {"id": "cystic_fibrosis_patho", "slide": 999, "question": "A client with cystic fibrosis experiences dysfunction of the exocrine glands and production of thick, tenacious mucus. Which symptom is typically the first pulmonary manifestation?", "options": ["Hemoptysis", "Dyspnea on exertion", "Chronic productive cough", "Clubbing of the fingers"], "answer": "Chronic productive cough", "rationale": "According to Lower Respiratory MS1 slide 34, 'Cough is the first pulmonary symptom' in cystic fibrosis due to dysfunction of exocrine glands producing thick mucus and impaired mucociliary clearance. Hemoptysis occurs later in disease progression. Dyspnea on exertion develops as lung function declines. Digital clubbing is a late sign of chronic hypoxemia. While all these can occur in CF, cough is specifically identified as the initial pulmonary manifestation in the lecture material."}, {"id": "cystic_fibrosis_treatment", "slide": 999, "question": "A client with cystic fibrosis is prescribed pancreatic enzyme replacement. When should these medications be administered?", "options": ["On an empty stomach, 30 minutes before meals", "With meals and snacks", "At bedtime only", "Once daily in the morning"], "answer": "With meals and snacks", "rationale": "Lower Respiratory MS1 slide 36 specifies that 'pancreatic enzyme replacement' should be administered 'with meals and snacks' for CF patients with pancreatic insufficiency to properly digest nutrients. Taking enzymes on an empty stomach would provide no benefit since there are no nutrients to digest. Taking them at bedtime is not indicated. Once daily dosing would be insufficient for proper nutrient absorption throughout the day."}, {"id": "emphysema_technique", "slide": 999, "question": "For a client with emphysema, which breathing technique promotes gas exchange and reduces work of breathing?", "options": ["Breathing in through pursed lips and out through the nose", "Breathing in through the nose and out through pursed lips", "Rapid shallow breathing", "Holding breath for 20 seconds between breaths"], "answer": "Breathing in through the nose and out through pursed lips", "rationale": "Quiz Review #19 under 'Emphysema \u2013 Gas Exchange Strategies' specifies 'breathing in through the nose and out through pursed lips' to prolong exhalation and improve gas exchange in emphysema patients. Pursed-lip breathing in reverse (in through pursed lips) is not described in the materials. Abdominal breathing focuses on diaphragmatic movement but doesn't address the specific nose/pursed-lip technique. Holding breath prevents normal gas exchange and would be harmful."}, {"id": "home_oxygen_safety", "slide": 999, "question": "A client is prescribed home oxygen therapy. Which safety measure is most important?", "options": ["Keep oxygen at least 10 feet from heat sources", "Avoid using petroleum-based lotions", "Ensure proper equipment fitting", "All of the above"], "answer": "All of the above", "rationale": "Quiz Review #19 under 'Home Oxygen Therapy \u2013 Safety & Skin Care' identifies that oxygen 'increases fire risk' and patients must 'avoid petroleum-based products (more flammable),' 'assess skin breakdown at pressure points,' and ensure 'equipment must be clean and properly fitted.' Keeping oxygen away from outlets is good practice but not the most critical safety measure mentioned. Using extension cords is unsafe with oxygen equipment. Storing cylinders in the garage increases fire risk and is not recommended."}, {"id": "tb_manifestations", "slide": 999, "question": "Which clinical manifestations are characteristic of tuberculosis?", "options": ["Fatigue, hemoptysis, night sweats", "Productive cough, fever, weight gain", "Dyspnea, wheezing, chest tightness", "Sore throat, nasal congestion, rhinorrhea"], "answer": "Fatigue, hemoptysis, night sweats", "rationale": "Quiz Review #19 under 'Tuberculosis (TB) Expected clinical manifestations' lists: fatigue, hemoptysis, night sweats, weight loss, anorexia, and low-grade afternoon fever as characteristic symptoms. Productive cough with fever suggests bacterial pneumonia. Dyspnea with wheezing indicates asthma or COPD exacerbation. Sore throat with congestion suggests viral upper respiratory infection rather than TB."}, {"id": "pneumonia_oxygenation", "slide": 999, "question": "When caring for a client with pneumonia and low oxygen saturation, which positioning maximizes lung expansion?", "options": ["Supine position", "Trendelenburg position", "High Fowler position", "Left lateral position"], "answer": "High Fowler position", "rationale": "Quiz Review #19 under 'Pneumonia \u2013 Oxygenation & Secretion Management' states that 'positioning that maximizes lung expansion' is priority for low oxygen saturation in pneumonia. High Fowler position accomplishes this by allowing maximum chest expansion and lung inflation. Supine position would decrease lung expansion. Trendelenburg position is contraindicated as it can cause respiratory distress. Left lateral position may help with specific lung segments but is not the primary position for oxygenation."}, {"id": "airway_clearance", "slide": 999, "question": "Before performing airway clearance therapies like percussion and postural drainage, the nurse should first:", "options": ["Administer pain medication", "Assess lung fields to identify target areas", "Apply supplemental oxygen", "Have suction equipment ready"], "answer": "Assess lung fields to identify target areas", "rationale": "Quiz Review #19 under 'Pneumonia \u2013 Oxygenation & Secretion Management' specifies that 'first action is always assessment of lung fields to identify target areas' before airway clearance therapies like percussion and postural drainage. Pain medication may be needed but assessment comes first. Supplemental oxygen may be indicated but doesn't replace the need for assessment. Suction equipment should be ready but assessment determines if it's needed."}, {"id": "resp_acidosis", "slide": 999, "question": "A client with COPD has ABG results showing low pH and elevated PaCO2. This indicates:", "options": ["Metabolic alkalosis", "Respiratory acidosis", "Metabolic acidosis", "Respiratory alkalosis"], "answer": "Respiratory acidosis", "rationale": "Quiz Review #19 under 'Acid\u2013Base Balance (ABGs)' defines respiratory acidosis as 'low pH, elevated PaCO\u2082, normal bicarbonate in uncompensated states, caused by hypoventilation or airway obstruction.' Metabolic alkalosis would show high pH with metabolic changes. Respiratory alkalosis would show high pH with low PaCO2. Metabolic acidosis would show low pH with low bicarbonate."}, {"id": "aspiration_risk", "slide": 999, "question": "Which finding in a client indicates risk for aspiration and requires immediate follow-up?", "options": ["Clear speech after drinking water", "Coughing with eating", "Normal oxygen saturation", "Ability to swallow pills easily"], "answer": "Coughing with eating", "rationale": "Quiz Review #19 under 'Dysphagia & Aspiration Risk' lists 'coughing with eating' as a finding requiring 'immediate follow-up' for aspiration risk. Clear speech after drinking water indicates no current aspiration risk. Hoarse voice after swallowing is also listed as a concerning sign. Normal oxygen saturation doesn't rule out aspiration risk. Ability to swallow pills easily is not a reliable indicator of swallowing safety."}, {"id": "bronchodilator_outcomes", "slide": 999, "question": "Following effective bronchodilator therapy, the nurse would expect to observe:", "options": ["Increased wheezing and accessory muscle use", "Decreased oxygen saturation", "Improved breathing effort and reduced respiratory rate", "Increased sputum production and cough"], "answer": "Improved breathing effort and reduced respiratory rate", "rationale": "Quiz Review #19 under 'Client Outcomes \u2013 Effective Bronchodilator Therapy' lists: decreased wheezing, reduced accessory muscle use, improved oxygen saturation, decreased respiratory rate, easier breathing effort. Increased wheezing would indicate ineffective therapy. Decreased oxygen saturation would suggest worsening respiratory status. Increased sputum suggests infection or inadequate clearance. No change in respiratory rate would indicate lack of improvement."}, {"id": "acute_bronchitis", "slide": 999, "question": "A client is diagnosed with acute bronchitis. Which medication is most appropriate for symptom management?", "options": ["Antitussive agents like dextromethorphan", "Expectorant agents like guaifenesin", "Antibiotics for 7-10 days", "Inhaled corticosteroids"], "answer": "Expectorant agents like guaifenesin", "rationale": "Lower Respiratory MS1 slide 5 states that acute bronchitis treatment includes antitussive agents like dextromethorphan or expectorant guaifenesin, with broad-spectrum antibiotics for 7-10 days if bacterial. Since most cases are viral, expectorants are often the first-line treatment. Antitussives suppress cough but don't address the underlying cause. Antibiotics are not routinely prescribed for viral bronchitis. Inhaled corticosteroids are used for asthma/COPD, not acute bronchitis."}, {"id": "influenza_spread", "slide": 999, "question": "How is influenza primarily spread?", "options": ["Through contaminated food and water", "Through droplet infection", "Through direct skin contact", "Through insect vectors"], "answer": "Through droplet infection", "rationale": "Lower Respiratory MS1 slide 6 states that influenza spreads through droplet infection, similar to the common cold but with different symptoms. Food/water contamination would indicate a gastrointestinal pathogen. Direct skin contact is not the primary transmission route. Insect vectors are not involved in influenza transmission."}, {"id": "respiratory_anatomy", "slide": 999, "question": "The respiratory center that controls breathing is located in the:", "options": ["Cerebellum", "Medulla oblongata", "Pons", "Cerebral cortex"], "answer": "Medulla oblongata", "rationale": "Upper Respiratory MS1 slide 4 states that the respiratory center is located in the medulla oblongata and stimulated by changing CO2 and O2 levels in arterial blood. The cerebellum controls coordination and balance. The pons assists with respiratory control but is not the primary center. The cerebral cortex controls voluntary functions and consciousness."}, {"id": "thorax_assessment", "slide": 999, "question": "When assessing the thorax, the nurse should auscultate the lungs:", "options": ["Only on the anterior chest", "Only on the posterior chest", "Bilaterally in a systematic manner", "Only if crackles are heard"], "answer": "Bilaterally in a systematic manner", "rationale": "Upper Respiratory MS1 slide 7 states that lung auscultation should be performed bilaterally in a systematic manner. Anterior chest assessment alone misses posterior lung fields. Posterior assessment alone misses anterior fields. Systematic bilateral assessment ensures complete evaluation. Auscultation only when crackles are heard would miss other important findings."}, {"id": "coarse_crackles", "slide": 999, "question": "Coarse crackles heard during lung auscultation are typically caused by:", "options": ["Fluid in the alveoli", "Narrowing of small airways", "Secretions in larger airways", "Fibrotic changes in lung tissue"], "answer": "Secretions in larger airways", "rationale": "Upper Respiratory MS1 slide 7 describes coarse crackles as caused by secretions accumulating in larger airways, usually cleared with coughing. Fine crackles are caused by fluid in alveoli. Narrowing of small airways causes wheezes. Fibrotic changes in lung tissue cause crackles but are typically fine, not coarse."}, {"id": "rifampin_tb", "slide": 999, "question": "A client prescribed rifampin for tuberculosis develops reddish-orange colored secretions. The nurse understands this is:", "options": ["An allergic reaction requiring immediate discontinuation", "A harmless side effect of the medication", "A sign of treatment failure", "An indication to increase the dose"], "answer": "A harmless side effect of the medication", "rationale": "In Class Quiz 19 review states 'Rifampin - TB drug, REDDISH/ORAGNE SECRETIONS' indicating this is a harmless side effect. An allergic reaction would require immediate discontinuation and show different symptoms like rash or anaphylaxis. A sign of treatment failure would show worsening clinical symptoms. Increasing the dose would not address discoloration and could cause toxicity."}, {"id": "tb_diagnosis", "slide": 999, "question": "A client has a positive TB skin test but no active disease. Which diagnostic test should be used to confirm latent TB?", "options": ["Repeat tuberculin skin test in 3 months", "QuantiFERON-TB Gold blood test", "Chest X-ray only", "Sputum culture for acid-fast bacilli"], "answer": "QuantiFERON-TB Gold blood test", "rationale": "In Class Quiz 19 review states 'If you have +TB test intradermally, you will always test positive. Must use QuantiFERON or Chest x-ray.' Repeat skin testing is not useful due to persistent positivity. Chest X-ray alone cannot confirm latent TB. Sputum culture is for active TB diagnosis, not latent."}, {"id": "antitussive_action", "slide": 999, "question": "An antitussive medication works by:", "options": ["Thinning respiratory secretions", "Suppressing the cough reflex in the brain", "Relaxing bronchial smooth muscle", "Reducing airway inflammation"], "answer": "Suppressing the cough reflex in the brain", "rationale": "In Class Quiz 19 review states 'What does an anti-tussive: SUPPRESSES COUGH REFLEX.' Expectorants thin secretions rather than suppress cough. Bronchodilators relax smooth muscle but don't affect cough reflex. Anti-inflammatory agents reduce inflammation but don't directly suppress cough."}, {"id": "codeine_side_effects", "slide": 999, "question": "A client prescribed codeine for cough suppression should be monitored for which side effects?", "options": ["Hypertension and tachycardia", "Drowsiness and sedation", "Nausea and vomiting", "Increased respiratory rate"], "answer": "Drowsiness and sedation", "rationale": "In Class Quiz 19 review states 'Side effect of codeine: DROWSINESS AND SEDATION.' Hypertension and tachycardia are not typical opioid side effects. Nausea/vomiting can occur but sedation is the primary CNS effect. Increased respiratory rate would be paradoxical and not expected with opioids."}, {"id": "isoniazid_duration", "slide": 999, "question": "Isoniazid (INH) for latent tuberculosis infection is typically prescribed for:", "options": ["2 weeks", "1 month", "6 months", "9 months"], "answer": "9 months", "rationale": "In Class Quiz 19 review states 'How long Isoniazid, how long to prescribe? 9 MONTHS.' 2 weeks would be inadequate for LTBI treatment. 1 month is insufficient duration. 6 months is shorter than recommended for full protection."}, {"id": "mdi_purpose", "slide": 999, "question": "The primary purpose of using a metered-dose inhaler (MDI) is to:", "options": ["Reduce medication side effects", "Increase medication delivery to the lungs", "Decrease treatment frequency", "Eliminate the need for spacers"], "answer": "Increase medication delivery to the lungs", "rationale": "In Class Quiz 19 review states 'Why use a metered dose inhaler? TO INCREASE THE INTAKE OF THE MEDICATION REACHING THE LUNGS.' MDIs create a fine mist for optimal lung deposition. Reducing dosage would not address delivery issues. Decreasing frequency would not improve delivery. Eliminating spacers would worsen delivery in patients who need them."}, {"id": "mdi_spacer", "slide": 999, "question": "A spacer is used with a metered-dose inhaler (MDI) to:", "options": ["Reduce medication dosage requirements", "Improve delivery of medication into the lungs", "Prevent medication interactions", "Decrease treatment cost"], "answer": "Improve delivery of medication into the lungs", "rationale": "Quiz Review #19 under 'Metered-Dose Inhalers (MDIs) & Spacers' states 'A spacer is used to improve delivery of medication into the lungs.' This provides time for proper aerosolization. Reducing dosage requirements is not the primary purpose. Spacers don't prevent interactions. Treatment cost is not affected by spacer use."}, {"id": "inhaled_corticosteroid_rinse", "slide": 999, "question": "After using inhaled corticosteroids, the client should rinse their mouth to prevent:", "options": ["Dry mouth and throat irritation", "Oral thrush and candidiasis", "Bad taste and nausea", "Increased heart rate"], "answer": "Oral thrush and candidiasis", "rationale": "Quiz Review #19 under 'Metered-Dose Inhalers (MDIs) & Spacers' states 'After inhaled corticosteroids, the client should rinse the mouth to prevent oral complications such as thrush or oral candidiasis.' Dry mouth is not the primary concern. Oral thrush is the specific complication mentioned. Bad taste is possible but not the main reason. Heart rate changes are not associated with inhaled corticosteroids."}, {"id": "rapid_relief_medications", "slide": 999, "question": "Rapid relief bronchodilator medications are primarily used for:", "options": ["Long-term inflammation prevention", "Acute dyspnea, wheezing, and accessory muscle use", "Daily maintenance therapy", "Prevention of asthma attacks"], "answer": "Acute dyspnea, wheezing, and accessory muscle use", "rationale": "Quiz Review #19 under 'Bronchodilators vs. Anti-inflammatory Therapy' states rapid relief medications are 'used for acute dyspnea, wheezing, and accessory muscle use' by 'relaxing bronchial smooth muscle.' Long-term control medications are for inflammation prevention. Daily maintenance therapy describes controller medications. Prevention of attacks is a goal but not the immediate use."}, {"id": "opioid_cough_monitoring", "slide": 999, "question": "A client prescribed codeine for cough suppression should be monitored for opioid-related side effects including:", "options": ["Hypertension and tachycardia", "Sedation, constipation, and urinary retention", "Nausea, vomiting, and diarrhea", "Increased respiratory rate and wheezing"], "answer": "Sedation, constipation, and urinary retention", "rationale": "Quiz Review #19 under 'Antitussives & Cough Management' states opioid-based cough medications require monitoring for 'sedation, constipation, urinary retention.' These are classic opioid side effects. Hypertension and tachycardia are not typical opioid effects. Nausea/vomiting occur but sedation is the primary concern. Increased respiratory rate would be unexpected with opioid use."}, {"id": "tb_medication_timing", "slide": 999, "question": "Rifampin for tuberculosis treatment should be taken:", "options": ["With meals to improve absorption", "On an empty stomach", "With antacids to prevent stomach upset", "At bedtime to minimize side effects"], "answer": "On an empty stomach", "rationale": "Quiz Review #19 under 'Tuberculosis (TB) Expected clinical manifestations' states rifampin should be taken 'on an empty stomach' for proper absorption. Taking with meals reduces effectiveness. Antacids don't affect rifampin timing. Bedtime dosing doesn't address the absorption requirement."}, {"id": "pneumonia_fluids", "slide": 999, "question": "To thin respiratory secretions in pneumonia, the nurse should encourage:", "options": ["Increased fluid intake", "Decreased fluid intake to reduce sputum volume", "Thickened liquids only", "Carbonated beverages"], "answer": "Increased fluid intake", "rationale": "Quiz Review #19 under 'Pneumonia \u2013 Oxygenation & Secretion Management' emphasizes that 'thinning secretions requires adequate fluid intake' to facilitate clearance in pneumonia patients. Dehydration thickens secretions and impairs ciliary function. Decreased fluid intake would worsen secretion viscosity. Thickened liquids are prescribed for dysphagia, not to thin secretions. Carbonated beverages don't provide the sustained hydration needed for secretion management."}, {"id": "copd_upright_positioning", "slide": 999, "question": "Upright positioning in COPD improves:", "options": ["Diaphragmatic excursion and lung expansion", "Blood pressure and cardiac output", "Urine output and kidney function", "Sleep quality and duration"], "answer": "Diaphragmatic excursion and lung expansion", "rationale": "Upright positioning allows better diaphragmatic excursion and lung expansion, improving ventilation and gas exchange in COPD."}, {"id": "tracheostomy_suctioning_priority", "slide": 999, "question": "Before performing tracheostomy suctioning, the nurse's first action should be to:", "options": ["Hyperoxygenate the patient", "Collect respiratory assessment data", "Prepare suction equipment", "Administer pain medication"], "answer": "Collect respiratory assessment data", "rationale": "Collecting respiratory data first ensures suctioning is indicated and helps determine the appropriate timing for hyperoxygenation."}, {"id": "home_oxygen_fire_safety", "slide": 999, "question": "Home oxygen therapy increases fire risk. Which precaution is most important?", "options": ["Keep oxygen at least 10 feet from electrical outlets", "Avoid petroleum-based products and open flames", "Use extension cords for oxygen concentrators", "Store oxygen cylinders in the garage"], "answer": "Avoid petroleum-based products and open flames", "rationale": "Oxygen supports combustion, so avoiding petroleum-based products (which are flammable) and open flames is critical for fire safety."}, {"id": "respiratory_acidosis_details", "slide": 999, "question": "In uncompensated respiratory acidosis, which ABG findings are expected?", "options": ["pH elevated, PaCO2 decreased, HCO3 normal", "pH decreased, PaCO2 elevated, HCO3 normal", "pH decreased, PaCO2 normal, HCO3 elevated", "pH elevated, PaCO2 elevated, HCO3 decreased"], "answer": "pH decreased, PaCO2 elevated, HCO3 normal", "rationale": "Respiratory acidosis shows decreased pH and elevated PaCO2. In uncompensated states, bicarbonate remains normal initially."}, {"id": "aspiration_hoarse_voice", "slide": 999, "question": "A client with hoarse voice after swallowing should be evaluated for:", "options": ["Gastroesophageal reflux disease", "Aspiration risk requiring immediate follow-up", "Laryngitis that will resolve spontaneously", "Allergic reaction to food"], "answer": "Aspiration risk requiring immediate follow-up", "rationale": "Hoarse voice after swallowing indicates possible aspiration and requires immediate evaluation to prevent complications."}];
window.availableExams = window.availableExams || [];
window.availableExams.push({id: 'chronic_respiratory_exam', name: 'Chronic Respiratory Diseases Exam', data: window.chronicrespiratoryexamExamData});
console.log('Created exam module: Chronic Respiratory Diseases Exam with 38 questions');
window.customMissions = window.customMissions || [];
window.customMissions = window.customMissions.concat([{"id": "M-004", "type": "mission", "numerical_id": 4, "title": "The Irregular Pulse: AFib Management", "category": "Cardiovascular / Arrhythmia", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "James O'Connell", "age": 67, "gender": "Male", "mrn": "3920-JO", "dob": "03/15/1959", "weight": "95 kg", "height": "180 cm", "allergies": "Codeine (Nausea)"}, "chief_complaint": "Palpitations and 'fluttering' in chest.", "hpi": "Mr. O'Connell presents to the clinic reporting intermittent palpitations for the last 2 weeks. He states, 'It feels like a bird is trapped in my chest.' He denies chest pain. He has a history of 'mild AFib' dating back 5 years but stopped taking his blood thinner (Apixaban) 6 months ago due to cost. He reports feeling increasingly fatigued and short of breath when climbing stairs.", "pmh": "Paroxysmal Atrial Fibrillation, Hypertension, Hyperlipidemia, Obstructive Sleep Apnea.", "sh": "Retired police officer. Social drinker (2-3 beers/day). Smoker (1 pack/day). Low sodium diet (non-compliant).", "ros": {"cardio": "Irregularly irregular rhythm. HR 110-120bpm. No murmurs.", "resp": "Mild dyspnea on exertion. Lungs clear.", "neuro": "Alert & Oriented x4. No facial droop or slurred speech.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}}, "exhibits": [{"title": "ECG Strip (10:00)", "type": "text", "content": "<strong>Rhythm:</strong> Atrial Fibrillation with Rapid Ventricular Response (RVR).<br><strong>Rate:</strong> 118 bpm.<br><strong>Intervals:</strong> Absent P waves. Fibrillatory waves present. QRS narrow (0.08s)."}, {"title": "Coagulation Panel", "type": "table", "data": [{"lab": "PT", "val": "12.0 sec", "status": "Normal"}, {"lab": "INR", "val": "1.0", "status": "Subtherapeutic"}, {"lab": "aPTT", "val": "30 sec", "status": "Normal"}], "content": "Information not available"}, {"title": "Echocardiogram Report", "type": "text", "content": "Left Atrial Enlargement. LVEF 50%. No left atrial appendage thrombus visualized."}], "steps": [{"type": "extended_sata", "prompt": "The nurse admits Mr. O'Connell. Which assessment findings are consistent with Atrial Fibrillation with RVR? Select all that apply.", "options": ["Heart rate > 100 bpm", "Visible P waves on ECG", "Irregularly irregular pulse", "Palpitations", "Pulse deficit (Apical > Radial)", "Widened QRS complex > 0.12s"], "answer": [0, 1], "rationale": "AFib is characterized by chaotic atrial activity (no P waves) and an irregular ventricular response. RVR implies a rate > 100. A pulse deficit is common as not all beats generate enough pressure to be palpable peripherally. QRS is typically narrow unless there is aberrant conduction."}, {"type": "matrix", "prompt": "The provider orders medications. For each drug, indicate the primary purpose in this scenario.", "rows": ["Diltiazem (Cardizem) IV", "Heparin IV Drip", "Metoprolol PO", "Amiodarone IV"], "columns": ["Rate Control", "Rhythm Control", "Anticoagulation"], "answer": {"Diltiazem (Cardizem) IV": "Rate Control", "Heparin IV Drip": "Anticoagulation", "Metoprolol PO": "Rate Control", "Amiodarone IV": "Rhythm Control"}, "rationale": "Diltiazem and Metoprolol are rate control agents (slowing AV conduction). Heparin prevents thrombus formation (stroke prevention). Amiodarone is an antiarrhythmic used to restore/maintain sinus rhythm (rhythm control)."}, {"type": "bowtie", "prompt": "The patient suddenly develops slurred speech and right-sided weakness. Prioritize the immediate response.", "center_condition": {"options": ["Hemorrhagic Stroke", "Ischemic Stroke (Embolic)", "Transient Ischemic Attack", "Bell's Palsy"], "answer": "Ischemic Stroke (Embolic)"}, "left_actions": {"options": ["Activate Stroke Team/Code Stroke", "Start Heparin Bolus", "Administer tPA immediately", "Obtain Non-contrast CT Head", "Preparation for synchronized cardioversion"], "answer": ["Activate Stroke Team/Code Stroke", "Obtain Non-contrast CT Head"]}, "right_monitor": {"options": ["NIHSS Stroke Scale", "PT/INR", "Pupillary Response", "Serum Glucose", "Urine Output"], "answer": ["NIHSS Stroke Scale", "Serum Glucose"]}, "rationale": "The greatest risk in AFib is embolic stroke (clot leaving the LA appendage). Slurred speech and weakness are classic signs. Immediate action is to call a Stroke Code and get a CT to rule out hemorrhage. Glucose is checked to rule out hypoglycemia mimics. tPA is NOT given until hemorrhage is ruled out."}]}, {"id": "M-005", "type": "mission", "numerical_id": 5, "title": "The Silent Killer: Hypertensive Urgency", "category": "Cardiovascular / HTN", "difficulty": "Functions", "patient_profile": {"demographics": {"name": "Sarah Jenkins", "age": 55, "gender": "Female", "mrn": "5512-SJ", "dob": "06/20/1971", "weight": "80 kg", "height": "165 cm", "allergies": "NKDA"}, "chief_complaint": "Severe pulsating headache and nosebleed.", "hpi": "Ms. Jenkins came to the ER with a pounding headache (8/10) and epistaxis that wouldn't stop for 20 mins. She ran out of her 'blood pressure pills' 4 days ago. She denies chest pain, shortness of breath, or blurred vision.", "pmh": "Hypertension (non-compliant), Anxiety.", "sh": "Accountant. Reports 'tax season stress'.", "ros": {"neuro": "Alert. headache 8/10. No focal deficits.", "cardio": "BP 210/110 mmHg. HR 92. Strong pulses.", "eye": "No papilledema noted on fundoscopy.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}}, "exhibits": [{"title": "Vital Signs", "type": "table", "data": [{"param": "BP", "val": "210/110 mmHg"}, {"param": "HR", "val": "92 bpm"}, {"param": "SpO2", "val": "98%"}, {"param": "Temp", "val": "98.6 F"}], "content": "Information not available"}, {"title": "Comprehensive Metabolic Panel", "type": "table", "data": [{"lab": "Creatinine", "val": "0.9 mg/dL", "status": "Normal"}, {"lab": "BUN", "val": "15 mg/dL", "status": "Normal"}, {"lab": "Estimated GFR", "val": ">60", "status": "Normal"}, {"lab": "Potassium", "val": "4.0 mEq/L", "status": "Normal"}], "content": "Information not available"}, {"title": "Urinalysis", "type": "text", "content": "Protein: Negative. Blood: Negative. Glucose: Negative. (No renal damage)"}], "steps": [{"type": "matrix", "prompt": "The nurse assesses Ms. Jenkins. Determine which findings indicate 'Target Organ Damage' vs 'No Target Organ Damage'.", "rows": ["Creatinine 0.9 mg/dL", "Severe Headache", "Proteinuria (Negative)", "Chest Pain / Troponin elevation", "Epistaxis (Nosebleed)"], "columns": ["Evidence of Organ Damage", "No Evidence of Organ Damage"], "answer": {"Creatinine 0.9 mg/dL": "No Evidence of Organ Damage", "Severe Headache": "No Evidence of Organ Damage", "Proteinuria (Negative)": "No Evidence of Organ Damage", "Chest Pain / Troponin elevation": "Evidence of Organ Damage", "Epistaxis (Nosebleed)": "No Evidence of Organ Damage"}, "rationale": "Urgency is defined by BP > 180/120 WITHOUT organ damage. Headache and epistaxis are symptoms but not organ 'damage' like MI (chest pain), renal failure (high Cr), or stroke."}, {"type": "bowtie", "prompt": "Based on the assessment (High BP, No Organ Damage), prioritize the care plan.", "center_condition": {"options": ["Hypertensive Emergency", "Hypertensive Urgency", "Ischemic Stroke", "Anxiety Attack"], "answer": "Hypertensive Urgency"}, "left_actions": {"options": ["Administer IV Nitroprusside", "Administer Oral Clonidine", "Administer Oral Captopril", "Place in quiet, dark room", "Prepare for intubation"], "answer": ["Administer Oral Clonidine", "Place in quiet, dark room"]}, "right_monitor": {"options": ["BP every 15-30 mins", "Continuous Arterial Line", "Hourly Urine Output", "Neuro checks q1h", "Continuous EEG"], "answer": ["BP every 15-30 mins", "Neuro checks q1h"]}, "rationale": "The diagnosis is Urgency. Treatment involves ORAL agents (Clonidine/Captopril) to lower BP gradually over 24-48h. IV agents are for Emergency. Reducing stimuli assists in lowering BP. Neuro checks ensure no progression to stroke."}, {"type": "extended_sata", "prompt": "Ms. Jenkins is discharged. Which statements require further teaching? Select all that apply.", "options": ["I can stop the medication when my headache goes away.", "I should avoid salty foods like canned soups.", "If I miss a dose, I will double up the next day.", "I will buy a home blood pressure cuff.", "I will schedule a follow-up with my PCP in 1 week."], "answer": [0, 1], "rationale": "Hypertension is a silent, lifelong condition. Medication adherence is crucial even when asymptomatic. Doubling doses can cause dangerous hypotension."}]}, {"id": "M-008", "type": "mission", "numerical_id": 8, "title": "Fluid Overload: CHF Management", "category": "Cardiovascular / HF", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Walter White", "age": 70, "gender": "Male", "mrn": "8291-WW", "dob": "01/01/1956", "weight": "100 kg (up 4kg)", "height": "175 cm", "allergies": "NKDA"}, "chief_complaint": "Swollen legs and can't breathe when lying down.", "hpi": "Mr. White reports increasing edema over the last week. He has been sleeping in a recliner (3-pillow orthopnea). He admits to eating ham and pizza for the Super Bowl 2 days ago.", "pmh": "Heart Failure (HFrEF - EF 35%), MI x2, Hyperlipidemia.", "ros": {"resp": "Crackles in bilateral bases. Doze 34. SpO2 90% RA.", "cardio": "S3 Gallop. JVD present.", "gi": "Abdominal bloating (ascites).", "neuro": "Alert and oriented x3. PEERLA.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Software engineer. Works from home. High stress. Enjoys hiking."}, "exhibits": [{"title": "BNP and Electrolytes", "type": "table", "data": [{"lab": "BNP", "val": "1200 pg/mL", "status": "High"}, {"lab": "Sodium", "val": "134 mEq/L", "status": "Low Normal"}, {"lab": "Potassium", "val": "4.5 mEq/L", "status": "Normal"}, {"lab": "Creatinine", "val": "1.4 mg/dL", "status": "Elevated"}], "content": "Information not available"}, {"title": "Chest X-Ray", "type": "text", "content": "Cardiomegaly. Pulmonary vascular congestion. Bilateral pleural effusions."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Differentiate the patient's symptoms between Right-Sided and Left-Sided Heart Failure.", "rows": ["Jugular Venous Distention (JVD)", "Crackles / Pulmonary Edema", "Peripheral Edema (Legs)", "Orthopnea (SOB lying flat)", "Ascites / Hepatosplenomegaly"], "columns": ["Right-Sided HF", "Left-Sided HF"], "answer": {"Jugular Venous Distention (JVD)": "Right-Sided HF", "Crackles / Pulmonary Edema": "Left-Sided HF", "Peripheral Edema (Legs)": "Right-Sided HF", "Orthopnea (SOB lying flat)": "Left-Sided HF", "Ascites / Hepatosplenomegaly": "Right-Sided HF"}, "rationale": "Left HF backs up into the Lungs (Crackles, Orthopnea). Right HF backs up into the Rest of the body (JVD, Ascites, Edema). This patient has biventricular failure."}, {"type": "bowtie", "prompt": "The patient becomes increasingly dyspneic, SpO2 drops to 85%, and he starts coughing pink frothy sputum. Take immediate action.", "center_condition": {"options": ["Flash Pulmonary Edema", "Pneumonia", "Pulmonary Embolism", "COPD Exacerbation"], "answer": "Flash Pulmonary Edema"}, "left_actions": {"options": ["Administer IV Furosemide", "Place High Flow Oxygen / BiPAP", "Lay patient flat", "Administer IV Fluids", "Administer Morphine (if protocol allows)"], "answer": ["Administer IV Furosemide", "Place High Flow Oxygen / BiPAP"]}, "right_monitor": {"options": ["Urine Output", "SpO2 and Respiratory Effort", "Blood Cultures", "D-Dimer", "Peak Flow"], "answer": ["Urine Output", "SpO2 and Respiratory Effort"]}, "rationale": "Pink frothy sputum is pathognomonic for Flash Pulmonary Edema. This is an AIRWAY emergency. Diuretics (Lasix) remove fluid. Positive pressure ventilation (BiPAP) pushes fluid out of alveoli. Laying flat kills the patient."}, {"type": "extended_sata", "prompt": "The patient stabilizes. Which discharge instructions are appropriate? Select all that apply.", "options": ["Weigh yourself daily at the same time", "Restrict fluid intake to 1.5 - 2L per day", "Limit Sodium intake to < 2g per day", "Take Ibuprofen for aches and pains", "Call provider if you gain 3 lbs in a day or 5 lbs in a week"], "answer": [0, 1], "rationale": "Daily weights are the best indicator of fluid status. NSAIDs (Ibuprofen) cause sodium retention and are contraindicated in HF."}]}, {"id": "M-009", "type": "mission", "numerical_id": 9, "title": "The Fainting Gardener: Aortic Stenosis", "category": "Cardiovascular / Structural", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Martha Stewart (No relation)", "age": 78, "gender": "Female", "mrn": "1290-MS", "dob": "02/14/1948", "weight": "62 kg", "height": "160 cm", "allergies": "Penicillin (Rash)"}, "chief_complaint": "Passed out while watering roses.", "hpi": "Ms. Stewart reports a 3-month history of chest tightness when walking uphill, which she attributed to 'old age'. Today, she felt lightheaded while gardening in the sun and woke up on the grass. Her daughter witnessed the syncope and called 911. She denies palpitations or incontinence.", "pmh": "Hypertension, Hyperlipidemia, Osteoporosis.", "sh": "Retired librarian. Lives with daughter. Active gardener.", "ros": {"cardio": "Harsh systolic crescendo-decrescendo murmur at 2nd Intercostal space, Right Sternal Border. Radiates to carotids. Delayed carotid upstroke.", "resp": "Mild dyspnea on exertion. Lungs clear.", "neuro": "Alert. No focal deficits.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}}, "exhibits": [{"title": "Echocardiogram", "type": "text", "content": "<strong>Finding:</strong> Severe Calcific Aortic Stenosis.<br><strong>Valve Area:</strong> 0.8 cm\u00b2 (Critical < 1.0).<br><strong>Mean Gradient:</strong> 45 mmHg (High).<br><strong>LVEF:</strong> 55% with concentric LV hypertrophy."}, {"title": "ECG", "type": "text", "content": "Normal Sinus Rhythm at 72 bpm. Left Ventricular Hypertrophy (Voltage criteria met)."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "The nurse auscultates the patient's heart sounds. Differentiate the murmurs based on location and timing.", "rows": ["Systolic Murmur at Right 2nd ICS", "Systolic Murmur at Apex (radiation to axilla)", "Diastolic Murmur at Left Sternal Border", "Continuous machine-like murmur"], "columns": ["Aortic Stenosis", "Mitral Regurgitation", "Aortic Regurgitation", "Patent Ductus Arteriosus"], "answer": {"Systolic Murmur at Right 2nd ICS": "Aortic Stenosis", "Systolic Murmur at Apex (radiation to axilla)": "Mitral Regurgitation", "Diastolic Murmur at Left Sternal Border": "Aortic Regurgitation", "Continuous machine-like murmur": "Patent Ductus Arteriosus"}, "rationale": "Aortic Stenosis is a systolic ejection murmur heard best at the aortic area (R 2nd ICS). Mitral Regurgitation is a pansystolic murmur at the apex. Aortic Regurgitation is a diastolic decrescendo murmur."}, {"type": "extended_sata", "prompt": "Ms. Stewart is admitted for TAVR workup. Which nursing interventions are appropriate for her safety? Select all that apply.", "options": ["Encourage vigorous walking to build stamina", "Instruct to change positions slowly (dangle legs)", "Administer Nitroglycerin SL for chest pain", "Maintain strict intake and output", "Teach valsalva maneuver for palpitations"], "answer": [0, 1], "rationale": "Patients with fixed outlet obstruction (AS) are preload dependent. Nitroglycerin causes vasodilation, dropping preload and potentially causing fatal hypotension/syncope. Vigorous exercise increases demand that the heart cannot meet. Valsalva reduces preload."}, {"type": "bowtie", "prompt": "The patient reports chest pressure (Angina). The nurse prepares to act.", "center_condition": {"options": ["Unstable Angina", "Aortic Stenosis Demand Ischemia", "Myocardial Infarction", "Costochondritis"], "answer": "Aortic Stenosis Demand Ischemia"}, "left_actions": {"options": ["Administer Nitroglycerin", "Administer Oxygen", "Place in Semi-Fowlers", "Start Morphine IV", "Prepare for emergency balloon valvuloplasty"], "answer": ["Administer Oxygen", "Place in Semi-Fowlers"]}, "right_monitor": {"options": ["Blood Pressure", "Troponin", "ST segments", "Temperature", "CBC"], "answer": ["Blood Pressure", "ST segments"]}, "rationale": "In AS, the hypertrophied muscle needs more oxygen, but the valve limits flow. Nitro is risky! Oxygen increases supply. Rest (Semi-Fowlers) decreases demand. BP must be preserved to push blood through the stenotic valve."}]}, {"id": "M-010", "type": "mission", "numerical_id": 10, "title": "The Friction Rub: Acute Pericarditis", "category": "Cardiovascular / Inflammatory", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Kevin Durant (Not that one)", "age": 35, "gender": "Male", "mrn": "3535-KD", "dob": "09/29/1990", "weight": "85 kg", "height": "190 cm", "allergies": "NKDA"}, "chief_complaint": "Sharp, stabbing chest pain.", "hpi": "Mr. Durant recovered from a 'bad flu' 2 weeks ago. Now presents with retrosternal chest pain that is 9/10, sharp, and pleuritic (worse with deep breath). He states, 'It feels better when I sit up and lean forward.'", "pmh": "None significant.", "ros": {"cardio": "High-pitched scratching sound heard at Left Lower Sternal Border (Friction Rub).", "resp": "Shallow breathing due to pain.", "gen": "Low grade fever (100.2 F).", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Construction worker. Lives alone. Smokes 1 pack/day. Social drinker."}, "exhibits": [{"title": "ECG (12-Lead)", "type": "text", "content": "Diffuse ST-segment elevation in all precordial leads (concave up). PR-segment depression in Lead II."}, {"title": "Labs", "type": "table", "data": [{"lab": "Troponin", "val": "0.1 ng/mL", "status": "Mild Elev"}, {"lab": "ESR", "val": "80 mm/hr", "status": "High"}, {"lab": "CRP", "val": "15 mg/L", "status": "High"}, {"lab": "WBC", "val": "12,000", "status": "Elevated"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Differentiate Pericarditis from Myocardial Infarction based on clinical presentation.", "rows": ["Pain relieved by Nitroglycerin", "Pain relieved by Leaning Forward", "ST Elevation is diffuse (all leads)", "ST Elevation is localized (Coronary territory)", "Radiation to left arm/jaw"], "columns": ["Pericarditis", "Myocardial Infarction"], "answer": {"Pain relieved by Nitroglycerin": "Myocardial Infarction", "Pain relieved by Leaning Forward": "Pericarditis", "ST Elevation is diffuse (all leads)": "Pericarditis", "ST Elevation is localized (Coronary territory)": "Myocardial Infarction", "Radiation to left arm/jaw": "Myocardial Infarction"}, "rationale": "Pericarditis pain is positional and pleuritic (inflammatory). MI pain is ischemic and often radiates. Diffuse vs Localized ST elevation is the key EKG discriminator."}, {"type": "extended_sata", "prompt": "Which medications does the nurse anticipate administering? Select all that apply.", "options": ["Ibuprofen 600mg PO TID", "Colchicine 0.6mg PO BID", "Prednisone 40mg PO Daily", "Morphine 2mg IV Push", "Heparin Drip"], "answer": [0, 1], "rationale": "High dose NSAIDs (Ibuprofen/Aspirin) are first line. Colchicine is added to reduce recurrence. Steroids (Prednisone) are second-line as they increase recurrence risk. Anticoagulants (Heparin) are contraindicated due to risk of hemopericardium (bleeding into the sac)."}, {"type": "bowtie", "prompt": "The patient suddenly develops jugular venous distention, muffled heart sounds, and hypotension. Prioritize the complication.", "center_condition": {"options": ["Cardiac Tamponade", "Septic Shock", "Tension Pneumothorax", "Papillary Muscle Rupture"], "answer": "Cardiac Tamponade"}, "left_actions": {"options": ["Prepare for Pericardiocentesis", "Start Dopamine Infusion", "Administer IV Fluid Bolus", "Needle Decompression", "Chest Tube Insertion"], "answer": ["Prepare for Pericardiocentesis", "Administer IV Fluid Bolus"]}, "right_monitor": {"options": ["Pulsus Paradoxus", "Urine Output", "Temperature", "Blood Cultures", "Pedal Edema"], "answer": ["Pulsus Paradoxus", "Urine Output"]}, "rationale": "Beck's Triad (JVD, Muffled Sounds, Hypotension) confirms Tamponade. The fluid compresses the heart. Pericardiocentesis (draining the fluid) is the cure. IV fluids maximize preload to maintain output temporarily. Pulsus Paradoxus (drop in SBP > 10 during inspiration) is the classic sign."}]}, {"id": "M-011", "type": "mission", "numerical_id": 11, "title": "The Silent Squeeze: NSTEMI", "category": "Cardiovascular / Ischemic", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Robert De Niro (Character actor)", "age": 72, "gender": "Male", "mrn": "1111-RD", "dob": "08/17/1954", "weight": "88 kg", "height": "177 cm", "allergies": "Aspirin (GI Upset - Not Anaphylaxis)"}, "chief_complaint": "Indigestion and jaw pain.", "hpi": "Mr. De Niro presents with burning epigastric pain and aching in his jaw that started after a heavy meal. He took Tums with no relief. He denies 'crushing' chest pain but feels nauseous and sweaty.", "pmh": "Type 2 Diabetes, Hypertension, Smoker (30 pack years).", "ros": {"cardio": "HR 90, BP 150/92. Regular rhythm.", "gi": "Epigastric tenderness.", "gen": "Diaphoretic, pale.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Office manager. Married with 2 children. Nonsmoker. Denies alcohol use."}, "exhibits": [{"title": "ECG (12-Lead)", "type": "text", "content": "Sinus Rhythm. ST-segment depression in leads V4-V6. T-wave inversion in II, III, aVF. (No ST Elevation)."}, {"title": "Troponin I", "type": "table", "data": [{"lab": "0 Hour", "val": "0.02 ng/mL", "status": "Negative"}, {"lab": "3 Hour", "val": "1.50 ng/mL", "status": "Critical High"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Differentiate NSTEMI from STEMI and Unstable Angina based on the findings.", "rows": ["Elevated Troponin", "ST-Segment Elevation", "ST-Segment Depression / T-wave Inversion", "Chest Pain at Rest", "Full Thickness Myocardial Damage"], "columns": ["NSTEMI", "STEMI", "Unstable Angina"], "answer": {"Elevated Troponin": "NSTEMI", "ST-Segment Elevation": "STEMI", "ST-Segment Depression / T-wave Inversion": "NSTEMI", "Chest Pain at Rest": "NSTEMI", "Full Thickness Myocardial Damage": "STEMI"}, "rationale": "NSTEMI and STEMI both have positive troponins (cell death). STEMI has ST Elevation (full thickness blockage). NSTEMI has Depression/Inversion (partial blockage). Unstable Angina has pain but NEGATIVE troponins."}, {"type": "extended_sata", "prompt": "The patient has an allergy to Aspirin (GI Upset). Which actions are appropriate? Select all that apply.", "options": ["Administer Aspirin 325mg anyway (Benefits outweigh risk)", "Administer Clopidogrel (Plavix) as alternative", "Administer Heparin Drip", "Administer Nitroglycerin SL", "Hold all antiplatelets", "Pre-medicate with Famotidine (Pepcid) and give Aspirin"], "answer": [0, 1], "rationale": "GI Upset is an intolerance, not anaphylaxis, but typically if severe, we switch to Plavix (Clopidogrel). Heparin prevents clot growth. Nitro dilates coronaries. We generally don't force Aspirin if the patient reports bad reactions unless the provider overrides."}, {"type": "bowtie", "prompt": "The patient's pain increases to 10/10 despite 3 nitroglycerins. BP drops to 88/50. Prioritize.", "center_condition": {"options": ["Cardiogenic Shock", "Right Ventricular Infarction", "Gastric Ulcer Perforation", "Vasovagal Response"], "answer": "Right Ventricular Infarction"}, "left_actions": {"options": ["Administer IV Fluid Bolus", "Administer Nitroglycerin", "Administer Morphine", "Obtain Right-Sided ECG", "Dim the room lights"], "answer": ["Administer IV Fluid Bolus", "Obtain Right-Sided ECG"]}, "right_monitor": {"options": ["BP Response to Fluids", "Jugular Venous Distention", "Abdominal Girth", "Pupils", "Hand Grip Strength"], "answer": ["BP Response to Fluids", "Jugular Venous Distention"]}, "rationale": "Inferior/Posterior mis (leads II, III, aVF) often involve the Right Ventricle. RV infarcts are PRELOAD DEPENDENT. Nitro drops preload and causes hypotension. The treatment is FLUIDS to push blood through the right side."}]}, {"id": "M-012", "type": "mission", "numerical_id": 12, "title": "Disconnected: Complete Heart Block", "category": "Cardiovascular / Electrical", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Eleanor Rigby", "age": 82, "gender": "Female", "mrn": "1212-ER", "dob": "11/11/1944", "weight": "55 kg", "height": "160 cm", "allergies": "NKDA"}, "chief_complaint": "Dizziness and near-syncope.", "hpi": "Ms. Rigby felt deeply dizzy while picking up rice in the church. She had to sit down to avoid fainting. She reports generalized fatigue for a week.", "pmh": "Lyme Disease (History of), Hypothyroidism.", "ros": {"cardio": "Bradycardia. HR 34 bpm. BP 90/50.", "neuro": "Confused, slow to respond.", "gen": "Pale, cool extremities.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Retired veteran. Lives in assisted living. Former smoker (quit 20 years ago)."}, "exhibits": [{"title": "ECG Strip", "type": "text", "content": "<strong>Rate:</strong> Atrial 80 bpm, Ventricular 34 bpm.<br><strong>Rhythm:</strong> P waves regular. QRS complexes regular. <strong>NO association</strong> between P and QRS. (P waves march through QRS)."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Identify the type of AV Block based on the description.", "rows": ["PR interval constant, dropping QRS occasionally", "PR interval lengthens until QRS drops", "Complete dissociation of P and QRS", "PR interval > 0.20s, no dropped beats", "Ventricular rate approx 20-40 bpm"], "columns": ["1st Degree", "2nd Degree Type I (Wenckebach)", "2nd Degree Type II", "3rd Degree (Complete)"], "answer": {"PR interval constant, dropping QRS occasionally": "2nd Degree Type II", "PR interval lengthens until QRS drops": "2nd Degree Type I (Wenckebach)", "Complete dissociation of P and QRS": "3rd Degree (Complete)", "PR interval > 0.20s, no dropped beats": "1st Degree", "Ventricular rate approx 20-40 bpm": "3rd Degree (Complete)"}, "rationale": "3rd degree block is a complete divorce between Atria and Ventricles. The ventricles rely on a slow escape rhythm (20-40 bpm). Wenckebach gives a warning (lengthening PR). Type II drops without warning."}, {"type": "extended_sata", "prompt": "The nurse acts on the bradycardia. Which interventions are indicated? Select all that apply.", "options": ["Apply Transcutaneous Pacing Pads", "Administer Atropine 1mg IV", "Administer Adenosine 6mg IP", "Prepare for Transvenous Pacer insertion", "Start Dopamine infusion", "Administer Metoprolol"], "answer": [0, 1], "rationale": "Pacing is the definitive treatment for 3rd degree block. Atropine *may* be tried but often fails in high blocks. Dopamine increases heart rate/BP. Adenosine/Metoprolol slow the heart further and are CONTRAINDICATED."}, {"type": "bowtie", "prompt": "Ms. Rigby becomes unresponsive. No palpable pulse. Monitor shows the same rhythm (PEA). Prioritize.", "center_condition": {"options": ["Pulseless Electrical Activity (PEA)", "Asystole", "Ventricular Fibrillation", "Stroke"], "answer": "Pulseless Electrical Activity (PEA)"}, "left_actions": {"options": ["Start CPR", "Defibrillate (Shock) 200J", "Administer Epinephrine 1mg", "Check H's and T's", "Give Atropine"], "answer": ["Start CPR", "Administer Epinephrine 1mg"]}, "right_monitor": {"options": ["Rhythm Check q2 mins", "End-Tidal CO2", "Pupils", "Temperature", "Blood Glucose"], "answer": ["Rhythm Check q2 mins", "End-Tidal CO2"]}, "rationale": "PEA is a rhythm on the monitor but NO pulse. You CANNOT shock PEA. You must do CPR and give Epi. H's and T's (Hypovolemia, Hypoxia, etc.) must be ruled out."}]}, {"id": "M-013", "type": "mission", "numerical_id": 13, "title": "The Leaky Valve: Mitral Regurgitation", "category": "Cardiovascular / Structural", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Tom Jones", "age": 65, "gender": "Male", "mrn": "1313-TJ", "dob": "06/07/1961", "weight": "90 kg", "height": "175 cm", "allergies": "Sulfa"}, "chief_complaint": "Shortness of breath and fatigue.", "hpi": "Mr. Jones reports he gets winded walking to the mailbox. He used to sing powerfully but now lacks the breath. He has a history of Rheumatic Fever as a child.", "pmh": "Rheumatic Heart Disease, Atrial Fibrillation.", "ros": {"cardio": "Holosystolic murmur heard best at Apex, radiating to Axilla.", "resp": "Bibasilar crackles.", "gen": "1+ Pitting edema.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Librarian. Lives with 3 cats. Nonsmoker. Occasional glass of wine."}, "exhibits": [{"title": "Echocardiogram", "type": "text", "content": "Severe Mitral Regurgitation. Regurgitant fraction 55%. Dilated Left Atrium. LVEF 45%."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Correlate the pathophysiology of Mitral Regurgitation with the clinical findings.", "rows": ["Blood flows backward from LV to LA", "Increased pressure in Pulmonary Veins", "Dilation of Left Atrium", "Decreased Cardiac Output"], "columns": ["Cause of Murmur", "Cause of Dyspnea/Crackles", "Risk for AFib", "Cause of Fatigue"], "answer": {"Blood flows backward from LV to LA": "Cause of Murmur", "Increased pressure in Pulmonary Veins": "Cause of Dyspnea/Crackles", "Dilation of Left Atrium": "Risk for AFib", "Decreased Cardiac Output": "Cause of Fatigue"}, "rationale": "The leak (murmur) causes backflow into the LA, which backs up into lungs (dyspnea). The stretched LA disrupts electrical pathways (AFib). The forward flow is reduced (Fatigue)."}, {"type": "extended_sata", "prompt": "Mr. Jones is scheduled for Mitral Valve Repair. Which pre-op orders are appropriate? Select all that apply.", "options": ["Administer Furosemide (Lasix) for fluid overload", "Administer Warfarin (Coumadin) for AFib", "Start IV Antibiotics (Prophylaxis)", "Encourage high sodium diet", "Dental clearance exam", "Discontinue all beta blockers"], "answer": [0, 1], "rationale": "Diuretics manage the heart failure symptoms. Anticoagulation prevents stroke from AFib. Dental clearance is MANDATORY before valve surgery to prevent Endocarditis from oral bacteria. Antibiotics are given *intra-op*, not days before."}, {"type": "bowtie", "prompt": "Post-op, Mr. Jones has a mechanical valve. He asks about his lifestyle. Prioritize the education.", "center_condition": {"options": ["Mechanical Valve Management", "Bioprosthetic Valve Management", "Heart Transplant", "Pacemaker Care"], "answer": "Mechanical Valve Management"}, "left_actions": {"options": ["Lifelong Warfarin Therapy", "Aspirin only", "Antibiotic Prophylaxis for dental work", "Avoid leafy greens completely", "No MRI scans allowed"], "answer": ["Lifelong Warfarin Therapy", "Antibiotic Prophylaxis for dental work"]}, "right_monitor": {"options": ["INR 2.5 - 3.5", "INR 1.0", "Clicking sound (Normal)", "Resting HR < 60", "Daily weight"], "answer": ["INR 2.5 - 3.5", "Clicking sound (Normal)"]}, "rationale": "Mechanical valves last forever but clot easily. They require LIFELONG Warfarin with a higher INR target (2.5-3.5). The valve makes a distinct 'clicking' sound. Antibiotic prophylaxis is needed for invasive procedures."}]}, {"id": "M-014", "type": "mission", "numerical_id": 14, "title": "The Ticking Time Bomb: AAA", "category": "Cardiovascular / Vascular", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "Clint Eastwood (Tough guy)", "age": 88, "gender": "Male", "mrn": "1414-CE", "dob": "05/31/1938", "weight": "80 kg", "height": "188 cm", "allergies": "Contrast Dye"}, "chief_complaint": "Constant gnawing back pain.", "hpi": "Mr. Eastwood complains of a dull ache in his lower back and abdomen that is not affected by movement. He says he feels 'a heartbeat in his stomach'.", "pmh": "Smoker (50 pack years), Hypertension, CAD.", "ros": {"gi": "Pulsatile mass palpable in periumbilical area.", "cardio": "Bruit heard over abdominal aorta. BP 170/90.", "neuro": "Intact. No leg weakness.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Nursing home resident. Widowed. Assistance required for ADLs."}, "exhibits": [{"title": "Ultrasound Abdomen", "type": "text", "content": "Fusiform aneurysm of the abdominal aorta measuring 5.8 cm in diameter."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "The nurse assesses the patient. Identify signs of Rupture vs Stable Aneurysm.", "rows": ["Pulsatile abdominal mass", "Sudden severe back/flank pain", "Hypotension / Tachycardia", "Systolic Bruit", "Grey Turner's Sign (Flank Ecchymosis)"], "columns": ["Stable / Intact AAA", "Ruptured AAA / Emergency"], "answer": {"Pulsatile abdominal mass": "Stable / Intact AAA", "Sudden severe back/flank pain": "Ruptured AAA / Emergency", "Hypotension / Tachycardia": "Ruptured AAA / Emergency", "Systolic Bruit": "Stable / Intact AAA", "Grey Turner's Sign (Flank Ecchymosis)": "Ruptured AAA / Emergency"}, "rationale": "A stable AAA presents with a mass and bruit. Rupture causes massive internal bleeding -> Shock (Low BP, High HR), severe tearing pain, and bruising on the flanks (Grey Turner's)."}, {"type": "extended_sata", "prompt": "The AAA is 5.8 cm (surgical threshold). Mr. Eastwood is pre-op. What are the priority actions? Select all that apply.", "options": ["Control Blood Pressure (Keep SBP < 120)", "Administer IV fluids bolus to increase pressure", "Palpate the mass deeply to assess size", "Assess peripheral pulses (Femoral, Popliteal, Pedal)", "Keep patient calm / strict bedrest", "Screen for renal function (Creatinine)"], "answer": [0, 1], "rationale": "Priority #1: Prevent rupture by lowering BP (Anti-impulse therapy). DEEP PALPATION IS CONTRAINDICATED (can rupture it). Pulses establish a baseline. Renal function is key as the repair involves clamping above renal arteries."}, {"type": "bowtie", "prompt": "Post-EVAR (Endovascular Repair), the patient's urine output drops to 10ml/hr and BP rises to 190/100. Prioritize.", "center_condition": {"options": ["Graft Migration / Renal Occlusion", "Dehydration", "Post-op Pain", "Infection"], "answer": "Graft Migration / Renal Occlusion"}, "left_actions": {"options": ["Notify Surgeon Immediately", "Fluid Bolus", "Administer IV Labetalol", "Bladder Scan", "Check Pedal Pulses"], "answer": ["Notify Surgeon Immediately", "Administer IV Labetalol"]}, "right_monitor": {"options": ["Serum Creatinine", "WBC Count", "Pedal Pulses", "Pain Score", "Oxygen Saturation"], "answer": ["Serum Creatinine", "Pedal Pulses"]}, "rationale": "A sudden drop in urine output post-AAA repair suggests the stent graft may have migrated and covered the renal arteries. This is a SURGICAL EMERGENCY. High BP puts stress on the graft site and must be controlled (Labetalol). Creatinine confirms renal hit."}]}, {"id": "M-015", "type": "mission", "numerical_id": 15, "title": "The Spiked T-Wave: Hyperkalemia", "category": "Cardiovascular / Electrolyte", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "Banana Man", "age": 45, "gender": "Male", "mrn": "1515-BM", "dob": "12/12/1980", "weight": "80 kg", "height": "180 cm", "allergies": "NKDA"}, "chief_complaint": "Weakness and palpitations.", "hpi": "Patient with End Stage Renal Disease (ESRD) missed dialysis yesterday. He reports feeling 'heavy' in his legs and having a fluttering chest.", "pmh": "ESRD, Hypertension.", "ros": {"cardio": "Irregular rhythm. HR 50.", "neuro": "Muscle weakness, paresthesias.", "gi": "Nausea.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Chef. High sodium diet. Smokes cigars occasionally. Social drinker."}, "exhibits": [{"title": "ECG", "type": "text", "content": "Tall, peaked T-waves. Widened QRS complex. Provisid Prolonged PR interval."}, {"title": "Chemistry", "type": "table", "data": [{"lab": "Potassium", "val": "7.2 mEq/L", "status": "Critical High"}, {"lab": "Creatinine", "val": "6.5 mg/dL", "status": "High (Baseline)"}, {"lab": "Sodium", "val": "135 mEq/L", "status": "Normal"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Prioritize the medications for Hyperkalemia based on their mechanism of action.", "rows": ["Calcium Gluconate", "Regular Insulin IV + Dextrose", "Albuterol Nebulizer", "Sodium Polystyrene Sulfonate (Kayexalate)", "Furosemide (Lasix)"], "columns": ["Stabilize Cardiac Membrane (Immediate Protection)", "Shift K+ Into Cells (Temporary)", "Excrete K+ from Body (Permanent)"], "answer": {"Calcium Gluconate": "Stabilize Cardiac Membrane (Immediate Protection)", "Regular Insulin IV + Dextrose": "Shift K+ Into Cells (Temporary)", "Albuterol Nebulizer": "Shift K+ Into Cells (Temporary)", "Sodium Polystyrene Sulfonate (Kayexalate)": "Excrete K+ from Body (Permanent)", "Furosemide (Lasix)": "Excrete K+ from Body (Permanent)"}, "rationale": "Remember 'C Big K Drop'. Calcium protects the heart (FIRST priority if EKG changes). Insulin/Albuterol hide K+ in the cell. Kayexalate/Lasix/Dialysis actually remove it."}, {"type": "extended_sata", "prompt": "The nurse prepares the Insulin/Dextrose cocktail. Which safety checks are required? Select all that apply.", "options": ["Verify Regular Insulin (Not NPH/Lantus)", "Check Blood Glucose prior to administration", "Administer via central line only", "Push Dextrose slowly to avoid vein irritation", "Monitor BG every hour after administration", "Give Insulin first, then wait 30 mins for Dextrose"], "answer": [0, 1], "rationale": "Only Regular insulin can be given IV. Dextrose is given WITH insulin to prevent hypoglycemia. Vein irritation is common with D50. Hypoglycemia is the main risk, so hourly checks are mandatory."}, {"type": "bowtie", "prompt": "Despite meds, the QRS widens to 0.20s and heart rate drops to 30. Patient loses consciousness. Prioritize.", "center_condition": {"options": ["Cardiac Arrest (V-Fib/Asystole)", "Hypoglycemia", "Stroke", "Seizure"], "answer": "Cardiac Arrest (V-Fib/Asystole)"}, "left_actions": {"options": ["Start CPR", "Emergency Dialysis", "Give more Calcium", "Intubate", "Pronounce Death"], "answer": ["Start CPR", "Emergency Dialysis"]}, "right_monitor": {"options": ["Pulse Check", "Capnography", "Potassium Level", "Pupils", "Urine Output"], "answer": ["Pulse Check", "Potassium Level"]}, "rationale": "Widening QRS signals impending sine-wave and asystole. Meds failed. CRP keeps him alive until Dialysis (the only thing that will pull the K+ fast enough) can be started. This is a Code Blue situation."}]}, {"id": "M-016", "type": "mission", "numerical_id": 16, "title": "The Failing Pump: Cardiogenic Shock", "category": "Cardiovascular / Shock", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "Arthur Dent", "age": 58, "gender": "Male", "mrn": "1616-AD", "dob": "03/11/1968", "weight": "95 kg", "height": "180 cm", "allergies": "Penicillin"}, "chief_complaint": "Post-MI confusion and cold skin.", "hpi": "Mr. Dent had a massive Anterior MI 2 days ago. He was stable initially but the nurse now finds him confused, with cold/clammy skin and decreased urine output.", "pmh": "STEMI (2 days ago), Hyperlipidemia.", "ros": {"cardio": "HR 110 (Sinus Tach). BP 80/50.", "resp": "Crackles halfway up lung fields.", "gen": "Skin cool, mottled knees.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Chef. High sodium diet. Smokes cigars occasionally. Social drinker."}, "exhibits": [{"title": "Hemodynamics", "type": "table", "data": [{"param": "Cardiac Index", "val": "1.8 L/min/m2", "status": "Low (< 2.2)"}, {"param": "PCWP (Wedge)", "val": "25 mmHg", "status": "High (> 18)"}, {"param": "SVR", "val": "2200", "status": "High (Vasoconstricted)"}], "content": "Information not available"}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Distinguish Cardiogenic Shock from Hypovolemic Shock based on the findings.", "rows": ["Low Blood Pressure", "High Heart Rate", "Pulmonary Crackles / High PCWP", "Flat Jugular Veins", "Cold/Clammy Skin"], "columns": ["Cardiogenic Shock", "Hypovolemic Shock", "Both"], "answer": {"Low Blood Pressure": "Both", "High Heart Rate": "Both", "Pulmonary Crackles / High PCWP": "Cardiogenic Shock", "Flat Jugular Veins": "Hypovolemic Shock", "Cold/Clammy Skin": "Both"}, "rationale": "Both shocks cause low BP/high HR/cold skin. The differentiator is FLUID STATUS. Cardiogenic is WET (Crackles, High Wedge). Hypovolemic is DRY (Flat veins, Low Wedge)."}, {"type": "extended_sata", "prompt": "The provider orders Dobutamine. Which actions are consistent with this therapy? Select all that apply.", "options": ["Monitor for ventricular arrhythmias (PVCs/VT)", "Titrate to keep SBP > 90 mmHg", "Expect a decrease in cardiac contractility", "Administer via central line if possible", "Give with Beta Bockers to prevent tachycardia"], "answer": [0, 1], "rationale": "Dobutamine is an inotrope (squeuzer). It INCREASES contractility but can irritate the heart (arrhythmias). It is a vesicant (central line preferred). Beta blockers would oppose its effect."}, {"type": "bowtie", "prompt": "Despite Dobutamine, BP drops to 70/40. The patient is obtunded. Prioritize the next level of support.", "center_condition": {"options": ["Refractory Cardiogenic Shock", "Septic Shock", "Anaphylaxis", "Stroke"], "answer": "Refractory Cardiogenic Shock"}, "left_actions": {"options": ["Prepare for Intra-Aortic Balloon Pump (IABP)", "Give 2L Fluid Bolus", "Start CPR", "Administer Epinephrine", "Give Lasix"], "answer": ["Prepare for Intra-Aortic Balloon Pump (IABP)", "Administer Epinephrine"]}, "right_monitor": {"options": ["Pedal Pulses (Limb Ischemia)", "Pupils", "Bowel Sounds", "WBC Count", "Temperature"], "answer": ["Pedal Pulses (Limb Ischemia)", "Bowel Sounds"]}, "rationale": "Medical management failed. The heart needs mechanical help. IABP reduces afterload and increases coronary perfusion. Fluids kill this patient (lungs are full). Epi (Levophed preferred) may be needed for severe hypotension. IABP carries risk of limb ischemia."}]}, {"id": "M-017", "type": "mission", "numerical_id": 17, "title": "The Painful Walk: PAD", "category": "Cardiovascular / Vascular", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Walker Texas Ranger", "age": 62, "gender": "Male", "mrn": "1717-CR", "dob": "03/10/1964", "weight": "85 kg", "height": "180 cm", "allergies": "NKDA"}, "chief_complaint": "Leg pain when walking.", "hpi": "Mr. Ranger reports 'burning' in his calves when he walks more than 1 block. The pain stops exactly 2 minutes after he sits down (Intermittent Claudication).", "pmh": "High Cholesterol, Smoker.", "ros": {"musc": "Calf atrophy.", "skin": "Legs are shiny, hairless, and cool to touch. Toenails are thickened.", "cardio": "Pedal pulses 1+ (Weak).", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Librarian. Lives with 3 cats. Nonsmoker. Occasional glass of wine."}, "exhibits": [{"title": "Ankle-Brachial Index (ABI)", "type": "text", "content": "<strong>Right Leg:</strong> 0.65<br><strong>Left Leg:</strong> 0.70<br>(Normal 0.9 - 1.3. < 0.9 indicates PAD)."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Detailed assessment of the legs. Classify findings as Arterial (PAD) or Venous (PVD).", "rows": ["Pain worsens with elevation", "Pain improves with elevation", "Skin is cool/pale", "Skin is warm/brown/edematous", "Ulcers on toes (punched out)", "Ulcers on ankles (irregular borders)"], "columns": ["Peripheral Arterial Disease (PAD)", "Peripheral Venous Disease (PVD)"], "answer": {"Pain worsens with elevation": "Peripheral Arterial Disease (PAD)", "Pain improves with elevation": "Peripheral Venous Disease (PVD)", "Skin is cool/pale": "Peripheral Arterial Disease (PAD)", "Skin is warm/brown/edematous": "Peripheral Venous Disease (PVD)", "Ulcers on toes (punched out)": "Peripheral Arterial Disease (PAD)", "Ulcers on ankles (irregular borders)": "Peripheral Venous Disease (PVD)"}, "rationale": "Arterial = Problem getting blood DOWN (Gravity helps, Elevation hurts). Venous = Problem getting blood UP (Elevation helps, Gravity hurts)."}, {"type": "extended_sata", "prompt": "Which instructions are appropriate for Mr. Ranger? Select all that apply.", "options": ["Apply heating pads to feet for warmth", "Walk until pain starts, rest, then walk again", "Monitor feet daily for injuries/sores", "Wear compression stockings", "Avoid crossing legs", "Smoking cessation is critical"], "answer": [0, 1], "rationale": "Heating pads are dangerous due to decreased sensation (burn risk). Compression stockings constrict arteries further (contraindicated in PAD, good for Venous). Walking builds collateral circulation. Crossing legs obstructs flow."}, {"type": "bowtie", "prompt": "Mr. Ranger calls reporting his right foot is suddenly cold, numb, and 'white'. He cannot move his toes. Prioritize.", "center_condition": {"options": ["Acute Arterial Occlusion", "Deep Vein Thrombosis", "Cellulitis", "Gout"], "answer": "Acute Arterial Occlusion"}, "left_actions": {"options": ["Prepare for Embolectomy/Thrombolysis", "Apply warm compress", "Elevate the leg", "Administer NSAIDs", "Consult Social Work"], "answer": ["Prepare for Embolectomy/Thrombolysis"]}, "right_monitor": {"options": ["The 6 P's (Pain, Pallor, Pulselessness...)", "INR", "WBC", "Uric Acid", "Oral Mucosa moisture"], "answer": ["The 6 P's (Pain, Pallor, Pulselessness...)"]}, "rationale": "This is the '6 P's' emergency. A clot has completely blocked the artery. The limb will die in hours without blood. Immediate surgical (embolectomy) or medical (TPA) intervention is needed. Elevation makes ischemia WORSE."}]}, {"id": "M-018", "type": "mission", "numerical_id": 18, "title": "Cold Hands: Buerger's & Raynaud's", "category": "Cardiovascular / Vascular", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Frosty Snow", "age": 30, "gender": "Male", "mrn": "1818-FS", "dob": "12/25/1995", "weight": "70 kg", "height": "175 cm", "allergies": "NKDA"}, "chief_complaint": "Fingertips turning black and painful.", "hpi": "Mr. Snow is a heavy smoker. He reports his fingers turn white, then blue, then red when he goes outside. Recently, he developed small ulcers on his fingertips that won't heal.", "pmh": "Smoker (2 packs/day since age 15).", "ros": {"skin": "Gangrenous updates on right index and middle fingertips.", "cardio": "Radial pulses palpable. Ulnar pulses weak.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Nursing home resident. Widowed. Assistance required for ADLs."}, "exhibits": [{"title": "Angiogram", "type": "text", "content": "Corkscrew collateral vessels in the hands (Pathognomonic for Buerger's Disease)."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Compare Raynaud's Phenomenon vs Buerger's Disease (Thromboangiitis Obliterans).", "rows": ["Review of Systems: Vasospasm triggered by cold/stress", "Review of Systems: Inflammation/Clotting of small vessels", "Strongly associated with Autoimmune (Lupus)", "Strongly associated with Smoking", "Can lead to amputation"], "columns": ["Raynaud's", "Buerger's", "Both"], "answer": {"Review of Systems: Vasospasm triggered by cold/stress": "Both", "Review of Systems: Inflammation/Clotting of small vessels": "Buerger's", "Strongly associated with Autoimmune (Lupus)": "Raynaud's", "Strongly associated with Smoking": "Buerger's", "Can lead to amputation": "Buerger's"}, "rationale": "Raynaud's is a functional spasm (rarely causes tissue loss unless severe). Buerger's is an inflammatory clotting disease EXCLUSIVELY linked to smoking that destroys distal vessels."}, {"type": "extended_sata", "prompt": "The patient asks how to save his fingers. Which instructions are valid? Select all that apply.", "options": ["You MUST stop smoking completely (even patches/gum are bad)", "Wear gloves when reaching into the freezer", "Move to a warmer climate", "Use caffeine to stimulate circulation", "Stress management techniques", "Take Calcium Channel Blockers (Nifedipine) as prescribed"], "answer": [0, 1], "rationale": "For Buerger's, total nicotine cessation is the ONLY cure. Even NRT (patches) can perpetuate it. Caffeine is a vasoconstrictor (avoid!). CCBs prevent vasospasm."}, {"type": "bowtie", "prompt": "Mr. Snow presents with throbbing pain in his hand. The finger is black and smells foul. Prioritize.", "center_condition": {"options": ["Wet Gangrene", "Dry Gangrene", "Paronychia", "Contact Dermatitis"], "answer": "Wet Gangrene"}, "left_actions": {"options": ["Prepare for Amputation", "Administer IV Antibiotics", "Apply heat", "Start Heparin", "Soak in water"], "answer": ["Prepare for Amputation", "Administer IV Antibiotics"]}, "right_monitor": {"options": ["Sepsis signs (Fever, BP)", "Finger movement", "Pain scale", "Cholesterol", "Capillary Refill"], "answer": ["Sepsis signs (Fever, BP)"]}, "rationale": "Wet gangrene (foul smell, black) implies infection on top of dead tissue. This is a sepsis risk. The dead tissue must be removed (amputation). Antibiotics cover the infection."}]}, {"id": "M-019", "type": "mission", "numerical_id": 19, "title": "The Tearing Pain: Aortic Dissection", "category": "Cardiovascular / Emergency", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "Dr. Strange (Surgeon)", "age": 50, "gender": "Male", "mrn": "1919-DS", "dob": "11/11/1976", "weight": "80 kg", "height": "185 cm", "allergies": "NKDA"}, "chief_complaint": "Sudden onset 'tearing' chest pain radiating to back.", "hpi": "Patient was lifting weights when he felt a 'rip' in his chest that shot between his shoulder blades. Pain is 10/10.", "pmh": "Marfan Syndrome, Hypertension.", "ros": {"cardio": "BP Right Arm: 190/100. BP Left Arm: 140/80. (Pulse Deficit).", "neuro": " numbness in left hand.", "gen": "Diaphoretic, anxious.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Truck driver. Divorced. Smokes 2 packs/day. Sedentary lifestyle."}, "exhibits": [{"title": "Chest CT Angio", "type": "text", "content": "Type A Dissection (Ascending Aorta) extending to the arch. False lumen visualized."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Compare Myocardial Infarction vs Aortic Dissection presentation.", "rows": ["Pain Description: 'Crushing / Elephant on chest'", "Pain Description: 'Tearing / Ripping / Shearing'", "Radiation to Jaw/Arm", "Radiation to Back/Scapula", "BP asymmetry (>20mmHg difference between arms)"], "columns": ["Myocardial Infarction", "Aortic Dissection"], "answer": {"Pain Description: 'Crushing / Elephant on chest'": "Myocardial Infarction", "Pain Description: 'Tearing / Ripping / Shearing'": "Aortic Dissection", "Radiation to Jaw/Arm": "Myocardial Infarction", "Radiation to Back/Scapula": "Aortic Dissection", "BP asymmetry (>20mmHg difference between arms)": "Aortic Dissection"}, "rationale": "The hallmark of dissection is 'tearing' pain to the back and unequal BPs (because the tear blocks flow to one subclavian artery)."}, {"type": "extended_sata", "prompt": "The diagnosis is Type A Dissection (Surgical Emergency). While waiting for the OR, what are the nursing priorities? Select all that apply.", "options": ["Administer IV Esmolol (Beta Blocker)", "Administer IV Nitroprusside (Vasodilator)", "Maintain SBP 100-110 mmHg", "Maintain HR < 60 bpm", "Start Heparin Drip", "Encourage patient to bear down"], "answer": [0, 1], "rationale": "We must reduce shear stress (dP/dt). Beta blockers (Esmolol) are given FIRST to lower heart rate. Then Vasodilators (Nitroprusside) to lower BP. If you give Nitro first, reflex tachycardia will tear the aorta further. Heparin causes fatal bleeding."}, {"type": "bowtie", "prompt": "Suddenly, BP drops to 60/40, JVD appears, and heart sounds become muffled. Prioritize.", "center_condition": {"options": ["Cardiac Tamponade (Rupture)", "Stroke", "Spinal Ischemia", "Panic Attack"], "answer": "Cardiac Tamponade (Rupture)"}, "left_actions": {"options": ["Rapid Transfusion Protocol", "Immediate Thoracotomy / Pericardiocentesis", "Give Aspirin", "Start CPR", "Offer ice chips"], "answer": ["Immediate Thoracotomy / Pericardiocentesis"]}, "right_monitor": {"options": ["ECG voltage (Electrical Alternans)", "Pupins", "Urine Output", "Pedal Pulses", "Deep Tendon Reflexes"], "answer": ["ECG voltage (Electrical Alternans)"]}, "rationale": "The dissection has ruptured retrograde into the pericardium (Tamponade). This is usually fatal without instant drainage/repair. Beck's triad (JVD, Hypotension, Muffled sounds) is the key."}]}, {"id": "M-020", "type": "mission", "numerical_id": 20, "title": "The Vegetation: Infective Endocarditis", "category": "Cardiovascular / Inflammatory", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Johnny Rotten (Punk rocker)", "age": 28, "gender": "Male", "mrn": "2020-JR", "dob": "01/31/1998", "weight": "65 kg", "height": "175 cm", "allergies": "NKDA"}, "chief_complaint": "Fevers and fatigue.", "hpi": "Patient reports 2 weeks of high fevers, night sweats, and joint pain. He admits to IV drug use (Heroin).", "pmh": "IV Drug Abuse, Hepatitis C.", "ros": {"cardio": "New Systolic Murmur (Tricuspid Regurgitation).", "skin": "Splinter hemorrhages under fingernails. Painful red nodes on fingers (Osler's Nodes). Painless spots on palms (Janeway Lesions).", "eye": "Roth Spots on retina.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Retired veteran. Lives in assisted living. Former smoker (quit 20 years ago)."}, "exhibits": [{"title": "Blood Cultures", "type": "text", "content": "Positive for Staphylococcus Aureus (MRSA) in 2/2 bottles."}, {"title": "Echocardiogram", "type": "text", "content": "Large mobile vegetation (1.2 cm) on the Tricuspid Valve."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Match the dermatological sign to its description.", "rows": ["Painful, raised red nodes on finger pads", "Painless flat red spots on palms/soles", "Linear dark streaks under fingernails", "Retinal hemorrhages with pale centers"], "columns": ["Osler's Nodes", "Janeway Lesions", "Splinter Hemorrhages", "Roth Spots"], "answer": {"Painful, raised red nodes on finger pads": "Osler's Nodes", "Painless flat red spots on palms/soles": "Janeway Lesions", "Linear dark streaks under fingernails": "Splinter Hemorrhages", "Retinal hemorrhages with pale centers": "Roth Spots"}, "rationale": "Oslers = Ouch (Painful/Immune complex). Janeway = Painless (Embolic). Splinter = Embolic. Roth = Embolic/Immunologic."}, {"type": "extended_sata", "prompt": "Which orders are priority for this patient? Select all that apply.", "options": ["Start IV Vancomycin (after cultures)", "Start IV Penicillin G", "Consult Cardiac Surgery", "Monitor for signs of Pulmonary Embolism", "Monitor for signs of Stroke", "Place PICC Line for long-term antibiotics"], "answer": [0, 1], "rationale": "MRSA requires Vancomycin. Tricuspid vegetations embolize to the LUNGS (PE), not the brain (Stroke), because it's on the right side. Surgery consult is needed for large vegetations. Treatment is 4-6 weeks, so a PICC is needed (though risky in IVDA, it's necessary)."}, {"type": "bowtie", "prompt": "Patient develops sudden shortness of breath and pleuritic chest pain. SpO2 drops to 88%. Prioritize.", "center_condition": {"options": ["Septic Emboli to Lungs (PE)", "Pneumonia", "Stroke", "MI"], "answer": "Septic Emboli to Lungs (PE)"}, "left_actions": {"options": ["Administer Oxygen", "Prepare for Heparin", "Start Chest PT", "Give Nitroglycerin", "Offer ice chips"], "answer": ["Administer Oxygen"]}, "right_monitor": {"options": ["Respiratory Rate", "INR", "Neuro Checks", "IV Site", "Respiratory effort"], "answer": ["Respiratory Rate"]}, "rationale": "Right-sided endocarditis (Tricuspid, common in IVDA) shoots emboli to the lungs. This causes septic pulmonary emboli. Oxygen is priority. Anticoagulation (Heparin) is controversial/contraindicated in infective endocarditis due to cerebral bleed risk (mycotic aneurysm)."}]}]);
console.log('Injected 15 NGN missions from cardio_missions_gen');
window.customMissions = window.customMissions || [];
window.customMissions = window.customMissions.concat([{"id": "M-021", "type": "mission", "numerical_id": 21, "title": "The Sweet Coma: HHS Management", "category": "Diabetes / Emergency", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Esther Williams", "age": 82, "gender": "Female", "mrn": "2121-EW", "dob": "11/11/1944", "weight": "70 kg", "height": "162 cm", "allergies": "Latex"}, "chief_complaint": "Valid confusion and profound weakness found by son.", "hpi": "Ms. Williams has had a UTI for 1 week but didn't take her antibiotics. She has been drinking juice to 'flush it out'. Her son found her lethargic and unable to stand. He states she has been urinating frequently for days.", "pmh": "Type 2 Diabetes, Dementia (Mild), Hypertension.", "ros": {"neuro": "Lethargic, disoriented to time/place. GCS 13.", "gen": "Severe dehydration, dry mucous membranes, poor skin turgor.", "resp": "No Kussmaul respirations. Breath does NOT smell fruity.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Retired veteran. Lives in assisted living. Former smoker (quit 20 years ago)."}, "exhibits": [{"title": "Stat Labs", "type": "table", "data": [{"lab": "Glucose", "val": "850 mg/dL", "status": "Critical High"}, {"lab": "pH", "val": "7.38", "status": "Normal"}, {"lab": "Bicarbonate", "val": "24 mEq/L", "status": "Normal"}, {"lab": "Ketones", "val": "Negative", "status": "Normal"}, {"lab": "Serum Osmolality", "val": "340 mOsm/kg", "status": "Critical High (>320)"}], "content": "Information not available"}, {"title": "Electrolytes", "type": "text", "content": "Sodium: 148 mEq/L (Hypernatremia due to dehydration). Potassium: 4.8 mEq/L. BUN: 60 mg/dL (Pre-renal azotemia)."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "The nurse reviews the lab results. Differentiate HHS from DKA based on Ms. Williams' presentation.", "rows": ["Blood Glucose > 600 mg/dL", "Presence of Serum Ketones", "Acidosis (pH < 7.35)", "Profound Dehydration (>10L deficit)", "Mental Status Changes (Coma/Stupor)"], "columns": ["HHS", "DKA", "Both"], "answer": {"Blood Glucose > 600 mg/dL": "Both", "Presence of Serum Ketones": "DKA", "Acidosis (pH < 7.35)": "DKA", "Profound Dehydration (>10L deficit)": "HHS", "Mental Status Changes (Coma/Stupor)": "HHS"}, "rationale": "HHS (Hyperosmolar Hyperglycemic State) is characterized by extreme hyperglycemia (>600) and hyperosmolarity (>320) leading to profound dehydration and neurological changes. Unlike DKA, there is enough circulating insulin to prevent ketosis/acidosis."}, {"type": "extended_sata", "prompt": "Which orders does the nurse anticipate for initial resuscitation? Select all that apply.", "options": ["Start IV Fluids (0.9% NS) at 1L/hr", "Administer IV Regular Insulin Bolus (0.1 units/kg)", "Administer IV Sodium Bicarbonate", "Monitor Potassium levels hourly", "Insert Foley Catheter", "Start D5W Infusion"], "answer": [0, 1], "rationale": "Fluid resuscitation is the absolute priority to fix the hyperosmolarity. IV Insulin is used to lower BG. Potassium must be monitored as insulin shifts K+ into cells. A Foley is needed to track output accurately during massive fluid replacement."}, {"type": "bowtie", "prompt": "During treatment, the patient becomes responsive but complains of muscle cramps. Her K+ drops to 3.2 mEq/L. Prioritize the plan.", "center_condition": {"options": ["Hypokalemia", "Cerebral Edema", "Fluid Overload", "Hypoglycemia"], "answer": "Hypokalemia"}, "left_actions": {"options": ["Hold Insulin Infusion", "Add Potassium Chloride to IV Fluids", "Give Kayexalate", "Administer IV Calcium Gluconate", "Start D50W Ampule"], "answer": ["Hold Insulin Infusion", "Add Potassium Chloride to IV Fluids"]}, "right_monitor": {"options": ["Continuous EKG", "Hourly Neuro Checks", "Daily Weights", "Fingerstick Glucose", "Urine Specific Gravity"], "answer": ["Continuous EKG", "Fingerstick Glucose"]}, "rationale": "Insulin drives Potassium into the cell. If K+ drops below 3.3, insulin MUST be held to prevent life-threatening arrhythmias (VT/VF). Repletion (IV KCl) is urgent. EKG provides real-time monitoring of cardiac stability."}]}, {"id": "M-022", "type": "mission", "numerical_id": 22, "title": "The Rule of 15: Acute Hypoglycemia", "category": "Diabetes / Acute", "difficulty": "Basic", "patient_profile": {"demographics": {"name": "Ben Carter", "age": 19, "gender": "Male", "mrn": "2290-BC", "dob": "07/04/2007", "weight": "75 kg", "height": "178 cm", "allergies": "Peanuts"}, "chief_complaint": "Shaking, sweating, and 'feeling disconnected'.", "hpi": "Ben just finished soccer practice. He took his insulin before practice but didn't eat his snack. He is alert but anxious.", "pmh": "Type 1 Diabetes (Diagnosed age 10).", "ros": {"neuro": "Tremors, anxiety, slight confusion.", "cardio": "Results in Tachycardia (105 bpm).", "global": "Diaphoresis (Sweating) and Hunger.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Check feet for ulcers.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Retired school teacher. Lives with spouse. Nonsmoker. Occasional alcohol."}, "exhibits": [{"title": "Fingerstick Glucose", "type": "text", "content": "<strong>Result:</strong> 52 mg/dL"}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Classify the patient's symptoms as Adrenergic (catecholamine release) or Neuroglycopenic (brain glucose deprivation).", "rows": ["Tremors / Shaking", "Confusion / Difficulty Concentrating", "Diaphoresis (Sweating)", "Tachycardia (Palpitations)", "Slurred Speech / Drowsiness"], "columns": ["Adrenergic (Warning Signs)", "Neuroglycopenic (Late Signs)"], "answer": {"Tremors / Shaking": "Adrenergic (Warning Signs)", "Confusion / Difficulty Concentrating": "Neuroglycopenic (Late Signs)", "Diaphoresis (Sweating)": "Adrenergic (Warning Signs)", "Tachycardia (Palpitations)": "Adrenergic (Warning Signs)", "Slurred Speech / Drowsiness": "Neuroglycopenic (Late Signs)"}, "rationale": "The body releases epinephrine to raise BG, causing shaking/sweating/tachycardia. If uncorrected, the brain runs out of fuel, causing confusion/coma (Neuroglycopenia)."}, {"type": "extended_sata", "prompt": "Ben is conscious and can swallow. Which food items serve as appropriate '15g' rapid-acting carbohydrates? Select all that apply.", "options": ["4 oz (1/2 cup) Apple Juice", "1 tablespoon of Honey", "1 cup of Diet Soda", "3-4 Glucose Tablets", "A chocolate bar (Snickers)", "Standard size Bagel with Cream Cheese"], "answer": [0, 1], "rationale": "Treatment requires simple sugars. Diet soda has no sugar. Chocolate and Bagels contain fat/protein which delays absorption."}, {"type": "bowtie", "prompt": "Ben's roommate finds him later unconscious and unable to swallow. BG is 30 mg/dL. Prioritize the emergency response.", "center_condition": {"options": ["Severe Hypoglycemia", "Diabetic Ketoacidosis", "Seizure Disorder", "Vasovagal Syncope"], "answer": "Severe Hypoglycemia"}, "left_actions": {"options": ["Administer IM Glucagon", "Force feed oral juice", "Administer IV D50W (If access)", "Call 911", "Start Insulin Drip"], "answer": ["Administer IM Glucagon", "Call 911"]}, "right_monitor": {"options": ["Airway/Aspiration risk", "Return of Consciousness", "Urine Ketones", "Deep Tendon Reflexes", "Pupillary Response"], "answer": ["Airway/Aspiration risk", "Return of Consciousness"]}, "rationale": "An unconscious patient is an aspiration risk; NEVER put anything in their mouth. IM Glucagon mobilizes liver glycogen. 911 is needed. Monitoring airway (side-lying position) is critical due to vomiting risk from Glucagon."}]}, {"id": "M-023", "type": "mission", "numerical_id": 23, "title": "Tech Failure: Insulin Pump Malfunction", "category": "Diabetes / Technology", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Lisa Kudrow (Not that one)", "age": 28, "gender": "Female", "mrn": "2323-LK", "dob": "05/05/1998", "weight": "60 kg", "height": "165 cm", "allergies": "Adhesive tape"}, "chief_complaint": "Persistent Hyperglycemia and pump alarm 'Occlusion'.", "hpi": "Lisa notes her BG has been >300 mg/dL for 4 hours despite bolusing via pump. Pump shows 'No Delivery'. She feels nauseous.", "pmh": "Type 1 Diabetes (Pump user x 5 years).", "ros": {"gen": "Increased thirst, frequent urination, fatigue.", "skin": "Pump site is red and tender (possible kink/infection).", "gi": "Mild nausea.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gu": "No complaints. Urine clear.", "musc": "Full ROM. No deformity."}, "sh": "Construction worker. Lives alone. Smokes 1 pack/day. Social drinker."}, "exhibits": [{"title": "Glucose Log", "type": "text", "content": "12:00 - 180 mg/dL<br>14:00 - 240 mg/dL (Bolused)<br>16:00 - 350 mg/dL (Now)"}, {"title": "Ketone Strip", "type": "text", "content": "Result: Moderate Ketones Detected. (Risk of DKA)"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Troubleshoot the pump failure. Match the potential cause to the component.", "rows": ["Cannula kinked under skin", "Tubing caught in door/zipper", "Reservoir empty", "Battery dead", "Bad absorption (Scar tissue)"], "columns": ["Infusion Site Issue", "Mechanical/Tubing Issue", "Device Power Issue"], "answer": {"Cannula kinked under skin": "Infusion Site Issue", "Tubing caught in door/zipper": "Mechanical/Tubing Issue", "Reservoir empty": "Mechanical/Tubing Issue", "Battery dead": "Device Power Issue", "Bad absorption (Scar tissue)": "Infusion Site Issue"}, "rationale": "Systematic troubleshooting: Check the Site (kinks, infection), the Line (air bubbles, clogs), and the Pump (battery, settings)."}, {"type": "extended_sata", "prompt": "The pump is confirmed to be malfunctioning. What are the priority actions to prevent DKA? Select all that apply.", "options": ["Disconnect the pump immediately", "Administer a correction bolus via syringe/pen (Manual injection)", "Keep bolusing with the pump until alarm clears", "Calculate total daily dose for backup plan", "Change the infusion set and new site rotation", "Check for ketones"], "answer": [0, 1], "rationale": "Manual insulin is required to fix the high BG immediately because the pump is unreliable. Disconnecting prevents accidental bolus if it suddenly works. Ketones confirm insulin deficiency."}, {"type": "bowtie", "prompt": "Ketones are positive. The patient needs a backup plan while the pump is off. Prioritize.", "center_condition": {"options": ["Impending DKA", "HHS", "Pump Failure", "Hypoglycemia"], "answer": "Pump Failure"}, "left_actions": {"options": ["Give stat Long-Acting Insulin (Glargine)", "Give stat Rapid-Acting Insulin (Lispro)", "Resume pump immediately", "Call Tech Support", "Change bed linens"], "answer": ["Give stat Long-Acting Insulin (Glargine)", "Give stat Rapid-Acting Insulin (Lispro)"]}, "right_monitor": {"options": ["BG every 2 hours", "Ketones every void", "Pump settings", "Battery life", "Clotting time"], "answer": ["BG every 2 hours", "Ketones every void"]}, "rationale": "Only Short-acting insulin is in the pump. When disconnected, the patient has NO basal insulin. They need manual Long-Acting (Basal) and Rapid-Acting (Bolus) to survive until the pump is replaced. Monitoring for ketone clearance is vital."}]}, {"id": "M-024", "type": "mission", "numerical_id": 24, "title": "Morning Highs: Somogyi vs Dawn", "category": "Diabetes / Chronic", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Gary Oldman (maybe?)", "age": 60, "gender": "Male", "mrn": "2424-GO", "dob": "03/21/1966", "weight": "82 kg", "height": "175 cm", "allergies": "NKDA"}, "chief_complaint": "Waking up with high blood sugar every morning.", "hpi": "Mr. Oldman reports his fasting BG is ~250 mg/dL every morning for the past week. He thought his insulin wasn't working, so he INCREASED his bedtime NPH dose 3 days ago, but the morning numbers got WORSE. He reports vivid nightmares and night sweats.", "pmh": "Type 2 Diabetes (Insulin dependent), Obstructive Sleep Apnea.", "ros": {"neuro": "Morning headaches. Groggy.", "gen": "Waking up with damp sheets (Night sweats).", "endo": "Polyuria upon waking.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Software engineer. Works from home. High stress. Enjoys hiking."}, "exhibits": [{"title": "Glucose Log", "type": "text", "content": "Bedtime (2200): 110 mg/dL<br>3 AM: 55 mg/dL (Hypoglycemia)<br>Breakfast (0700): 260 mg/dL (Rebound Hyperglycemia)"}, {"title": "Current Meds", "type": "table", "data": [{"drug": "NPH Insulin", "dose": "30 units", "freq": "Bedtime (2200)"}, {"drug": "Metformin", "dose": "1000 mg", "freq": "BID"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Interpret the cause of morning hyperglycemia based on the 3AM check.", "rows": ["3AM Glucose is Low (< 70)", "3AM Glucose is Normal/High (> 100)", "Patient reports Night Sweats / Nightmares", "Caused by rebound hormone release (Glucagon/Epi)", "Caused by natural Growth Hormone release"], "columns": ["Somogyi Effect", "Dawn Phenomenon"], "answer": {"3AM Glucose is Low (< 70)": "Somogyi Effect", "3AM Glucose is Normal/High (> 100)": "Dawn Phenomenon", "Patient reports Night Sweats / Nightmares": "Somogyi Effect", "Caused by rebound hormone release (Glucagon/Epi)": "Somogyi Effect", "Caused by natural Growth Hormone release": "Dawn Phenomenon"}, "rationale": "Somogyi = Rebound hyperglycemia following nocturnal hypoglycemia (Low at 3AM). The body panic-dumps sugar. Dawn = Natural circadian rhythm GH release causing insulin resistance (High/Normal at 3AM). Night sweats are a sign of hypoglycemia."}, {"type": "extended_sata", "prompt": "Based on the diagnosis of Somogyi Effect, which interventions are appropriate? Select all that apply.", "options": ["Increase the bedtime NPH dose", "Decrease the bedtime NPH dose", "Add a protein-heavy bedtime snack", "Check BG at 3 AM for the next few nights", "Switch dinner to an earlier time"], "answer": [0, 1], "rationale": "The problem is Hypoglycemia while sleeping. We need to prevent the drop. Decreasing the insulin or adding a snack helps carry the sugar through the night. Increasing the dose (which the patient did) worsens the effect."}, {"type": "bowtie", "prompt": "A month later, Gary returns. His 3AM BG is now 140, but his morning fasting is 180. Prioritize the new plan.", "center_condition": {"options": ["Dawn Phenomenon", "Somogyi Effect", "Insulin Resistance", "Medication Non-compliance"], "answer": "Dawn Phenomenon"}, "left_actions": {"options": ["Increase Bedtime NPH", "Decrease Bedtime NPH", "Stop bedtime snack", "Start Glipizide", "Offer ice chips"], "answer": ["Increase Bedtime NPH"]}, "right_monitor": {"options": ["Fasting Morning Glucose", "3AM Glucose", "HbA1c", "Urine Microalbumin", "Pain Score"], "answer": ["Fasting Morning Glucose", "3AM Glucose"]}, "rationale": "If the 3AM blood sugar is normal/high, and morning is high, it is Dawn Phenomenon (not enough insulin to cover the GH surge). The treatment is to INCREASE the insulin to cover the dawn rise."}]}, {"id": "M-025", "type": "mission", "numerical_id": 25, "title": "Flu Season: Sick Day Rules", "category": "Diabetes / Education", "difficulty": "Basic", "patient_profile": {"demographics": {"name": "Tina Fey (Not really)", "age": 42, "gender": "Female", "mrn": "2525-TF", "dob": "05/18/1984", "weight": "65 kg", "height": "165 cm", "allergies": "Sulfa"}, "chief_complaint": "Flu symptoms and loss of appetite.", "hpi": "Tina has the flu. She hasn't eaten in 24 hours due to nausea. She called the clinic asking if she should skip her Lantus (Basal) insulin tonight because she 'didn't eat dinner'.", "pmh": "Type 1 Diabetes.", "ros": {"gi": "Nausea, vomiting x1.", "gen": "Fever 101.5 F, Chills, Body Aches.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Nursing home resident. Widowed. Assistance required for ADLs."}, "exhibits": [{"title": "Blood Glucose", "type": "text", "content": "<strong>Current:</strong> 245 mg/dL (Elevated due to stress response)"}, {"title": "Ketones", "type": "text", "content": "Trace Ketones in urine."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "extended_sata", "prompt": "The nurse educates Tina on 'Sick Day Rules'. Which instructions are vital? Select all that apply.", "options": ["NEVER stop taking your insulin, even if not eating", "Check blood glucose every 3-4 hours", "Check urine ketones if BG > 240 mg/dL", "Force fluids (4-6 oz every 30 mins) to prevent dehydration", "If you cannot eat solid food, drink sugar-containing liquids (juice/gatorade) to maintain BG", "Go to the ER immediately for temperature > 100 F"], "answer": [0, 1], "rationale": "Illness increases cortisol, which raises BG even without food. Hydration is key to flushing ketones. Carbohydrates are still needed to prevent starvation ketosis, so liquid calories are used if solids aren't tolerated. Fever alone isn't an ER trip unless persistent/high."}, {"type": "matrix", "prompt": "Tina asks when she needs to call the doctor or go to the ER. Classify the scenarios.", "rows": ["Vomiting more than once / unable to verify fluids", "Blood Glucose > 250 for > 24 hours despite extra insulin", "Moderate to Large Ketones in urine", "Temperature of 100.5 F", "Confusion or heavy breathing (Kussmaul)"], "columns": ["Call Provider / Seek Emergency Care", "Continue Sick Day Management at Home"], "answer": {"Vomiting more than once / unable to verify fluids": "Call Provider / Seek Emergency Care", "Blood Glucose > 250 for > 24 hours despite extra insulin": "Call Provider / Seek Emergency Care", "Moderate to Large Ketones in urine": "Call Provider / Seek Emergency Care", "Temperature of 100.5 F": "Continue Sick Day Management at Home", "Confusion or heavy breathing (Kussmaul)": "Call Provider / Seek Emergency Care"}, "rationale": "Inability to keep fluids down is an emergency (DKA risk). Moderate/Large ketones indicate impending DKA. Mild fever is expected with flu."}, {"type": "bowtie", "prompt": "Tina calls back 6 hours later. She can't stop vomiting and feels 'breathless'. Prioritize the complication.", "center_condition": {"options": ["Diabetic Ketoacidosis (DKA)", "Hypoglycemia", "Gastroenteritis", "Dehydration"], "answer": "Diabetic Ketoacidosis (DKA)"}, "left_actions": {"options": ["Advise to go to ER immediately", "Take extra Zofran", "Drink more water", "Take extra Lantus", "Document findings in chart"], "answer": ["Advise to go to ER immediately"]}, "right_monitor": {"options": ["Anion Gap / ABG", "Serum Amylase", "Urine Culture", "Stool for Ova/Parasites", "Hand Grip Strength"], "answer": ["Anion Gap / ABG"]}, "rationale": "Persistent vomiting + Breathlessness (Kussmaul) + T1DM = DKA until proven otherwise. Home management has failed. She needs IV fluids and insulin. We monitor the Anion Gap to gauge acidosis severity."}]}, {"id": "M-026", "type": "mission", "numerical_id": 26, "title": "Sugar for Two: Gestational Diabetes", "category": "Diabetes / OB", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Maria Von Trapp", "age": 32, "gender": "Female", "mrn": "2626-MT", "dob": "02/14/1994", "weight": "85 kg", "height": "165 cm", "allergies": "NKDA"}, "chief_complaint": "Failed 1-hour Glucose Tolerance Test.", "hpi": "Maria is G3 P2 at 26 weeks gestation. Her 1-hour GTT came back at 155 mg/dL. She admits to craving pasta and ice cream.", "pmh": "Polycystic Ovarian Syndrome (PCOS), Obesity (BMI 31). Prev baby was 9lbs 2oz.", "ros": {"gen": "Fatigue.", "abdo": "Fundal height 28cm (Large for dates).", "gu": "Frequency of urination (normal for pregnancy?).", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Sensation intact in extremities (or diminished if neuropathy).", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "skin": "Check feet for ulcers.", "musc": "Full ROM. No deformity."}, "sh": "Office manager. Married with 2 children. Nonsmoker. Denies alcohol use."}, "exhibits": [{"title": "3-Hour GTT Results", "type": "table", "data": [{"time": "Fasting", "val": "98 mg/dL", "status": "High (>95)"}, {"time": "1 Hour", "val": "190 mg/dL", "status": "High (>180)"}, {"time": "2 Hour", "val": "165 mg/dL", "status": "High (>155)"}, {"time": "3 Hour", "val": "130 mg/dL", "status": "Normal (<140)"}], "content": "Information not available"}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "The patient is diagnosed with GDM. Assess the risks to the Fetus vs the Mother.", "rows": ["Macrosomia (Large size)", "Neonatal Hypoglycemia", "Type 2 Diabetes later in life", "Pre-eclampsia", "Shoulder Dystocia (Birth Injury)"], "columns": ["Fetal Risk", "Maternal Risk", "Both"], "answer": {"Macrosomia (Large size)": "Fetal Risk", "Neonatal Hypoglycemia": "Fetal Risk", "Type 2 Diabetes later in life": "Both", "Pre-eclampsia": "Maternal Risk", "Shoulder Dystocia (Birth Injury)": "Fetal Risk"}, "rationale": "High sugar crosses the placenta (fat baby), but insulin does NOT. The baby makes its own insulin, leading to hypoglycemia at birth. Mom is at risk for Pre-eclampsia and future T2DM."}, {"type": "extended_sata", "prompt": "Maria asks about diet changes. Which instructions are appropriate? Select all that apply.", "options": ["Eliminate ALL carbohydrates from your diet", "Eat 3 meals and 3 snacks spaced evenly", "Monitor ketones in morning urine", "Bedtime snack should include protein", "Aim for weight loss of 5-10 lbs during remainder of pregnancy"], "answer": [0, 1], "rationale": "We NEVER restrict calories to cause weight loss in pregnancy (ketosis hurts the baby). We spread carbs out to prevent spikes. Protein at bedtime prevents morning hypoglycemia."}, {"type": "bowtie", "prompt": "Post-delivery, the baby weighs 10lbs 5oz. At 1 hour of life, the baby is jittery and lethargic. Prioritize.", "center_condition": {"options": ["Neonatal Hypoglycemia", "Sepsis", "Respiratory Distress Syndrome", "Drug Withdrawal"], "answer": "Neonatal Hypoglycemia"}, "left_actions": {"options": ["Breastfeed immediately", "Give IV Dextrose", "Check Heelstick Glucose", "Place under warmer", "Call NICU"], "answer": ["Breastfeed immediately", "Check Heelstick Glucose"]}, "right_monitor": {"options": ["Temperature", "Rooting Reflex", "Bilirubin", "O2 Sat", "Deep Tendon Reflexes"], "answer": ["Temperature", "Rooting Reflex"]}, "rationale": "The baby's pancreas is pumping out insulin to handle Mom's sugar. Now that the cord is cut, the sugar supply is gone, but the insulin remains. Result: Crash. Feed immediately to neutralize the insulin."}]}, {"id": "M-027", "type": "mission", "numerical_id": 27, "title": "Recess Emergency: Pediatric T1DM", "category": "Diabetes / Peds", "difficulty": "Basic", "patient_profile": {"demographics": {"name": "Timmy Turner", "age": 8, "gender": "Male", "mrn": "2727-TT", "dob": "05/05/2018", "weight": "28 kg", "height": "130 cm", "allergies": "Bees"}, "chief_complaint": "Stomach ache and bedwetting.", "hpi": "Timmy's mother brings him in because he has started wetting the bed again after being potty trained for years. He has lost 5 lbs in 2 weeks despite eating 'like a horse'.", "pmh": "None.", "ros": {"gen": "Polydipsia (Thirsty), Polyphagia (Hungry), Polyuria.", "gi": "Vague abdominal pain.", "neuro": "Irritable.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Nursing home resident. Widowed. Assistance required for ADLs."}, "exhibits": [{"title": "Random Glucose", "type": "text", "content": "450 mg/dL"}, {"title": "HbA1c", "type": "text", "content": "11.2% (Diagnostic for Diabetes)"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Compare the 'Honeymoon Phase' vs 'Diagnosis' in Type 1 Diabetes.", "rows": ["Pancreas produces NO insulin", "Pancreas produces SOME insulin temporarily", "Insulin requirements decrease drastically", "Risk of DKA is highest", "Occurs shortly after starting insulin therapy"], "columns": ["Diagnosis Phase", "Honeymoon Phase"], "answer": {"Pancreas produces NO insulin": "Diagnosis Phase", "Pancreas produces SOME insulin temporarily": "Honeymoon Phase", "Insulin requirements decrease drastically": "Honeymoon Phase", "Risk of DKA is highest": "Diagnosis Phase", "Occurs shortly after starting insulin therapy": "Honeymoon Phase"}, "rationale": "After starting insulin, the rested pancreas may sputter out a last bit of insulin (Honeymoon), making control easy. Parents think 'he's cured'. He is not. It will fail completely soon."}, {"type": "extended_sata", "prompt": "Timmy is ready for school. What must be in his backpack? Select all that apply.", "options": ["Glucagon Emergency Kit", "Snacks (Granola bar/Juice box)", "Insulin Pen", "A note excusing him from Gym class", "Blood Glucose Meter", "Sharps container"], "answer": [0, 1], "rationale": "T1DM kids MUST participate in Gym (exercise helps), but they need snacks to prevent lows. Glucagon is for emergencies. Sharps are usually kept in the nurse's office, not the backpack (safety)."}, {"type": "bowtie", "prompt": "At a birthday party, Timmy eats cake and plays tag. He gets shaky and pale. BG is 60. Prioritize.", "center_condition": {"options": ["Exercise-Induced Hypoglycemia", "Hyperglycemia", "Sugar Crash", "Anxiety"], "answer": "Exercise-Induced Hypoglycemia"}, "left_actions": {"options": ["Give 4oz Juice", "Give Insulin Bolus", "Send him home", "Give Glucagon", "Give Diet Soda"], "answer": ["Give 4oz Juice"]}, "right_monitor": {"options": ["Recheck BG in 15 mins", "Call 911", "Urine Ketones", "Temperature", "Pain Score"], "answer": ["Recheck BG in 15 mins"]}, "rationale": "Exercise increases insulin sensitivity + Cake bolus = Mismatch. Consuming simple sugar (Juice) is the Rule of 15. Glucagon is only if unconscious. Recheck in 15 mins."}]}, {"id": "M-028", "type": "mission", "numerical_id": 28, "title": "The Hidden Nail: Neuropathy", "category": "Diabetes / Chronic", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Lt. Dan", "age": 55, "gender": "Male", "mrn": "2828-LD", "dob": "09/01/1971", "weight": "90 kg", "height": "180 cm", "allergies": "Iodine"}, "chief_complaint": "Foot smells bad.", "hpi": "Lt. Dan noticed a foul odor when taking off his boots. He found a rusty nail embedded in his left heel. He felt NO pain. He recalls stepping on something 'crunchy' 3 weeks ago.", "pmh": "Type 2 Diabetes (Uncontrolled A1c 10%), Smoker.", "ros": {"neuro": "Loss of protective sensation (Monofilament test).", "skin": "2cm ulcer on calcaneus. Purulent drainage. Redness ascending the ankle.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Retired school teacher. Lives with spouse. Nonsmoker. Occasional alcohol."}, "exhibits": [{"title": "Wound Culture", "type": "text", "content": "Polymicrobial growth (Gram + Cocci and Gram - Rods)."}, {"title": "X-Ray Foot", "type": "text", "content": "Air in soft tissue. Possible Osteomyelitis (bone infection)."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Differentiate Neuropathic Pain vs Ischemic Pain in the diabetic foot.", "rows": ["Burning / Tingling / Electric Shocks", "Pain with walking (Claudication)", "Worse at night (under covers)", "Relieved by dangling legs", "Loss of sensation (Numbness)"], "columns": ["Neuropathic", "Ischemic"], "answer": {"Burning / Tingling / Electric Shocks": "Neuropathic", "Pain with walking (Claudication)": "Ischemic", "Worse at night (under covers)": "Neuropathic", "Relieved by dangling legs": "Ischemic", "Loss of sensation (Numbness)": "Neuropathic"}, "rationale": "Neuropathy is nerve damage (burning/numbness). Ischemia is blood flow block (pain with demand). Dan has neuropathy (didn't feel the nail)."}, {"type": "extended_sata", "prompt": "The nurse teaches foot care. Which statements by Lt. Dan indicate understanding? Select all that apply.", "options": ["I will soak my feet in hot water daily to clean them.", "I will use a mirror to inspect the bottom of my feet daily.", "I will cut my toenails in a rounded curve.", "I will never walk barefoot, even at home.", "I will apply lotion between my toes to keep them moist.", "I will shake out my shoes before putting them on."], "answer": [0, 1], "rationale": "Soaking softens skin (bad). Hot water burns (he can't feel it). Cutting rounded causes ingrown nails (cut straight across). Lotion between toes causes fungus (Athlete's foot)."}, {"type": "bowtie", "prompt": "The redness spreads up the calf. Fever 102 F. BG 350. Prioritize.", "center_condition": {"options": ["Sepsis 2/2 Osteomyelitis", "Gout Flare", "Deep Vein Thrombosis", "Charcot Foot"], "answer": "Sepsis 2/2 Osteomyelitis"}, "left_actions": {"options": ["Start IV Broad Spectrum Abx", "Prepare for Amputation/Debridement", "Apply Compression", "Administer Colchicine", "Blood Cultures x2"], "answer": ["Start IV Broad Spectrum Abx", "Blood Cultures x2"]}, "right_monitor": {"options": ["Lactate Level", "WBC Trend", "Uric Acid", "D-Dimer", "Pain Score"], "answer": ["Lactate Level", "WBC Trend"]}, "rationale": "Ascending redness + Fever = Systemic Infection (Sepsis). Osteomyelitis is hard to cure. Antibiotics and Debridement are key. Lactate tracks sepsis severity."}]}, {"id": "M-029", "type": "mission", "numerical_id": 29, "title": "Blurred Lines: Retinopathy", "category": "Diabetes / Chronic", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Stevie Wonder (Musician)", "age": 60, "gender": "Male", "mrn": "2929-SW", "dob": "05/13/1966", "weight": "75 kg", "height": "175 cm", "allergies": "NKDA"}, "chief_complaint": "Lots of 'floaters' and sudden vision loss in right eye.", "hpi": "Mr. Wonder reports seeing 'black spiderwebs' for a week. Today, a 'curtain' fell over his right eye vision.", "pmh": "Type 1 Diabetes (40 years), Hypertension.", "ros": {"eye": "Visual acuity 20/200 OD, 20/40 OS.", "neuro": "No pain. Just visual loss.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Librarian. Lives with 3 cats. Nonsmoker. Occasional glass of wine."}, "exhibits": [{"title": "Fundoscopy", "type": "text", "content": "Proliferative Retinopathy. Neovascularization. Vitreous Hemorrhage visible."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Match the eye complication to the symptom.", "rows": ["Curtain falling over vision / Flashes of light", "Cloudy / Blurry vision (gradual)", "Central vision loss (wavy lines)", "Tunnel vision (peripheral loss)", "Floating spots / Spiderwebs"], "columns": ["Retinal Detachment", "Cataracts", "Macular Degeneration", "Glaucoma", "Vitreous Hemorrhage"], "answer": {"Curtain falling over vision / Flashes of light": "Retinal Detachment", "Cloudy / Blurry vision (gradual)": "Cataracts", "Central vision loss (wavy lines)": "Macular Degeneration", "Tunnel vision (peripheral loss)": "Glaucoma", "Floating spots / Spiderwebs": "Vitreous Hemorrhage"}, "rationale": "High sugar damages vessels --> New weak vessels grow (Neovascularization) --> They bleed (Hemorrhage/Floaters) or pull the retina off (Detachment/Curtain)."}, {"type": "extended_sata", "prompt": "Mr. Wonder is scheduled for Vitrectomy. Which pre-op instructions are vital? Select all that apply.", "options": ["You must stop anticoagulant medications", "You will need to maintain 'face-down' positioning post-op", "Control blood pressure strictly", "Avoid heavy lifting or straining (Valsalva)", "Eye drops will be needed for weeks", "You can drive yourself home"], "answer": [0, 1], "rationale": "Bleeding is the enemy. BP and straining increase ocular pressure. Face-down positioning is for gas bubbles (often used, but straining/BP are universal priorities)."}, {"type": "bowtie", "prompt": "Post-op, he complains of severe pain and nausea. Eye is rock hard. Prioritize.", "center_condition": {"options": ["Acute Glaucoma (IOP spike)", "Infection", "Normal Healing", "Migraine"], "answer": "Acute Glaucoma (IOP spike)"}, "left_actions": {"options": ["Administer IV Mannitol", "Administer Morphine", "Apply eye patch", "Keep head of bed elevated", "Change bed linens"], "answer": ["Administer IV Mannitol", "Keep head of bed elevated"]}, "right_monitor": {"options": ["Intraocular Pressure", "WBC", "Temperature", "Pupil Shape", "Pupillary Response"], "answer": ["Intraocular Pressure"]}, "rationale": "Severe pain + Nausea + 'Rock Hard' Eye = Acute Angle Closure Glaucoma. The drainage is blocked. Mannitol draws fluid out. Elevation helps drain. This causes permanent blindness if not fixed."}]}, {"id": "M-030", "type": "mission", "numerical_id": 30, "title": "The Contrast Clash: Lactic Acidosis", "category": "Diabetes / Pharma", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Stan Lee", "age": 75, "gender": "Male", "mrn": "3030-SL", "dob": "12/28/1951", "weight": "70 kg", "height": "170 cm", "allergies": "Shellfish"}, "chief_complaint": "Muscle pain and hyperventilation.", "hpi": "Mr. Lee had a CT Scan with contrast 2 days ago for abdominal pain. He didn't stop his Metformin. Now he feels weak, muscles ache, and he is breathing fast.", "pmh": "Type 2 Diabetes, CKD Stage 3.", "ros": {"resp": "Kussmaul breathing (Deep/Rapid).", "musc": "Generalized myalgia.", "gi": "Abdominal pain/diarrhea.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "neuro": "Alert and oriented x3. PEERLA.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Librarian. Lives with 3 cats. Nonsmoker. Occasional glass of wine."}, "exhibits": [{"title": "Arterial Blood Gas (ABG)", "type": "text", "content": "pH: 7.25 (Acidotic)<br>pCO2: 30 mmHg (Low - Compensating)<br>HCO3: 14 mEq/L (Low - Metabolic)"}, {"title": "Lactate", "type": "text", "content": "6.5 mmol/L (Critical High)"}, {"title": "Creatinine", "type": "text", "content": "2.8 mg/dL (Acute Kidney Injury)"}], "steps": [{"type": "matrix", "prompt": "Analyze the drug-drug/disease interaction.", "rows": ["Metformin mechanism", "IV Contrast effect", "Result of combination", "Kidney's role"], "columns": ["Increases Glucose Uptake", "Causes Vasoconstriction/AKI", "Inhibits Lactate clearance", "Excretes Metformin"], "answer": {"Metformin mechanism": "Increases Glucose Uptake", "IV Contrast effect": "Causes Vasoconstriction/AKI", "Result of combination": "Inhibits Lactate clearance", "Kidney's role": "Excretes Metformin"}, "rationale": "Contrast dye hurts the kidneys (AKI). The kidneys excrete Metformin. If kidneys fail, Metformin builds up to toxic levels. Metformin blocks the liver from recycling lactate. Result: Lactic Acidosis."}, {"type": "extended_sata", "prompt": "Which interventions are appropriate for Lactic Acidosis? Select all that apply.", "options": ["IV Sodium Bicarbonate (if pH < 7.1)", "Hemodialysis", "Administer IV Insulin", "Fluid Resuscitation", "Stop Metformin indefinitely", "Administer Acetylcysteine (Mucomyst)"], "answer": [0, 1], "rationale": "Dialysis is the most effective way to remove both the Metformin and the Acid. Fluids flush the kidneys. Mucomyst protects kidneys from contrast (though late now). Insulin is for DKA, not Lactic Acidosis."}, {"type": "bowtie", "prompt": "Mr. Lee's pH drops to 7.10. He becomes bradycardic. Prioritize.", "center_condition": {"options": ["Refractory Acidosis / Cardiac Instability", "Hypoglycemia", "Respiratory Failure", "Anaphylaxis"], "answer": "Refractory Acidosis / Cardiac Instability"}, "left_actions": {"options": ["Emergent Dialysis", "Intubate and Hyperventilate", "Give Atropine", "Give Epinephrine", "Place patient in Reverse Trendelenburg"], "answer": ["Emergent Dialysis", "Intubate and Hyperventilate"]}, "right_monitor": {"options": ["Potassium (Correction of acidosis shifts K)", "O2 Sat", "BP", "Temp", "Hand Grip Strength"], "answer": ["Potassium (Correction of acidosis shifts K)", "BP"]}, "rationale": "Severe acidosis stops the heart (denatures proteins/enzymes). Dialysis is the only fix. Hyperventilation (mechanical) helps blow off CO2 to compensate for the metabolic acid."}]}]);
console.log('Injected 10 NGN missions from diabetes_missions_gen');
window.customMissions = window.customMissions || [];
window.customMissions = window.customMissions.concat([{"id": "M-031", "type": "mission", "numerical_id": 31, "title": "The Fluid War: CHF vs Kidney", "category": "Combined / Complex", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Kenny Rogers", "age": 78, "gender": "Male", "mrn": "3131-KR", "dob": "08/21/1948", "weight": "100 kg", "height": "180 cm", "allergies": "NKDA"}, "chief_complaint": "Shortness of breath and swelling.", "hpi": "Mr. Rogers has HFrEF (EF 25%) and Diabetic Nephropathy (CKD 4). He presents with worsening dyspnea. His creatinine is 2.5 (Baseline 1.8).", "pmh": "Type 2 Diabetes, Heart Failure, CKD.", "ros": {"resp": "Crackles halfway up.", "cardio": "+3 Pitting Edema.", "gu": "Decreased urine output.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Chef. High sodium diet. Smokes cigars occasionally. Social drinker."}, "exhibits": [{"title": "Labs", "type": "table", "data": [{"lab": "BNP", "val": "2400", "status": "Critical High"}, {"lab": "Creatinine", "val": "2.8 mg/dL", "status": "Rising (AKI)"}, {"lab": "Potassium", "val": "5.5 mEq/L", "status": "High"}, {"lab": "Glucose", "val": "280 mg/dL", "status": "High"}], "content": "Information not available"}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Evaluate the treatment conflict: Heart vs Kidney.", "rows": ["Administer High-Dose IV Furosemide", "Administer IV Fluids (NS)", "Administer ACE Inhibitor (Lisinopril)", "Administer Spironolactone"], "columns": ["Helps Heart / Hurts Kidney", "Helps Kidney / Hurts Heart", "Bad for Both"], "answer": {"Administer High-Dose IV Furosemide": "Helps Heart / Hurts Kidney", "Administer IV Fluids (NS)": "Helps Kidney / Hurts Heart", "Administer ACE Inhibitor (Lisinopril)": "Helps Heart / Hurts Kidney", "Administer Spironolactone": "Bad for Both"}, "rationale": "Diuretics offload the heart but can cause pre-renal AKI. Fluids fix the kidney (perfuse it) but drown the heart. ACEs protect the heart remodeling but lower GFR initially. Spironolactone causes Hyperkalemia (K=5.5), so it's bad for this patient."}, {"type": "extended_sata", "prompt": "The provider orders 'Bumex drip'. Which monitoring is essential? Select all that apply.", "options": ["Hourly Urine Output", "Daily Weights", "Monitor Potassium (Hypokalemia)", "Monitor Magnesium", "Monitor BP for hypotension", "Check Blood Glucose q1h"], "answer": [0, 1], "rationale": "Strong loop diuretics (Bumetanide) cause massive electrolyte loss (K+, Mg++) and can tank BP. Glucose monitoring isn't strictly q1h for diuretics compared to insulin."}, {"type": "bowtie", "prompt": "Creatinine jumps to 3.5. Urine output stops (Anuria). Lung sounds wet. Prioritize.", "center_condition": {"options": ["Cardiorenal Syndrome", "Urinary Retention", "Dehydration", "Sepsis"], "answer": "Cardiorenal Syndrome"}, "left_actions": {"options": ["Prepare for Dialysis (CRRT)", "Give 2L Fluid Bolus", "Increase Diuretic", "Give Kayexalate", "Reassure the patient"], "answer": ["Prepare for Dialysis (CRRT)"]}, "right_monitor": {"options": ["Oxygen Saturation", "Daily Weight", "Foley Catheter", "Neuro Status", "Urine Color"], "answer": ["Oxygen Saturation", "Foley Catheter"]}, "rationale": "The kidneys have shut down (Anuria) despite/because of heart treatment. Diuretics won't work if kidneys can't filter. CRRT (Continuous Dialysis) is needed to pull fluid without crashing BP."}]}, {"id": "M-032", "type": "mission", "numerical_id": 32, "title": "The Masked Threat: Beta Blockers", "category": "Combined / Pharma", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Bruce Banner", "age": 40, "gender": "Male", "mrn": "3232-BB", "dob": "12/18/1986", "weight": "80 kg", "height": "175 cm", "allergies": "NKDA"}, "chief_complaint": "Passed out at work.", "hpi": "Mr. Banner has T1DM and recently had a heart attack, so he was started on Metoprolol. He reports he 'didn't feel anything coming' before he woke up on the floor with paramedics.", "pmh": "Type 1 Diabetes, CAD (Post-MI Stent).", "ros": {"cardio": "HR 58 bpm (Resting). BP 110/70.", "neuro": "Groggy.", "gen": "Sweaty (Diaphoretic).", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Retired veteran. Lives in assisted living. Former smoker (quit 20 years ago)."}, "exhibits": [{"title": "Medication List", "type": "table", "data": [{"drug": "Metoprolol Tartrate", "dose": "50mg BID", "class": "Beta Blocker"}, {"drug": "Insulin Glargine", "dose": "20 units HS", "class": "Long Acting"}, {"drug": "Insulin Lispro", "dose": "Sliding Scale", "class": "Rapid Acting"}], "content": "Information not available"}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Evaluate the signs of Hypoglycemia in a patient on Beta Blockers.", "rows": ["Tachycardia (Palpitations)", "Tremors / Shaking", "Diaphoresis (Sweating)", "Hunger", "Anxiety"], "columns": ["Masked/Blocked by Metoprolol", "NOT Blocked (Still visible)"], "answer": {"Tachycardia (Palpitations)": "Masked/Blocked by Metoprolol", "Tremors / Shaking": "Masked/Blocked by Metoprolol", "Diaphoresis (Sweating)": "NOT Blocked (Still visible)", "Hunger": "NOT Blocked (Still visible)", "Anxiety": "Masked/Blocked by Metoprolol"}, "rationale": "Beta blockers block the sympathetic 'fight or flight' response (High HR, Shaking). They do NOT block Cholinergic symptoms like Sweating and Hunger. The patient must rely on sweating as their warning sign."}, {"type": "extended_sata", "prompt": "What teaching is CRITICAL for this patient? Select all that apply.", "options": ["You must check your blood sugar more frequently, especially before driving", "If you sweat excessively, check your sugar immediately", "Stop taking Metoprolol if you feel low", "Carry a glucagon kit and glucose tabs", "Eat a high protein diet to prevent lows"], "answer": [0, 1], "rationale": "Since the early warning system (palpitations) is broken, frequent checking is the only safety net. Sweating is the one reliable sign left. Never stop cardiac meds abruptly."}, {"type": "bowtie", "prompt": "Mr. Banner's HR drops to 40 and BG is 45. He is conscious. Prioritize.", "center_condition": {"options": ["Beta Blocker Toxicity", "Severe Hypoglycemia with Bradycardia", "Heart Block", "Stroke"], "answer": "Severe Hypoglycemia with Bradycardia"}, "left_actions": {"options": ["Administer IV D50W / Oral Glucose", "Administer Atropine", "Administer Glucagon (IV)", "Start Pacing", "Apply warm compress"], "answer": ["Administer IV D50W / Oral Glucose"]}, "right_monitor": {"options": ["Blood Glucose Re-check", "Heart Rate Recovery", "Troponin", "Temperature", "Bowel Sounds"], "answer": ["Blood Glucose Re-check", "Heart Rate Recovery"]}, "rationale": "Hypoglycemia must be treated first. Unlike non-BB patients, his HR won't spike to compensate. Glucagon *might* ensure sugar release but IV D50 is definitive if available. Glucagon is also the antidote for Beta Blocker overdose (increases contractility)."}]}, {"id": "M-033", "type": "mission", "numerical_id": 33, "title": "Breath vs Sugar: Steroid Spike", "category": "Combined / Endocrine", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Darth Vader (Breathing issues)", "age": 65, "gender": "Male", "mrn": "3333-DV", "dob": "11/01/1961", "weight": "110 kg", "height": "200 cm", "allergies": "Latex"}, "chief_complaint": "COPD Exacerbation.", "hpi": "Patient admitted for wheezing and low O2. Started on IV Solu-Medrol (Methylprednisolone) q6h. Now his blood sugar is skyrocketing.", "pmh": "COPD, Type 2 Diabetes.", "ros": {"resp": "Wheezing resolved.", "endo": "Polydipsia/Polyuria.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Truck driver. Divorced. Smokes 2 packs/day. Sedentary lifestyle."}, "exhibits": [{"title": "Glucose Log", "type": "text", "content": "Admission: 140.<br>Day 1 on Steroids: 280.<br>Day 2 on Steroids: 350.<br>Day 3 on Steroids: 440."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Understanding Glucocorticoids. Match the effect to the system.", "rows": ["Increases Liver Gluconeogenesis (Sugar production)", "Increases Insulin Resistance in cells", "Reduces Inflammation in airways", "Causes Sodium/Water Retention"], "columns": ["Desired Effect (Lungs)", "Adverse Effect (Diabetes)", "Adverse Effect (Heart)"], "answer": {"Increases Liver Gluconeogenesis (Sugar production)": "Adverse Effect (Diabetes)", "Increases Insulin Resistance in cells": "Adverse Effect (Diabetes)", "Reduces Inflammation in airways": "Desired Effect (Lungs)", "Causes Sodium/Water Retention": "Adverse Effect (Heart)"}, "rationale": "Steroids are a double-edged sword. They save the lungs but wreck the sugar control and raise BP (fluid retention)."}, {"type": "extended_sata", "prompt": "How should the nurse adjust the care plan? Select all that apply.", "options": ["Increase frequency of BG checks (q4h or q6h)", "Request increased Insulin coverage (Sliding scale + Basal)", "Stop the steroids immediately", "Restrict oral fluid intake", "Monitor for signs of infection (Steroids suppress immune system)"], "answer": [0, 1], "rationale": "We cannot stop the steroids (breathing is priority). We must chase the sugar with MORE insulin. Infection risk is high due to hyperglycemia + immune suppression."}, {"type": "bowtie", "prompt": "Mr. Vader becomes confused and develops deep, rapid breathing. Ketones are Trace. Glucose 550. Prioritize.", "center_condition": {"options": ["HHS", "DKA", "COPD Narcosis", "Stroke"], "answer": "HHS"}, "left_actions": {"options": ["Start IV Insulin Infusion", "IV Fluids 0.9% NS", "BiPAP", "Give 2 amps Bicarb", "Administer IV Acetaminophen"], "answer": ["Start IV Insulin Infusion", "IV Fluids 0.9% NS"]}, "right_monitor": {"options": ["Serum Osmolality", "pH", "CO2 Level", "WBC", "Clotting time"], "answer": ["Serum Osmolality", "pH"]}, "rationale": "High sugar + Confusion + Trace Ketones (not large) favors HHS, though DKA is possible. Steroids push T2DM into HHS territory. Hydration and Insulin are the fix."}]}, {"id": "M-034", "type": "mission", "numerical_id": 34, "title": "Cheap & Effective: Thiazide Risks", "category": "Combined / Pharma", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Penny Pincher", "age": 65, "gender": "Female", "mrn": "3434-PP", "dob": "04/04/1961", "weight": "85 kg", "height": "160 cm", "allergies": "Sulfa (Mild rash)"}, "chief_complaint": "Gout flare and High Sugar.", "hpi": "Prescribed Hydrochlorothiazide (HCTZ) 25mg for HTN 1 month ago. Now her big toe hurts (Podagra) and her fasting sugars are up.", "pmh": "Hypertension, Pre-Diabetes, Gout.", "ros": {"musc": "Red, hot, swollen right great toe.", "endo": "Thirsty.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Software engineer. Works from home. High stress. Enjoys hiking."}, "exhibits": [{"title": "Metabolic Panel", "type": "table", "data": [{"lab": "Glucose", "val": "160 mg/dL", "status": "High (Prev 110)"}, {"lab": "Uric Acid", "val": "9.5 mg/dL", "status": "High"}, {"lab": "Potassium", "val": "3.3 mEq/L", "status": "Low"}, {"lab": "Calcium", "val": "10.5 mg/dL", "status": "High Normal"}], "content": "Information not available"}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Identify the metabolic side effects of Thiazide Diuretics.", "rows": ["Effect on Blood Glucose", "Effect on Uric Acid", "Effect on Potassium", "Effect on Calcium", "Effect on Lipids (Cholesterol)"], "columns": ["Increases (Hyper)", "Decreases (Hypo)"], "answer": {"Effect on Blood Glucose": "Increases (Hyper)", "Effect on Uric Acid": "Increases (Hyper)", "Effect on Potassium": "Decreases (Hypo)", "Effect on Calcium": "Increases (Hyper)", "Effect on Lipids (Cholesterol)": "Increases (Hyper)"}, "rationale": "HyperGLUC (Glycemia, Lipids, Uric Acid, Calcium). Hypokalemia. HCTZ is cheap but metabolically 'dirty'."}, {"type": "extended_sata", "prompt": "Ms. Pincher has a Sulfa allergy. Which actions are appropriate? Select all that apply.", "options": ["Stop HCTZ immediately", "Monitor for cross-sensitivity reaction", "Prescribe Losartan (ARB) instead", "Prescribe Furosemide (Lasix) instead", "Increase HCTZ dose"], "answer": [0, 1], "rationale": "Thiazides are Sulfonamides. While cross-reaction is rare, a rash history makes it risky. ARBs are safe and metabolically neutral. Lasix is ALSO a Sulfa drug!"}, {"type": "bowtie", "prompt": "Patient develops severe leg cramps and palpitations. EKG shows U-waves. Prioritize.", "center_condition": {"options": ["Hypokalemia", "Hypercalcemia", "Gout Attack", "Stroke"], "answer": "Hypokalemia"}, "left_actions": {"options": ["Oral Potassium Replacement", "IV Potassium Bolus", "Muscle Relaxers", "Magnesium Sulfate", "Apply warm compress"], "answer": ["Oral Potassium Replacement"]}, "right_monitor": {"options": ["Telemetry / EKG", "Urine pH", "Serum Potassium", "Calcium", "Pedal Pulses"], "answer": ["Telemetry / EKG", "Serum Potassium"]}, "rationale": "Leg cramps + U waves = Hypokalemia (Low K). Thiazides waste potassium. Oral replacement is preferred if stable; IV if unstable/critical."}]}, {"id": "M-035", "type": "mission", "numerical_id": 35, "title": "Sugar in Urine: SGLT2 Risks", "category": "Combined / Pharma", "difficulty": "Functions", "patient_profile": {"demographics": {"name": "Candace Sweet", "age": 45, "gender": "Female", "mrn": "3535-CS", "dob": "02/02/1981", "weight": "90 kg", "height": "165 cm", "allergies": "Yeast"}, "chief_complaint": "Vaginal itching and nausea.", "hpi": "Started Empagliflozin (Jardiance) 2 weeks ago for T2DM and Heart Failure prevention. Reports severe itching and now feels 'sick to her stomach'.", "pmh": "Type 2 Diabetes, Heart Failure (HFpEF).", "ros": {"gu": "Thick white discharge (Yeast infection).", "gi": "Nausea/Vomiting.", "resp": "Mild tachypnea.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "neuro": "Alert and oriented x3. PEERLA.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Retired veteran. Lives in assisted living. Former smoker (quit 20 years ago)."}, "exhibits": [{"title": "Labs", "type": "table", "data": [{"lab": "Blood Glucose", "val": "180 mg/dL", "status": "Mildly Elevated"}, {"lab": "pH", "val": "7.28", "status": "Acidotic"}, {"lab": "Bicarbonate", "val": "16 mEq/L", "status": "Low"}, {"lab": "Anion Gap", "val": "18", "status": "High"}, {"lab": "Urine Ketones", "val": "Large", "status": "Critical"}], "content": "Information not available"}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Evaluate the mechanism of SGLT2 Inhibitors.", "rows": ["Blocks reabsorption of glucose in kidneys", "Causes Glycosuria (Sugar in urine)", "Increases risk of UTI / Yeast infections", "Reduces Heart Failure hospitalizations"], "columns": ["True", "False"], "answer": {"Blocks reabsorption of glucose in kidneys": "True", "Causes Glycosuria (Sugar in urine)": "True", "Increases risk of UTI / Yeast infections": "True", "Reduces Heart Failure hospitalizations": "True"}, "rationale": "SGLT2s (Flozins) make you pee out sugar. Sugar loves bacteria/yeast, hence infections. They are miracle drugs for Heart Failure."}, {"type": "extended_sata", "prompt": "The patient has 'Euglycemic DKA' (DKA with normal-ish sugar). Why? Select all that apply.", "options": ["The drug lowers blood sugar via urine, masking the severity", "The body is starving for carbs and breaking down fat (Ketones)", "The patient stopped taking Insulin", "The patient is dehydrated", "Only occurs in Type 1 Diabetes"], "answer": [0, 1], "rationale": "Euglycemic DKA is a rare but dangerous SGLT2 side effect. The sugar is low (peed out), but the acidosis (ketones) is raging. Providers miss it because the glucometer says '180', not '600'."}, {"type": "bowtie", "prompt": "The diagnosis is Euglycemic DKA. Prioritize the plan.", "center_condition": {"options": ["Euglycemic DKA", "Yeast Infection", "Gastroenteritis", "Lactic Acidosis"], "answer": "Euglycemic DKA"}, "left_actions": {"options": ["Stop SGLT2 Inhibitor", "Start Insulin Drip + Dextrose", "Give Oral Fluconazole", "Give Antibiotics", "Check tympanic temperature"], "answer": ["Stop SGLT2 Inhibitor", "Start Insulin Drip + Dextrose"]}, "right_monitor": {"options": ["Anion Gap closure", "Urine Culture", "Vaginal pH", "Daily Weight", "Serum Albumin"], "answer": ["Anion Gap closure"]}, "rationale": "We must turn off the ketosis with Insulin. But since sugar is already low (180), we MUST give Dextrose (Sugar) WITH the insulin to prevent hypoglycemia. This is counter-intuitive but life-saving."}]}, {"id": "M-036", "type": "mission", "numerical_id": 36, "title": "The Golden Hour: Sepsis", "category": "Critical Care / Sepsis", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "Florence Nightinghost", "age": 88, "gender": "Female", "mrn": "3636-FN", "dob": "05/12/1938", "weight": "50 kg", "height": "160 cm", "allergies": "Penicillin"}, "chief_complaint": "Confusion and shaking chills.", "hpi": "Ms. Nightinghost comes from a SNF with a Foley catheter. She is obtunded and febrile. Staff report decreased urine output for 24 hours.", "pmh": "Dementia, Bedbound, History of UTIs.", "ros": {"gen": "Temp 103.5 F (39.7 C). BP 80/40. HR 125.", "resp": "RR 28. O2 Sat 92% RA.", "skin": "Mottled extremities.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "musc": "Full ROM. No deformity."}, "sh": "Yoga instructor. Vegans diet. Nonsmoker. No alcohol."}, "exhibits": [{"title": "Lactate", "type": "text", "content": "5.5 mmol/L (Critical High)"}, {"title": "Urinalysis", "type": "text", "content": "Positive for Nitrites, Leukocyte Esterase, and WBCs (TNTC)."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Prioritize the Sepsis Core Measure (1-Hour Bundle).", "rows": ["Measure Lactate Level", "Obtain Blood Cultures", "Administer Broad Spectrum Antibiotics", "Administer 30ml/kg Crystalloid Bolus", "Start Vasopressors"], "columns": ["First 15 Mins", "Within 1 Hour", "Only if Fluid Resuscitation Fails"], "answer": {"Measure Lactate Level": "First 15 Mins", "Obtain Blood Cultures": "First 15 Mins", "Administer Broad Spectrum Antibiotics": "Within 1 Hour", "Administer 30ml/kg Crystalloid Bolus": "Within 1 Hour", "Start Vasopressors": "Only if Fluid Resuscitation Fails"}, "rationale": "Lactate and Cultures MUST come first. Antibiotics cannot be given until cultures are drawn (unless delay > 45 mins). Fluids are given concurrently. Pressors are only for refractory hypotension."}, {"type": "extended_sata", "prompt": "The patient weighs 50kg. The provider orders 30ml/kg Normal Saline. Calculate and implement.", "options": ["Total Volume = 1500 mL", "Total Volume = 3000 mL", "Set pump rate to 999 ml/hr (Wide Open)", "Run over 24 hours", "Monitor for crackles (Pulmonary Edema)", "Warm the fluids if possible"], "answer": [0, 1], "rationale": "50kg * 30ml = 1500ml. This is a BOLUS, meaning give it FAST (999 rate). Warming prevents hypothermia. Lung checks are vital in elderly patients to prevent overload."}, {"type": "bowtie", "prompt": "After 1500ml fluid, BP is still 85/50. Lactate is 6.0. Prioritize.", "center_condition": {"options": ["Septic Shock", "Cardiogenic Shock", "Anaphylaxis", "Fluid Overload"], "answer": "Septic Shock"}, "left_actions": {"options": ["Start Norepinephrine (Levophed)", "Give Albumin", "Give Lasix", "Start Dopamine", "Offer ice chips"], "answer": ["Start Norepinephrine (Levophed)"]}, "right_monitor": {"options": ["MAP > 65", "CVP", "Urine Output", "Pupils", "Hand Grip Strength"], "answer": ["MAP > 65", "Urine Output"]}, "rationale": "Fluid refractory hypotension = Septic Shock. The drug of choice is Norepinephrine (Levophed). The goal is Mean Arterial Pressure (MAP) > 65 to perfuse organs (Kidneys/Brain)."}]}, {"id": "M-037", "type": "mission", "numerical_id": 37, "title": "White Out: ARDS", "category": "Critical Care / Respiratory", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "Bane (Mask guy)", "age": 45, "gender": "Male", "mrn": "3737-BB", "dob": "07/19/1981", "weight": "120 kg", "height": "190 cm", "allergies": "NKDA"}, "chief_complaint": "Can't breathe.", "hpi": "Admitted for severe Pancreatitis. Now developing worsening hypoxia despite 100% BiPAP.", "pmh": "Alcohol Use Disorder, Pancreatitis.", "ros": {"resp": "RR 40. SpO2 82% on 100% FiO2.", "cv": "Tachycardic.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Librarian. Lives with 3 cats. Nonsmoker. Occasional glass of wine."}, "exhibits": [{"title": "Chest X-Ray", "type": "text", "content": "Bilateral diffuse fluffy infiltrates ('White Out'). No cardiomegaly."}, {"title": "ABG", "type": "text", "content": "ph 7.20, pO2 55, pCO2 60, HCO3 22. (Combined Acidosis with Hypoxia)."}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Diagnose ARDS based on the Berlin Criteria.", "rows": ["Timing: Within 1 week of insult", "Chest Imaging: Bilateral Opacities", "Edema Origin: Not fully explained by Heart Failure", "Oxygenation: PaO2/FiO2 ratio < 300"], "columns": ["Met", "Not Met"], "answer": {"Timing: Within 1 week of insult": "Met", "Chest Imaging: Bilateral Opacities": "Met", "Edema Origin: Not fully explained by Heart Failure": "Met", "Oxygenation: PaO2/FiO2 ratio < 300": "Met"}, "rationale": "Pancreatitis triggers systemic inflammation -> Leaky lung capillaries -> Non-cardiogenic pulmonary edema (ARDS). P/F ratio = 55 / 1.0 = 55 (Severe ARDS < 100)."}, {"type": "extended_sata", "prompt": "The patient is intubated. Which ventilator strategies protect the lung? Select all that apply.", "options": ["Low Tidal Volume (6ml/kg PBW)", "High Tidal Volume (10-12ml/kg)", "High PEEP (Positive End Expiratory Pressure)", "Zero PEEP", "Permissive Hypercapnia (Allowing high CO2)", "Maintain Plateau Pressure < 30 cmH2O"], "answer": [0, 1], "rationale": "Baby Lungs concept: Use Low Volumes to prevent volutrauma. Use High PEEP to recruit alveoli. Allow CO2 to rise (as long as pH > 7.2) to spare the lungs. Keep pressure low."}, {"type": "bowtie", "prompt": "O2 Sat remains 85% despite optimal vent settings. Prioritize the rescue therapy.", "center_condition": {"options": ["Refractory Hypoxemia", "Pneumothorax", "Ventilator Disconnect", "Sedation Failure"], "answer": "Refractory Hypoxemia"}, "left_actions": {"options": ["Prone Positioning (Face Down)", "Administer Neuromuscular Blockade (Paralysis)", "Start Nitric Oxide", "ECMO Consult", "Suction"], "answer": ["Prone Positioning (Face Down)", "Administer Neuromuscular Blockade (Paralysis)"]}, "right_monitor": {"options": ["P/F Ratio", "Train of Four (Twitch monitor)", "Facial Pressure Ulcers", "Bowel Sounds", "Capillary Refill"], "answer": ["P/F Ratio", "Train of Four (Twitch monitor)"]}, "rationale": "Proning recruits the posterior lung fields (where most alveoli are). Paralysis (Nimbex) reduces oxygen consumption by muscles. Train of Four ensures they are paralyzed enough but not overdosed."}]}, {"id": "M-038", "type": "mission", "numerical_id": 38, "title": "The Headache: Pediatric DKA", "category": "Critical Care / Peds", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "Eleven (Stranger Things)", "age": 12, "gender": "Female", "mrn": "3838-EL", "dob": "11/11/2014", "weight": "40 kg", "height": "150 cm", "allergies": "Waffles"}, "chief_complaint": "Vomiting and breathing funny.", "hpi": "Newly diagnosed T1DM. Parents report she has been drinking water from the toilet bowl (polydipsia). Now drowsy.", "pmh": "None.", "ros": {"resp": "Kussmaul respirations (Deep/Fast). Fruity odor.", "neuro": "GCS 10 (Confused).", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Yoga instructor. Vegans diet. Nonsmoker. No alcohol."}, "exhibits": [{"title": "Labs", "type": "text", "content": "Glucose: 700. pH: 7.05. HCO3: 8. Anion Gap: 24."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Fluid management in Pediatric DKA is controversial. Weigh the risks.", "rows": ["Rapid bolus of 40ml/kg", "Slow correction over 48 hours", "Risk of Cerebral Edema", "Risk of Shock"], "columns": ["Too Fast (Dangerous)", "Standard Care (Safe)"], "answer": {"Rapid bolus of 40ml/kg": "Too Fast (Dangerous)", "Slow correction over 48 hours": "Standard Care (Safe)", "Risk of Cerebral Edema": "Too Fast (Dangerous)", "Risk of Shock": "Standard Care (Safe)"}, "rationale": "In kids, dropping osmolarity too fast creates a gradient where fluid rushes into the brain -> Cerebral Edema (Fatal). We give moderate fluids (10-20ml/kg) and correct slowly."}, {"type": "extended_sata", "prompt": "Which signs indicate developing Cerebral Edema? Select all that apply.", "options": ["Sudden severe headache", "Bradypnea (respiratory slowing)", "Hypertension with Bradycardia (Cushing's Triad)", "Improved mental status", "Incontinence", "Fixed dilated pupils"], "answer": [0, 1], "rationale": "Any neurological deterioration in a DKA kid is Cerebral Edema until proven otherwise. Cushing's Triad is a late sign of herniation."}, {"type": "bowtie", "prompt": "Eleven grabs her head, screams, and becomes unresponsive. HR 50. BP 160/90. Prioritize.", "center_condition": {"options": ["Cerebral Herniation", "Hypoglycemia", "Stroke", "Seizure"], "answer": "Cerebral Herniation"}, "left_actions": {"options": ["Mannitol IV Push", "Hypertonic Saline (3%)", "Lay flat", "Elevate Head of Bed", "Decrease IV Rate"], "answer": ["Mannitol IV Push", "Elevate Head of Bed"]}, "right_monitor": {"options": ["Pupillary Response", "GCS", "Urine Output", "Serum Na", "Clotting time"], "answer": ["Pupillary Response", "GCS"]}, "rationale": "Cushing's Triad confirmed. The brain is herniating. We must shrink the brain NOW. Mannitol or 3% Saline draws water out. Elevate head to drain venous blood. Reduce maintenance fluids."}]}, {"id": "M-039", "type": "mission", "numerical_id": 39, "title": "The Pressure Cooker: HTN Crisis", "category": "Critical Care / CV", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Pressure Pete", "age": 50, "gender": "Male", "mrn": "3939-PP", "dob": "10/10/1976", "weight": "90 kg", "height": "175 cm", "allergies": "NKDA"}, "chief_complaint": "Worst headache of my life and blurred vision.", "hpi": "Ran out of BP meds 3 days ago. Now presents with confusion and chest pain.", "pmh": "Resistant Hypertension, CKD.", "ros": {"cv": "BP 240/140.", "neuro": "Papilledema (swollen optic disc) on exam.", "mi": "ST depression in V5.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity.", "gen": "Temp 98.6\u00b0F, HR 72, RR 16, BP 120/80, O2 Sat 98% on RA"}, "sh": "Truck driver. Divorced. Smokes 2 packs/day. Sedentary lifestyle."}, "exhibits": [{"title": "Meds Available", "type": "text", "content": "Nitroprusside, Labetalol, Nicardipine, Hydralazine."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Distinguish Hypertensive Urgency vs Emergency.", "rows": ["BP > 180/120", "Evidence of End Organ Damage (Heart, Brain, Kidney)", "Requires IV Drip Admission", "Treat with Oral agents slowly", "Headache alone"], "columns": ["Urgency", "Emergency", "Both"], "answer": {"BP > 180/120": "Both", "Evidence of End Organ Damage (Heart, Brain, Kidney)": "Emergency", "Requires IV Drip Admission": "Emergency", "Treat with Oral agents slowly": "Urgency", "Headache alone": "Urgency"}, "rationale": "The number (180/120) is the same. The difference is Organ Damage. Pete has chest pain (Heart) and confusion (Brain), so it is EMERGENCY."}, {"type": "extended_sata", "prompt": "We start a Nitroprusside drip. What are the rules? Select all that apply.", "options": ["Protect the IV bag from light (Opaque cover)", "Monitor Thiocyanate/Cyanide levels if used > 24hrs", "Lower BP to 120/80 within 1 hour", "Lower BP by max 25% in first hour", "Monitor continuous arterial line BP"], "answer": [0, 1], "rationale": "Nitroprusside turns into CYANIDE in the light/body. Never drop BP too fast (stroke risk from hypoperfusion) - max 25% drop initially. Art line is mandatory for potent vasodilators."}, {"type": "bowtie", "prompt": "After 24 hours, Pete becomes confused again and smells like 'bitter almonds'. Lactic acid is rising. Prioritize.", "center_condition": {"options": ["Cyanide Toxicity", "Stroke", "Hypotension", "Renal Failure"], "answer": "Cyanide Toxicity"}, "left_actions": {"options": ["Stop Nitroprusside", "Administer Sodium Thiosulfate", "Start dialysis", "Increase oxygen", "Administer IV Acetaminophen"], "answer": ["Stop Nitroprusside", "Administer Sodium Thiosulfate"]}, "right_monitor": {"options": ["Thiocyanate Level", "Lactate", "Pupils", "BP", "Urine Color"], "answer": ["Thiocyanate Level", "Lactate"]}, "rationale": "Bitter almonds + Acidosis on Nitroprusside = Cyanide Poisoning. Stop the drug. Give Thiosulfate (antidote)."}]}, {"id": "M-040", "type": "mission", "numerical_id": 40, "title": "Flatline: Code Blue", "category": "Critical Care / ACLS", "difficulty": "Critical", "patient_profile": {"demographics": {"name": "John Doe", "age": 60, "gender": "Male", "mrn": "4040-JD", "dob": "01/01/1966", "weight": "80 kg", "height": "180 cm", "allergies": "Unknown"}, "chief_complaint": "Unresponsive.", "hpi": "Patient found unresponsive in the public bathroom by housekeeping staff. CPR was initiated immediately by bystanders. EMS reported downtime of approximately 8 minutes before arrival. Defibrillated x1 in field with return of pulse, then lost pulse again during transport.", "pmh": "Unknown.", "ros": {"gen": "Pulseless. Apneic.", "cardio": "Regular rate and rhythm. S1/S2 audible. No murmurs.", "resp": "Lungs clear to auscultation bilaterally. No distress.", "neuro": "Alert and oriented x3. PEERLA.", "gi": "Abdomen soft, non-tender. Bowel sounds active.", "gu": "No complaints. Urine clear.", "skin": "Warm and dry. No rashes.", "musc": "Full ROM. No deformity."}, "sh": "Retired veteran. Lives in assisted living. Former smoker (quit 20 years ago)."}, "exhibits": [{"title": "Monitor", "type": "text", "content": "Shows Ventricular Fibrillation (V-Fib)."}, {"title": "Current Medications", "type": "table", "data": [{"drug": "Lisinopril", "dose": "10mg daily", "route": "PO"}, {"drug": "Atorvastatin", "dose": "40mg daily", "route": "PO"}, {"drug": "Multivitamin", "dose": "1 tab daily", "route": "PO"}, {"drug": "Metformin", "dose": "500mg BID", "route": "PO"}], "content": "Information not available"}, {"title": "Labs", "type": "text", "content": "WBC: 8.5, Hgb: 14.2, Plt: 250, Na: 140, K: 4.2, BUN: 18, Cr: 1.0"}], "steps": [{"type": "matrix", "prompt": "Review the ACLS Algorithms. Match the treatment to the rhythm.", "rows": ["Ventricular Fibrillation (V-Fib)", "Ventricular Tachycardia (Pulseless)", "Asystole (Flatline)", "PEA (Rhythm but no pulse)"], "columns": ["Shockable", "Not Shockable"], "answer": {"Ventricular Fibrillation (V-Fib)": "Shockable", "Ventricular Tachycardia (Pulseless)": "Shockable", "Asystole (Flatline)": "Not Shockable", "PEA (Rhythm but no pulse)": "Not Shockable"}, "rationale": "If they are dead (pulseless), check if the heart is shaking (Fib/Tach). If yes, SHOCK IT. If it's silent (Asystole/PEA), shocking does nothing. Just CPR + Epi."}, {"type": "extended_sata", "prompt": "You are running the code. Which actions are High Quality CPR? Select all that apply.", "options": ["Rate 100-120 compressions/min", "Depth at least 2 inches (5cm)", "Allow full chest recoil", "Minimize interruptions (< 10 seconds)", "Give breaths every 6 seconds (if advanced airway)", "Switch compressor every 5 cycles (2 mins)", "Hyperventilate to blow off CO2"], "answer": [0, 1], "rationale": "Hyperventilation kills (increases intrathoracic pressure, decreases venous return). Everything else is standard ACLS."}, {"type": "bowtie", "prompt": "We get ROSC (Return of Spontaneous Circulation). Patient follows commands? NO. Prioritize post-arrest care.", "center_condition": {"options": ["Targeted Temperature Management (TTM)", "Dialysis", "Immediate Extubation", "Family meeting"], "answer": "Targeted Temperature Management (TTM)"}, "left_actions": {"options": ["Cool to 32-36 C", "Maintain Normothermia", "Sedate and Paralyze (if shivering)", "Obtain 12-Lead ECG", "Change bed linens"], "answer": ["Cool to 32-36 C", "Sedate and Paralyze (if shivering)"]}, "right_monitor": {"options": ["Core Temperature (Esophageal)", "EEG", "Blood Glucose", "Urine Output", "Hand Grip Strength"], "answer": ["Core Temperature (Esophageal)", "EEG"]}, "rationale": "If the patient doesn't wake up after ROSC, we cool them (Therapeutic Hypothermia) to preserve brain function. Shivering fights the cooling and must be stopped. 12-Lead is also crucial to look for STEMI."}]}]);
console.log('Injected 10 NGN missions from comorbid_missions_gen');
window.customMissions = window.customMissions || [];
window.customMissions = window.customMissions.concat([{"id": "M-041", "numerical_id": 41, "type": "mission", "title": "The Fever: Community-Acquired Pneumonia", "category": "Acute Respiratory / Pneumonia", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Margaret Chen", "age": 72, "gender": "Female", "mrn": "4141-MC", "dob": "03/15/1952", "weight": "145 lbs", "height": "5'2\"", "allergies": "Penicillin (rash)"}, "chief_complaint": "Fever and productive cough for 3 days.", "hpi": "72-year-old female presents with 3-day history of fever, chills, and productive cough with yellow sputum. Reports pleuritic chest pain on right side. No recent travel or sick contacts. History of COPD on home oxygen.", "pmh": "COPD (on 2L home O2), Hypertension, Osteoarthritis.", "ros": {"gen": "Temp 101.8\u00b0F, HR 102, RR 24, BP 148/88, O2 Sat 91% on RA", "resp": "Productive cough with yellow sputum, pleuritic chest pain right side", "cv": "No chest pain at rest", "neuro": "Alert and oriented, no confusion", "cardio": "Regular rate and rhythm, no murmurs", "gi": "No nausea, vomiting, or abdominal pain", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "Chest X-Ray", "type": "text", "content": "Right lower lobe infiltrate with air bronchograms. No pleural effusion."}, {"title": "Sputum Culture", "type": "text", "content": "Pending - Gram stain shows gram-positive cocci in pairs."}, {"title": "Labs", "type": "text", "content": "WBC 18.2 (neutrophilic predominance), CRP 156 mg/L, Procalcitonin 0.8 ng/mL"}], "steps": [{"type": "extended_sata", "prompt": "Mrs. Chen is diagnosed with community-acquired pneumonia. Which nursing interventions are priority? (Select all that apply)", "options": ["Administer prescribed antibiotics within 1 hour", "Monitor respiratory status every 2 hours", "Encourage deep breathing and coughing", "Maintain semi-Fowler's position", "Provide adequate hydration", "Assess for antibiotic side effects", "Monitor oxygen saturation continuously"], "answer": [0, 1], "rationale": "All interventions are essential for pneumonia management including timely antibiotics, respiratory monitoring, mobilization of secretions, positioning, hydration, side effect monitoring, and oxygenation assessment."}, {"type": "matrix", "prompt": "Match the pneumonia classification with appropriate treatment duration:", "rows": [{"text": "Mild CAP (CURB-65 score 0-1)"}, {"text": "Moderate CAP (CURB-65 score 2)"}, {"text": "Severe CAP (CURB-65 score 3-5)"}, {"text": "Healthcare-associated pneumonia"}], "columns": ["5-7 days", "7-10 days", "10-14 days", "14-21 days"], "answer": {"Mild CAP (CURB-65 score 0-1)": "5-7 days", "Moderate CAP (CURB-65 score 2)": "7-10 days", "Severe CAP (CURB-65 score 3-5)": "10-14 days", "Healthcare-associated pneumonia": "14-21 days"}, "rationale": "Treatment duration varies by pneumonia severity and risk factors. Mild cases need shorter courses, severe or healthcare-associated cases require longer treatment."}, {"type": "bowtie", "prompt": "Mrs. Chen develops increased shortness of breath and O2 sat drops to 85%. Prioritize the acute respiratory distress intervention.", "center_condition": {"options": ["Respiratory Failure", "Pneumothorax", "Pulmonary Edema", "Bronchospasm"], "answer": "Respiratory Failure"}, "left_actions": {"options": ["Apply oxygen via non-rebreather mask", "Prepare for intubation", "Administer bronchodilators", "Start IV fluids", "Call rapid response"], "answer": ["Apply oxygen via non-rebreather mask", "Prepare for intubation", "Call rapid response"]}, "right_monitor": {"options": ["ABG analysis", "Chest X-ray", "Cardiac enzymes", "Respiratory rate and pattern", "Level of consciousness"], "answer": ["ABG analysis", "Respiratory rate and pattern", "Level of consciousness"]}, "rationale": "Acute respiratory failure requires immediate oxygenation, preparation for advanced airway management, and continuous monitoring of respiratory status and mental status changes."}]}, {"id": "M-042", "numerical_id": 42, "type": "mission", "title": "The Persistent Cough: Acute Bronchitis", "category": "Acute Respiratory / Bronchitis", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Robert Martinez", "age": 45, "gender": "Male", "mrn": "4284-RM", "dob": "07/22/1979", "weight": "180 lbs", "height": "5'10\"", "allergies": "None"}, "chief_complaint": "Persistent cough and chest congestion for 5 days.", "hpi": "45-year-old male presents with 5-day history of productive cough with clear-to-white sputum, mild chest tightness, and low-grade fever. Symptoms began after upper respiratory infection. Smokes 1 pack/day for 25 years. No shortness of breath at rest.", "pmh": "Smoking history, Seasonal allergies.", "ros": {"gen": "Temp 99.2\u00b0F, HR 78, RR 18, BP 132/84, O2 Sat 97% on RA", "resp": "Productive cough with clear sputum, mild wheezing, no hemoptysis", "cardio": "Regular rate and rhythm, no murmurs", "neuro": "Alert and oriented, no confusion", "gi": "No nausea or abdominal pain", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "Chest X-Ray", "type": "text", "content": "Clear lung fields. No infiltrates or effusions. Normal cardiac silhouette."}, {"title": "Spirometry", "type": "text", "content": "FEV1 85% predicted, FVC normal. Mild obstructive pattern noted."}, {"title": "Labs", "type": "text", "content": "WBC 9.8, CRP 12 mg/L (mild elevation)"}], "steps": [{"type": "extended_sata", "prompt": "Mr. Martinez is diagnosed with acute bronchitis. Which interventions are appropriate? (Select all that apply)", "options": ["Prescribe antibiotics immediately", "Recommend smoking cessation counseling", "Encourage hydration and humidified air", "Teach effective coughing techniques", "Schedule follow-up in 2 weeks if symptoms persist", "Administer bronchodilators as prescribed", "Monitor for signs of pneumonia development", "Prescribe codeine cough syrup", "Advise complete bed rest for 1 week"], "answer": [0, 1], "rationale": "Acute bronchitis is typically viral and self-limiting. Key interventions include smoking cessation, hydration, coughing techniques, and monitoring for complications. Antibiotics are not routinely prescribed, and complete bed rest/codeine are not recommended."}, {"type": "matrix", "prompt": "Match the bronchitis symptom with appropriate nursing intervention:", "rows": [{"text": "Productive cough with thick sputum"}, {"text": "Chest tightness and wheezing"}, {"text": "Fever and malaise"}, {"text": "Smoking history"}], "columns": ["Antibiotic therapy", "Hydration and humidification", "Bronchodilator administration", "Smoking cessation counseling", "Antipyretic medication", "Chest physiotherapy"], "answer": {"Productive cough with thick sputum": "Hydration and humidification", "Chest tightness and wheezing": "Bronchodilator administration", "Fever and malaise": "Antipyretic medication", "Smoking history": "Smoking cessation counseling"}, "rationale": "Each bronchitis symptom requires specific nursing interventions: hydration for sputum clearance, bronchodilators for wheezing, antipyretics for fever, and smoking cessation counseling."}, {"type": "bowtie", "prompt": "Mr. Martinez develops worsening shortness of breath and chest pain. Identify the priority intervention.", "center_condition": {"options": ["Pneumonia", "Bronchospasm", "Pulmonary Embolism", "Myocardial Infarction"], "answer": "Bronchospasm"}, "left_actions": {"options": ["Administer albuterol nebulizer", "Position upright with arms supported", "Apply oxygen via nasal cannula", "Prepare for intubation", "Give aspirin 325mg", "Start IV fluids"], "answer": ["Administer albuterol nebulizer", "Position upright with arms supported"]}, "right_monitor": {"options": ["Oxygen saturation", "Respiratory rate and pattern", "Peak flow measurements", "Cardiac rhythm", "Blood pressure", "Temperature"], "answer": ["Oxygen saturation", "Respiratory rate and pattern"]}}]}, {"id": "M-043", "numerical_id": 43, "type": "mission", "title": "The Wheezing Patient: Asthma Exacerbation", "category": "Acute Respiratory / Asthma", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Sarah Johnson", "age": 28, "gender": "Female", "mrn": "4392-SJ", "dob": "11/08/1996", "weight": "135 lbs", "height": "5'6\"", "allergies": "Environmental allergens, Aspirin"}, "chief_complaint": "Severe shortness of breath and wheezing.", "hpi": "28-year-old female with known asthma presents with acute exacerbation. Reports increased wheezing, chest tightness, and SOB over past 2 hours. Used rescue inhaler 6 times in last hour with minimal relief. Peak flow 250 L/min (personal best 450 L/min).", "pmh": "Moderate persistent asthma, Allergic rhinitis.", "ros": {"gen": "Temp 98.6\u00b0F, HR 110, RR 28, BP 142/88, O2 Sat 93% on RA", "resp": "Severe wheezing, prolonged expiratory phase, intercostal retractions", "cardio": "Tachycardia, no murmurs", "neuro": "Anxious but alert", "gi": "No nausea", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "Arterial Blood Gas", "type": "text", "content": "pH 7.38, PaCO2 38 mmHg, PaO2 68 mmHg, HCO3 22 mEq/L, O2 Sat 93%"}, {"title": "Peak Flow Measurement", "type": "text", "content": "250 L/min (55% of personal best). Severe obstruction."}, {"title": "Chest X-Ray", "type": "text", "content": "Hyperinflated lungs with no infiltrates. Normal cardiac silhouette."}], "steps": [{"type": "extended_sata", "prompt": "Ms. Johnson is experiencing a severe asthma exacerbation. Which interventions are priority? (Select all that apply)", "options": ["Administer high-dose albuterol/ipratropium nebulizer", "Apply oxygen to maintain SpO2 >94%", "Start systemic corticosteroids", "Assess peak flow every 30 minutes", "Position in high Fowler's position", "Monitor for signs of respiratory fatigue", "Prepare magnesium sulfate infusion", "Administer oral antibiotics", "Encourage oral intake of fluids"], "answer": [0, 1], "rationale": "Severe asthma exacerbation requires aggressive bronchodilation, oxygen, steroids, frequent monitoring, positioning, and fatigue assessment. Antibiotics and oral fluids are not indicated for acute asthma."}, {"type": "matrix", "prompt": "Match the asthma severity indicator with appropriate action:", "rows": [{"text": "Peak flow 40-50% of personal best"}, {"text": "PaO2 <60 mmHg on room air"}, {"text": "Silent chest on auscultation"}, {"text": "PaCO2 >42 mmHg (respiratory acidosis)"}], "columns": ["Home management", "Office/clinic visit", "Emergency department", "Intensive care admission", "Immediate intubation", "Oral corticosteroids"], "answer": {"Peak flow 40-50% of personal best": "Emergency department", "PaO2 <60 mmHg on room air": "Intensive care admission", "Silent chest on auscultation": "Immediate intubation", "PaCO2 >42 mmHg (respiratory acidosis)": "Immediate intubation"}, "rationale": "Asthma severity indicators guide escalation of care: moderate obstruction requires ED visit, hypoxemia needs ICU, silent chest indicates impending respiratory failure requiring intubation."}, {"type": "bowtie", "prompt": "Despite aggressive treatment, Ms. Johnson becomes unresponsive with agonal respirations. Identify the emergency condition.", "center_condition": {"options": ["Respiratory Arrest", "Status Epilepticus", "Cardiac Arrest", "Hypoglycemic Coma"], "answer": "Respiratory Arrest"}, "left_actions": {"options": ["Begin CPR", "Administer epinephrine IM", "Intubate and mechanically ventilate", "Administer dextrose IV", "Defibrillate", "Give benzodiazepines"], "answer": ["Begin CPR", "Intubate and mechanically ventilate"]}, "right_monitor": {"options": ["End-tidal CO2", "Cardiac rhythm", "Oxygen saturation", "Blood glucose", "Seizure activity", "Temperature"], "answer": ["End-tidal CO2", "Cardiac rhythm"]}}]}, {"id": "M-044", "numerical_id": 44, "type": "mission", "title": "The Breathless Chronic: COPD Exacerbation", "category": "Acute Respiratory / COPD", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "William Thompson", "age": 68, "gender": "Male", "mrn": "4498-WT", "dob": "02/14/1956", "weight": "160 lbs", "height": "5'8\"", "allergies": "Morphine (nausea)"}, "chief_complaint": "Increased shortness of breath and productive cough.", "hpi": "68-year-old male with severe COPD presents with exacerbation. Reports increased SOB, cough with green sputum, and fatigue over 3 days. Currently on 3L home O2. Last exacerbation 2 months ago required hospitalization.", "pmh": "Severe COPD (FEV1 35% predicted), Coronary artery disease, HTN.", "ros": {"gen": "Temp 99.8\u00b0F, HR 92, RR 26, BP 158/92, O2 Sat 88% on 3L NC", "resp": "Increased work of breathing, expiratory wheezes, rhonchi, productive cough", "cardio": "Irregular rhythm, no murmurs", "neuro": "Alert but anxious", "gi": "No nausea or vomiting", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "Arterial Blood Gas", "type": "text", "content": "pH 7.32, PaCO2 55 mmHg, PaO2 52 mmHg, HCO3 28 mEq/L, O2 Sat 88%"}, {"title": "Chest X-Ray", "type": "text", "content": "Hyperinflated lungs with flattened diaphragms. No acute infiltrates."}, {"title": "Sputum Culture", "type": "text", "content": "Pending - Gram stain shows many neutrophils with mixed flora."}], "steps": [{"type": "extended_sata", "prompt": "Mr. Thompson is admitted with COPD exacerbation. Which interventions are essential? (Select all that apply)", "options": ["Increase oxygen to maintain SpO2 88-92%", "Administer bronchodilators and corticosteroids", "Obtain sputum culture", "Monitor for respiratory acidosis", "Provide pulmonary hygiene therapy", "Assess for cor pulmonale", "Administer prophylactic antibiotics", "Encourage 3L/min continuous oxygen", "Schedule incentive spirometry q2h"], "answer": [0, 1], "rationale": "COPD exacerbation management focuses on controlled oxygenation, bronchodilation, steroids, cultures, monitoring acidosis, pulmonary hygiene, and cardiac assessment. High-flow oxygen and prophylactic antibiotics are not indicated."}, {"type": "matrix", "prompt": "Match the COPD assessment finding with appropriate intervention:", "rows": [{"text": "PaCO2 55 mmHg, pH 7.32"}, {"text": "O2 saturation 88% on 3L NC"}, {"text": "Green productive sputum"}, {"text": "Increased work of breathing"}], "columns": ["Increase oxygen flow rate", "Prepare for non-invasive ventilation", "Obtain sputum culture", "Administer antibiotics", "Administer sedatives", "Provide chest physiotherapy"], "answer": {"PaCO2 55 mmHg, pH 7.32": "Prepare for non-invasive ventilation", "O2 saturation 88% on 3L NC": "Administer antibiotics", "Green productive sputum": "Obtain sputum culture", "Increased work of breathing": "Provide chest physiotherapy"}, "rationale": "COPD exacerbation findings require specific interventions: respiratory acidosis needs NIV, hypoxemia suggests infection requiring antibiotics, purulent sputum needs culture, and increased WOB benefits from pulmonary hygiene."}, {"type": "bowtie", "prompt": "Mr. Thompson develops altered mental status and respiratory fatigue. Identify the critical complication.", "center_condition": {"options": ["Respiratory Acidosis", "Acute Coronary Syndrome", "Pneumonia", "Pulmonary Embolism"], "answer": "Respiratory Acidosis"}, "left_actions": {"options": ["Apply BiPAP ventilation", "Administer naloxone", "Give nitroglycerin", "Start heparin infusion", "Administer bronchodilators", "Prepare for intubation"], "answer": ["Apply BiPAP ventilation", "Administer bronchodilators"]}, "right_monitor": {"options": ["Arterial blood gases", "Mental status", "Respiratory rate and pattern", "Cardiac enzymes", "D-dimer levels", "White blood cell count"], "answer": ["Arterial blood gases", "Mental status"]}}]}, {"id": "M-045", "numerical_id": 45, "type": "mission", "title": "The Sudden Shortness: Pulmonary Embolism", "category": "Acute Respiratory / Pulmonary Embolism", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Jennifer Davis", "age": 52, "gender": "Female", "mrn": "4567-JD", "dob": "09/30/1972", "weight": "165 lbs", "height": "5'4\"", "allergies": "Contrast dye (rash)"}, "chief_complaint": "Sudden onset shortness of breath and chest pain.", "hpi": "52-year-old female presents with acute onset SOB and pleuritic chest pain 2 hours ago. Pain worse with inspiration. Recent 8-hour car trip. No cough, hemoptysis, or leg swelling. History of oral contraceptives.", "pmh": "Oral contraceptive use, Migraine headaches.", "ros": {"gen": "Temp 98.4\u00b0F, HR 105, RR 24, BP 138/82, O2 Sat 94% on RA", "resp": "Dyspnea, pleuritic chest pain, clear breath sounds", "cardio": "Tachycardia, no murmurs or gallops", "neuro": "Alert and oriented", "gi": "No nausea", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "EKG", "type": "text", "content": "Sinus tachycardia. S1Q3T3 pattern. No ST changes."}, {"title": "D-Dimer", "type": "text", "content": "2.8 mcg/mL (elevated >0.5)"}, {"title": "CT Pulmonary Angiogram", "type": "text", "content": "Filling defect in right main pulmonary artery consistent with pulmonary embolism."}], "steps": [{"type": "extended_sata", "prompt": "Ms. Davis is diagnosed with pulmonary embolism. Which interventions are priority? (Select all that apply)", "options": ["Administer heparin infusion", "Apply oxygen to maintain SpO2 >95%", "Monitor vital signs every 15 minutes", "Assess for signs of bleeding", "Provide pain management", "Encourage ambulation", "Prepare for catheter-directed thrombolysis", "Administer prophylactic antibiotics", "Apply sequential compression devices"], "answer": [0, 1], "rationale": "PE management requires anticoagulation, oxygenation, frequent monitoring, bleeding assessment, and pain control. Early ambulation and prophylactic antibiotics are contraindicated. Compression devices are for DVT prevention, not acute PE treatment."}, {"type": "matrix", "prompt": "Match the pulmonary embolism risk factor with appropriate prophylactic measure:", "rows": [{"text": "Post-surgical patient"}, {"text": "Immobilized patient"}, {"text": "Oral contraceptive use"}, {"text": "Cancer patient"}], "columns": ["Low molecular weight heparin", "Warfarin therapy", "Compression stockings", "Inferior vena cava filter", "Aspirin therapy", "Early mobilization"], "answer": {"Post-surgical patient": "Low molecular weight heparin", "Immobilized patient": "Compression stockings", "Oral contraceptive use": "Early mobilization", "Cancer patient": "Low molecular weight heparin"}, "rationale": "Different risk factors require different prophylaxis: surgery needs LMWH, immobilization needs mechanical prophylaxis, hormonal contraception needs mobilization, cancer needs anticoagulation."}, {"type": "bowtie", "prompt": "Ms. Davis develops hemodynamic instability with BP 85/50. Identify the complication requiring immediate intervention.", "center_condition": {"options": ["Massive Pulmonary Embolism", "Tension Pneumothorax", "Cardiac Tamponade", "Aortic Dissection"], "answer": "Massive Pulmonary Embolism"}, "left_actions": {"options": ["Administer thrombolytics", "Perform needle decompression", "Prepare pericardiocentesis", "Administer vasopressors", "Perform pericardiocentesis", "Prepare for surgical embolectomy"], "answer": ["Administer thrombolytics", "Administer vasopressors"]}, "right_monitor": {"options": ["Cardiac output", "Blood pressure", "Oxygen saturation", "ECG changes", "Chest pain", "Mental status"], "answer": ["Blood pressure", "Mental status"]}}]}, {"id": "M-046", "numerical_id": 46, "type": "mission", "title": "The Fluid in the Chest: Pleural Effusion", "category": "Acute Respiratory / Pleural Effusion", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Michael Rodriguez", "age": 61, "gender": "Male", "mrn": "4623-MR", "dob": "05/14/1963", "weight": "175 lbs", "height": "5'9\"", "allergies": "Lidocaine"}, "chief_complaint": "Shortness of breath and chest pain.", "hpi": "61-year-old male presents with progressive SOB over 2 weeks and right-sided chest pain. Pain worse with deep inspiration. History of congestive heart failure. No fever or cough.", "pmh": "Congestive heart failure (EF 35%), Hypertension, Diabetes mellitus.", "ros": {"gen": "Temp 98.1\u00b0F, HR 88, RR 22, BP 152/94, O2 Sat 92% on RA", "resp": "Decreased breath sounds right lower lobe, dullness to percussion", "cardio": "S3 gallop, bilateral lower extremity edema 2+", "neuro": "Alert and oriented", "gi": "Mild abdominal distension", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "Chest X-Ray", "type": "text", "content": "Right-sided pleural effusion with blunting of costophrenic angle. Cardiomegaly noted."}, {"title": "Echocardiogram", "type": "text", "content": "Ejection fraction 35%. Global hypokinesis. Moderate mitral regurgitation."}, {"title": "Thoracentesis Results", "type": "text", "content": "Transudative effusion. Protein 2.8 g/dL, LDH 180 IU/L. Negative for infection."}], "steps": [{"type": "extended_sata", "prompt": "Mr. Rodriguez has a large pleural effusion secondary to heart failure. Which nursing interventions are essential? (Select all that apply)", "options": ["Monitor respiratory status every 4 hours", "Measure and record chest tube drainage", "Assess for signs of respiratory distress", "Administer diuretics as prescribed", "Position on affected side to improve drainage", "Monitor for subcutaneous emphysema", "Encourage deep breathing exercises", "Prepare for thoracentesis procedure", "Apply petroleum jelly to chest tube site"], "answer": [0, 1], "rationale": "Pleural effusion management includes monitoring, positioning, diuretics for underlying cause, deep breathing, and preparation for procedures. Chest tubes and air leaks are not present. Petroleum jelly is not used for site care."}, {"type": "matrix", "prompt": "Match the pleural effusion characteristic with appropriate nursing consideration:", "rows": [{"text": "Transudative effusion"}, {"text": "Exudative effusion"}, {"text": "Large volume effusion"}, {"text": "Post-thoracentesis"}], "columns": ["Treat underlying heart failure", "Obtain sputum culture", "Monitor for re-expansion pulmonary edema", "Administer broad-spectrum antibiotics", "Encourage mobility", "Assess puncture site for air leaks"], "answer": {"Transudative effusion": "Treat underlying heart failure", "Exudative effusion": "Obtain sputum culture", "Large volume effusion": "Monitor for re-expansion pulmonary edema", "Post-thoracentesis": "Assess puncture site for air leaks"}, "rationale": "Different effusion types require different approaches: transudative needs cardiac treatment, exudative suggests infection requiring cultures, large effusions risk re-expansion edema, and post-procedure needs leak assessment."}, {"type": "bowtie", "prompt": "During thoracentesis, Mr. Rodriguez develops acute shortness of breath and tachycardia. Identify the complication.", "center_condition": {"options": ["Re-expansion Pulmonary Edema", "Pneumothorax", "Hemothorax", "Air Embolism"], "answer": "Re-expansion Pulmonary Edema"}, "left_actions": {"options": ["Apply high-flow oxygen", "Insert chest tube", "Administer diuretics", "Stop the procedure immediately", "Give blood products", "Hyperventilate the patient"], "answer": ["Apply high-flow oxygen", "Stop the procedure immediately"]}, "right_monitor": {"options": ["Respiratory rate and oxygen saturation", "Blood pressure and heart rate", "Chest tube drainage", "Breath sounds", "Level of consciousness", "Urine output"], "answer": ["Respiratory rate and oxygen saturation", "Blood pressure and heart rate"]}}]}, {"id": "M-047", "numerical_id": 47, "type": "mission", "title": "The Failing Lungs: Acute Respiratory Distress Syndrome", "category": "Acute Respiratory / ARDS", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "David Chen", "age": 34, "gender": "Male", "mrn": "4789-DC", "dob": "03/22/1990", "weight": "190 lbs", "height": "6'0\"", "allergies": "None"}, "chief_complaint": "Severe shortness of breath requiring intubation.", "hpi": "34-year-old male intubated for ARDS secondary to septic shock from perforated appendix. Surgery 48 hours ago. Currently sedated and mechanically ventilated. PaO2/FiO2 ratio 180. On norepinephrine and broad-spectrum antibiotics.", "pmh": "No significant history.", "ros": {"gen": "Temp 101.4\u00b0F, HR 110, RR 16 (vent), BP 118/72 on NE 8 mcg/min, O2 Sat 92%", "resp": "Bilateral crackles, decreased breath sounds, chest X-ray shows bilateral infiltrates", "cardio": "Regular rhythm on telemetry", "neuro": "Sedated, following commands when aroused", "gi": "Abdomen soft, surgical dressing clean/dry", "gu": "Foley catheter draining clear urine"}}, "exhibits": [{"title": "Arterial Blood Gas", "type": "text", "content": "pH 7.42, PaCO2 45 mmHg, PaO2 144 mmHg, HCO3 28 mEq/L on FiO2 80%"}, {"title": "Chest X-Ray", "type": "text", "content": "Bilateral diffuse alveolar infiltrates consistent with ARDS. ET tube in good position."}, {"title": "Ventilator Settings", "type": "text", "content": "AC mode, VT 480 mL, RR 16, PEEP 12 cmH2O, FiO2 80%, Pplat 28 cmH2O"}], "steps": [{"type": "extended_sata", "prompt": "Mr. Chen is mechanically ventilated with ARDS. Which nursing interventions are critical? (Select all that apply)", "options": ["Maintain PEEP \u226510 cmH2O to prevent derecruitment", "Monitor plateau pressure <30 cmH2O", "Perform daily sedation vacations", "Elevate head of bed to 45 degrees", "Provide lung-protective ventilation", "Administer neuromuscular blockers if needed", "Encourage incentive spirometry", "Maintain fluid balance", "Monitor for ventilator-associated pneumonia"], "answer": [0, 1], "rationale": "ARDS management focuses on lung protection, PEEP maintenance, pressure monitoring, sedation management, positioning, fluid balance, and VAP prevention. Incentive spirometry and neuromuscular blockers are not routinely used in ARDS."}, {"type": "matrix", "prompt": "Match the ARDS ventilator parameter with appropriate nursing response:", "rows": [{"text": "Plateau pressure >30 cmH2O"}, {"text": "PaO2/FiO2 ratio <200"}, {"text": "Auto-PEEP present"}, {"text": "Patient-ventilator dyssynchrony"}], "columns": ["Decrease tidal volume", "Increase sedation", "Increase PEEP", "Decrease respiratory rate", "Prone positioning", "Neuromuscular blockade"], "answer": {"Plateau pressure >30 cmH2O": "Decrease tidal volume", "PaO2/FiO2 ratio <200": "Prone positioning", "Auto-PEEP present": "Increase sedation", "Patient-ventilator dyssynchrony": "Neuromuscular blockade"}, "rationale": "ARDS ventilator management requires specific responses: high pressure needs volume reduction, severe hypoxemia needs proning, auto-PEEP needs sedation, dyssynchrony may need paralysis."}, {"type": "bowtie", "prompt": "Mr. Chen develops hypotension and tachycardia while on high PEEP. Identify the complication.", "center_condition": {"options": ["Tension Pneumothorax", "Cardiac Tamponade", "Decreased Cardiac Output", "Pulmonary Embolism"], "answer": "Decreased Cardiac Output"}, "left_actions": {"options": ["Decrease PEEP", "Insert chest tube", "Administer vasopressors", "Perform pericardiocentesis", "Anticoagulation", "Fluid bolus"], "answer": ["Decrease PEEP", "Fluid bolus"]}, "right_monitor": {"options": ["Blood pressure", "Heart rate", "Cardiac output", "Urine output", "Chest tube drainage", "CVP"], "answer": ["Blood pressure", "Urine output"]}}]}, {"id": "M-048", "numerical_id": 48, "type": "mission", "title": "The Collapsed Lung: Pneumothorax", "category": "Acute Respiratory / Pneumothorax", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Amanda Foster", "age": 26, "gender": "Female", "mrn": "4856-AF", "dob": "12/05/1998", "weight": "125 lbs", "height": "5'4\"", "allergies": "Penicillin"}, "chief_complaint": "Sudden chest pain and shortness of breath.", "hpi": "26-year-old female presents with acute onset right-sided chest pain and SOB after coughing episode. Pain sharp, worse with inspiration. No trauma history. Tall, thin build. Smokes occasionally.", "pmh": "None.", "ros": {"gen": "Temp 98.8\u00b0F, HR 105, RR 28, BP 128/78, O2 Sat 91% on RA", "resp": "Decreased breath sounds right upper lobe, hyperresonant percussion", "cardio": "Tachycardia, no murmurs", "neuro": "Anxious but alert", "gi": "No nausea", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "Chest X-Ray", "type": "text", "content": "Right-sided pneumothorax with 35% lung collapse. Trachea deviated to left. No mediastinal shift."}, {"title": "CT Chest", "type": "text", "content": "Spontaneous pneumothorax. No blebs/bullae identified. Lung re-expanded after chest tube placement."}, {"title": "Chest Tube", "type": "text", "content": "Right chest tube to water seal. Tidaling present. Air leak noted in water seal chamber."}], "steps": [{"type": "extended_sata", "prompt": "Ms. Foster has a spontaneous pneumothorax with chest tube. Which nursing interventions are essential? (Select all that apply)", "options": ["Monitor air leak in water seal chamber", "Keep chest tube system below patient level", "Assess respiratory status every 15-30 minutes", "Encourage coughing and deep breathing", "Monitor for subcutaneous emphysema", "Clamp chest tube during transport", "Maintain upright position", "Assess chest tube insertion site", "Prepare for pleurodesis if recurrent"], "answer": [0, 1], "rationale": "Pneumothorax management requires air leak monitoring, proper drainage system positioning, frequent assessments, subcutaneous air checks, positioning, and site care. Coughing/deep breathing and clamping are contraindicated. Pleurodesis is for recurrent cases."}, {"type": "matrix", "prompt": "Match the chest tube assessment finding with appropriate nursing action:", "rows": [{"text": "Continuous air bubbling in water seal"}, {"text": "Chest tube becomes dislodged"}, {"text": "Tidaling absent in water seal"}, {"text": "Bright red blood in drainage"}], "columns": ["Notify physician immediately", "Apply occlusive dressing with petroleum jelly", "Increase wall suction", "Milk the chest tube", "Assess for tube kinking", "Prepare for needle decompression"], "answer": {"Continuous air bubbling in water seal": "Assess for tube kinking", "Chest tube becomes dislodged": "Apply occlusive dressing with petroleum jelly", "Tidaling absent in water seal": "Notify physician immediately", "Bright red blood in drainage": "Notify physician immediately"}, "rationale": "Chest tube complications require specific responses: continuous bubbling suggests leak, dislodgement needs occlusive dressing, absent tidaling indicates obstruction or resolution, bright blood suggests hemorrhage requiring immediate attention."}, {"type": "bowtie", "prompt": "Ms. Foster develops acute respiratory distress with tracheal deviation. Identify the tension pneumothorax.", "center_condition": {"options": ["Tension Pneumothorax", "Hemothorax", "Pulmonary Embolism", "Cardiac Tamponade"], "answer": "Tension Pneumothorax"}, "left_actions": {"options": ["Needle decompression 2nd intercostal space", "Chest tube insertion", "Administer oxygen", "Pericardiocentesis", "Anticoagulation", "Fluid resuscitation"], "answer": ["Needle decompression 2nd intercostal space", "Administer oxygen"]}, "right_monitor": {"options": ["Respiratory rate and oxygen saturation", "Blood pressure and heart rate", "Breath sounds", "Tracheal position", "Chest tube drainage", "Level of consciousness"], "answer": ["Blood pressure and heart rate", "Tracheal position"]}}]}, {"id": "M-049", "numerical_id": 49, "type": "mission", "title": "The Silent Aspiration: Aspiration Pneumonia", "category": "Acute Respiratory / Aspiration", "difficulty": "Intermediate", "patient_profile": {"demographics": {"name": "Patricia Nguyen", "age": 78, "gender": "Female", "mrn": "4921-PN", "dob": "08/17/1946", "weight": "140 lbs", "height": "5'3\"", "allergies": "Codeine"}, "chief_complaint": "Fever and productive cough.", "hpi": "78-year-old female with dementia presents with fever and productive cough. Witnessed choking on food yesterday. Increasing confusion over past 24 hours. Lives alone, difficulty with ADLs.", "pmh": "Alzheimer's dementia, Hypertension, Osteoarthritis.", "ros": {"gen": "Temp 102.1\u00b0F, HR 96, RR 24, BP 148/86, O2 Sat 93% on 2L NC", "resp": "Crackles right lower lobe, productive cough with foul-smelling sputum", "cardio": "Regular rhythm, no murmurs", "neuro": "Confused, oriented to person only", "gi": "No bowel sounds in all quadrants", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "Chest X-Ray", "type": "text", "content": "Right lower lobe infiltrate with air bronchograms. Possible aspiration pattern."}, {"title": "Sputum Culture", "type": "text", "content": "Mixed oral flora. No predominant pathogen isolated."}, {"title": "Swallow Evaluation", "type": "text", "content": "Severe dysphagia with silent aspiration. Recommend thickened liquids and pureed diet."}], "steps": [{"type": "extended_sata", "prompt": "Ms. Nguyen has aspiration pneumonia. Which nursing interventions are priority? (Select all that apply)", "options": ["Elevate head of bed to 45 degrees during meals", "Provide speech therapy consultation", "Administer antibiotics as prescribed", "Monitor oxygen saturation continuously", "Assist with oral care every 2 hours", "Encourage oral intake of thin liquids", "Assess swallowing ability before meals", "Monitor for signs of sepsis", "Implement aspiration precautions"], "answer": [0, 1], "rationale": "Aspiration pneumonia management focuses on positioning, speech therapy, antibiotics, oral care, swallowing assessment, sepsis monitoring, and aspiration precautions. Thin liquids increase aspiration risk."}, {"type": "matrix", "prompt": "Match the aspiration risk factor with appropriate preventive measure:", "rows": [{"text": "Impaired swallowing"}, {"text": "Altered level of consciousness"}, {"text": "Poor oral hygiene"}, {"text": "Supine positioning"}], "columns": ["Speech therapy evaluation", "Frequent oral care", "Elevate head of bed", "Thickened liquids", "Nasogastric tube feeding", "Sedation vacation"], "answer": {"Impaired swallowing": "Speech therapy evaluation", "Altered level of consciousness": "Sedation vacation", "Poor oral hygiene": "Frequent oral care", "Supine positioning": "Elevate head of bed"}, "rationale": "Aspiration prevention targets specific risk factors: swallowing problems need therapy evaluation, altered consciousness needs sedation assessment, poor hygiene needs oral care, positioning needs elevation."}, {"type": "bowtie", "prompt": "Ms. Nguyen develops respiratory distress with O2 sat dropping to 85%. Identify the acute complication.", "center_condition": {"options": ["Acute Respiratory Failure", "Pulmonary Edema", "Bronchospasm", "Pleural Effusion"], "answer": "Acute Respiratory Failure"}, "left_actions": {"options": ["Apply high-flow oxygen", "Administer bronchodilators", "Position upright", "Prepare for intubation", "Administer diuretics", "Perform thoracentesis"], "answer": ["Apply high-flow oxygen", "Position upright"]}, "right_monitor": {"options": ["Respiratory rate and oxygen saturation", "Mental status", "Arterial blood gases", "Chest X-ray changes", "White blood cell count", "Sputum characteristics"], "answer": ["Respiratory rate and oxygen saturation", "Mental status"]}}]}, {"id": "M-050", "numerical_id": 50, "type": "mission", "title": "The Ventilated Infection: VAP", "category": "Acute Respiratory / VAP", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "James Wilson", "age": 55, "gender": "Male", "mrn": "5098-JW", "dob": "01/30/1969", "weight": "200 lbs", "height": "6'1\"", "allergies": "Sulfa drugs"}, "chief_complaint": "Fever and increased secretions while mechanically ventilated.", "hpi": "55-year-old male mechanically ventilated for 7 days post-trauma. Developed fever and increased respiratory secretions yesterday. On sedation and analgesia. Tracheostomy placed 3 days ago. Last ventilator circuit change was 2 days ago.", "pmh": "Traumatic brain injury, Rib fractures, Pneumothorax.", "ros": {"gen": "Temp 101.8\u00b0F, HR 98, RR 18 (vent), BP 132/78, O2 Sat 94% on FiO2 50%", "resp": "Coarse breath sounds, increased secretions, ventilator alarms sounding", "cardio": "Regular rhythm", "neuro": "Sedated, following simple commands", "gi": "Soft abdomen, tube feeds running", "gu": "Foley catheter draining adequate urine"}}, "exhibits": [{"title": "Chest X-Ray", "type": "text", "content": "New right lower lobe infiltrate. ET tube in good position. No pneumothorax."}, {"title": "Endotracheal Aspirate Culture", "type": "text", "content": "Pseudomonas aeruginosa isolated. Sensitive to piperacillin-tazobactam."}, {"title": "White Blood Cell Count", "type": "text", "content": "18.5 K/uL with 85% neutrophils. Bandemia present."}], "steps": [{"type": "extended_sata", "prompt": "Mr. Wilson has developed ventilator-associated pneumonia. Which interventions are essential? (Select all that apply)", "options": ["Obtain cultures before starting antibiotics", "Change ventilator circuit immediately", "Elevate head of bed to 30-45 degrees", "Perform oral care with chlorhexidine", "Administer empiric broad-spectrum antibiotics", "Maintain sedation vacation protocols", "Change central lines prophylactically", "Monitor for multidrug-resistant organisms", "Implement strict hand hygiene"], "answer": [0, 1], "rationale": "VAP prevention and treatment require cultures before antibiotics, positioning, oral care, empiric antibiotics, sedation management, MDR monitoring, and hand hygiene. Circuit changes and line changes are not routinely indicated."}, {"type": "matrix", "prompt": "Match the VAP risk factor with appropriate preventive strategy:", "rows": [{"text": "Prolonged mechanical ventilation"}, {"text": "Supine positioning"}, {"text": "Poor oral hygiene"}, {"text": "Gastric colonization"}], "columns": ["Daily sedation interruption", "Head of bed elevation", "Chlorhexidine oral care", "Subglottic secretion drainage", "Prophylactic antibiotics", "Early mobilization"], "answer": {"Prolonged mechanical ventilation": "Daily sedation interruption", "Supine positioning": "Head of bed elevation", "Poor oral hygiene": "Chlorhexidine oral care", "Gastric colonization": "Subglottic secretion drainage"}, "rationale": "VAP prevention targets specific risk factors: prolonged ventilation needs sedation breaks, supine position needs elevation, poor hygiene needs chlorhexidine, gastric contents need subglottic drainage."}, {"type": "bowtie", "prompt": "Mr. Wilson develops septic shock with BP 78/45. Identify the critical condition requiring immediate intervention.", "center_condition": {"options": ["Septic Shock", "Cardiogenic Shock", "Hypovolemic Shock", "Distributive Shock"], "answer": "Septic Shock"}, "left_actions": {"options": ["Administer broad-spectrum antibiotics", "Start norepinephrine infusion", "Give 30 mL/kg fluid bolus", "Transfuse packed red blood cells", "Administer dobutamine", "Prepare for CRRT"], "answer": ["Administer broad-spectrum antibiotics", "Give 30 mL/kg fluid bolus"]}, "right_monitor": {"options": ["Mean arterial pressure", "Urine output", "Lactate levels", "Central venous pressure", "Mixed venous oxygen saturation", "Arterial blood gases"], "answer": ["Mean arterial pressure", "Urine output"]}}]}]);
console.log('Injected 10 NGN missions from acute_respiratory_missions_full');
window.customMissions = window.customMissions || [];
window.customMissions = window.customMissions.concat([{"id": "M-051", "numerical_id": 51, "type": "mission", "title": "Acute Coronary Syndrome: Complete NGN Assessment", "category": "Advanced NGN Practice", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Robert Johnson", "age": 58, "gender": "Male", "mrn": "5107-RJ", "dob": "06/15/1966", "weight": "195 lbs", "height": "5'11\"", "allergies": "Aspirin (rash), Shellfish"}, "chief_complaint": "Chest pain and shortness of breath.", "hpi": "58-year-old male presents to ED with substernal chest pain radiating to left arm and jaw, associated with shortness of breath and diaphoresis. Pain started 2 hours ago while mowing lawn. Pain is 8/10, described as pressure. No relief with rest or nitroglycerin. History of hypertension and hyperlipidemia.", "pmh": "Hypertension, Hyperlipidemia, Former smoker (quit 5 years ago).", "ros": {"gen": "Diaphoretic, anxious, pain 8/10", "resp": "Shortness of breath, clear breath sounds", "cardio": "Chest pain radiating to left arm and jaw", "neuro": "Alert and oriented, no focal deficits", "gi": "No nausea or vomiting", "gu": "No urinary symptoms"}}, "exhibits": [{"title": "ECG", "type": "text", "content": "ST elevation in leads II, III, aVF. Reciprocal ST depression in leads I, aVL. Heart rate 95 bpm, sinus rhythm."}, {"title": "Cardiac Enzymes", "type": "text", "content": "Troponin I: 0.15 ng/mL (elevated), CK-MB: 25 ng/mL, Total CK: 180 IU/L"}, {"title": "Vital Signs", "type": "text", "content": "BP: 158/94 mmHg, HR: 95 bpm, RR: 22/min, O2 Sat: 96% on RA, Temp: 98.6\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Mr. Johnson is experiencing an ST-elevation myocardial infarction. Which nursing interventions are priority within the first hour?", "options": ["Administer aspirin 325mg orally", "Administer nitroglycerin 0.4mg sublingual", "Establish IV access with large bore catheter", "Administer morphine 2-4mg IV for pain", "Obtain 12-lead ECG", "Administer oxygen to maintain SpO2 >94%", "Start cardiac monitoring", "Prepare for emergent cardiac catheterization"], "answer": [0, 2, 4, 5, 6, 7], "rationale": "Priority interventions for STEMI include MONA-B (Morphine, Oxygen, Nitroglycerin, Aspirin, Beta-blockers) plus ECG, IV access, cardiac monitoring, and preparation for reperfusion therapy. Nitroglycerin is contraindicated in inferior STEMI with potential right ventricular involvement."}, {"type": "matrix", "prompt": "Match the ECG finding with the corresponding coronary artery territory:", "rows": [{"text": "ST elevation in leads II, III, aVF"}, {"text": "ST elevation in leads V1-V4"}, {"text": "ST elevation in leads I, aVL, V5-V6"}, {"text": "ST elevation in leads V7-V9"}], "columns": ["Left anterior descending artery", "Right coronary artery", "Left circumflex artery", "Posterior descending artery"], "answer": {"ST elevation in leads II, III, aVF": "Right coronary artery", "ST elevation in leads V1-V4": "Left anterior descending artery", "ST elevation in leads I, aVL, V5-V6": "Left circumflex artery", "ST elevation in leads V7-V9": "Posterior descending artery"}, "rationale": "ECG changes correlate with specific coronary artery territories: inferior leads (II, III, aVF) indicate RCA involvement, anterior leads (V1-V4) indicate LAD involvement, lateral leads (I, aVL, V5-V6) indicate LCX involvement."}, {"type": "bowtie", "prompt": "Mr. Johnson develops ventricular tachycardia with pulse. Identify the immediate treatment priority.", "center_condition": {"options": ["Ventricular Tachycardia", "Atrial Fibrillation", "Supraventricular Tachycardia", "Ventricular Fibrillation"], "answer": "Ventricular Tachycardia"}, "left_actions": {"options": ["Defibrillate immediately", "Administer amiodarone 150mg IV", "Perform synchronized cardioversion", "Administer adenosine 6mg IV", "Start CPR", "Administer epinephrine 1mg IV"], "answer": ["Perform synchronized cardioversion", "Administer amiodarone 150mg IV"]}, "right_monitor": {"options": ["Cardiac rhythm", "Blood pressure", "Level of consciousness", "End-tidal CO2", "Cardiac output", "Urine output"], "answer": ["Cardiac rhythm", "Blood pressure"]}, "rationale": "Ventricular tachycardia with pulse requires synchronized cardioversion and antiarrhythmic therapy. Continuous monitoring of rhythm and blood pressure is essential during treatment."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about STEMI management timing:", "text": "For optimal outcomes in ST-elevation myocardial infarction, [BLANK_1] should be performed within [BLANK_2] minutes of hospital arrival, and [BLANK_3] should be administered within [BLANK_4] minutes.", "blanks": [{"correct": "percutaneous coronary intervention"}, {"correct": "90"}, {"correct": "fibrinolysis"}, {"correct": "30"}], "options": ["percutaneous coronary intervention", "90", "fibrinolysis", "30", "60", "cardiac catheterization", "120", "thrombolytics"], "rationale": "American Heart Association guidelines recommend PCI within 90 minutes of hospital arrival and fibrinolytic therapy within 30 minutes for optimal STEMI outcomes."}, {"type": "highlight_select", "prompt": "Review the following assessment data and identify all findings that indicate cardiogenic shock development:", "text": "Patient post-STEMI with ongoing chest pain. Blood pressure 88/60 mmHg, heart rate 120 bpm, respiratory rate 28/min, urine output 15 mL/hour. Cardiac index 1.8 L/min/m\u00b2, systemic vascular resistance 1800 dynes/sec/cm\u2075. Pulmonary capillary wedge pressure 28 mmHg. Serum lactate 4.2 mmol/L.", "highlights": [{"text": "Blood pressure 88/60 mmHg", "correct": true}, {"text": "heart rate 120 bpm", "correct": true}, {"text": "respiratory rate 28/min", "correct": false}, {"text": "urine output 15 mL/hour", "correct": true}, {"text": "Cardiac index 1.8 L/min/m\u00b2", "correct": true}, {"text": "systemic vascular resistance 1800 dynes/sec/cm\u2075", "correct": true}, {"text": "Pulmonary capillary wedge pressure 28 mmHg", "correct": true}, {"text": "Serum lactate 4.2 mmol/L", "correct": true}], "selection_mode": "multiple", "instruction": "Click on all assessment findings that indicate developing cardiogenic shock:", "rationale": "Cardiogenic shock is indicated by hypotension, tachycardia, oliguria, low cardiac index, elevated SVR (compensatory), elevated PCWP, and lactic acidosis. Tachypnea alone is not specific to cardiogenic shock."}]}, {"id": "M-052", "numerical_id": 52, "type": "mission", "title": "COPD Management: GOLD Guidelines & Exacerbation", "category": "Chronic Respiratory Diseases", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Margaret Simmons", "age": 68, "gender": "Female", "mrn": "5208-MS", "dob": "09/22/1956", "weight": "140 lbs", "height": "5'4\"", "allergies": "None"}, "chief_complaint": "Increasing shortness of breath and cough with sputum production.", "hpi": "68-year-old female with severe COPD (GOLD Group D) presents with 3-day history of worsening dyspnea, increased cough with green sputum, and low-grade fever. She reports using her rescue inhaler more frequently. Her baseline oxygen saturation at home is 92% on room air. She has a history of multiple COPD exacerbations requiring hospitalization.", "pmh": "Severe COPD (FEV1 35% predicted), Coronary artery disease s/p stent, Hypertension, Osteoporosis.", "ros": {"gen": "Mild fever, increased work of breathing, using accessory muscles", "resp": "Severe dyspnea, cough with green sputum, decreased breath sounds with expiratory wheezes", "cardio": "Regular rhythm, no murmurs", "neuro": "Alert and oriented, no confusion", "gi": "No nausea or vomiting", "gu": "No urinary symptoms", "msk": "Mild muscle weakness, no edema"}}, "exhibits": [{"title": "Pulmonary Function Tests", "type": "text", "content": "FEV1: 1.2 L (35% predicted), FVC: 2.8 L (78% predicted), FEV1/FVC: 0.43 (43%), DLCO: 45% predicted"}, {"title": "Arterial Blood Gas", "type": "text", "content": "pH: 7.32, PaCO2: 52 mmHg, PaO2: 58 mmHg, HCO3: 26 mEq/L, O2 Sat: 88% on RA"}, {"title": "Chest X-ray", "type": "text", "content": "Hyperinflation with flattened diaphragms, increased AP diameter, peripheral vascular pruning, no acute infiltrates"}, {"title": "Vital Signs", "type": "text", "content": "BP: 142/88 mmHg, HR: 92 bpm, RR: 26/min, O2 Sat: 88% on RA, Temp: 99.2\u00b0F"}, {"title": "Laboratory Results", "type": "text", "content": "WBC: 14,200/\u03bcL, Neutrophils: 78%, CRP: 45 mg/L, BNP: 180 pg/mL"}], "steps": [{"type": "extended_sata", "prompt": "Margaret Simmons is experiencing a moderate COPD exacerbation. Which nursing interventions are appropriate for her management?", "options": ["Administer nebulized albuterol 2.5mg and ipratropium 0.5mg every 4 hours", "Initiate oxygen therapy to maintain SpO2 >92%", "Start systemic corticosteroids (prednisone 40mg daily)", "Administer azithromycin 500mg daily for 5 days", "Encourage pursed-lip breathing and diaphragmatic breathing techniques", "Provide smoking cessation counseling and nicotine replacement", "Schedule pulmonary rehabilitation referral", "Monitor for signs of respiratory failure requiring NIV"], "answer": [0, 1, 2, 3, 4, 7], "rationale": "COPD exacerbation management follows GOLD guidelines: bronchodilators (albuterol/ipratropium), oxygen therapy, systemic corticosteroids, and antibiotics for purulent sputum. Pursed-lip breathing helps control dyspnea. Smoking cessation is always indicated. NIV may be needed for respiratory failure. Pulmonary rehab is important but not immediate priority."}, {"type": "matrix", "prompt": "Match the GOLD COPD assessment criteria with the appropriate classification:", "rows": [{"text": "FEV1 \u226580% predicted with minimal symptoms"}, {"text": "FEV1 50-79% predicted with increasing breathlessness"}, {"text": "FEV1 30-49% predicted with decreased exercise capacity"}, {"text": "FEV1 <30% predicted or FEV1 <50% with respiratory failure"}], "columns": ["GOLD Group A (Low risk, fewer symptoms)", "GOLD Group B (Low risk, more symptoms)", "GOLD Group C (High risk, fewer symptoms)", "GOLD Group D (High risk, more symptoms)"], "answer": {"FEV1 \u226580% predicted with minimal symptoms": "GOLD Group A (Low risk, fewer symptoms)", "FEV1 50-79% predicted with increasing breathlessness": "GOLD Group B (Low risk, more symptoms)", "FEV1 30-49% predicted with decreased exercise capacity": "GOLD Group C (High risk, fewer symptoms)", "FEV1 <30% predicted or FEV1 <50% with respiratory failure": "GOLD Group D (High risk, more symptoms)"}, "rationale": "GOLD classification combines spirometry (risk assessment) with symptom burden. Group A/B have preserved lung function (FEV1 \u226550%), Group C/D have FEV1 <50%. A/C have fewer symptoms, B/D have more symptoms/more exacerbations."}, {"type": "bowtie", "prompt": "Ms. Simmons develops worsening respiratory distress with increased work of breathing. Identify the appropriate intervention.", "center_condition": {"options": ["Mild COPD exacerbation", "Moderate COPD exacerbation", "Severe COPD exacerbation", "Acute respiratory failure"], "answer": "Severe COPD exacerbation"}, "left_actions": {"options": ["Increase oxygen to maintain SpO2 >95%", "Start non-invasive ventilation (NIV)", "Administer intravenous corticosteroids", "Increase bronchodilator frequency", "Prepare for endotracheal intubation", "Call respiratory therapist for airway clearance"], "answer": ["Start non-invasive ventilation (NIV)", "Administer intravenous corticosteroids"]}, "right_monitor": {"options": ["Respiratory rate and pattern", "Arterial blood gases", "Level of consciousness", "Vital signs every 15 minutes", "Cardiac rhythm", "Urine output"], "answer": ["Respiratory rate and pattern", "Arterial blood gases"]}, "rationale": "Severe COPD exacerbation with increased work of breathing indicates impending respiratory failure requiring NIV and IV steroids. Close monitoring of respiratory status, ABGs, mental status, and vital signs is essential to detect deterioration."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about COPD oxygen therapy:", "text": "In patients with severe COPD and chronic CO2 retention, oxygen therapy should be titrated to maintain SpO2 between [BLANK_1] to avoid [BLANK_2] and [BLANK_3] while preventing [BLANK_4].", "blanks": [{"correct": "88-92%"}, {"correct": "respiratory depression"}, {"correct": "CO2 narcosis"}, {"correct": "severe hypoxemia"}], "options": ["88-92%", "94-98%", "respiratory depression", "respiratory alkalosis", "CO2 narcosis", "metabolic acidosis", "severe hypoxemia", "tissue hypoxia"], "rationale": "In COPD patients with chronic hypercapnia, high-flow oxygen can cause respiratory depression and CO2 narcosis by removing the hypoxic drive to breathe. Target SpO2 88-92% balances preventing severe hypoxemia while avoiding respiratory depression."}, {"type": "highlight_select", "prompt": "Review the following assessment data and identify all findings consistent with acute-on-chronic hypercapnic respiratory failure:", "text": "COPD patient with acute exacerbation. Respiratory rate 32/min, shallow breathing, accessory muscle use. Blood pressure 158/92 mmHg, heart rate 110 bpm. Arterial blood gas: pH 7.28, PaCO2 68 mmHg, PaO2 52 mmHg, HCO3 28 mEq/L. Patient reports headache and confusion. Oxygen saturation 85% on room air.", "highlights": [{"text": "Respiratory rate 32/min", "correct": true}, {"text": "shallow breathing", "correct": true}, {"text": "accessory muscle use", "correct": true}, {"text": "Blood pressure 158/92 mmHg", "correct": false}, {"text": "heart rate 110 bpm", "correct": true}, {"text": "pH 7.28", "correct": true}, {"text": "PaCO2 68 mmHg", "correct": true}, {"text": "PaO2 52 mmHg", "correct": true}, {"text": "HCO3 28 mEq/L", "correct": true}, {"text": "headache and confusion", "correct": true}, {"text": "Oxygen saturation 85% on room air", "correct": true}], "selection_mode": "multiple", "instruction": "Click on all findings consistent with acute-on-chronic hypercapnic respiratory failure:", "rationale": "Acute-on-chronic hypercapnic respiratory failure shows: tachypnea, shallow breathing, accessory muscle use, tachycardia, respiratory acidosis (low pH, high PaCO2, compensatory high HCO3), hypoxemia, and CO2 narcosis symptoms (headache, confusion). Hypertension is not typical."}]}, {"id": "M-053", "numerical_id": 53, "type": "mission", "title": "Chronic Asthma: Control & Self-Management", "category": "Chronic Respiratory Diseases", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "David Chen", "age": 32, "gender": "Male", "mrn": "5309-DC", "dob": "11/08/1992", "weight": "180 lbs", "height": "5'10\"", "allergies": "Dust mites, pollen, cats"}, "chief_complaint": "Frequent asthma symptoms despite daily medications.", "hpi": "32-year-old male with moderate persistent asthma presents for follow-up. He reports using his rescue inhaler 3-4 times per week and waking up 2-3 times per month with asthma symptoms. His ACT score is 18. He works as a teacher and reports increased symptoms during school year due to dust and chalk. He denies smoking but lives with a cat.", "pmh": "Moderate persistent asthma diagnosed at age 8, Allergic rhinitis, Exercise-induced bronchospasm.", "ros": {"gen": "No fever, good energy level", "resp": "Intermittent wheezes, occasional cough, denies shortness of breath at rest", "cardio": "Regular rhythm, no murmurs", "neuro": "Alert and oriented", "gi": "No GI symptoms", "gu": "No urinary symptoms", "skin": "No rashes"}}, "exhibits": [{"title": "Spirometry Results", "type": "text", "content": "Pre-bronchodilator FEV1: 2.8 L (78% predicted), Post-bronchodilator FEV1: 3.4 L (95% predicted), FVC: 4.2 L, FEV1/FVC: 0.81"}, {"title": "Asthma Control Test (ACT)", "type": "text", "content": "Score: 18/25 (not well controlled). Reports rescue inhaler use 3-4 days/week, symptoms affecting activities 2-3 days/week, nighttime awakenings 2-3 times/month."}, {"title": "Peak Flow Monitoring", "type": "text", "content": "Personal best: 450 L/min, Current average: 380 L/min, Variability: 15-20%"}, {"title": "Allergy Testing", "type": "text", "content": "Positive for dust mites (4+), cat dander (3+), pollen (3+), negative for foods"}, {"title": "Vital Signs", "type": "text", "content": "BP: 118/76 mmHg, HR: 72 bpm, RR: 16/min, O2 Sat: 98% on RA, Temp: 98.4\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "David Chen has poorly controlled moderate persistent asthma. Which interventions are appropriate for improving his asthma control?", "options": ["Step up controller medication to medium-dose ICS + LABA", "Provide asthma action plan with peak flow monitoring", "Recommend removing cat from home environment", "Teach proper inhaler technique and spacer use", "Initiate allergen immunotherapy (shots)", "Prescribe montelukast (Singulair) as add-on therapy", "Schedule pulmonary function testing every 3-6 months", "Educate on trigger avoidance and environmental controls"], "answer": [0, 1, 2, 3, 7], "rationale": "Poorly controlled moderate asthma requires stepping up therapy per GINA guidelines. Asthma action plan and peak flow monitoring are essential. Cat removal addresses major allergen trigger. Proper inhaler technique is crucial. Environmental controls help reduce allergen exposure. PFT monitoring guides therapy but not immediate priority."}, {"type": "matrix", "prompt": "Match the asthma severity classification with the appropriate characteristics:", "rows": [{"text": "Intermittent asthma"}, {"text": "Mild persistent asthma"}, {"text": "Moderate persistent asthma"}, {"text": "Severe persistent asthma"}], "columns": ["Symptoms \u22642 days/week, nighttime awakenings \u22642/month", "Symptoms >2 days/week but <1/day, nighttime awakenings 3-4/month", "Daily symptoms, nighttime awakenings >1/week, some limitation of activity", "Continuous symptoms, frequent nighttime awakenings, extremely limited activity"], "answer": {"Intermittent asthma": "Symptoms \u22642 days/week, nighttime awakenings \u22642/month", "Mild persistent asthma": "Symptoms >2 days/week but <1/day, nighttime awakenings 3-4/month", "Moderate persistent asthma": "Daily symptoms, nighttime awakenings >1/week, some limitation of activity", "Severe persistent asthma": "Continuous symptoms, frequent nighttime awakenings, extremely limited activity"}, "rationale": "GINA asthma severity is classified by symptom frequency, nighttime awakenings, and activity limitation. Intermittent has minimal symptoms. Mild has symptoms >2x/week. Moderate has daily symptoms with activity limitation. Severe has continuous symptoms and extreme limitation."}, {"type": "bowtie", "prompt": "During a follow-up visit, David reports acute asthma symptoms with peak flow 60% of personal best. Identify the appropriate action.", "center_condition": {"options": ["Well-controlled asthma", "Not well-controlled asthma", "Acute asthma exacerbation", "Status asthmaticus"], "answer": "Acute asthma exacerbation"}, "left_actions": {"options": ["Administer rescue inhaler (albuterol) 4-6 puffs", "Start oral corticosteroids", "Administer oxygen to maintain SpO2 >95%", "Prepare for emergency department transfer", "Increase daily controller medication", "Teach pursed-lip breathing"], "answer": ["Administer rescue inhaler (albuterol) 4-6 puffs", "Start oral corticosteroids"]}, "right_monitor": {"options": ["Peak flow measurements", "Respiratory rate and oxygen saturation", "Work of breathing and accessory muscle use", "Level of consciousness", "Heart rate and blood pressure", "Response to treatment"], "answer": ["Peak flow measurements", "Respiratory rate and oxygen saturation"]}, "rationale": "Peak flow <60% personal best indicates severe exacerbation requiring immediate rescue inhaler, oral steroids, and oxygen. Close monitoring of peak flow, respiratory status, and treatment response is essential. Transfer may be needed if no improvement."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about asthma inhaler technique:", "text": "Proper metered-dose inhaler technique requires [BLANK_1] the inhaler, [BLANK_2] completely, and [BLANK_3] slowly while [BLANK_4] for 10 seconds before exhaling.", "blanks": [{"correct": "shaking"}, {"correct": "exhaling"}, {"correct": "inhaling"}, {"correct": "holding breath"}], "options": ["shaking", "priming", "exhaling", "inhaling", "holding breath", "coughing", "rinsing mouth", "waiting 1 minute"], "rationale": "Correct MDI technique: shake inhaler, exhale completely, inhale slowly and deeply, hold breath for 10 seconds, then exhale. Poor technique results in 80-90% of medication depositing in mouth/throat instead of lungs."}, {"type": "highlight_select", "prompt": "Review the patient's asthma action plan and identify all components that are correctly included:", "text": "Green Zone: Peak flow >80% personal best, no symptoms. Take daily controller medications. Yellow Zone: Peak flow 50-80% personal best, mild symptoms. Take rescue inhaler every 3-4 hours, add oral steroids if needed, call provider within 24 hours. Red Zone: Peak flow <50% personal best, severe symptoms. Take rescue inhaler immediately, call 911 or go to ED, use epinephrine if available.", "highlights": [{"text": "Green Zone: Peak flow >80% personal best, no symptoms. Take daily controller medications.", "correct": true}, {"text": "Yellow Zone: Peak flow 50-80% personal best, mild symptoms. Take rescue inhaler every 3-4 hours, add oral steroids if needed, call provider within 24 hours.", "correct": true}, {"text": "Red Zone: Peak flow <50% personal best, severe symptoms. Take rescue inhaler immediately, call 911 or go to ED, use epinephrine if available.", "correct": true}, {"text": "Take rescue inhaler every 3-4 hours", "correct": true}, {"text": "add oral steroids if needed", "correct": true}, {"text": "call provider within 24 hours", "correct": true}, {"text": "Take rescue inhaler immediately", "correct": true}, {"text": "call 911 or go to ED", "correct": true}, {"text": "use epinephrine if available", "correct": true}], "selection_mode": "multiple", "instruction": "Click on all correctly included components of the asthma action plan:", "rationale": "A comprehensive asthma action plan includes three zones (green, yellow, red) with specific peak flow thresholds, symptom descriptions, medication adjustments, and when to seek help. This plan correctly follows NAEPP guidelines for self-management."}]}, {"id": "M-054", "numerical_id": 54, "type": "mission", "title": "Bronchiectasis: Airway Clearance & Infection Management", "category": "Chronic Respiratory Diseases", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Patricia Morales", "age": 45, "gender": "Female", "mrn": "5410-PM", "dob": "04/16/1979", "weight": "135 lbs", "height": "5'6\"", "allergies": "Penicillin (rash)"}, "chief_complaint": "Chronic cough with daily sputum production and recurrent infections.", "hpi": "45-year-old female with non-CF bronchiectasis presents with 2-week history of increased cough and thick green sputum production. She reports 4-5 similar episodes per year requiring antibiotics. She performs daily airway clearance but finds it increasingly difficult. Her baseline oxygen saturation is 94% on room air.", "pmh": "Non-CF bronchiectasis (post-viral), Recurrent pneumonia, Primary ciliary dyskinesia, Anxiety.", "ros": {"gen": "Fatigued, no fever currently", "resp": "Chronic productive cough, coarse crackles in right lower lobe, decreased breath sounds", "cardio": "Regular rhythm, no murmurs", "neuro": "Alert and oriented", "gi": "No GI symptoms", "gu": "No urinary symptoms", "msk": "No clubbing or edema"}}, "exhibits": [{"title": "High-Resolution CT Chest", "type": "text", "content": "Bronchiectasis with bronchial wall thickening and dilation in right lower lobe. Tree-in-bud opacities suggestive of small airway infection. No pulmonary fibrosis."}, {"title": "Sputum Culture", "type": "text", "content": "Pseudomonas aeruginosa (moderate growth), normal flora. No methicillin-resistant organisms."}, {"title": "Pulmonary Function Tests", "type": "text", "content": "FEV1: 2.1 L (65% predicted), FVC: 3.0 L (78% predicted), FEV1/FVC: 0.70, TLC: 110% predicted"}, {"title": "Inflammatory Markers", "type": "text", "content": "CRP: 28 mg/L (elevated), ESR: 45 mm/hr (elevated), WBC: 11,500/\u03bcL with left shift"}, {"title": "Vital Signs", "type": "text", "content": "BP: 128/82 mmHg, HR: 78 bpm, RR: 18/min, O2 Sat: 94% on RA, Temp: 98.8\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Patricia Morales has bronchiectasis with acute exacerbation. Which nursing interventions are appropriate for her care?", "options": ["Teach active cycle of breathing technique (ACBT) for airway clearance", "Administer inhaled tobramycin for Pseudomonas infection", "Encourage hydration with 2-3 liters of fluid daily", "Schedule influenza and pneumococcal vaccinations", "Monitor for hemoptysis and teach bleeding precautions", "Refer for pulmonary rehabilitation program", "Educate on proper hand hygiene to prevent infection spread", "Assess nutritional status and provide dietary counseling"], "answer": [0, 2, 3, 4, 6, 7], "rationale": "Bronchiectasis management focuses on airway clearance (ACBT), hydration for mucus thinning, vaccinations for prevention, bleeding precautions due to hemoptysis risk, infection prevention, and nutrition. Inhaled tobramycin is for chronic Pseudomonas but not acute exacerbation. Pulmonary rehab is beneficial but not immediate priority."}, {"type": "matrix", "prompt": "Match the bronchiectasis complication with the appropriate nursing intervention:", "rows": [{"text": "Massive hemoptysis"}, {"text": "Acute respiratory failure"}, {"text": "Chronic malnutrition"}, {"text": "Recurrent infections"}], "columns": ["Position patient on affected side, prepare for bronchoscopy", "Administer oxygen, prepare for intubation if needed", "High-calorie diet, nutritional supplements, monitor weight", "Antibiotic therapy, vaccination, hand hygiene education", "Chest physiotherapy, bronchodilators, mucolytics", "Psychological support, medication compliance"], "answer": {"Massive hemoptysis": "Position patient on affected side, prepare for bronchoscopy", "Acute respiratory failure": "Administer oxygen, prepare for intubation if needed", "Chronic malnutrition": "High-calorie diet, nutritional supplements, monitor weight", "Recurrent infections": "Antibiotic therapy, vaccination, hand hygiene education"}, "rationale": "Bronchiectasis complications require specific interventions: hemoptysis needs positioning and bronchoscopy preparation, respiratory failure requires oxygen support, malnutrition needs nutritional support, and recurrent infections require antibiotic/vaccination strategies."}, {"type": "bowtie", "prompt": "During airway clearance, Patricia develops increased shortness of breath and wheezing. Identify the appropriate intervention.", "center_condition": {"options": ["Airway clearance technique failure", "Bronchospasm induced by treatment", "Pneumothorax development", "Ineffective cough effort"], "answer": "Bronchospasm induced by treatment"}, "left_actions": {"options": ["Administer short-acting bronchodilator", "Stop airway clearance immediately", "Position patient in tripod position", "Apply oxygen via nasal cannula", "Administer inhaled corticosteroid", "Call respiratory therapist"], "answer": ["Administer short-acting bronchodilator", "Stop airway clearance immediately"]}, "right_monitor": {"options": ["Respiratory rate and oxygen saturation", "Peak expiratory flow rate", "Wheezing and breath sounds", "Heart rate and blood pressure", "Level of consciousness", "Sputum production and color"], "answer": ["Respiratory rate and oxygen saturation", "Peak expiratory flow rate"]}, "rationale": "Bronchospasm during airway clearance requires immediate bronchodilator administration, stopping the procedure, and oxygen support. Close monitoring of respiratory status and lung function is essential to ensure resolution."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about bronchiectasis airway clearance:", "text": "The active cycle of breathing technique (ACBT) consists of [BLANK_1] breathing to mobilize secretions, followed by [BLANK_2] to clear them, and [BLANK_3] to relax the airways, performed [BLANK_4] times daily.", "blanks": [{"correct": "deep"}, {"correct": "forced expiratory technique"}, {"correct": "breathing control"}, {"correct": "2-3"}], "options": ["deep", "shallow", "forced expiratory technique", "huff coughing", "breathing control", "pursed-lip breathing", "2-3", "4-6", "daily", "as needed"], "rationale": "ACBT is a 3-phase technique: deep breathing to mobilize secretions, forced expiratory technique (FET) or huff coughing to clear them, and breathing control to relax airways. It should be performed 2-3 times daily for optimal mucus clearance in bronchiectasis."}, {"type": "highlight_select", "prompt": "Review the patient's sputum characteristics and identify all findings consistent with bronchiectasis exacerbation:", "text": "Patient with bronchiectasis presents with increased cough. Sputum is thick, purulent, and foul-smelling. Volume increased to 30-50 mL daily. Color changed from clear/yellow to green. Contains blood streaks. Culture shows Pseudomonas aeruginosa. Patient reports fatigue and decreased exercise tolerance.", "highlights": [{"text": "thick, purulent, and foul-smelling", "correct": true}, {"text": "Volume increased to 30-50 mL daily", "correct": true}, {"text": "Color changed from clear/yellow to green", "correct": true}, {"text": "Contains blood streaks", "correct": true}, {"text": "Culture shows Pseudomonas aeruginosa", "correct": true}, {"text": "Patient reports fatigue", "correct": true}, {"text": "decreased exercise tolerance", "correct": true}], "selection_mode": "multiple", "instruction": "Click on all findings consistent with bronchiectasis exacerbation:", "rationale": "Bronchiectasis exacerbation shows increased sputum volume (>25 mL/day), purulent/foul-smelling sputum, color change, hemoptysis, positive cultures (often Pseudomonas), and systemic symptoms like fatigue and reduced exercise tolerance."}]}, {"id": "M-055", "numerical_id": 55, "type": "mission", "title": "Cystic Fibrosis: Comprehensive Management & Exacerbation", "category": "Genetic Lung Diseases", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Jordan Rivera", "age": 24, "gender": "Male", "mrn": "5511-JR", "dob": "02/14/2000", "weight": "145 lbs", "height": "5'8\"", "allergies": "None"}, "chief_complaint": "Increased cough and shortness of breath over the past week.", "hpi": "24-year-old male with cystic fibrosis (homozygous \u0394F508) presents with pulmonary exacerbation. He reports increased cough with thick green sputum, shortness of breath, and decreased exercise tolerance. He has been compliant with airway clearance and enzymes but missed some nebulized treatments. His baseline FEV1 is 45% predicted.", "pmh": "Cystic fibrosis diagnosed at birth, Pancreatic insufficiency, CF-related diabetes, Recurrent Pseudomonas infections, Depression.", "ros": {"gen": "Fatigued, recent 5 lb weight loss", "resp": "Increased cough with green sputum, dyspnea on exertion, decreased breath sounds with crackles", "cardio": "Regular rhythm, no murmurs", "neuro": "Alert and oriented, no confusion", "gi": "No abdominal pain, regular bowel movements", "gu": "No urinary symptoms", "msk": "Muscle wasting noted, decreased exercise tolerance"}}, "exhibits": [{"title": "Pulmonary Function Tests", "type": "text", "content": "FEV1: 1.8 L (42% predicted), FVC: 3.2 L (65% predicted), FEV1/FVC: 0.56, DLCO: 55% predicted"}, {"title": "Sputum Culture", "type": "text", "content": "Pseudomonas aeruginosa (moderate growth), Staphylococcus aureus (light growth), normal flora"}, {"title": "Sweat Chloride Test", "type": "text", "content": "Chloride: 102 mEq/L (diagnostic for CF, normal <40 mEq/L)"}, {"title": "Chest CT", "type": "text", "content": "Bronchiectasis with mucous plugging, tree-in-bud opacities, air trapping, no pneumothorax"}, {"title": "Laboratory Results", "type": "text", "content": "CRP: 65 mg/L (elevated), WBC: 12,500/\u03bcL, Hemoglobin A1c: 7.8%, Vitamin D: 18 ng/mL (deficient)"}, {"title": "Vital Signs", "type": "text", "content": "BP: 118/74 mmHg, HR: 88 bpm, RR: 20/min, O2 Sat: 92% on RA, Temp: 99.4\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Jordan Rivera is experiencing a cystic fibrosis pulmonary exacerbation. Which nursing interventions are appropriate for his management?", "options": ["Administer intravenous antibiotics for 10-14 days based on culture results", "Perform chest physiotherapy and airway clearance every 4 hours", "Provide pancreatic enzyme replacement with meals and snacks", "Monitor blood glucose levels due to CF-related diabetes", "Administer vitamin D and fat-soluble vitamin supplements", "Encourage high-calorie, high-protein diet with oral supplements", "Teach proper nebulizer technique for inhaled medications", "Assess for signs of cor pulmonale and right heart failure"], "answer": [0, 1, 2, 3, 4, 5, 7], "rationale": "CF exacerbation management includes IV antibiotics for 10-14 days, aggressive airway clearance, pancreatic enzymes, glucose monitoring for CFRD, vitamin supplementation, nutritional support, and monitoring for pulmonary hypertension/cor pulmonale. Nebulizer technique is important but not immediate priority during acute exacerbation."}, {"type": "matrix", "prompt": "Match the cystic fibrosis complication with the appropriate monitoring parameter:", "rows": [{"text": "Pulmonary exacerbation"}, {"text": "Malnutrition"}, {"text": "CF-related diabetes"}, {"text": "Liver disease"}, {"text": "Infertility"}], "columns": ["Fasting blood glucose and HbA1c", "Weight, BMI, and nutritional intake", "Liver function tests and abdominal ultrasound", "Semen analysis and hormone levels", "FEV1, sputum culture, and oxygen saturation", "Sweat chloride testing"], "answer": {"Pulmonary exacerbation": "FEV1, sputum culture, and oxygen saturation", "Malnutrition": "Weight, BMI, and nutritional intake", "CF-related diabetes": "Fasting blood glucose and HbA1c", "Liver disease": "Liver function tests and abdominal ultrasound", "Infertility": "Semen analysis and hormone levels"}, "rationale": "CF complications require specific monitoring: pulmonary exacerbations need lung function and culture monitoring, malnutrition requires nutritional assessment, CFRD needs glycemic control monitoring, liver disease requires hepatic function tests, and infertility needs reproductive hormone evaluation."}, {"type": "bowtie", "prompt": "During airway clearance, Jordan develops hemoptysis. Identify the appropriate intervention.", "center_condition": {"options": ["Minor hemoptysis (<5 mL)", "Moderate hemoptysis (5-30 mL)", "Massive hemoptysis (>30 mL)", "Bronchiectasis bleeding"], "answer": "Moderate hemoptysis (5-30 mL)"}, "left_actions": {"options": ["Stop airway clearance immediately", "Position patient on affected side", "Administer tranexamic acid", "Prepare for bronchoscopy", "Call for emergency bronchoscopy team", "Apply ice packs to chest"], "answer": ["Stop airway clearance immediately", "Position patient on affected side", "Prepare for bronchoscopy"]}, "right_monitor": {"options": ["Amount and color of blood expectorated", "Vital signs every 15 minutes", "Oxygen saturation continuously", "Signs of airway obstruction", "Hemoglobin and hematocrit", "Coagulation studies"], "answer": ["Amount and color of blood expectorated", "Vital signs every 15 minutes", "Oxygen saturation continuously", "Signs of airway obstruction"]}, "rationale": "Moderate hemoptysis in CF requires immediate cessation of airway clearance, positioning on affected side to protect unaffected lung, and preparation for bronchoscopy. Close monitoring of bleeding amount, vital signs, oxygenation, and airway patency is essential."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about cystic fibrosis transmembrane conductance regulator (CFTR) modulators:", "text": "CFTR modulators such as ivacaftor (Kalydeco) and elexacaftor/tezacaftor/ivacaftor (Trikafta) work by [BLANK_1] the defective CFTR protein to [BLANK_2] chloride transport across epithelial cells, leading to [BLANK_3] mucus viscosity and [BLANK_4] pulmonary function in eligible patients.", "blanks": [{"correct": "correcting"}, {"correct": "restore"}, {"correct": "decreased"}, {"correct": "improved"}], "options": ["correcting", "blocking", "restore", "inhibit", "decreased", "increased", "improved", "declined", "stable", "worsened"], "rationale": "CFTR modulators correct the defective CFTR protein function to restore chloride transport, decrease mucus viscosity, and improve pulmonary function. These therapies target the underlying genetic defect in CF rather than just treating symptoms."}, {"type": "highlight_select", "prompt": "Review the patient's cystic fibrosis complications and identify all that require immediate intervention:", "text": "24-year-old male with CF presents with pulmonary exacerbation. He has pancreatic insufficiency requiring enzyme replacement. He has CF-related diabetes with HbA1c 7.8%. Vitamin D level is 18 ng/mL. Recent sputum culture shows Pseudomonas aeruginosa. He reports infertility concerns. Chest CT shows bronchiectasis. He has been adherent to airway clearance therapy.", "highlights": [{"text": "pancreatic insufficiency requiring enzyme replacement", "correct": false}, {"text": "CF-related diabetes with HbA1c 7.8%", "correct": true}, {"text": "Vitamin D level is 18 ng/mL", "correct": true}, {"text": "Recent sputum culture shows Pseudomonas aeruginosa", "correct": true}, {"text": "He reports infertility concerns", "correct": false}, {"text": "Chest CT shows bronchiectasis", "correct": false}, {"text": "He has been adherent to airway clearance therapy", "correct": false}], "selection_mode": "multiple", "instruction": "Click on all CF complications that require immediate intervention:", "rationale": "Immediate intervention needed for: poorly controlled CFRD (HbA1c 7.8% requires glycemic management), vitamin D deficiency (18 ng/mL is severely deficient and increases infection risk), and Pseudomonas infection (requires antibiotic therapy). Pancreatic insufficiency and infertility are chronic issues, bronchiectasis is expected in CF, and adherence to therapy is positive."}]}, {"id": "M-056", "numerical_id": 56, "type": "mission", "title": "Interstitial Lung Disease: Progressive Fibrosis Management", "category": "Fibrotic Lung Diseases", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Eleanor Thompson", "age": 72, "gender": "Female", "mrn": "5612-ET", "dob": "05/28/1952", "weight": "130 lbs", "height": "5'4\"", "allergies": "Morphine (nausea)"}, "chief_complaint": "Progressive shortness of breath and dry cough for 18 months.", "hpi": "72-year-old female with idiopathic pulmonary fibrosis presents for routine follow-up. She reports worsening dyspnea on exertion, now unable to walk one block. Dry cough is persistent. She denies fever, chest pain, or hemoptysis. She has been on supplemental oxygen for 6 months. Recent 6-minute walk test showed 180 meters with desaturation to 82%.", "pmh": "Idiopathic pulmonary fibrosis diagnosed 2 years ago, Hypertension, Osteoarthritis, Gastroesophageal reflux disease.", "ros": {"gen": "Appears chronically ill, oxygen dependent", "resp": "Severe resting dyspnea, dry cough, inspiratory crackles at bases, clubbing present", "cardio": "Regular rhythm, no murmurs, signs of pulmonary hypertension", "neuro": "Alert and oriented, no confusion", "gi": "GERD symptoms well controlled", "gu": "No urinary symptoms", "msk": "Joint pain from osteoarthritis, decreased mobility"}}, "exhibits": [{"title": "High-Resolution CT Chest", "type": "text", "content": "UIP pattern with honeycombing, traction bronchiectasis, and reticular opacities predominantly in subpleural and basal distribution"}, {"title": "Pulmonary Function Tests", "type": "text", "content": "FEV1: 1.4 L (55% predicted), FVC: 1.8 L (58% predicted), FEV1/FVC: 0.78, TLC: 65% predicted, DLCO: 35% predicted"}, {"title": "6-Minute Walk Test", "type": "text", "content": "Distance: 180 meters, Baseline SpO2: 94% on 2L NC, Nadir SpO2: 82%, Borg dyspnea score: 7/10"}, {"title": "Echocardiogram", "type": "text", "content": "Estimated pulmonary artery pressure: 45 mmHg (elevated), RV systolic pressure: 50 mmHg, normal LV function"}, {"title": "Laboratory Results", "type": "text", "content": "BNP: 350 pg/mL (elevated), ESR: 28 mm/hr, ANA: negative, RF: negative, Anti-CCP: negative"}, {"title": "Vital Signs", "type": "text", "content": "BP: 138/82 mmHg, HR: 78 bpm, RR: 22/min, O2 Sat: 92% on 2L NC, Temp: 98.2\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Eleanor Thompson has advanced idiopathic pulmonary fibrosis. Which nursing interventions are appropriate for her symptom management?", "options": ["Titrate oxygen to maintain SpO2 >88% during rest and activity", "Administer antifibrotic therapy (pirfenidone or nintedanib)", "Provide pulmonary rehabilitation with exercise training", "Treat gastroesophageal reflux aggressively to prevent aspiration", "Monitor for signs of pulmonary hypertension and right heart failure", "Educate on lung transplant evaluation and listing process", "Administer corticosteroids for acute exacerbations only", "Encourage smoking cessation and environmental toxin avoidance"], "answer": [0, 1, 3, 4, 5, 7], "rationale": "IPF management includes oxygen therapy, antifibrotic medications, GERD treatment to prevent microaspiration, monitoring for cor pulmonale, lung transplant education, and toxin avoidance. Pulmonary rehab is beneficial but may not be tolerated in advanced disease. Steroids are not indicated for stable IPF."}, {"type": "matrix", "prompt": "Match the interstitial lung disease pattern with the associated prognosis:", "rows": [{"text": "Usual interstitial pneumonia (UIP)"}, {"text": "Nonspecific interstitial pneumonia (NSIP)"}, {"text": "Cryptogenic organizing pneumonia (COP)"}, {"text": "Acute interstitial pneumonia (AIP)"}], "columns": ["Excellent prognosis with treatment", "Good prognosis, often responds to steroids", "Poor prognosis, progressive fibrosis", "Variable prognosis, may be reversible", "Acute onset, high mortality without treatment", "Chronic progressive course"], "answer": {"Usual interstitial pneumonia (UIP)": "Poor prognosis, progressive fibrosis", "Nonspecific interstitial pneumonia (NSIP)": "Good prognosis, often responds to steroids", "Cryptogenic organizing pneumonia (COP)": "Excellent prognosis with treatment", "Acute interstitial pneumonia (AIP)": "Acute onset, high mortality without treatment"}, "rationale": "ILD prognosis varies by pattern: UIP (IPF) has poor prognosis with progressive fibrosis, NSIP responds well to steroids, COP has excellent prognosis with treatment, AIP has acute onset and high mortality."}, {"type": "bowtie", "prompt": "During a clinic visit, Eleanor develops acute respiratory distress with oxygen desaturation to 75%. Identify the appropriate intervention.", "center_condition": {"options": ["Acute IPF exacerbation", "Pneumothorax", "Pulmonary embolism", "Acute heart failure exacerbation"], "answer": "Acute IPF exacerbation"}, "left_actions": {"options": ["Increase oxygen to maintain SpO2 >88%", "Administer high-dose corticosteroids", "Prepare for non-invasive ventilation", "Obtain urgent chest CT", "Administer broad-spectrum antibiotics", "Contact lung transplant team"], "answer": ["Increase oxygen to maintain SpO2 >88%", "Administer high-dose corticosteroids"]}, "right_monitor": {"options": ["Oxygen saturation continuously", "Respiratory rate and pattern", "Vital signs every 15-30 minutes", "Level of consciousness", "Chest pain or pleurisy", "Response to corticosteroids"], "answer": ["Oxygen saturation continuously", "Respiratory rate and pattern"]}, "rationale": "Acute IPF exacerbation requires immediate oxygen supplementation, high-dose corticosteroids, and possible NIV. Close monitoring of oxygenation, respiratory status, vital signs, and mental status is essential to detect deterioration."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about idiopathic pulmonary fibrosis antifibrotic therapy:", "text": "Antifibrotic medications for IPF such as pirfenidone and nintedanib work by [BLANK_1] the fibrotic process through [BLANK_2] of fibroblast proliferation and [BLANK_3] of extracellular matrix deposition, leading to [BLANK_4] in lung function decline.", "blanks": [{"correct": "slowing"}, {"correct": "inhibition"}, {"correct": "reduction"}, {"correct": "slowed"}], "options": ["slowing", "accelerating", "inhibition", "stimulation", "reduction", "increase", "slowed", "accelerated", "reversed", "halted"], "rationale": "Antifibrotic therapy slows IPF progression by inhibiting fibroblast proliferation and reducing extracellular matrix deposition, resulting in slowed decline in lung function rather than reversal of fibrosis."}, {"type": "highlight_select", "prompt": "Review the patient's clinical findings and identify all that indicate poor prognosis in idiopathic pulmonary fibrosis:", "text": "72-year-old female with IPF. DLCO 35% predicted. 6MWD 180 meters with desaturation to 82%. Pulmonary artery pressure 45 mmHg. On 2L supplemental oxygen. Recent acute exacerbation 3 months ago. Age 72 years. BMI 22. No comorbidities.", "highlights": [{"text": "DLCO 35% predicted", "correct": true}, {"text": "6MWD 180 meters with desaturation to 82%", "correct": true}, {"text": "Pulmonary artery pressure 45 mmHg", "correct": true}, {"text": "On 2L supplemental oxygen", "correct": true}, {"text": "Recent acute exacerbation 3 months ago", "correct": true}, {"text": "Age 72 years", "correct": true}, {"text": "BMI 22", "correct": false}, {"text": "No comorbidities", "correct": false}], "selection_mode": "multiple", "instruction": "Click on all findings that indicate poor prognosis in IPF:", "rationale": "Poor prognostic factors in IPF include: low DLCO (<40%), poor 6MWD with desaturation, pulmonary hypertension, oxygen dependence, recent acute exacerbation, and older age. Normal BMI and absence of comorbidities are not poor prognostic indicators."}]}, {"id": "M-057", "numerical_id": 57, "type": "mission", "title": "Pulmonary Fibrosis: Antifibrotic Therapy & Symptom Control", "category": "Fibrotic Lung Diseases", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Robert Callahan", "age": 65, "gender": "Male", "mrn": "5713-RC", "dob": "08/12/1959", "weight": "170 lbs", "height": "5'11\"", "allergies": "Sulfa drugs (rash)"}, "chief_complaint": "Progressive shortness of breath and fatigue for 2 years.", "hpi": "65-year-old male with progressive pulmonary fibrosis presents for routine monitoring. He reports worsening dyspnea limiting activities to short walks. He has dry cough and fatigue. He was started on nintedanib 6 months ago. His oxygen saturation at rest is 90% on room air, dropping to 84% with minimal exertion. Recent PFTs show continued decline.", "pmh": "Progressive pulmonary fibrosis (likely IPF), Hypertension, Coronary artery disease s/p stent, Gastroesophageal reflux disease.", "ros": {"gen": "Fatigued, reports weight loss of 10 lbs in 6 months", "resp": "Severe exertional dyspnea, dry cough, inspiratory crackles at bases, digital clubbing", "cardio": "Regular rhythm, JVD present, peripheral edema 1+", "neuro": "Alert and oriented, mild confusion at times", "gi": "GERD symptoms present, on PPI therapy", "gu": "No urinary symptoms", "msk": "Generalized weakness, decreased exercise tolerance"}}, "exhibits": [{"title": "High-Resolution CT Chest", "type": "text", "content": "Extensive fibrosis with honeycombing, traction bronchiectasis, and reticular opacities in subpleural distribution. Progressive changes compared to 6 months ago."}, {"title": "Pulmonary Function Tests", "type": "text", "content": "FEV1: 1.6 L (48% predicted), FVC: 2.2 L (52% predicted), FEV1/FVC: 0.73, TLC: 58% predicted, DLCO: 28% predicted (decline from 35% 6 months ago)"}, {"title": "Echocardiogram", "type": "text", "content": "Pulmonary artery systolic pressure: 55 mmHg (elevated), right ventricular enlargement, moderate tricuspid regurgitation, preserved LV function"}, {"title": "Laboratory Results", "type": "text", "content": "BNP: 450 pg/mL (elevated), Troponin: 0.08 ng/mL (elevated), CRP: 25 mg/L, ESR: 35 mm/hr"}, {"title": "Medication List", "type": "text", "content": "Nintedanib 150mg BID, Omeprazole 40mg daily, Lisinopril 10mg daily, Aspirin 81mg daily, Oxygen 2L NC with exertion"}, {"title": "Vital Signs", "type": "text", "content": "BP: 142/88 mmHg, HR: 82 bpm, RR: 24/min, O2 Sat: 88% on RA, Temp: 98.6\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Robert Callahan has progressive pulmonary fibrosis on antifibrotic therapy. Which nursing interventions are appropriate for his management?", "options": ["Monitor for nintedanib side effects (diarrhea, nausea, weight loss)", "Assess oxygen saturation before and after exertion", "Educate on pulmonary rehabilitation benefits", "Monitor for signs of pulmonary hypertension progression", "Administer influenza and pneumococcal vaccinations", "Provide nutritional counseling for weight maintenance", "Assess for GERD symptoms and medication adherence", "Coordinate with palliative care for symptom management"], "answer": [0, 1, 3, 4, 5, 6, 7], "rationale": "Management includes monitoring antifibrotic side effects, oxygen assessment, pulmonary hypertension signs, vaccinations, nutrition, GERD management, and palliative care coordination. Pulmonary rehab education is beneficial but monitoring side effects and symptoms takes priority."}, {"type": "matrix", "prompt": "Match the antifibrotic medication with its mechanism of action:", "rows": [{"text": "Pirfenidone"}, {"text": "Nintedanib"}, {"text": "Prednisone"}, {"text": "N-acetylcysteine"}], "columns": ["Tyrosine kinase inhibitor targeting VEGF, FGF, and PDGF receptors", "Anti-inflammatory and antifibrotic effects through multiple pathways", "Antioxidant effects on glutathione production", "Broad-spectrum corticosteroid with anti-inflammatory effects", "Inhibits collagen synthesis and fibroblast proliferation", "Reduces oxidative stress and inflammation"], "answer": {"Pirfenidone": "Inhibits collagen synthesis and fibroblast proliferation", "Nintedanib": "Tyrosine kinase inhibitor targeting VEGF, FGF, and PDGF receptors", "Prednisone": "Broad-spectrum corticosteroid with anti-inflammatory effects", "N-acetylcysteine": "Antioxidant effects on glutathione production"}, "rationale": "Antifibrotic mechanisms: pirfenidone inhibits collagen synthesis, nintedanib is a tyrosine kinase inhibitor, prednisone provides anti-inflammatory effects, N-acetylcysteine acts as an antioxidant."}, {"type": "bowtie", "prompt": "During a clinic visit, Robert develops acute chest pain and worsening dyspnea. Identify the appropriate intervention.", "center_condition": {"options": ["Acute coronary syndrome", "Pulmonary embolism", "Spontaneous pneumothorax", "Acute heart failure exacerbation"], "answer": "Spontaneous pneumothorax"}, "left_actions": {"options": ["Administer supplemental oxygen", "Obtain urgent chest X-ray", "Prepare for needle decompression if tension pneumothorax", "Administer anticoagulation therapy", "Start IV nitroglycerin infusion", "Prepare for chest tube insertion"], "answer": ["Administer supplemental oxygen", "Obtain urgent chest X-ray", "Prepare for needle decompression if tension pneumothorax"]}, "right_monitor": {"options": ["Respiratory rate and oxygen saturation", "Chest pain severity and location", "Vital signs every 15 minutes", "Breath sounds for asymmetry", "Level of consciousness", "Cardiac rhythm"], "answer": ["Respiratory rate and oxygen saturation", "Chest pain severity and location"]}, "rationale": "Spontaneous pneumothorax in fibrotic lung disease requires immediate oxygen, chest X-ray confirmation, and preparation for needle decompression if tension physiology develops. Close monitoring of respiratory status, pain, vital signs, and breath sounds is essential."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about pulmonary fibrosis oxygen therapy:", "text": "In patients with pulmonary fibrosis, long-term oxygen therapy (LTOT) is indicated when resting PaO2 is [BLANK_1] mmHg or less, or when oxygen saturation falls below [BLANK_2] during sleep or exertion, to prevent [BLANK_3] and improve [BLANK_4].", "blanks": [{"correct": "55"}, {"correct": "88%"}, {"correct": "pulmonary hypertension"}, {"correct": "survival"}], "options": ["55", "60", "88%", "90%", "pulmonary hypertension", "respiratory failure", "survival", "exercise tolerance", "quality of life", "symptom control"], "rationale": "LTOT criteria for pulmonary fibrosis: PaO2 \u226455 mmHg at rest, or SpO2 <88% during sleep/exertion. LTOT prevents pulmonary hypertension progression and improves survival in hypoxemic patients."}, {"type": "highlight_select", "prompt": "Review the patient's pulmonary fibrosis assessment findings and identify all that indicate disease progression:", "text": "65-year-old male with pulmonary fibrosis on nintedanib. Recent PFTs show DLCO decline from 35% to 28%. 6MWD decreased to 180 meters. Pulmonary artery pressure increased to 55 mmHg. BNP elevated to 450 pg/mL. On 2L oxygen with exertion. Reports increased fatigue. Weight loss of 10 lbs in 6 months.", "highlights": [{"text": "DLCO decline from 35% to 28%", "correct": true}, {"text": "6MWD decreased to 180 meters", "correct": true}, {"text": "Pulmonary artery pressure increased to 55 mmHg", "correct": true}, {"text": "BNP elevated to 450 pg/mL", "correct": true}, {"text": "On 2L oxygen with exertion", "correct": true}, {"text": "Reports increased fatigue", "correct": true}, {"text": "Weight loss of 10 lbs in 6 months", "correct": true}], "selection_mode": "multiple", "instruction": "Click on all findings that indicate pulmonary fibrosis progression:", "rationale": "Disease progression indicators include: declining DLCO, reduced exercise capacity (6MWD), worsening pulmonary hypertension, elevated BNP (right heart strain), increased oxygen requirements, fatigue, and weight loss (cachexia)."}]}, {"id": "M-058", "numerical_id": 58, "type": "mission", "title": "Sarcoidosis: Multi-System Management & Immunosuppression", "category": "Systemic Lung Diseases", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Marcus Johnson", "age": 42, "gender": "Male", "mrn": "5814-MJ", "dob": "03/19/1982", "weight": "185 lbs", "height": "6'0\"", "allergies": "None"}, "chief_complaint": "Chronic cough and progressive shortness of breath for 8 months.", "hpi": "42-year-old male with sarcoidosis diagnosed 1 year ago presents for follow-up. He reports worsening exertional dyspnea, chronic dry cough, and fatigue. He was started on prednisone 6 months ago with some improvement, but symptoms recurred when dose was tapered. Recent chest CT shows progression of mediastinal lymphadenopathy and pulmonary infiltrates. He denies fever, night sweats, or weight loss.", "pmh": "Stage II sarcoidosis with pulmonary and mediastinal involvement, Hypertension, GERD.", "ros": {"gen": "Fatigued, no fever or weight loss", "resp": "Chronic dry cough, progressive exertional dyspnea, clear breath sounds", "cardio": "Regular rhythm, no murmurs", "neuro": "Alert and oriented, no focal deficits", "skin": "No rashes or lesions", "msk": "No joint pain or swelling", "eyes": "No visual changes or eye pain"}}, "exhibits": [{"title": "High-Resolution CT Chest", "type": "text", "content": "Extensive mediastinal and hilar lymphadenopathy, bilateral upper lobe predominant reticulonodular infiltrates, peribronchial thickening, no honeycombing"}, {"title": "Pulmonary Function Tests", "type": "text", "content": "FEV1: 2.6 L (68% predicted), FVC: 3.4 L (72% predicted), FEV1/FVC: 0.76, DLCO: 58% predicted, TLC: 85% predicted"}, {"title": "Laboratory Results", "type": "text", "content": "ACE level: 85 U/L (elevated), Calcium: 11.2 mg/dL (elevated), ESR: 45 mm/hr (elevated), CRP: 28 mg/L (elevated)"}, {"title": "Echocardiogram", "type": "text", "content": "Normal left and right ventricular function, no pulmonary hypertension, mild pericardial effusion"}, {"title": "Medication List", "type": "text", "content": "Prednisone 20mg daily, Omeprazole 40mg daily, Lisinopril 10mg daily, Albuterol inhaler PRN"}, {"title": "Vital Signs", "type": "text", "content": "BP: 128/82 mmHg, HR: 78 bpm, RR: 18/min, O2 Sat: 96% on RA, Temp: 98.4\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Marcus Johnson has progressive sarcoidosis with pulmonary involvement. Which nursing interventions are appropriate for his management?", "options": ["Monitor for corticosteroid side effects (weight gain, hyperglycemia, mood changes)", "Assess for signs of hypercalcemia and calcium-related complications", "Educate on proper inhaler technique for supplemental bronchodilators", "Monitor ACE levels and inflammatory markers for disease activity", "Schedule regular ophthalmologic exams for ocular sarcoidosis screening", "Encourage smoking cessation if applicable", "Assess for signs of cardiac involvement (arrhythmias, heart block)", "Provide patient education on immunosuppressive therapy adherence"], "answer": [0, 1, 3, 4, 6, 7], "rationale": "Sarcoidosis management includes monitoring corticosteroid side effects, hypercalcemia complications, disease activity markers, ocular screening, cardiac involvement, and medication adherence. Smoking cessation is not applicable here. Inhaler technique is secondary."}, {"type": "matrix", "prompt": "Match the sarcoidosis complication with the appropriate monitoring parameter:", "rows": [{"text": "Hypercalcemia"}, {"text": "Cardiac sarcoidosis"}, {"text": "Ocular sarcoidosis"}, {"text": "Neurologic sarcoidosis"}, {"text": "Renal sarcoidosis"}], "columns": ["Serum calcium and PTH levels", "EKG and echocardiogram", "Visual acuity and slit lamp exam", "MRI brain and lumbar puncture", "Creatinine and urinalysis", "Pulmonary function tests", "ACE levels and ESR"], "answer": {"Hypercalcemia": "Serum calcium and PTH levels", "Cardiac sarcoidosis": "EKG and echocardiogram", "Ocular sarcoidosis": "Visual acuity and slit lamp exam", "Neurologic sarcoidosis": "MRI brain and lumbar puncture", "Renal sarcoidosis": "Creatinine and urinalysis"}, "rationale": "Sarcoidosis can affect multiple organs requiring specific monitoring: hypercalcemia needs calcium/PTH monitoring, cardiac involvement requires EKG/echo, ocular needs visual exams, neurologic requires MRI/LP, renal needs creatinine/urinalysis."}, {"type": "bowtie", "prompt": "During a clinic visit, Marcus reports acute onset of blurry vision in his right eye. Identify the appropriate intervention.", "center_condition": {"options": ["Ocular sarcoidosis flare", "Corticosteroid-induced cataract", "Hypertensive retinopathy", "Diabetic retinopathy"], "answer": "Ocular sarcoidosis flare"}, "left_actions": {"options": ["Administer topical corticosteroids to the eye", "Urgent ophthalmology consultation", "Increase systemic prednisone dose", "Check visual acuity in both eyes", "Assess for pain or photophobia", "Administer eye drops for intraocular pressure"], "answer": ["Urgent ophthalmology consultation", "Check visual acuity in both eyes"]}, "right_monitor": {"options": ["Visual acuity changes", "Intraocular pressure", "Signs of uveitis (redness, pain)", "Response to treatment", "Systemic symptoms", "ACE levels"], "answer": ["Visual acuity changes", "Signs of uveitis (redness, pain)"]}, "rationale": "Ocular sarcoidosis can cause sudden vision changes requiring urgent ophthalmology evaluation and visual acuity assessment. Close monitoring of vision and signs of inflammation is essential for timely intervention."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about sarcoidosis treatment:", "text": "Corticosteroids remain the [BLANK_1] for treating symptomatic sarcoidosis, with prednisone typically initiated at [BLANK_2] mg daily and tapered slowly over [BLANK_3] months to minimize disease [BLANK_4] and steroid-related complications.", "blanks": [{"correct": "first-line treatment"}, {"correct": "20-40"}, {"correct": "6-12"}, {"correct": "flare"}], "options": ["first-line treatment", "second-line treatment", "adjunctive treatment", "20-40", "10-20", "40-60", "6-12", "3-6", "12-24", "flare", "progression", "complications", "toxicity"], "rationale": "Corticosteroids are first-line for symptomatic sarcoidosis at 20-40mg prednisone daily, tapered slowly over 6-12 months to prevent disease flare and steroid complications."}, {"type": "highlight_select", "prompt": "Review the patient's sarcoidosis assessment findings and identify all that indicate active disease requiring treatment intensification:", "text": "42-year-old male with sarcoidosis. Reports worsening cough and dyspnea. ACE level 85 U/L. Calcium 11.2 mg/dL. ESR 45 mm/hr. Recent chest CT shows increased lymphadenopathy. PFTs stable. No ocular symptoms. No cardiac symptoms. On prednisone 20mg daily.", "highlights": [{"text": "Reports worsening cough and dyspnea", "correct": true}, {"text": "ACE level 85 U/L", "correct": true}, {"text": "Calcium 11.2 mg/dL", "correct": true}, {"text": "ESR 45 mm/hr", "correct": true}, {"text": "Recent chest CT shows increased lymphadenopathy", "correct": true}, {"text": "PFTs stable", "correct": false}, {"text": "No ocular symptoms", "correct": false}, {"text": "No cardiac symptoms", "correct": false}, {"text": "On prednisone 20mg daily", "correct": false}], "selection_mode": "multiple", "instruction": "Click on all findings that indicate active sarcoidosis requiring treatment intensification:", "rationale": "Active sarcoidosis indicators include: worsening symptoms, elevated ACE/calcium/ESR (inflammation markers), and radiographic progression. Stable PFTs, absence of symptoms in other organs, and current steroid therapy do not indicate the need for intensification."}]}, {"id": "M-059", "numerical_id": 59, "type": "mission", "title": "Obstructive Sleep Apnea: CPAP Therapy & Lifestyle Management", "category": "Sleep-Related Respiratory Disorders", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Jennifer Ramirez", "age": 55, "gender": "Female", "mrn": "5915-JR", "dob": "07/12/1969", "weight": "220 lbs", "height": "5'6\"", "allergies": "Penicillin (rash)"}, "chief_complaint": "Excessive daytime sleepiness and snoring for several years.", "hpi": "55-year-old female with obesity and suspected OSA presents for sleep study follow-up. She reports snoring loudly every night, witnessed apneas by her husband, and excessive daytime sleepiness causing difficulty concentrating at work. She falls asleep while driving occasionally. Recent polysomnography showed severe OSA with AHI of 45 events/hour. She was prescribed CPAP but reports difficulty tolerating it. BMI is 35.5.", "pmh": "Obesity, Hypertension, Type 2 Diabetes, Depression.", "ros": {"gen": "Excessive daytime sleepiness, fatigue", "resp": "Loud snoring, reports of apnea episodes, no dyspnea", "cardio": "Hypertension, no chest pain", "neuro": "Difficulty concentrating, morning headaches", "gi": "No GI symptoms", "msk": "Joint pain from osteoarthritis", "psych": "Depressed mood, low motivation"}}, "exhibits": [{"title": "Polysomnography Results", "type": "text", "content": "Apnea-Hypopnea Index (AHI): 45 events/hour (severe OSA), Oxygen nadir: 78%, Sleep efficiency: 85%, REM sleep: 12% of total sleep"}, {"title": "Epworth Sleepiness Scale", "type": "text", "content": "Score: 18/24 (severe excessive daytime sleepiness). High scores for sitting/reading, watching TV, and driving"}, {"title": "Anthropometric Measurements", "type": "text", "content": "BMI: 35.5 kg/m\u00b2, Neck circumference: 17 inches, Waist circumference: 42 inches"}, {"title": "Laboratory Results", "type": "text", "content": "HbA1c: 8.2%, Total cholesterol: 245 mg/dL, Triglycerides: 180 mg/dL, Morning cortisol: 15 \u03bcg/dL (normal)"}, {"title": "CPAP Download Data", "type": "text", "content": "Average usage: 4.5 hours/night, AHI on CPAP: 3.2 events/hour, Mask leaks: moderate"}, {"title": "Vital Signs", "type": "text", "content": "BP: 148/92 mmHg, HR: 78 bpm, RR: 16/min, O2 Sat: 96% on RA, Temp: 98.2\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Jennifer Ramirez has severe obstructive sleep apnea. Which nursing interventions are appropriate for her management?", "options": ["Educate on CPAP therapy benefits and proper mask fitting", "Monitor for mask leaks and skin breakdown at contact points", "Provide dietary counseling for weight management", "Assess for symptoms of depression and provide support", "Teach positional therapy (avoiding supine sleep position)", "Encourage regular exercise and physical activity", "Monitor blood pressure and cardiovascular complications", "Educate on driving safety and sleep-related accidents"], "answer": [0, 1, 2, 3, 5, 6, 7], "rationale": "OSA management includes CPAP education, mask care, weight management, depression screening, exercise promotion, cardiovascular monitoring, and driving safety education. Positional therapy is not primary for severe OSA."}, {"type": "matrix", "prompt": "Match the OSA severity classification with the corresponding AHI range:", "rows": [{"text": "Mild OSA"}, {"text": "Moderate OSA"}, {"text": "Severe OSA"}], "columns": ["AHI 5-15 events/hour", "AHI 15-30 events/hour", "AHI >30 events/hour", "AHI <5 events/hour (normal)", "AHI 30-45 events/hour"], "answer": {"Mild OSA": "AHI 5-15 events/hour", "Moderate OSA": "AHI 15-30 events/hour", "Severe OSA": "AHI >30 events/hour"}, "rationale": "OSA severity is classified by AHI: mild (5-15), moderate (15-30), severe (>30 events/hour). Normal is <5 events/hour."}, {"type": "bowtie", "prompt": "Jennifer reports persistent daytime sleepiness despite CPAP use. Identify the appropriate intervention.", "center_condition": {"options": ["Inadequate CPAP adherence", "Residual OSA despite CPAP", "CPAP mask leak", "Coexisting narcolepsy"], "answer": "Residual OSA despite CPAP"}, "left_actions": {"options": ["Download CPAP data to assess usage", "Adjust CPAP pressure settings", "Trial different mask types", "Add oral appliance therapy", "Evaluate for upper airway surgery", "Assess for other sleep disorders"], "answer": ["Download CPAP data to assess usage", "Adjust CPAP pressure settings"]}, "right_monitor": {"options": ["Epworth Sleepiness Scale scores", "CPAP usage hours per night", "Residual AHI on therapy", "Daytime sleepiness improvement", "Blood pressure control", "Weight changes"], "answer": ["Epworth Sleepiness Scale scores", "Residual AHI on therapy"]}, "rationale": "Residual OSA despite CPAP requires pressure adjustment and efficacy monitoring. CPAP data download and ESS scores help assess treatment response."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about OSA cardiovascular complications:", "text": "Obstructive sleep apnea is associated with [BLANK_1] hypertension due to [BLANK_2] during apneas, leading to increased [BLANK_3] activity and [BLANK_4] vascular resistance.", "blanks": [{"correct": "treatment-resistant"}, {"correct": "sympathetic activation"}, {"correct": "renin-angiotensin"}, {"correct": "systemic"}], "options": ["treatment-resistant", "mild", "labile", "sympathetic activation", "parasympathetic activation", "baroreceptor reflex", "renin-angiotensin", "hypothalamic-pituitary", "adrenergic", "systemic", "pulmonary", "peripheral", "central"], "rationale": "OSA causes treatment-resistant hypertension through sympathetic activation during apneas, stimulating renin-angiotensin system and increasing systemic vascular resistance."}, {"type": "highlight_select", "prompt": "Review the patient's OSA risk factors and identify all that contribute to disease severity:", "text": "55-year-old female with severe OSA. BMI 35.5 kg/m\u00b2. Neck circumference 17 inches. Reports loud snoring and witnessed apneas. Excessive daytime sleepiness. Hypertension. Type 2 diabetes. Postmenopausal. No alcohol use. No smoking history.", "highlights": [{"text": "BMI 35.5 kg/m\u00b2", "correct": true}, {"text": "Neck circumference 17 inches", "correct": true}, {"text": "Reports loud snoring and witnessed apneas", "correct": true}, {"text": "Excessive daytime sleepiness", "correct": true}, {"text": "Hypertension", "correct": true}, {"text": "Type 2 diabetes", "correct": true}, {"text": "Postmenopausal", "correct": true}, {"text": "No alcohol use", "correct": false}, {"text": "No smoking history", "correct": false}], "selection_mode": "multiple", "instruction": "Click on all factors that contribute to OSA severity:", "rationale": "OSA risk factors include: obesity (high BMI), anatomic factors (large neck), symptoms (snoring, apneas, sleepiness), comorbidities (HTN, DM), and female hormonal changes (postmenopausal). Absence of alcohol/smoking is not a risk factor."}]}, {"id": "M-060", "numerical_id": 60, "type": "mission", "title": "Occupational Lung Disease: Silicosis & Workplace Safety", "category": "Occupational Respiratory Disorders", "difficulty": "Advanced", "patient_profile": {"demographics": {"name": "Thomas Garcia", "age": 62, "gender": "Male", "mrn": "6016-TG", "dob": "11/25/1962", "weight": "165 lbs", "height": "5'9\"", "allergies": "None"}, "chief_complaint": "Progressive shortness of breath and chronic cough for 15 years.", "hpi": "62-year-old male with silicosis presents for disability evaluation. He worked as a sandblaster for 25 years before retiring 5 years ago. He reports progressive dyspnea on exertion, chronic productive cough with black sputum, and fatigue. He denies fever or hemoptysis. Recent chest X-ray shows progressive nodular opacities. He requires supplemental oxygen at night. Former smoker (quit 20 years ago, 20 pack-years).", "pmh": "Silicosis (complicated), Chronic bronchitis, Osteoarthritis, Hearing loss.", "ros": {"gen": "Fatigued, no recent weight loss", "resp": "Progressive exertional dyspnea, chronic cough with black sputum, crackles at bases", "cardio": "Regular rhythm, no murmurs", "neuro": "Alert and oriented", "skin": "No rashes", "msk": "Joint pain from osteoarthritis", "psych": "Frustrated with limitations"}}, "exhibits": [{"title": "Chest X-ray", "type": "text", "content": "Multiple small nodular opacities throughout both lungs, progressive massive fibrosis in upper lobes, pleural thickening, no pneumothorax"}, {"title": "High-Resolution CT Chest", "type": "text", "content": "Diffuse centrilobular nodules, conglomerate masses in upper lobes, traction bronchiectasis, honeycombing, pleural plaques"}, {"title": "Pulmonary Function Tests", "type": "text", "content": "FEV1: 1.8 L (52% predicted), FVC: 2.6 L (58% predicted), FEV1/FVC: 0.69, DLCO: 45% predicted, TLC: 75% predicted"}, {"title": "Arterial Blood Gas", "type": "text", "content": "pH: 7.38, PaCO2: 42 mmHg, PaO2: 68 mmHg, HCO3: 24 mEq/L, O2 Sat: 92% on RA"}, {"title": "Silica Exposure Assessment", "type": "text", "content": "25 years sandblasting without respiratory protection, estimated silica exposure >10 mg/m\u00b3-years, workplace safety violations documented"}, {"title": "Vital Signs", "type": "text", "content": "BP: 135/85 mmHg, HR: 82 bpm, RR: 20/min, O2 Sat: 92% on RA, Temp: 98.0\u00b0F"}], "steps": [{"type": "extended_sata", "prompt": "Thomas Garcia has complicated silicosis. Which nursing interventions are appropriate for his care?", "options": ["Educate on proper use of respiratory protective equipment", "Monitor for progression to progressive massive fibrosis", "Assess for complications (tuberculosis, lung cancer, autoimmune disease)", "Provide smoking cessation counseling and support", "Encourage pneumococcal and influenza vaccinations", "Monitor oxygen saturation and provide supplemental oxygen as needed", "Refer to occupational health clinic for workplace exposure assessment", "Teach energy conservation techniques and activity pacing"], "answer": [0, 1, 2, 3, 4, 5, 7], "rationale": "Silicosis management includes PPE education, monitoring disease progression and complications, smoking cessation, vaccinations, oxygen therapy, and energy conservation. Workplace assessment is important but not immediate priority."}, {"type": "matrix", "prompt": "Match the occupational lung disease with its characteristic exposure:", "rows": [{"text": "Silicosis"}, {"text": "Asbestosis"}, {"text": "Coal workers' pneumoconiosis"}, {"text": "Beryllium disease"}, {"text": "Farmer's lung"}], "columns": ["Silica dust from mining/sandblasting", "Asbestos fibers from insulation/mining", "Coal dust from mining", "Beryllium from aerospace/electronics", "Moldy hay (thermophilic actinomycetes)", "Cotton dust (byssinosis)", "Welding fumes"], "answer": {"Silicosis": "Silica dust from mining/sandblasting", "Asbestosis": "Asbestos fibers from insulation/mining", "Coal workers' pneumoconiosis": "Coal dust from mining", "Beryllium disease": "Beryllium from aerospace/electronics", "Farmer's lung": "Moldy hay (thermophilic actinomycetes)"}, "rationale": "Occupational lung diseases have specific exposures: silicosis from silica dust, asbestosis from asbestos, CWP from coal dust, beryllium disease from beryllium, farmer's lung from moldy hay."}, {"type": "bowtie", "prompt": "During a follow-up visit, Thomas develops acute respiratory distress with fever. Identify the appropriate intervention.", "center_condition": {"options": ["Acute silicosis exacerbation", "Silicotuberculosis", "Spontaneous pneumothorax", "Community-acquired pneumonia"], "answer": "Silicotuberculosis"}, "left_actions": {"options": ["Obtain sputum for acid-fast bacillus stain", "Start empiric tuberculosis treatment", "Administer broad-spectrum antibiotics", "Obtain chest X-ray and CT scan", "Isolate patient with airborne precautions", "Contact public health department"], "answer": ["Obtain sputum for acid-fast bacillus stain", "Obtain chest X-ray and CT scan"]}, "right_monitor": {"options": ["Sputum culture results", "Response to treatment", "Isolation compliance", "Contact tracing completion", "Respiratory status improvement", "Drug resistance testing"], "answer": ["Sputum culture results", "Response to treatment"]}, "rationale": "Silicotuberculosis requires prompt diagnostic workup with sputum AFB stain and imaging. Monitoring culture results and treatment response is essential for management."}, {"type": "drag_drop_cloze", "prompt": "Complete the statement about silicosis prevention:", "text": "Occupational exposure to respirable crystalline silica can be prevented through engineering controls such as [BLANK_1] ventilation and [BLANK_2] systems, combined with administrative controls like [BLANK_3] rotation and [BLANK_4] monitoring to maintain exposure below the OSHA PEL of 50 \u03bcg/m\u00b3.", "blanks": [{"correct": "local exhaust"}, {"correct": "wet processing"}, {"correct": "worker"}, {"correct": "airborne"}], "options": ["local exhaust", "general", "natural", "wet processing", "dry cutting", "high-speed", "worker", "task", "equipment", "airborne", "personal", "environmental", "routine", "periodic"], "rationale": "Silica exposure prevention includes local exhaust ventilation, wet processing systems, worker rotation, and airborne monitoring to maintain exposure below OSHA PEL of 50 \u03bcg/m\u00b3."}, {"type": "highlight_select", "prompt": "Review the patient's silicosis complications and identify all that increase mortality risk:", "text": "62-year-old male with complicated silicosis. Progressive massive fibrosis on imaging. FEV1 52% predicted. DLCO 45% predicted. Requires nocturnal oxygen. Former smoker. No active tuberculosis. No lung cancer diagnosis. No autoimmune disease.", "highlights": [{"text": "Progressive massive fibrosis on imaging", "correct": true}, {"text": "FEV1 52% predicted", "correct": true}, {"text": "DLCO 45% predicted", "correct": true}, {"text": "Requires nocturnal oxygen", "correct": true}, {"text": "Former smoker", "correct": true}, {"text": "No active tuberculosis", "correct": false}, {"text": "No lung cancer diagnosis", "correct": false}, {"text": "No autoimmune disease", "correct": false}], "selection_mode": "multiple", "instruction": "Click on all findings that increase mortality risk in silicosis:", "rationale": "Increased mortality risk in silicosis from: progressive massive fibrosis, reduced lung function (low FEV1/DLCO), oxygen dependence, and smoking history. Absence of TB, lung cancer, or autoimmune disease does not increase risk."}]}]);
console.log('Injected 10 NGN missions from advanced_missions');
window.availableExams = window.availableExams || [];
if(window.lectureExamData && window.lectureExamData.length > 0) {
    window.availableExams.push({id: 'original_cardiac', name: 'Cardiovascular & Diabetes Pharmacology Exam (Original)', data: window.lectureExamData});
    console.log('Included original cardiac exam with ' + window.lectureExamData.length + ' questions');
}

/* === FINAL REVIEW: MEDICAL-SURGICAL COMPREHENSIVE EXAM === */
window.finalReviewExamData = [
{"id":"fr_cardiac_cath","slide":999,"question":"A client is scheduled for a cardiac catheterization. Which assessment finding should the nurse report to the provider BEFORE the procedure?","options":["Blood pressure of 128/82 mmHg","Allergy to shellfish","Heart rate of 78 bpm","Last meal was 8 hours ago"],"answer":"Allergy to shellfish","rationale":"Shellfish allergy suggests a potential iodine/contrast dye allergy, which must be reported before cardiac catheterization to prevent an anaphylactic reaction. The other findings are within normal limits or expected pre-procedure."},
{"id":"fr_cardiac_cath_post","slide":999,"question":"Following a cardiac catheterization, which nursing intervention is the HIGHEST priority?","options":["Encourage ambulation within 1 hour","Monitor the insertion site for bleeding","Administer a full liquid diet","Elevate the head of bed to 90 degrees"],"answer":"Monitor the insertion site for bleeding","rationale":"Post-cardiac catheterization, the highest priority is monitoring the insertion site for bleeding or hematoma formation. The client should remain flat with the affected extremity extended, not ambulating."},
{"id":"fr_mri_safety","slide":999,"question":"A nurse is preparing a client for an MRI. Which action is essential before the procedure?","options":["Administer a sedative","Remove all metal objects from the client","Start an IV line with contrast dye","Place the client in a left lateral position"],"answer":"Remove all metal objects from the client","rationale":"MRI uses powerful magnets, so all metal objects must be removed. MRI is contraindicated in clients with pacemakers or ICDs. Sedation and IV contrast are not always required."},
{"id":"fr_stress_test","slide":999,"question":"A client undergoing an exercise stress test reports chest pain and dizziness. What is the nurse's FIRST action?","options":["Encourage the client to continue for 2 more minutes","Stop the test immediately and notify the provider","Administer sublingual nitroglycerin","Document the findings and continue monitoring"],"answer":"Stop the test immediately and notify the provider","rationale":"Chest pain and dizziness during a stress test indicate possible cardiac ischemia. The test must be stopped immediately and the provider notified. These are reportable symptoms that require immediate intervention."},
{"id":"fr_hypoxia_signs","slide":999,"question":"Which findings should the nurse recognize as early signs of hypoxia? (Select all that apply)","options":["Cyanosis","Restlessness","Tachycardia","Bradycardia","Light-headedness"],"answer":["Cyanosis","Restlessness","Tachycardia","Light-headedness"],"rationale":"Early signs of hypoxia include cyanosis, tachycardia (not bradycardia), restlessness, and light-headedness. Bradycardia is a late sign of severe hypoxia indicating impending cardiopulmonary arrest."},
{"id":"fr_post_bronch","slide":999,"question":"After a bronchoscopy, which nursing action is MOST important before allowing the client to eat or drink?","options":["Check the client's oxygen saturation","Verify the return of the gag reflex","Obtain a chest X-ray","Assess the client's pain level"],"answer":"Verify the return of the gag reflex","rationale":"After bronchoscopy, the client must remain NPO until the gag reflex returns to prevent aspiration. The throat is anesthetized during the procedure, and swallowing safely requires a functioning gag reflex."},
{"id":"fr_chest_tube","slide":999,"question":"A nurse is caring for a client with a chest tube. Which action is appropriate?","options":["Clamp the chest tube when ambulating the client","Keep the drainage system below the level of the chest","Coil the tubing with dependent loops to prevent kinking","Lower the head of bed to a flat position"],"answer":"Keep the drainage system below the level of the chest","rationale":"The chest tube drainage system must always remain below the level of the chest to promote gravity drainage and prevent backflow. Tubing should be kept straight without dependent loops. The head of bed should be elevated. Clamping is only done per specific provider orders."},
{"id":"fr_pleural_effusion","slide":999,"question":"A nurse assesses a client with a pleural effusion. Which finding does the nurse expect?","options":["Hyperresonance to percussion on the affected side","Increased chest wall movement on the affected side","Absent or diminished breath sounds on the affected side","Coarse crackles bilaterally"],"answer":"Absent or diminished breath sounds on the affected side","rationale":"Pleural effusion causes fluid accumulation in the pleural space, resulting in decreased chest wall movement, absent or diminished breath sounds, and dullness (not hyperresonance) to percussion on the affected side."},
{"id":"fr_resp_acidosis","slide":999,"question":"A client's ABG results show: pH 7.30, PaCO 55 mmHg, HCO 24 mEq/L. The nurse interprets this as:","options":["Respiratory alkalosis","Metabolic acidosis","Respiratory acidosis","Metabolic alkalosis"],"answer":"Respiratory acidosis","rationale":"pH 7.30 is acidotic (below 7.35). PaCO of 55 is elevated (above 45), indicating a respiratory cause. HCO of 24 is normal, indicating no metabolic compensation. This is uncompensated respiratory acidosis caused by hypoventilation."},
{"id":"fr_asthma_inhaler","slide":999,"question":"A nurse is teaching a client how to use a metered-dose inhaler (MDI). Which sequence is correct?","options":["Inhale quickly, press canister, exhale slowly","Shake inhaler, seal lips around mouthpiece, inhale slowly and deeply, hold breath","Press canister, take a quick breath, exhale through nose","Exhale fully, shake inhaler, inhale through nose, hold breath"],"answer":"Shake inhaler, seal lips around mouthpiece, inhale slowly and deeply, hold breath","rationale":"The correct MDI technique is: shake the inhaler, seal lips around the mouthpiece, take a slow deep inhalation while pressing the canister, then hold the breath for approximately 10 seconds to allow medication deposition in the airways."},
{"id":"fr_hiv_precautions","slide":999,"question":"A nurse is caring for a client diagnosed with HIV. Which type of precautions should the nurse implement?","options":["Airborne precautions","Droplet precautions","Contact precautions","Standard precautions"],"answer":"Standard precautions","rationale":"HIV is transmitted through blood and body fluids, not through airborne or droplet routes. Standard precautions are appropriate for all clients and are sufficient for HIV-positive clients."},
{"id":"fr_influenza_precautions","slide":999,"question":"A client is admitted with influenza. Which type of isolation precautions should the nurse initiate?","options":["Standard precautions only","Airborne precautions","Droplet precautions","Contact precautions"],"answer":"Droplet precautions","rationale":"Influenza is transmitted via large respiratory droplets. Droplet precautions (surgical mask within 3 feet, private room) are required in addition to standard precautions."},
{"id":"fr_flu_outbreak","slide":999,"question":"During an influenza outbreak on a nursing unit, which actions should the nurse implement? (Select all that apply)","options":["Restrict ill visitors from entering the unit","Administer antiviral medications within 48 hours of symptom onset","Place all clients on airborne precautions","Encourage staff with symptoms to continue working with a mask","Implement droplet precautions for symptomatic clients"],"answer":["Restrict ill visitors from entering the unit","Administer antiviral medications within 48 hours of symptom onset","Implement droplet precautions for symptomatic clients"],"rationale":"During an influenza outbreak: restrict ill visitors, administer antivirals within 48 hours, and implement droplet precautions. Influenza does not require airborne precautions. Ill staff should NOT continue working."},
{"id":"fr_fluid_overload","slide":999,"question":"Which assessment findings indicate fluid volume overload? (Select all that apply)","options":["Bounding pulses","Crackles in lung bases","Flat neck veins","Periorbital edema","Distended neck veins"],"answer":["Bounding pulses","Crackles in lung bases","Periorbital edema","Distended neck veins"],"rationale":"Fluid volume overload presents with bounding pulses, crackles in the lungs (pulmonary edema), periorbital edema, and distended (not flat) neck veins (JVD). Flat neck veins suggest dehydration."},
{"id":"fr_furosemide","slide":999,"question":"A client is receiving furosemide (Lasix). Which laboratory value should the nurse monitor MOST closely?","options":["Serum sodium","Serum calcium","Serum potassium","Serum magnesium"],"answer":"Serum potassium","rationale":"Furosemide is a loop diuretic that causes significant potassium loss. Hypokalemia can lead to life-threatening dysrhythmias. Monitoring serum potassium is the highest priority."},
{"id":"fr_hypoglycemia","slide":999,"question":"A nurse assesses a client with diabetes who is experiencing hypoglycemia. Which findings does the nurse expect? (Select all that apply)","options":["Shakiness","Tachycardia","Sweating","Hot dry skin","Cool clammy skin","Hunger"],"answer":["Shakiness","Tachycardia","Sweating","Cool clammy skin","Hunger"],"rationale":"Hypoglycemia presents with shakiness, tachycardia, sweating, blurred vision, cool clammy skin, hunger, and irritability. Hot dry skin is associated with hyperglycemia, not hypoglycemia."},
{"id":"fr_insulin_mixing","slide":999,"question":"A nurse is preparing to administer a mixed dose of NPH and regular insulin. What is the correct sequence?","options":["Withdraw NPH first, then withdraw regular insulin","Inject air into regular vial, inject air into NPH vial, withdraw NPH, withdraw regular","Inject air into NPH vial, inject air into regular vial, withdraw regular insulin, withdraw NPH","Withdraw regular insulin first, then inject air into NPH vial"],"answer":"Inject air into NPH vial, inject air into regular vial, withdraw regular insulin, withdraw NPH","rationale":"The correct sequence is: inject air into NPH (cloudy) first, inject air into regular (clear) second, withdraw regular insulin first (to prevent contamination), then withdraw NPH. Remember: 'Clear before cloudy.'"},
{"id":"fr_ppi","slide":999,"question":"A client asks the nurse why omeprazole has been prescribed. The nurse's BEST response is:","options":["It coats the stomach lining to prevent ulcers","It decreases gastric acid secretion to relieve acid indigestion and GERD","It neutralizes existing stomach acid immediately","It kills the bacteria causing your stomach ulcer"],"answer":"It decreases gastric acid secretion to relieve acid indigestion and GERD","rationale":"Omeprazole is a proton pump inhibitor (PPI) that decreases gastric acid secretion by inhibiting the hydrogen-potassium ATPase enzyme system. Its therapeutic effect is relief of GERD and acid indigestion."},
{"id":"fr_rectal_supp","slide":999,"question":"A nurse is administering a rectal suppository. Which position should the client be placed in?","options":["Right lateral position","Supine position","Left lateral (Sims) position","Prone position"],"answer":"Left lateral (Sims) position","rationale":"The left lateral (Sims) position is used for rectal suppository administration because it follows the natural curve of the sigmoid colon and rectum, facilitating insertion and retention."},
{"id":"fr_enteral_feeding","slide":999,"question":"A nurse is preparing to administer an enteral tube feeding. Place the steps in the correct sequence: 1) Evaluate tolerance, 2) Administer feeding, 3) Check residual, 4) Verify tube placement.","options":["4, 3, 2, 1","3, 4, 1, 2","2, 3, 4, 1","4, 2, 3, 1"],"answer":"4, 3, 2, 1","rationale":"The correct sequence for enteral feeding is: (4) Verify tube placement first (safety priority), (3) Check residual volume, (2) Administer the feeding, (1) Evaluate tolerance. Verification of placement prevents aspiration."},
{"id":"fr_transfusion_rxn","slide":999,"question":"A client receiving a blood transfusion develops hypotension, low back pain, and dark reddish urine. The nurse recognizes these as signs of:","options":["Febrile non-hemolytic reaction","Acute hemolytic transfusion reaction","Allergic transfusion reaction","Circulatory overload"],"answer":"Acute hemolytic transfusion reaction","rationale":"Hypotension, low back/flank pain, and dark or reddish urine (hemoglobinuria) are classic signs of an acute hemolytic transfusion reaction caused by ABO incompatibility. This is a medical emergency requiring immediate cessation of the transfusion."},
{"id":"fr_anemia_signs","slide":999,"question":"Which findings does the nurse expect in a client with anemia? (Select all that apply)","options":["Fatigue","Pallor","Bradycardia","Tachycardia","Brittle or spoon-shaped nails"],"answer":["Fatigue","Pallor","Tachycardia","Brittle or spoon-shaped nails"],"rationale":"Anemia causes decreased oxygen-carrying capacity, resulting in fatigue, pallor, tachycardia (compensatory), and brittle or spoon-shaped nails (koilonychia). Bradycardia is not expected; the heart rate increases to compensate for decreased oxygen delivery."},
{"id":"fr_iron_therapy","slide":999,"question":"A nurse is teaching a client about iron supplement therapy. Which statement by the client indicates understanding?","options":["I should take my iron with a glass of milk","I will take my iron with orange juice to help absorption","Dark stools mean I should stop the medication","I should take antacids with my iron to prevent stomach upset"],"answer":"I will take my iron with orange juice to help absorption","rationale":"Vitamin C (found in orange juice) increases iron absorption. Iron should NOT be taken with milk or antacids as they decrease absorption. Dark green or black stools are an expected side effect, not a reason to stop the medication."},
{"id":"fr_hemophilia","slide":999,"question":"A client with hemophilia presents with increased bruising. Which laboratory value is the nurse MOST concerned about?","options":["Hemoglobin level","White blood cell count","Platelet count","Serum iron level"],"answer":"Platelet count","rationale":"Hemophilia involves clotting factor deficiency, and increased bruising with a low platelet level is a significant concern for uncontrolled bleeding. The platelet count directly relates to the client's bleeding risk."},
{"id":"fr_opioid_tolerance","slide":999,"question":"A client receiving morphine for chronic pain requires increasingly higher doses to achieve the same level of pain relief. The nurse recognizes this as:","options":["Opioid addiction","Opioid tolerance","Opioid toxicity","Physical dependence"],"answer":"Opioid tolerance","rationale":"Opioid tolerance is the requirement for an increased dose to achieve the same analgesic effect. This is a normal physiological response, not addiction. Toxicity would present with respiratory depression and sedation."},
{"id":"fr_naloxone","slide":999,"question":"A client receiving IV morphine has a respiratory rate of 8 breaths/min and is difficult to arouse. Which medication should the nurse administer?","options":["Flumazenil","Naloxone","Epinephrine","Atropine"],"answer":"Naloxone","rationale":"Naloxone (Narcan) is the opioid reversal agent. Respiratory depression (rate below 12) and excessive sedation are signs of opioid toxicity requiring immediate naloxone administration. Flumazenil reverses benzodiazepines, not opioids."},
{"id":"fr_docusate","slide":999,"question":"A client is prescribed docusate (Colace) along with an opioid analgesic. The nurse explains that docusate is used to:","options":["Increase intestinal motility","Prevent opioid-induced constipation by softening stool","Reduce the risk of opioid toxicity","Enhance the analgesic effect of the opioid"],"answer":"Prevent opioid-induced constipation by softening stool","rationale":"Docusate is a stool softener that prevents opioid-induced constipation, a common side effect of opioid therapy. It works by allowing water and fat to penetrate the stool, making it softer and easier to pass."},
{"id":"fr_ckd_labs","slide":999,"question":"Which laboratory findings does the nurse expect in a client with chronic kidney disease?","options":["Decreased BUN and decreased creatinine","Increased BUN and increased creatinine","Decreased BUN and increased creatinine","Increased BUN and decreased creatinine"],"answer":"Increased BUN and increased creatinine","rationale":"In chronic kidney disease, the kidneys cannot adequately filter waste products, resulting in elevated BUN and creatinine levels. These are key indicators of declining renal function."},
{"id":"fr_hypovolemic_shock","slide":999,"question":"A nurse is assessing a client with suspected hypovolemic shock. Which findings does the nurse expect? (Select all that apply)","options":["Hypotension","Tachycardia","Oliguria","Bradycardia","Tachypnea"],"answer":["Hypotension","Tachycardia","Oliguria","Tachypnea"],"rationale":"Hypovolemic shock presents with hypotension (decreased circulating volume), tachycardia (compensatory), oliguria (decreased renal perfusion), and tachypnea (compensatory). Bradycardia is not expected; the heart rate increases to maintain cardiac output."},
{"id":"fr_anaphylaxis","slide":999,"question":"A client develops anaphylaxis after receiving IV antibiotics. Which medication should the nurse administer FIRST?","options":["Diphenhydramine","Methylprednisolone","Epinephrine","Albuterol"],"answer":"Epinephrine","rationale":"Epinephrine is the FIRST-line treatment for anaphylaxis. It causes bronchodilation and vasoconstriction, reversing the life-threatening effects. Diphenhydramine and corticosteroids are adjunct therapies given after epinephrine."},
{"id":"fr_hemorrhage","slide":999,"question":"A client is hemorrhaging from a wound on the forearm. What is the nurse's FIRST action?","options":["Apply a tourniquet above the wound","Apply direct pressure to the bleeding site","Elevate the extremity above the heart","Call the rapid response team"],"answer":"Apply direct pressure to the bleeding site","rationale":"The first action for hemorrhage control is applying direct pressure to the bleeding site. This is the most effective initial intervention to control bleeding. Tourniquets are used only when direct pressure fails."},
{"id":"fr_resp_distress","slide":999,"question":"A client in acute respiratory distress is dyspneic and anxious. Which position should the nurse place the client in?","options":["Supine with legs elevated","Trendelenburg position","High-Fowler's (head of bed elevated)","Prone position"],"answer":"High-Fowler's (head of bed elevated)","rationale":"Head of bed elevation (High-Fowler's position) promotes lung expansion and decreases the work of breathing. This is the priority intervention for acute respiratory distress."},
{"id":"fr_dehiscence","slide":999,"question":"On postoperative day 5, a client reports a 'popping' sensation at the surgical site. The nurse observes increased serosanguineous drainage and a visible opening of the incision. The nurse recognizes this as:","options":["Normal wound healing","Wound infection","Wound dehiscence","Wound evisceration"],"answer":"Wound dehiscence","rationale":"Dehiscence is the partial or total separation of wound layers. Classic signs include a 'popping' or 'giving way' sensation, increased serosanguineous drainage, and visible opening of the incision. The nurse should cover with sterile saline-moistened gauze and notify the provider."},
{"id":"fr_evisceration","slide":999,"question":"A postoperative client's abdominal organs are protruding through the surgical incision. Which actions should the nurse take? (Select all that apply)","options":["Attempt to reinsert the organs gently","Cover the organs with sterile saline-moistened gauze","Place the client in low-Fowler's position with knees flexed","Allow the client to eat and drink to maintain strength","Prepare the client for emergency surgery","Stay with the client and call for assistance"],"answer":["Cover the organs with sterile saline-moistened gauze","Place the client in low-Fowler's position with knees flexed","Prepare the client for emergency surgery","Stay with the client and call for assistance"],"rationale":"Evisceration is a surgical emergency. The nurse should: stay with the client, cover organs with sterile saline-moistened gauze (never reinsert), position in low-Fowler's with knees flexed to reduce tension, maintain NPO, and prepare for emergency surgery."},
{"id":"fr_head_injury","slide":999,"question":"A nurse is caring for a client with a head injury. Which finding is the EARLIEST indicator of neurological deterioration?","options":["Widening pulse pressure","Change in level of consciousness","Fixed and dilated pupils","Projectile vomiting"],"answer":"Change in level of consciousness","rationale":"A change in level of consciousness is the earliest and most sensitive indicator of neurological deterioration following a head injury. Widening pulse pressure and fixed pupils are late signs of increased intracranial pressure."},
{"id":"fr_burns_rule","slide":999,"question":"A client sustains burns to the entire anterior trunk and both arms. Using the Rule of Nines, the nurse calculates the total body surface area burned as:","options":["27%","36%","45%","18%"],"answer":"36%","rationale":"Using the Rule of Nines: anterior trunk = 18%, each arm = 9% (both arms = 18%). Total = 18% + 18% = 36% TBSA burned."},
{"id":"fr_dementia_incont","slide":999,"question":"A nurse is caring for an older adult client with dementia who has urinary incontinence. Which intervention is MOST appropriate?","options":["Insert an indwelling urinary catheter","Implement a scheduled toileting program","Restrict fluid intake after 6 PM","Apply adult incontinence briefs and check every 4 hours"],"answer":"Implement a scheduled toileting program","rationale":"A scheduled (timed) toileting program is the most appropriate intervention for clients with dementia and incontinence. It promotes continence while maintaining dignity. Indwelling catheters increase infection risk and should be avoided."},
{"id":"fr_transdermal","slide":999,"question":"A nurse is applying a new transdermal medication patch. Which actions are correct? (Select all that apply)","options":["Apply the new patch over the old one for better absorption","Remove the old patch before applying the new one","Date, time, and initial the new patch","Apply with bare hands to ensure proper adhesion","Wear clean gloves during application"],"answer":["Remove the old patch before applying the new one","Date, time, and initial the new patch","Wear clean gloves during application"],"rationale":"When applying a transdermal patch: remove the old patch first (to prevent overdose), date/time/initial the new patch, and wear clean gloves (to prevent medication absorption through the nurse's skin). Never apply a new patch over an old one."},
{"id":"fr_enteric_coated","slide":999,"question":"A client asks why they cannot crush their enteric-coated naproxen tablet. The nurse's BEST response is:","options":["Crushing would make the medication less effective","The coating protects the stomach by allowing the tablet to dissolve in the intestine","Crushing would cause the medication to work too quickly","The coating improves the taste of the medication"],"answer":"The coating protects the stomach by allowing the tablet to dissolve in the intestine","rationale":"Enteric-coated tablets are designed to dissolve in the intestine, not the stomach. Crushing or chewing would destroy this coating, exposing the gastric mucosa to the medication and increasing the risk of GI irritation and ulceration."},
{"id":"fr_otic_drops","slide":999,"question":"A nurse is administering otic drops to an adult client. Which technique is correct?","options":["Pull the auricle down and back","Pull the auricle up and back","Insert the dropper tip into the ear canal","Instill cold drops directly from the refrigerator"],"answer":"Pull the auricle up and back","rationale":"For adult clients, the auricle is pulled up and back to straighten the ear canal for proper medication delivery. For children under 3, the auricle is pulled down and back. Medication should be at room temperature, and the dropper should be held above (not inserted into) the ear canal."},
{"id":"fr_phlebitis","slide":999,"question":"A nurse assesses an IV site and notes redness, warmth, streak formation along the vein, and pain. The nurse recognizes these findings as:","options":["Infiltration","Phlebitis","Extravasation","Hematoma"],"answer":"Phlebitis","rationale":"Phlebitis is inflammation of the vein characterized by redness, warmth, streak formation along the vein, and pain at the IV site. Infiltration presents with edema, coolness, and swelling. The IV should be discontinued and restarted at a new site."},
{"id":"fr_infiltration","slide":999,"question":"Which findings indicate IV infiltration? (Select all that apply)","options":["Edema at or distal to the IV site","Warmth along the vein","Coolness at the IV site","Streak formation","Swelling at the IV site"],"answer":["Edema at or distal to the IV site","Coolness at the IV site","Swelling at the IV site"],"rationale":"IV infiltration occurs when IV fluid leaks into surrounding tissue. Signs include edema, coolness, and swelling at or distal to the IV site. Warmth and streak formation are signs of phlebitis, not infiltration."},
{"id":"fr_metformin","slide":999,"question":"A client taking metformin is scheduled for a CT scan with IV contrast dye. Which instruction should the nurse provide?","options":["Take an extra dose of metformin the morning of the procedure","Metformin must be held per protocol due to the risk of lactic acidosis","Switch to insulin the day before the procedure","No medication changes are needed"],"answer":"Metformin must be held per protocol due to the risk of lactic acidosis","rationale":"Metformin combined with IV contrast dye increases the risk of lactic acidosis, a potentially fatal complication. Metformin must be held before and after the procedure per facility protocol (typically 48 hours)."},
{"id":"fr_corticosteroids_glucose","slide":999,"question":"A client with diabetes is prescribed prednisone for an inflammatory condition. The nurse should monitor for which effect?","options":["Hypoglycemia","Increased blood glucose levels","Decreased white blood cell count","Hypotension"],"answer":"Increased blood glucose levels","rationale":"Corticosteroids (such as prednisone) increase blood glucose levels by promoting gluconeogenesis and decreasing insulin sensitivity. Clients with diabetes require closer blood glucose monitoring and potential medication adjustments."},
{"id":"fr_diphenhydramine","slide":999,"question":"A client is prescribed diphenhydramine before a blood transfusion. The nurse explains this is given to:","options":["Prevent fluid volume overload","Prevent a hemolytic transfusion reaction","Prevent mild allergic reactions such as urticaria and pruritus","Reduce the risk of infection"],"answer":"Prevent mild allergic reactions such as urticaria and pruritus","rationale":"Diphenhydramine is an antihistamine given as a transfusion premedication to prevent mild allergic reactions including urticaria (hives), pruritus (itching), and flushing. It does not prevent hemolytic reactions."},
{"id":"fr_digoxin","slide":999,"question":"A nurse is preparing to administer digoxin. Which action should the nurse take FIRST?","options":["Check the serum potassium level","Assess the apical pulse for one full minute","Verify the client's allergy status","Check the client's blood pressure"],"answer":"Assess the apical pulse for one full minute","rationale":"Before administering digoxin, the nurse must assess the apical pulse for one full minute. If the heart rate is below 60 bpm in an adult, the dose should be held and the provider notified. Digoxin is a high-alert medication that decreases heart rate and increases cardiac contractility."},
{"id":"fr_warfarin","slide":999,"question":"A client is taking warfarin. Which laboratory test does the nurse monitor to evaluate therapeutic effectiveness?","options":["aPTT","CBC","PT/INR","Serum potassium"],"answer":"PT/INR","rationale":"Warfarin effectiveness is monitored by PT/INR. The therapeutic INR range is typically 2.0-3.0. Warfarin inhibits vitamin K-dependent clotting factors. aPTT monitors heparin therapy, not warfarin."},
{"id":"fr_warfarin_teaching","slide":999,"question":"A nurse is teaching a client about warfarin therapy. Which statements indicate correct understanding? (Select all that apply)","options":["I should use a soft toothbrush","I can take aspirin for headaches","I should maintain a consistent intake of vitamin K foods","I should use an electric razor for shaving","I should avoid ginkgo and garlic supplements"],"answer":["I should use a soft toothbrush","I should maintain a consistent intake of vitamin K foods","I should use an electric razor for shaving","I should avoid ginkgo and garlic supplements"],"rationale":"Warfarin teaching: use a soft toothbrush and electric razor (bleeding precautions), maintain consistent vitamin K intake (not eliminate it), and avoid herbal supplements that increase bleeding (ginkgo, garlic, ginger). Aspirin increases bleeding risk and should be avoided unless prescribed."},
{"id":"fr_phenazopyridine","slide":999,"question":"A client with a urinary tract infection is prescribed phenazopyridine. Which information should the nurse include in client teaching?","options":["This medication will cure your infection","Expect your urine to turn bright orange or red-orange","Take this medication on an empty stomach","You will need to take this medication for several months"],"answer":"Expect your urine to turn bright orange or red-orange","rationale":"Phenazopyridine is a urinary analgesic that provides symptomatic relief of dysuria, urgency, and frequency. It does NOT treat the infection (an antibiotic is needed). Expected effects include bright orange or red-orange urine that may stain clothing. It is for temporary use only and should be taken after meals."},
{"id":"fr_insulin_types","slide":999,"question":"A nurse is reviewing insulin types. Which statement is correct?","options":["NPH insulin is clear and short-acting","Regular insulin is cloudy and intermediate-acting","Regular insulin is clear and short-acting","NPH insulin is clear and long-acting"],"answer":"Regular insulin is clear and short-acting","rationale":"Regular insulin is a clear solution and is short-acting. NPH insulin is a cloudy suspension and is intermediate-acting. Remember: 'Clear before cloudy' when mixing insulins."},
{"id":"fr_staple_removal","slide":999,"question":"A nurse is removing surgical staples. Which technique is correct?","options":["Use hemostats to pull the staple straight up","Use a staple remover; the staple should bend outward during removal","Pull the staple inward toward the incision line","Use scissors to cut the staple at each end"],"answer":"Use a staple remover; the staple should bend outward during removal","rationale":"Surgical staples are removed using a staple remover. The staple should bend outward (away from the incision) during removal to prevent tissue trauma and wound disruption."},
{"id":"fr_contact_derm","slide":999,"question":"A client presents with pruritus and a rash after exposure to a known skin irritant. The nurse suspects:","options":["Cellulitis","Contact dermatitis","Psoriasis","Herpes zoster"],"answer":"Contact dermatitis","rationale":"Contact dermatitis is caused by exposure to an irritant or allergen, resulting in pruritus (itching) and a localized rash at the site of exposure. Cellulitis is a bacterial infection, psoriasis is autoimmune, and herpes zoster follows a dermatome pattern."},
{"id":"fr_nsaid_teaching","slide":999,"question":"A client is prescribed enteric-coated naproxen. The nurse should teach the client that:","options":["Pain relief will be immediate after the first dose","It may take several weeks to achieve the full anti-inflammatory effect","The medication should be crushed and mixed with food","It should be taken on an empty stomach for best results"],"answer":"It may take several weeks to achieve the full anti-inflammatory effect","rationale":"NSAIDs like naproxen may take several weeks to achieve the full anti-inflammatory effect. Enteric-coated tablets should NOT be crushed or chewed. They should be taken with food to minimize GI irritation."},
{"id":"fr_nicotine_patch","slide":999,"question":"A nurse is teaching a client about nicotine replacement transdermal patches. Which instructions should the nurse include? (Select all that apply)","options":["Apply to clean, dry, hairless skin","Rotate application sites","Apply the new patch directly over the old one","Avoid applying near breast tissue","Date, time, and initial the patch"],"answer":["Apply to clean, dry, hairless skin","Rotate application sites","Avoid applying near breast tissue","Date, time, and initial the patch"],"rationale":"Nicotine patch instructions: apply to clean, dry, hairless skin; rotate sites to prevent skin irritation; avoid breast tissue; date/time/initial each patch. Always remove the old patch before applying a new one."}
];
window.availableExams = window.availableExams || [];
window.availableExams.push({id: 'final_review_medsurg', name: 'Final Review: Medical-Surgical Comprehensive Exam', data: window.finalReviewExamData});
console.log('Created exam module: Final Review Medical-Surgical Comprehensive Exam with ' + window.finalReviewExamData.length + ' questions');
</script>
</body>

</html>